

# Amyloid-Î<sup>2</sup> protein dimers isolated directly from Alzheimer's disease brains and memory

Nature Medicine

14, 837-842

DOI: 10.1038/nm1782

Citation Report

#	ARTICLE	IF	CITATIONS
2	Structural Studies of Copper(I) Complexes of Amyloid- $\beta$ Peptide Fragments: Formation of Two-Coordinate Bis(histidine) Complexes. <i>Angewandte Chemie - International Edition</i> , 2008, 47, 9084-9087.	7.2	133
4	The insulin paradox: aging, proteotoxicity and neurodegeneration. <i>Nature Reviews Neuroscience</i> , 2008, 9, 759-767.	4.9	282
5	The role of glycogen synthase kinase 3 in the early stages of Alzheimer's disease. <i>FEBS Letters</i> , 2008, 582, 3848-3854.	1.3	77
6	Amyloid- $\beta$ immunisation for Alzheimer's disease. <i>Lancet Neurology</i> , The, 2008, 7, 805-811.	4.9	149
7	Alzheimer's disease: $\beta$ -secretase inhibitors. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2008, 5, 169-175.	0.5	22
8	Cystatin C-Cathepsin B Axis Regulates Amyloid Beta Levels and Associated Neuronal Deficits in an Animal Model of Alzheimer's Disease. <i>Neuron</i> , 2008, 60, 247-257.	3.8	196
9	Polyglutamine neurodegeneration: protein misfolding revisited. <i>Trends in Neurosciences</i> , 2008, 31, 521-528.	4.2	325
10	Amyloid- $\beta$ Peptide ( $A\beta$ ) Neurotoxicity Is Modulated by the Rate of Peptide Aggregation: $A\beta$ Dimers and Trimers Correlate with Neurotoxicity. <i>Journal of Neuroscience</i> , 2008, 28, 11950-11958.	1.7	196
11	Canin vitro assessment provide relevant end points for cognitive drug programs?. <i>Expert Opinion on Drug Discovery</i> , 2008, 3, 1377-1382.	2.5	0
12	Amyloid- $\beta$ Dynamics Correlate with Neurological Status in the Injured Human Brain. <i>Science</i> , 2008, 321, 1221-1224.	6.0	270
13	Aggregated, Wild-Type Prion Protein Causes Neurological Dysfunction and Synaptic Abnormalities. <i>Journal of Neuroscience</i> , 2008, 28, 13258-13267.	1.7	60
14	Protection Mechanisms Against $\beta$ Aggregation. <i>Current Alzheimer Research</i> , 2008, 5, 548-554.	0.7	12
15	Effects of Grape Seed-derived Polyphenols on Amyloid $\beta$ -Protein Self-assembly and Cytotoxicity*. <i>Journal of Biological Chemistry</i> , 2008, 283, 32176-32187.	1.6	177
16	ALS precursor finally shaken into fibrils. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 18649-18650.	3.3	21
17	Novel Pharmacotherapies for Alzheimer's Disease. <i>Journal of the Korean Medical Association</i> , 2009, 52, 1059.	0.1	10
18	Mapping Cofilin-Actin Rods in Stressed Hippocampal Slices and the Role of cdc42 in Amyloid- $\beta$ -Induced Rods. <i>Journal of Alzheimer's Disease</i> , 2009, 18, 35-50.	1.2	58
19	Brain Imaging and Neuropathologic Mechanisms in Alzheimer's Disease: Vascular Versus Neurodegenerative and Amyloid- $\beta$ Versus Tau. <i>Journal of Alzheimer's Disease</i> , 2009, 18, 419-427.	1.2	1
20	Real-Time Imaging and Quantification of Amyloid- $\beta$ Peptide Aggregates by Novel Quantum-Dot Nanoprobes. <i>PLoS ONE</i> , 2009, 4, e8492.	1.1	60

#	ARTICLE	IF	CITATIONS
21	Transcriptome Analysis of Synaptoneurosomes Identifies Neuroplasticity Genes Overexpressed in Incipient Alzheimer's Disease. <i>PLoS ONE</i> , 2009, 4, e4936.	1.1	126
22	Basal Cerebral Metabolism May Modulate the Cognitive Effects of A $\beta$ in Mild Cognitive Impairment: An Example of Brain Reserve. <i>Journal of Neuroscience</i> , 2009, 29, 14770-14778.	1.7	217
23	Mitochondrial Cholesterol Loading Exacerbates Amyloid $\beta$ Peptide-Induced Inflammation and Neurotoxicity. <i>Journal of Neuroscience</i> , 2009, 29, 6394-6405.	1.7	134
24	Amyloid beta mediates memory formation. <i>Learning and Memory</i> , 2009, 16, 267-272.	0.5	141
25	Inconvenient facts about pathological amyloid fibrils. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 20555-20556.	3.3	10
26	HLA-DR Alleles in Amyloid $\beta$ -Peptide Autoimmunity: A Highly Immunogenic Role for the DRB1*1501 Allele. <i>Journal of Immunology</i> , 2009, 183, 3522-3530.	0.4	48
27	An update on the efficacy of non-steroidal anti-inflammatory drugs in Alzheimer's disease. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 1147-1168.	1.9	88
28	GluN2B subunit-containing NMDA receptor antagonists prevent A $\beta$ -mediated synaptic plasticity disruption in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 20504-20509.	3.3	142
29	Role of Amyloid- $\beta$ Glycine 33 in Oligomerization, Toxicity, and Neuronal Plasticity. <i>Journal of Neuroscience</i> , 2009, 29, 7582-7590.	1.7	95
30	A $\beta$ Immunotherapy Protects Morphology and Survival of Adult-Born Neurons in Doubly Transgenic APP/PS1 Mice. <i>Journal of Neuroscience</i> , 2009, 29, 14108-14119.	1.7	59
31	Increasing Cu bioavailability inhibits A $\beta$ oligomers and tau phosphorylation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 381-386.	3.3	259
32	Isolation and Characterization of Patient-derived, Toxic, High Mass Amyloid $\beta$ -Protein (A $\beta$ ) Assembly from Alzheimer Disease Brains. <i>Journal of Biological Chemistry</i> , 2009, 284, 32895-32905.	1.6	162
33	Nepriylsin Overexpression Inhibits Plaque Formation But Fails to Reduce Pathogenic A $\beta$ Oligomers and Associated Cognitive Deficits in Human Amyloid Precursor Protein Transgenic Mice. <i>Journal of Neuroscience</i> , 2009, 29, 1977-1986.	1.7	139
34	Progressive aggregation despite chaperone associations of a mutant SOD1-YFP in transgenic mice that develop ALS. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 1392-1397.	3.3	128
35	A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. <i>Neurology</i> , 2009, 73, 2061-2070.	1.5	677
36	A Reporter of Local Dendritic Translocation Shows Plaque-Related Loss of Neural System Function in APP-Transgenic Mice. <i>Journal of Neuroscience</i> , 2009, 29, 12636-12640.	1.7	54
37	Deviant Ryanodine Receptor-Mediated Calcium Release Resets Synaptic Homeostasis in Presymptomatic 3xTg-AD Mice. <i>Journal of Neuroscience</i> , 2009, 29, 9458-9470.	1.7	180
38	Amyloid deposits: Protection against toxic protein species?. <i>Cell Cycle</i> , 2009, 8, 1668-1674.	1.3	125

#	ARTICLE	IF	CITATIONS
39	Immunotherapy for Alzheimer's disease. <i>Immunotherapy</i> , 2009, 1, 461-469.	1.0	4
40	Anti-Amyloid Treatments in Alzheimers Disease. <i>Recent Patents on CNS Drug Discovery</i> , 2009, 4, 143-148.	0.9	10
41	Allele-specific RNAi Mitigates Phenotypic Progression in a Transgenic Model of Alzheimer's Disease. <i>Molecular Therapy</i> , 2009, 17, 1563-1573.	3.7	48
42	Absence of Pittsburgh Compound B Detection of Cerebral Amyloid $\beta^2$ in a Patient With Clinical, Cognitive, and Cerebrospinal Fluid Markers of Alzheimer Disease. <i>Archives of Neurology</i> , 2009, 66, 1557-62.	4.9	188
43	A Common Biological Mechanism in Cancer and Alzheimers Disease?. <i>Current Alzheimer Research</i> , 2009, 6, 196-204.	0.7	165
44	Thin, Stubby or Mushroom: Spine Pathology in Alzheimers Disease. <i>Current Alzheimer Research</i> , 2009, 6, 261-268.	0.7	100
45	Microglial Activation in Alzheimers Disease. <i>Current Alzheimer Research</i> , 2009, 6, 554-563.	0.7	77
46	Vaccination with $A\beta^2$ -Displaying Virus-Like Particles Reduces Soluble and Insoluble Cerebral $A\beta^2$ and Lowers Plaque Burden in APP Transgenic Mice. <i>Journal of Immunology</i> , 2009, 182, 7613-7624.	0.4	40
47	Lysosomal Modulatory Drugs for a Broad Strategy Against Protein Accumulation Disorders. <i>Current Alzheimer Research</i> , 2009, 6, 438-445.	0.7	14
48	Relevance of Transgenic Mouse Models to Human Alzheimer Disease. <i>Journal of Biological Chemistry</i> , 2009, 284, 6033-6037.	1.6	129
49	Reelin signaling antagonizes $\beta^2$ -amyloid at the synapse. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 15938-15943.	3.3	139
50	Cellular Prion Protein Mediates the Toxicity of $\beta^2$ -Amyloid Oligomers. <i>Archives of Neurology</i> , 2009, 66, 1325-8.	4.9	64
51	Synaptic Activity Reduces Intraneuronal $A\beta^2$ , Promotes APP Transport to Synapses, and Protects against $A\beta^2$ -Related Synaptic Alterations. <i>Journal of Neuroscience</i> , 2009, 29, 9704-9713.	1.7	119
52	RAGE Does Not Affect Amyloid Pathology in Transgenic Arc $A\beta^2$ Mice. <i>Neurodegenerative Diseases</i> , 2009, 6, 270-280.	0.8	22
53	Oligomeric amyloid $\beta^2$ associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 4012-4017.	3.3	734
54	Unique quadruplex structure and interaction of an RNA aptamer against bovine prion protein. <i>Nucleic Acids Research</i> , 2009, 37, 6249-6258.	6.5	94
55	A Specific Enzyme-Linked Immunosorbent Assay for Measuring $\beta^2$ -Amyloid Protein Oligomers in Human Plasma and Brain Tissue of Patients With Alzheimer Disease. <i>Archives of Neurology</i> , 2009, 66, 190-9.	4.9	182
56	Passive immunotherapy rapidly increases structural plasticity in a mouse model of Alzheimer disease. <i>Neurobiology of Disease</i> , 2009, 33, 213-220.	2.1	66

#	ARTICLE	IF	CITATIONS
57	JNK regulates APP cleavage and degradation in a model of Alzheimer's disease. <i>Neurobiology of Disease</i> , 2009, 33, 518-525.	2.1	134
58	Oral apolipoprotein A-I mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer's disease. <i>Neurobiology of Disease</i> , 2009, 34, 525-534.	2.1	117
59	Examination of potential mechanisms of amyloid-induced defects in neuronal transport. <i>Neurobiology of Disease</i> , 2009, 36, 11-25.	2.1	40
60	Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. <i>Neurobiology of Disease</i> , 2009, 35, 352-358.	2.1	298
61	Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral A $\beta$ assembly forms throughout life. <i>Neurobiology of Disease</i> , 2009, 36, 293-302.	2.1	117
62	Toward Structural Elucidation of the $\beta$ -Secretase Complex. <i>Structure</i> , 2009, 17, 326-334.	1.6	64
63	Chaperone signalling complexes in Alzheimer's disease. <i>Journal of Cellular and Molecular Medicine</i> , 2009, 13, 619-630.	1.6	120
64	Membrane-targeted strategies for modulating APP and A $\beta$ -mediated toxicity. <i>Journal of Cellular and Molecular Medicine</i> , 2009, 13, 249-261.	1.6	4
65	A $\beta$ aggregation and possible implications in Alzheimer's disease pathogenesis. <i>Journal of Cellular and Molecular Medicine</i> , 2009, 13, 412-421.	1.6	129
66	Calcium in the initiation, progression and as an effector of Alzheimer's disease pathology. <i>Journal of Cellular and Molecular Medicine</i> , 2009, 13, 2787-2799.	1.6	48
67	Neuronal death in Alzheimer's disease and therapeutic opportunities. <i>Journal of Cellular and Molecular Medicine</i> , 2009, 13, 4329-4348.	1.6	97
68	Stimulus pattern dependence of the Alzheimer's disease amyloid- $\beta$ 42 peptide's inhibition of long term potentiation in mouse hippocampal slices. <i>Brain Research</i> , 2009, 1269, 176-184.	1.1	34
69	A single dose of passive immunotherapy has extended benefits on synapses and neurites in an Alzheimer's disease mouse model. <i>Brain Research</i> , 2009, 1280, 178-185.	1.1	20
70	Conformation-dependent single-chain variable fragment antibodies specifically recognize beta-amyloid oligomers. <i>FEBS Letters</i> , 2009, 583, 579-584.	1.3	56
71	Simvastatin therapy prevents brain trauma-induced increases in $\beta$ -amyloid peptide levels. <i>Annals of Neurology</i> , 2009, 66, 407-414.	2.8	85
72	Cognition, reserve, and amyloid deposition in normal aging. <i>Annals of Neurology</i> , 2010, 67, 353-364.	2.8	313
74	Evaluation of $\beta$ -Alanine- and GABA-Substituted Peptides as Inhibitors of Disease-Linked Protein Aggregation. <i>ChemBioChem</i> , 2009, 10, 1982-1987.	1.3	8
75	Cytoskeletal pathologies of Alzheimer disease. <i>Cytoskeleton</i> , 2009, 66, 635-649.	4.4	152

#	ARTICLE	IF	CITATIONS
76	NMDA receptor-dependent signaling pathways that underlie amyloid $\beta$ protein disruption of LTP in the hippocampus. <i>Journal of Neuroscience Research</i> , 2009, 87, 1729-1736.	1.3	118
77	The small heat shock protein Hsp27 protects cortical neurons against the toxic effects of $\beta$ amyloid peptide. <i>Journal of Neuroscience Research</i> , 2009, 87, 3161-3175.	1.3	41
78	Alzheimer's Disease: From Pathology to Therapeutic Approaches. <i>Angewandte Chemie - International Edition</i> , 2009, 48, 3030-3059.	7.2	544
79	Common key-signals in learning and neurodegeneration: focus on excito-amino acids, $\beta$ -amyloid peptides and $\tau$ -synuclein. <i>Journal of Neural Transmission</i> , 2009, 116, 953-974.	1.4	8
80	Inflammasomes in infection and inflammation. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2009, 14, 522-35.	2.2	62
81	Formation of amyloid- $\beta$ oligomers in brain vascular smooth muscle cells transiently exposed to iron-induced oxidative stress. <i>Acta Neuropathologica</i> , 2009, 117, 557-567.	3.9	23
82	Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2009, 118, 103-113.	3.9	769
83	Classification and basic pathology of Alzheimer disease. <i>Acta Neuropathologica</i> , 2009, 118, 5-36.	3.9	805
84	Synaptic degeneration in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2009, 118, 167-179.	3.9	446
85	Mitochondria, cholesterol and amyloid $\beta$ peptide: a dangerous trio in Alzheimer disease. <i>Journal of Bioenergetics and Biomembranes</i> , 2009, 41, 417-423.	1.0	50
86	Amino acids variations in Amyloid- $\beta$ peptides, mitochondrial dysfunction, and new therapies for Alzheimer's disease. <i>Journal of Bioenergetics and Biomembranes</i> , 2009, 41, 457-464.	1.0	30
87	HIV Regulation of Amyloid Beta Production. <i>Journal of NeuroImmune Pharmacology</i> , 2009, 4, 213-217.	2.1	57
88	Interpeptide interactions induce helix to strand structural transition in $A\beta$ peptides. <i>Proteins: Structure, Function and Bioinformatics</i> , 2009, 77, 1-13.	1.5	141
89	Discovery of amyloid- $\beta$ aggregation inhibitors using an engineered assay for intracellular protein folding and solubility. <i>Protein Science</i> , 2009, 18, 277-286.	3.1	43
90	9,10-Anthraquinone hinders $\beta$ aggregation: How does a small molecule interfere with $A\beta$ peptide amyloid fibrillation?. <i>Protein Science</i> , 2009, 18, 792-800.	3.1	91
91	The PI3K-Akt-mTOR pathway regulates $A\beta$ oligomer induced neuronal cell cycle events. <i>Molecular Neurodegeneration</i> , 2009, 4, 14.	4.4	151
92	Calcium signaling in neurodegeneration. <i>Molecular Neurodegeneration</i> , 2009, 4, 20.	4.4	258
93	Acyl peptide hydrolase degrades monomeric and oligomeric amyloid-beta peptide. <i>Molecular Neurodegeneration</i> , 2009, 4, 33.	4.4	55

#	ARTICLE	IF	CITATIONS
94	Alzheimer's disease: synaptic dysfunction and A $\beta$ . <i>Molecular Neurodegeneration</i> , 2009, 4, 48.	4.4	388
95	Acute dosing of latrepirdine (Dimebon $\text{\textcircled{C}}$ ), a possible Alzheimer therapeutic, elevates extracellular amyloid- $\beta$ levels in vitro and in vivo. <i>Molecular Neurodegeneration</i> , 2009, 4, 51.	4.4	39
96	Does Alzheimer's disease begin in the brainstem?. <i>Neuropathology and Applied Neurobiology</i> , 2009, 35, 532-554.	1.8	170
97	Cellular prion protein mediates impairment of synaptic plasticity by amyloid- $\beta$ oligomers. <i>Nature</i> , 2009, 457, 1128-1132.	13.7	1,390
98	A prion protein connection. <i>Nature</i> , 2009, 457, 1090-1091.	13.7	49
99	When planets migrate. <i>Nature</i> , 2009, 457, 1091-1092.	13.7	1
100	Amyloid- $\beta$ as a positive endogenous regulator of release probability at hippocampal synapses. <i>Nature Neuroscience</i> , 2009, 12, 1567-1576.	7.1	444
101	Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. <i>Nature Reviews Neuroscience</i> , 2009, 10, 333-344.	4.9	967
102	Experience-dependent structural synaptic plasticity in the mammalian brain. <i>Nature Reviews Neuroscience</i> , 2009, 10, 647-658.	4.9	1,569
103	Unraveling infectious structures, strain variants and species barriers for the yeast prion [PSI <sup>+</sup> ]. <i>Nature Structural and Molecular Biology</i> , 2009, 16, 598-605.	3.6	75
104	Amyloid- $\beta$ protofibril levels correlate with spatial learning in Arctic Alzheimer's disease transgenic mice. <i>FEBS Journal</i> , 2009, 276, 995-1006.	2.2	79
105	Reduction of A $\beta$ <sub>42</sub> in brains of transgenic APP<sc>sw</sc> mice by 2- $\beta$ -chlorophenylaminophenylacetate. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2009, 36, 1099-1103.	0.9	1
106	CHF5074, a novel $\beta$ -secretase modulator, attenuates brain $\beta$ -amyloid pathology and learning deficit in a mouse model of Alzheimer's disease. <i>British Journal of Pharmacology</i> , 2009, 156, 982-993.	2.7	83
107	Reversal of temperature-induced conformational changes in the amyloid- $\beta$ peptide, A $\beta$ <sub>240</sub> , by the $\beta$ -sheet breaker peptides 16- $\beta$ <sub>23</sub> and 17- $\beta$ <sub>24</sub> . <i>British Journal of Pharmacology</i> , 2009, 158, 1165-1172.	2.7	10
108	Inhibition of Alzheimer's amyloid toxicity with a tricyclic pyrone molecule <i>in vitro</i> and <i>in vivo</i> . <i>Journal of Neurochemistry</i> , 2009, 108, 1097-1108.	2.1	68
109	A $\beta$ <sub>43</sub> is more frequent than A $\beta$ <sub>40</sub> in amyloid plaque cores from Alzheimer disease brains. <i>Journal of Neurochemistry</i> , 2009, 110, 697-706.	2.1	129
110	Attenuation of AD-like neuropathology by harnessing peripheral immune cells: local elevation of IL-10 and MMP-9. <i>Journal of Neurochemistry</i> , 2009, 111, 1409-1424.	2.1	99
111	Efficacy of acetyl-cholinesterase-inhibitor (ACHEI) treatment in Alzheimer's disease: A 21-month follow-up <i>in</i> a cereal world study. <i>Archives of Gerontology and Geriatrics</i> , 2009, 49, e6-e11.	1.4	14



#	ARTICLE	IF	CITATIONS
112	Protein aggregation kinetics, mechanism, and curve-fitting: A review of the literature. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2009, 1794, 375-397.	1.1	572
113	The binding of pullulan modified cholesteryl nanogels to A $\beta$ oligomers and their suppression of cytotoxicity. <i>Biomaterials</i> , 2009, 30, 5583-5591.	5.7	88
114	Synthesis and SAR of hydroxyethylamine based phenylcarboxyamides as inhibitors of BACE. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 2654-2660.	1.0	16
115	A chemical screening approach reveals that indole fluorescence is quenched by pre-fibrillar but not fibrillar amyloid- $\beta$ . <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 4952-4957.	1.0	25
116	Therapeutic strategies against protein misfolding in neurodegenerative diseases. <i>Expert Opinion on Drug Discovery</i> , 2009, 4, 71-84.	2.5	6
117	Recent Advances in the Identification of $\beta$ -Secretase Inhibitors To Clinically Test the A $\beta$ Oligomer Hypothesis of Alzheimer's Disease. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 6169-6188.	2.9	101
118	Insulin Receptor Dysfunction Impairs Cellular Clearance of Neurotoxic Oligomeric A $\beta$ . <i>Journal of Biological Chemistry</i> , 2009, 284, 18742-18753.	1.6	130
119	4 $\beta$ -Demethylnobiletin, a Bioactive Metabolite of Nobiletin Enhancing PKA/ERK/CREB Signaling, Rescues Learning Impairment Associated with NMDA Receptor Antagonism via Stimulation of the ERK Cascade. <i>Biochemistry</i> , 2009, 48, 7713-7721.	1.2	67
120	Side Chain Interactions Can Impede Amyloid Fibril Growth: Replica Exchange Simulations of A $\beta$ Peptide Mutant. <i>Journal of Physical Chemistry B</i> , 2009, 113, 11848-11857.	1.2	23
121	Association of Highly Compact Type II Diabetes Related Islet Amyloid Polypeptide Intermediate Species at Physiological Temperature Revealed by Diffusion NMR Spectroscopy. <i>Journal of the American Chemical Society</i> , 2009, 131, 7079-7085.	6.6	143
122	Chapter 3 Small-Molecule Protein-Protein Interaction Inhibitors as Therapeutic Agents for Neurodegenerative Diseases: Recent Progress and Future Directions. <i>Annual Reports in Medicinal Chemistry</i> , 2009, , 51-69.	0.5	8
123	Nicotinic Acetylcholine Receptor Signalling: Roles in Alzheimer's Disease and Amyloid Neuroprotection. <i>Pharmacological Reviews</i> , 2009, 61, 39-61.	7.1	256
124	Biophysical Analyses of Synthetic Amyloid- $\beta$ (1-42) Aggregates before and after Covalent Cross-Linking. Implications for Deducing the Structure of Endogenous Amyloid- $\beta$ Oligomers. <i>Biochemistry</i> , 2009, 48, 11796-11806.	1.2	44
125	Structure of the Amyloid- $\beta$ (1-42) Monomer Absorbed To Model Phospholipid Bilayers: A Molecular Dynamics Study. <i>Journal of Physical Chemistry B</i> , 2009, 113, 14480-14486.	1.2	75
126	Surface Plasmon Resonance Binding Kinetics of Alzheimer's Disease Amyloid $\beta$ Peptide-Capturing and Plaque-Binding Monoclonal Antibodies. <i>Biochemistry</i> , 2009, 48, 10405-10415.	1.2	72
127	Reassessing the amyloid cascade hypothesis of Alzheimer's disease. <i>International Journal of Biochemistry and Cell Biology</i> , 2009, 41, 1261-1268.	1.2	318
128	A $\beta$ -mediated ROS production by Cu ions: Structural insights, mechanisms and relevance to Alzheimer's disease. <i>Biochimie</i> , 2009, 91, 1212-1217.	1.3	232
129	Axonopathy and cytoskeletal disruption in degenerative diseases of the central nervous system. <i>Brain Research Bulletin</i> , 2009, 80, 217-223.	1.4	62



#	ARTICLE	IF	CITATIONS
130	Focus on: Amyloid $\beta$ . <i>Experimental Eye Research</i> , 2009, 89, 446-447.	1.2	10
131	The Alzheimer's disease mitochondrial cascade hypothesis: An update. <i>Experimental Neurology</i> , 2009, 218, 308-315.	2.0	181
132	Reduced IGF-1 Signaling Delays Age-Associated Proteotoxicity in Mice. <i>Cell</i> , 2009, 139, 1157-1169.	13.5	450
133	Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2009, 1792, 482-496.	1.8	291
134	Protein aggregation as a paradigm of aging. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2009, 1790, 980-996.	1.1	92
135	Imbalance between GABAergic and Glutamatergic Transmission Impairs Adult Neurogenesis in an Animal Model of Alzheimer's Disease. <i>Cell Stem Cell</i> , 2009, 5, 624-633.	5.2	180
136	Estrogen-induced plasticity from cells to circuits: predictions for cognitive function. <i>Trends in Pharmacological Sciences</i> , 2009, 30, 212-222.	4.0	251
137	Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease. <i>Neurobiology of Aging</i> , 2009, 30, 1026-1036.	1.5	558
138	Amyloid Deposition Is Associated with Impaired Default Network Function in Older Persons without Dementia. <i>Neuron</i> , 2009, 63, 178-188.	3.8	899
139	Synaptic transmission is impaired prior to plaque formation in amyloid precursor protein-overexpressing mice without altering behaviorally-correlated sharp wave ripple complexes. <i>Neuroscience</i> , 2009, 162, 1081-1090.	1.1	44
140	Amyloid- $\beta$ expression in retrosplenial cortex of triple transgenic mice: relationship to cholinergic axonal afferents from medial septum. <i>Neuroscience</i> , 2009, 164, 1334-1346.	1.1	16
141	Phospholipids block nuclear factor-kappa B and tau phosphorylation and inhibit amyloid-beta secretion in human neuroblastoma cells. <i>Neuroscience</i> , 2009, 164, 1744-1753.	1.1	21
142	Lipoprotein receptors and cholesterol in APP trafficking and proteolytic processing, implications for Alzheimer's disease. <i>Seminars in Cell and Developmental Biology</i> , 2009, 20, 191-200.	2.3	105
143	Reduced oligomeric and vascular amyloid- $\beta$ following immunization of TgCRND8 mice with an Alzheimer's DNA vaccine. <i>Vaccine</i> , 2009, 27, 1365-1376.	1.7	28
144	TrkA pathway activation induced by amyloid-beta (A $\beta$ ). <i>Molecular and Cellular Neurosciences</i> , 2009, 40, 365-373.	1.0	32
145	Pin1 affects Tau phosphorylation in response to A $\beta$ oligomers. <i>Molecular and Cellular Neurosciences</i> , 2009, 42, 75-80.	1.0	53
146	The Structure of A $\beta$ <sup>42</sup> C-Terminal Fragments Probed by a Combined Experimental and Theoretical Study. <i>Journal of Molecular Biology</i> , 2009, 387, 492-501.	2.0	84
147	( $\hat{\alpha}$ ) <sup>+</sup> -Epigallocatechin-3-Gallate (EGCG) Maintains $\beta$ -Casein in Its Pre-Fibrillar State without Redirecting Its Aggregation Pathway. <i>Journal of Molecular Biology</i> , 2009, 392, 689-700.	2.0	127

#	ARTICLE	IF	CITATIONS
148	Comparison of A $\beta$ levels in the brain of familial and sporadic Alzheimer's disease. <i>Neurochemistry International</i> , 2009, 55, 243-252.	1.9	60
149	Non-coding RNA transcripts: Sensors of neuronal stress, modulators of synaptic plasticity, and agents of change in the onset of Alzheimer's disease. <i>Neuroscience Letters</i> , 2009, 466, 81-88.	1.0	26
150	Human and rodent amyloid- $\beta$ peptides differentially bind heme: Relevance to the human susceptibility to Alzheimer's disease. <i>Archives of Biochemistry and Biophysics</i> , 2009, 487, 59-65.	1.4	82
151	Metallo-complex activation of neuroprotective signalling pathways as a therapeutic treatment for Alzheimer's disease. <i>Molecular BioSystems</i> , 2009, 5, 134-142.	2.9	30
152	The chemistry of Alzheimer's disease. <i>Chemical Society Reviews</i> , 2009, 38, 2698.	18.7	391
153	Interaction Between Amyloid- $\beta$ (1-42) Peptide and Phospholipid Bilayers: A Molecular Dynamics Study. <i>Biophysical Journal</i> , 2009, 96, 785-797.	0.2	108
154	Replica Exchange Simulations of the Thermodynamics of A $\beta$ Fibril Growth. <i>Biophysical Journal</i> , 2009, 96, 442-452.	0.2	95
155	Probing Energetics of A $\beta$ Fibril Elongation by Molecular Dynamics Simulations. <i>Biophysical Journal</i> , 2009, 96, 4428-4437.	0.2	49
156	Molecular Dynamics Simulations of Ibuprofen Binding to A $\beta$ Peptides. <i>Biophysical Journal</i> , 2009, 97, 2070-2079.	0.2	53
157	Structure-neurotoxicity relationships of amyloid $\beta$ -protein oligomers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 14745-14750.	3.3	701
158	$\beta$ -Amyloid Monomers Are Neuroprotective. <i>Journal of Neuroscience</i> , 2009, 29, 10582-10587.	1.7	350
159	Effect of $\beta$ -sheet propensity on peptide aggregation. <i>Journal of Chemical Physics</i> , 2009, 130, 145103.	1.2	123
160	Proteinopathy-induced neuronal senescence: a hypothesis for brain failure in Alzheimer's and other neurodegenerative diseases. <i>Alzheimer's Research and Therapy</i> , 2009, 1, 5.	3.0	77
161	Is Alzheimer's Disease a Result of Presynaptic Failure? - Synaptic Dysfunctions Induced by Oligomeric $\beta$ -Amyloid. <i>Reviews in the Neurosciences</i> , 2009, 20, 1-12.	1.4	125
162	The Quest for Small Molecules as Amyloid Inhibiting Therapies for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2009, 17, 33-47.	1.2	64
163	Probing the Effect of Amino-Terminal Truncation for A $\beta$ 1-40 Peptides. <i>Journal of Physical Chemistry B</i> , 2009, 113, 6692-6702.	1.2	40
164	Fibril Fragmentation Enhances Amyloid Cytotoxicity. <i>Journal of Biological Chemistry</i> , 2009, 284, 34272-34282.	1.6	326
165	Solid-phase synthesis of homodimeric peptides: preparation of covalently-linked dimers of amyloid $\beta$ peptide. <i>Chemical Communications</i> , 2009, , 6228.	2.2	39

#	ARTICLE	IF	CITATIONS
166	MAPK, $\beta$ -amyloid and synaptic dysfunction: the role of RAGE. Expert Review of Neurotherapeutics, 2009, 9, 1635-1645.	1.4	60
167	Diversity of kinetic pathways in amyloid fibril formation. Journal of Chemical Physics, 2009, 131, 111102.	1.2	87
168	Soluble Oligomers of Amyloid $\beta$ Protein Facilitate Hippocampal Long-Term Depression by Disrupting Neuronal Glutamate Uptake. Neuron, 2009, 62, 788-801.	3.8	818
169	The E693 <sup>T</sup> Mutation in Amyloid Precursor Protein Increases Intracellular Accumulation of Amyloid $\beta$ Oligomers and Causes Endoplasmic Reticulum Stress-Induced Apoptosis in Cultured Cells. American Journal of Pathology, 2009, 174, 957-969.	1.9	109
170	Prions: Protein Aggregation and Infectious Diseases. Physiological Reviews, 2009, 89, 1105-1152.	13.1	443
171	Changing perspectives regarding late-life dementia. Nature Reviews Neurology, 2009, 5, 649-658.	4.9	259
172	Dissecting Molecular Mechanisms in the Living Brain of Dementia Patients. Accounts of Chemical Research, 2009, 42, 842-850.	7.6	36
173	Apolipoprotein E receptors in the nervous system. Current Opinion in Lipidology, 2009, 20, 190-196.	1.2	70
174	Neurobiology of cognitive disorders. Current Opinion in Psychiatry, 2009, 22, 546-551.	3.1	24
175	Regulated Proteolysis of RAGE and $\beta$ PP as Possible Link Between Type 2 Diabetes Mellitus and Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 16, 865-878.	1.2	36
176	Neuropathology and Cognitive Impairment in Alzheimer Disease: A Complex but Coherent Relationship. Journal of Neuropathology and Experimental Neurology, 2009, 68, 1-14.	0.9	492
177	$\beta$ -amyloid <sub>1-42</sub> and $\beta$ -amyloid <sub>1-40</sub> in Alzheimer's disease. Nature Digest, 2009, 6, 26-27.	0.0	0
178	Does Alzheimer's Disease Result from Attempts at Repair or Protection After Transient Stress?. Journal of Alzheimer's Disease, 2009, 18, 371-380.	1.2	9
180	Memory Deficits in APP23/ <i>Abca1</i> <sup>+/+</sup> Mice Correlate with the Level of $\beta$ -Oligomers. ASN Neuro, 2009, 1, AN20090015.	1.5	53
181	Quantitative and Mechanistic Studies of $\beta$ -Amyloid; Immunotherapy. CNS and Neurological Disorders - Drug Targets, 2009, 8, 31-49.	0.8	46
182	$\beta$ -Amyloid: A Disease Target or a Synaptic Regulator Affecting Age-Related Neurotransmitter Changes?. Current Pharmaceutical Design, 2010, 16, 672-683.	0.9	30
183	Acute Effect on the $\beta$ Isoform Pattern in CSF in Response to $\beta$ -Secretase Modulator and Inhibitor Treatment in Dogs. Journal of Alzheimer's Disease, 2010, 21, 1005-1012.	1.2	61
184	Amyloid- $\beta$ Peptides Stimulate the Expression of the p75NTR Neurotrophin Receptor in SHSY5Y Human Neuroblastoma Cells and AD Transgenic Mice. Journal of Alzheimer's Disease, 2010, 19, 915-925.	1.2	76

#	ARTICLE	IF	CITATIONS
185	Neurotrophins Enhance CaMKII Activity and Rescue Amyloid- $\beta$ -Induced Deficits in Hippocampal Synaptic Plasticity. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 823-831.	1.2	86
186	Amyloid- $\beta$ Peptide and Oligomers in the Brain and Cerebrospinal Fluid of Aged Canines. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 637-646.	1.2	69
188	Dysfunction and recovery of synapses in prion disease: implications for neurodegeneration. <i>Biochemical Society Transactions</i> , 2010, 38, 482-487.	1.6	15
189	Alzheimer's disease and amyloid $\beta$ -peptide deposition in the brain: a matter of "aging"? <i>Biochemical Society Transactions</i> , 2010, 38, 539-544.	1.6	15
190	CHF5074, a Novel $\beta$ -Secretase Modulator, Restores Hippocampal Neurogenesis Potential and Reverses Contextual Memory Deficit in a Transgenic Mouse Model of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 159-173.	1.2	71
191	Hemoglobin-derived Peptides as Novel Type of Bioactive Signaling Molecules. <i>AAPS Journal</i> , 2010, 12, 658-669.	2.2	102
192	Current therapeutic targets for the treatment of Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2010, 10, 711-728.	1.4	101
193	Vaccination as a Therapeutic Approach to Alzheimer's Disease. <i>Mount Sinai Journal of Medicine</i> , 2010, 77, 17-31.	1.9	43
194	Contemporary Approaches to Alzheimer's Disease and Frontotemporal Dementia. <i>Methods in Molecular Biology</i> , 2010, 670, 1-9.	0.4	7
195	Synapse elimination during development and disease: immune molecules take centre stage. <i>Biochemical Society Transactions</i> , 2010, 38, 476-481.	1.6	113
196	$\beta$ -amyloid oligomers and cellular prion protein in Alzheimer's disease. <i>Journal of Molecular Medicine</i> , 2010, 88, 331-338.	1.7	75
197	Development and validation of sensitive and selective LC-MS/MS methods for the determination of BMS-708163, a $\beta$ -secretase inhibitor, in plasma and cerebrospinal fluid using deprotonated or formate adduct ions as precursor ions. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 2319-2326.	1.2	27
198	Analysis of microdissected human neurons by a sensitive ELISA reveals a correlation between elevated intracellular concentrations of A $\beta$ 42 and Alzheimer's disease neuropathology. <i>Acta Neuropathologica</i> , 2010, 119, 543-554.	3.9	61
199	Intraneuronal $\beta$ -amyloid accumulation and synapse pathology in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2010, 119, 523-541.	3.9	341
200	Reduced benefit from mnemonic strategies in early-stage Alzheimer's disease: a brief testing-the-limits paradigm for clinical practice. <i>Journal of Neurology</i> , 2010, 257, 1718-1726.	1.8	6
201	Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models. <i>Brain Structure and Function</i> , 2010, 214, 201-218.	1.2	36
202	Association of the RAGE G82S polymorphism with Alzheimer's disease. <i>Journal of Neural Transmission</i> , 2010, 117, 861-867.	1.4	47
203	Wild type but not mutant APP is involved in protective adaptive responses against oxidants. <i>Amino Acids</i> , 2010, 39, 271-283.	1.2	11

#	ARTICLE	IF	CITATIONS
204	Alzheimer's Disease Amyloid $\beta$ -Protein and Synaptic Function. <i>NeuroMolecular Medicine</i> , 2010, 12, 13-26.	1.8	122
205	Alzheimer's Disease and Neuronal Network Activity. <i>NeuroMolecular Medicine</i> , 2010, 12, 44-47.	1.8	26
206	An Overview of APP Processing Enzymes and Products. <i>NeuroMolecular Medicine</i> , 2010, 12, 1-12.	1.8	515
207	Adverse Stress, Hippocampal Networks, and Alzheimer's Disease. <i>NeuroMolecular Medicine</i> , 2010, 12, 56-70.	1.8	169
208	Nicotinic Receptors, Amyloid- $\beta$ , and Synaptic Failure in Alzheimer's Disease. <i>Journal of Molecular Neuroscience</i> , 2010, 40, 221-229.	1.1	54
209	Synapse Pathology in Psychiatric and Neurologic Disease. <i>Current Neurology and Neuroscience Reports</i> , 2010, 10, 207-214.	2.0	294
210	$^{11}\text{C}$ -PiB PET assessment of change in fibrillar amyloid- $\beta$ load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. <i>Lancet Neurology</i> , The, 2010, 9, 363-372.	4.9	674
211	Alzheimer's disease: clinical trials and drug development. <i>Lancet Neurology</i> , The, 2010, 9, 702-716.	4.9	1,033
212	Novel amyloid-beta specific scFv and VH antibody fragments from human and mouse phage display antibody libraries. <i>Journal of Neuroimmunology</i> , 2010, 223, 104-114.	1.1	22
213	Aberrant modulation of a delayed rectifier potassium channel by glutamate in Alzheimer's disease. <i>Neurobiology of Disease</i> , 2010, 37, 339-348.	2.1	10
214	Methylene blue fails to inhibit Tau and polyglutamine protein dependent toxicity in zebrafish. <i>Neurobiology of Disease</i> , 2010, 39, 265-271.	2.1	73
215	Preclinical Alzheimer disease: Brain oxidative stress, A $\beta$ peptide and proteomics. <i>Neurobiology of Disease</i> , 2010, 39, 221-228.	2.1	76
216	Immunization with the SDPM1 peptide lowers amyloid plaque burden and improves cognitive function in the APPswePSEN1(A246E) transgenic mouse model of Alzheimer's disease. <i>Neurobiology of Disease</i> , 2010, 39, 409-422.	2.1	10
217	Traumatic brain injury reduces soluble extracellular amyloid- $\beta$ in mice: A methodologically novel combined microdialysis-controlled cortical impact study. <i>Neurobiology of Disease</i> , 2010, 40, 555-564.	2.1	48
218	Principles governing oligomer formation in amyloidogenic peptides. <i>Current Opinion in Structural Biology</i> , 2010, 20, 187-195.	2.6	97
219	Biology of Amyloid: Structure, Function, and Regulation. <i>Structure</i> , 2010, 18, 1244-1260.	1.6	496
220	Alzheimer's disease: insights from <i>Drosophila melanogaster</i> models. <i>Trends in Biochemical Sciences</i> , 2010, 35, 228-235.	3.7	110
221	Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer's disease model mouse. <i>BMC Neuroscience</i> , 2010, 11, 130.	0.8	158

#	ARTICLE	IF	CITATIONS
222	Inhibition of AMPA receptor trafficking at hippocampal synapses by $\text{A}\beta$ -amyloid oligomers: the mitochondrial contribution. <i>Molecular Brain</i> , 2010, 3, 10.	1.3	55
223	Searching for new animal models of Alzheimer's disease. <i>European Journal of Pharmacology</i> , 2010, 626, 57-63.	1.7	44
224	Luteolin promotes long-term potentiation and improves cognitive functions in chronic cerebral hypoperfused rats. <i>European Journal of Pharmacology</i> , 2010, 627, 99-105.	1.7	65
225	Amyloid $\text{A}\beta$ and APP as biomarkers for Alzheimer's disease. <i>Experimental Gerontology</i> , 2010, 45, 23-29.	1.2	104
226	Different electrophysiological actions of 24- and 72-hour aggregated amyloid-beta oligomers on hippocampal field population spike in both anesthetized and awake rats. <i>Brain Research</i> , 2010, 1354, 227-235.	1.1	20
227	Kallikrein-related peptidase 6 in Alzheimer's disease and vascular dementia. <i>Brain Research</i> , 2010, 1363, 1-10.	1.1	41
228	Intracellular calcium signalling in Alzheimer's disease. <i>Journal of Cellular and Molecular Medicine</i> , 2010, 14, 30-41.	1.6	58
229	Basic mechanisms of neurodegeneration: a critical update. <i>Journal of Cellular and Molecular Medicine</i> , 2010, 14, 457-487.	1.6	330
230	Prion protein and $\text{A}\beta$ -related synaptic toxicity impairment. <i>EMBO Molecular Medicine</i> , 2010, 2, 306-314.	3.3	234
231	Role of the SNK-SPAR pathway in the development of Alzheimer's disease. <i>IUBMB Life</i> , 2010, 62, 214-221.	1.5	12
235	<i>APOE</i> predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. <i>Annals of Neurology</i> , 2010, 67, 122-131.	2.8	727
236	Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid $\text{A}\beta$ oligomers. <i>Annals of Neurology</i> , 2010, 68, 220-230.	2.8	123
237	Quantifying Prefibrillar Amyloids in vitro by Using a Thioflavin-Like Spectroscopic Method. <i>ChemBioChem</i> , 2010, 11, 1889-1895.	1.3	23
240	Combining Independent Drug Classes into Superior, Synergistically Acting Hybrid Molecules. <i>Angewandte Chemie - International Edition</i> , 2010, 49, 8743-8746.	7.2	43
241	Two-Dimensional Ultraviolet (2DUV) Spectroscopic Tools for Identifying Fibrillation Propensity of Protein Residue Sequences. <i>Angewandte Chemie - International Edition</i> , 2010, 49, 9666-9669.	7.2	32
242	Binding of amyloid peptides to domain-swapped dimers of other amyloid-forming proteins may prevent their neurotoxicity. <i>BioEssays</i> , 2010, 32, 1020-1024.	1.2	9
243	Amyloid $\text{A}\beta$ oligomers impair fear conditioned memory in a calcineurin-dependent fashion in mice. <i>Journal of Neuroscience Research</i> , 2010, 88, 2923-2932.	1.3	93
244	APP transgenic mice: The effect of active and passive immunotherapy in cognitive tasks. <i>Neuroscience and Biobehavioral Reviews</i> , 2010, 34, 487-499.	2.9	20

#	ARTICLE	IF	CITATIONS
245	The effects of cholesterol on learning and memory. <i>Neuroscience and Biobehavioral Reviews</i> , 2010, 34, 1366-1379.	2.9	87
246	Sebestenoids Aâ€“D, BACE1 inhibitors from <i>Cordia sebestena</i> . <i>Phytochemistry</i> , 2010, 71, 2168-2173.	1.4	36
247	An improved method for generating consistent soluble amyloid-beta oligomer preparations for in vitro neurotoxicity studies. <i>Journal of Neuroscience Methods</i> , 2010, 190, 171-179.	1.3	76
248	Structure-based design and synthesis of novel P2/P3 modified, non-peptidic Î²-secretase (BACE-1) inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 1924-1927.	1.0	24
249	Phospholipase A2 inhibitors protect against prion and AÎ² mediated synapse degeneration. <i>Molecular Neurodegeneration</i> , 2010, 5, 13.	4.4	36
250	Wnt-5a occludes AÎ² oligomer-induced depression of glutamatergic transmission in hippocampal neurons. <i>Molecular Neurodegeneration</i> , 2010, 5, 3.	4.4	107
251	Increased amyloidogenic processing of transgenic human APP in X11-like deficient mouse brain. <i>Molecular Neurodegeneration</i> , 2010, 5, 35.	4.4	30
252	The biochemical aftermath of anti-amyloid immunotherapy. <i>Molecular Neurodegeneration</i> , 2010, 5, 39.	4.4	38
253	Amyloid-Î²-Acetylcholinesterase complexes potentiate neurodegenerative changes induced by the AÎ² peptide. Implications for the pathogenesis of Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2010, 5, 4.	4.4	96
254	Î±-synuclein induced synapse damage is enhanced by amyloid-Î² <sub>1-42</sub> . <i>Molecular Neurodegeneration</i> , 2010, 5, 55.	4.4	43
255	A molecular dynamics study of the early stages of amyloidâ€“(1â€“(42) oligomerization: The role of lipid membranes. <i>Proteins: Structure, Function and Bioinformatics</i> , 2010, 78, 2533-2545.	1.5	52
256	Longâ€“term potentiation (LTP) of human sensoryâ€“evoked potentials. <i>Wiley Interdisciplinary Reviews: Cognitive Science</i> , 2010, 1, 766-773.	1.4	45
257	Nanoimaging for protein misfolding diseases. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2010, 2, 526-543.	3.3	40
258	The metabolic enhancer piracetam ameliorates the impairment of mitochondrial function and neurite outgrowth induced by AÎ² amyloid peptide. <i>British Journal of Pharmacology</i> , 2010, 160, 246-257.	2.7	42
259	Methylâ€“aspartate receptors are required for synaptic targeting of Alzheimerâ€™s toxic amyloidâ€“(2 peptide oligomers. <i>Journal of Neurochemistry</i> , 2010, 115, 1520-1529.	2.1	141
260	Yeast as a model for studying Alzheimer's disease. <i>FEMS Yeast Research</i> , 2010, 10, 961-969.	1.1	52
261	Progressive accumulation of amyloidâ€“(2 oligomers in Alzheimerâ€™s disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteins. <i>FEBS Journal</i> , 2010, 277, 3051-3067.	2.2	188
262	Emerging roles of Wnts in the adult nervous system. <i>Nature Reviews Neuroscience</i> , 2010, 11, 77-86.	4.9	558



#	ARTICLE	IF	CITATIONS
263	Traumatic brain injury and amyloid- $\beta^2$ pathology: a link to Alzheimer's disease?. <i>Nature Reviews Neuroscience</i> , 2010, 11, 361-370.	4.9	469
264	Structural conversion of neurotoxic amyloid- $\beta^2$ oligomers to fibrils. <i>Nature Structural and Molecular Biology</i> , 2010, 17, 561-567.	3.6	956
265	Neurotoxicity of Alzheimer's disease A $\beta^2$ peptides is induced by small changes in the A $\beta^2$ 42 to A $\beta^2$ 40 ratio. <i>EMBO Journal</i> , 2010, 29, 3408-3420.	3.5	455
266	Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APP <sup>swe</sup> /PSEN1 <sup>E9</sup> mouse model of Alzheimer's disease. <i>Molecular Psychiatry</i> , 2010, 15, 272-285.	4.1	240
267	The prion protein as a receptor for amyloid- $\beta^2$ . <i>Nature</i> , 2010, 466, E3-E4.	13.7	239
268	LaurÃ©n et al. reply. <i>Nature</i> , 2010, 466, E4-E5.	13.7	13
269	Initiation and propagation of neurodegeneration. <i>Nature Medicine</i> , 2010, 16, 1201-1204.	15.2	40
270	The benefits and limitations of animal models for translational research in neurodegenerative diseases. <i>Nature Medicine</i> , 2010, 16, 1210-1214.	15.2	301
271	Amyloid beta from axons and dendrites reduces local spine number and plasticity. <i>Nature Neuroscience</i> , 2010, 13, 190-196.	7.1	295
272	Amyloid- $\beta^2$ -induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. <i>Nature Neuroscience</i> , 2010, 13, 812-818.	7.1	1,390
273	Protein aggregation diseases: pathogenicity and therapeutic perspectives. <i>Nature Reviews Drug Discovery</i> , 2010, 9, 237-248.	21.5	639
274	Oligomeric A $\beta^2$ in Alzheimer's Disease: Relationship to Plaque and Tangle Pathology, <i>APOE</i> Genotype and Cerebral Amyloid Angiopathy. <i>Brain Pathology</i> , 2010, 20, 468-480.	2.1	57
275	Higher Soluble Amyloid $\beta^2$ Concentration in Frontal Cortex of Young Adults than in Normal Elderly or Alzheimer's Disease. <i>Brain Pathology</i> , 2010, 20, 787-793.	2.1	41
276	Small molecule <i> $\beta^2$ </i>-amyloid inhibitors that stabilize protofibrillar structures <i>in vitro</i> improve cognition and pathology in a mouse model of Alzheimer's disease. <i>European Journal of Neuroscience</i> , 2010, 31, 203-213.	1.2	53
277	Mitochondrial trafficking and the provision of energy and calcium buffering at excitatory synapses. <i>European Journal of Neuroscience</i> , 2010, 32, 231-240.	1.2	132
278	The turn formation at positions 22 and 23 in the 42-mer amyloid $\beta^2$ peptide: The emerging role in the pathogenesis of Alzheimer's disease. <i>Geriatrics and Gerontology International</i> , 2010, 10, S169-79.	0.7	19
279	Simulation of Two Dimensional Ultraviolet (2DUV) Spectroscopy of Amyloid Fibrils. <i>Nature Precedings</i> , 2010, , .	0.1	0
280	The central role of T-cell memory in Alzheimer's disease vaccination. <i>Ageing Research</i> , 2010, 1, 5.	0.8	1

#	ARTICLE	IF	CITATIONS
281	Cerebrospinal Fluid from Alzheimer's Disease Patients Promotes Amyloid $\beta$ -Protein Oligomerization. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 81-86.	1.2	9
282	Synapses, synaptic activity and intraneuronal $A\beta$ in Alzheimer's disease. <i>Frontiers in Aging Neuroscience</i> , 2010, 2, .	1.7	40
283	Are NSAIDs useful to treat Alzheimer's disease or mild cognitive impairment?. <i>Frontiers in Aging Neuroscience</i> , 2010, 2, .	1.7	119
284	How do soluble oligomers of amyloid $\beta$ -protein impair hippocampal synaptic plasticity?. <i>Frontiers in Cellular Neuroscience</i> , 2010, 4, 5.	1.8	27
285	Transgenic Expression of the Amyloid- $\beta$ Precursor Protein-Intracellular Domain Does Not Induce Alzheimer's Disease-Like Traits In Vivo. <i>PLoS ONE</i> , 2010, 5, e11609.	1.1	23
286	Amyloid- $\beta$ Oligomer Specificity Mediated by the IgM Isotype - Implications for a Specific Protective Mechanism Exerted by Endogenous Auto-Antibodies. <i>PLoS ONE</i> , 2010, 5, e13928.	1.1	53
287	Multiple Events Lead to Dendritic Spine Loss in Triple Transgenic Alzheimer's Disease Mice. <i>PLoS ONE</i> , 2010, 5, e15477.	1.1	145
288	$\beta$ -Amyloid 1-42 Oligomers Impair Function of Human Embryonic Stem Cell-Derived Forebrain Cholinergic Neurons. <i>PLoS ONE</i> , 2010, 5, e15600.	1.1	47
289	The Concentration of Soluble Extracellular Amyloid- $\beta$ Protein in Acute Brain Slices from CRND8 Mice. <i>PLoS ONE</i> , 2010, 5, e15709.	1.1	48
290	Cognitive Deficits Associated with Alteration of Synaptic Metaplasticity Precede Plaque Deposition in $A\beta$ PP23 Transgenic Mice. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 1367-1381.	1.2	35
291	Differential effects of amyloid-beta peptide aggregation status on in vivo retinal neurotoxicity. <i>Eye and Brain</i> , 2010, 2, 121.	3.8	4
292	Brain amyloid $\beta$ ; protein and memory disruption in Alzheimer's disease. <i>Neuropsychiatric Disease and Treatment</i> , 2010, 6, 605.	1.0	22
293	Centro de Biología Molecular "Severo Ochoa": A Center for Basic Research into Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 325-335.	1.2	0
294	Amyloid- $\beta$ ; Immunotherapy for Alzheimer's Disease. <i>CNS and Neurological Disorders - Drug Targets</i> , 2010, 9, 197-206.	0.8	80
295	Are $\beta$ -secretase inhibitors detrimental for Alzheimer's disease patients?. <i>Journal of Alzheimer's Disease</i> , 2010, 22, 401-404.	1.2	10
296	Modeling Presenilin-Dependent Familial Alzheimer's Disease: Emphasis on Presenilin Substrate-Mediated Signaling and Synaptic Function. <i>International Journal of Alzheimer's Disease</i> , 2010, 2010, 1-11.	1.1	25
297	Alzheimer's Disease: A General Introduction and Pathomechanism. <i>Journal of Alzheimer's Disease</i> , 2010, 22, S5-S19.	1.2	143
298	Protein homeostasis and aging in neurodegeneration. <i>Journal of Cell Biology</i> , 2010, 190, 719-729.	2.3	336

#	ARTICLE	IF	CITATIONS
299	Î2-Secretase Inhibitor Potency Is Decreased by Aberrant Î2-Cleavage Location of the "Swedish Mutant" Amyloid Precursor Protein. <i>Journal of Biological Chemistry</i> , 2010, 285, 1634-1642.	1.6	33
300	Amyloid Î2-Protein Dimers Rapidly Form Stable Synaptotoxic Protofibrils. <i>Journal of Neuroscience</i> , 2010, 30, 14411-14419.	1.7	232
301	ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing ApoE receptor recycling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 12011-12016.	3.3	304
302	Estrogen Actions in the Brain and the Basis for Differential Action in Men and Women: A Case for Sex-Specific Medicines. <i>Pharmacological Reviews</i> , 2010, 62, 155-198.	7.1	567
303	Î2-Amyloid Causes Depletion of Synaptic Vesicles Leading to Neurotransmission Failure. <i>Journal of Biological Chemistry</i> , 2010, 285, 2506-2514.	1.6	153
304	Metabolic Compensation and Depression in Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010, 29, 37-45.	0.7	18
305	Enrichment of cholesterol in microdissected Alzheimer's disease senile plaques as assessed by mass spectrometry. <i>Journal of Lipid Research</i> , 2010, 51, 598-605.	2.0	95
306	Danish dementia mice suggest that loss of function and not the amyloid cascade causes synaptic plasticity and memory deficits. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 20822-20827.	3.3	62
307	Genetic reduction of striatal-enriched tyrosine phosphatase (STEP) reverses cognitive and cellular deficits in an Alzheimer's disease mouse model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 19014-19019.	3.3	179
308	Inherent Anti-amyloidogenic Activity of Human Immunoglobulin Î3 Heavy Chains. <i>Journal of Biological Chemistry</i> , 2010, 285, 1066-1074.	1.6	18
309	The Large Hydrophilic Loop of Presenilin 1 Is Important for Regulating Î3-Secretase Complex Assembly and Dictating the Amyloid Î2 Peptide (AÎ2) Profile without Affecting Notch Processing*. <i>Journal of Biological Chemistry</i> , 2010, 285, 8527-8536.	1.6	13
310	Inhibitors of Catalase-Amyloid Interactions Protect Cells from Î2-Amyloid-Induced Oxidative Stress and Toxicity. <i>Journal of Biological Chemistry</i> , 2010, 285, 38933-38943.	1.6	92
311	High-molecular-weight Î2-Amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. <i>FASEB Journal</i> , 2010, 24, 2716-2726.	0.2	230
312	Complex environment experience rescues impaired neurogenesis, enhances synaptic plasticity, and attenuates neuropathology in familial Alzheimer's disease-linked APP <sup>swe</sup> /PS1 <sup>E9</sup> mice. <i>FASEB Journal</i> , 2010, 24, 1667-1681.	0.2	162
313	Group II Metabotropic Glutamate Receptor Stimulation Triggers Production and Release of Alzheimer's Amyloid Î2 <sub>42</sub> from Isolated Intact Nerve Terminals. <i>Journal of Neuroscience</i> , 2010, 30, 3870-3875.	1.7	78
314	PI3 kinase signaling is involved in AÎ2-induced memory loss in <i>Drosophila</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 7060-7065.	3.3	111
315	Generation and Therapeutic Efficacy of Highly Oligomer-Specific Î2-Amyloid Antibodies. <i>Journal of Neuroscience</i> , 2010, 30, 10369-10379.	1.7	97
316	Inhibition of Calcineurin-mediated Endocytosis and Î±-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptors Prevents Amyloid Î2 Oligomer-induced Synaptic Disruption. <i>Journal of Biological Chemistry</i> , 2010, 285, 7619-7632.	1.6	158

#	ARTICLE	IF	CITATIONS
317	Age-Related Progressive Synaptic Dysfunction: The Critical Role of Presenilin 1. <i>Reviews in the Neurosciences</i> , 2010, 21, 239-50.	1.4	10
318	Antibodies Targeted to the Brain with Image-Guided Focused Ultrasound Reduces Amyloid- $\beta^2$ Plaque Load in the TgCRND8 Mouse Model of Alzheimer's Disease. <i>PLoS ONE</i> , 2010, 5, e10549.	1.1	319
319	Lewy Body Dementia. , 2010, , 705-705.		0
320	Identification of Low Molecular Weight Pyroglutamate A $\beta^2$ Oligomers in Alzheimer Disease. <i>Journal of Biological Chemistry</i> , 2010, 285, 41517-41524.	1.6	91
321	Alzheimer's Disease and the Amyloid- $\beta^2$ Peptide. <i>Journal of Alzheimer's Disease</i> , 2010, 19, 311-323.	1.2	1,270
322	Molecular mechanisms of neurodegeneration in Alzheimer's disease. <i>Human Molecular Genetics</i> , 2010, 19, R12-R20.	1.4	561
323	Reimagining Alzheimer's Diseaseâ€”An Age-Based Hypothesis. <i>Journal of Neuroscience</i> , 2010, 30, 16755-16762.	1.7	330
324	Fibrillar Oligomers Nucleate the Oligomerization of Monomeric Amyloid $\beta^2$ but Do Not Seed Fibril Formation. <i>Journal of Biological Chemistry</i> , 2010, 285, 6071-6079.	1.6	143
325	Expression of $\beta^2$ -Amyloid Induced Age-Dependent Presynaptic and Axonal Changes in <i>Drosophila</i> . <i>Journal of Neuroscience</i> , 2010, 30, 1512-1522.	1.7	120
326	Single-cell mechanics provides a sensitive and quantitative means for probing amyloid- $\beta^2$ peptide and neuronal cell interactions. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 13872-13877.	3.3	65
327	A Mouse Model of Amyloid $\beta^2$ Oligomers: Their Contribution to Synaptic Alteration, Abnormal Tau Phosphorylation, Glial Activation, and Neuronal Loss<i>In Vivo</i>. <i>Journal of Neuroscience</i> , 2010, 30, 4845-4856.	1.7	348
328	Binding of amyloid $\beta^2$ peptide to $\beta^2$ <sub>2</sub> adrenergic receptor induces PKAâ€”dependent AMPA receptor hyperactivity. <i>FASEB Journal</i> , 2010, 24, 3511-3521.	0.2	73
329	Microglial Receptor for Advanced Glycation End Product-Dependent Signal Pathway Drives $\beta^2$ -Amyloid-Induced Synaptic Depression and Long-Term Depression Impairment in Entorhinal Cortex. <i>Journal of Neuroscience</i> , 2010, 30, 11414-11425.	1.7	101
330	Adult Neurogenesis: A Potential Tool for Early Diagnosis in Alzheimer's Disease?. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 395-408.	1.2	32
331	Astrocytes in Alzheimer's Disease: Emerging Roles in Calcium Dysregulation and Synaptic Plasticity. <i>Journal of Alzheimer's Disease</i> , 2010, 22, 699-714.	1.2	78
332	Stabilization of neurotoxic Alzheimer amyloid- $\beta^2$ oligomers by protein engineering. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 15595-15600.	3.3	304
333	Synthetic amyloid- $\beta^2$ oligomers impair long-term memory independently of cellular prion protein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 2295-2300.	3.3	435
334	Amyloid- $\beta^2$ as a Modulator of Synaptic Plasticity. <i>Journal of Alzheimer's Disease</i> , 2010, 22, 741-763.	1.2	225

#	ARTICLE	IF	CITATIONS
335	Glutamate carboxypeptidase II: an amyloid peptide-degrading enzyme with physiological function in the brain. <i>FASEB Journal</i> , 2010, 24, 4491-4502.	0.2	29
336	Blocking ADAM10 synaptic trafficking generates a model of sporadic Alzheimer's disease. <i>Brain</i> , 2010, 133, 3323-3335.	3.7	71
337	ADF/Cofilin-Actin Rods in Neurodegenerative Diseases. <i>Current Alzheimer Research</i> , 2010, 7, 241-250.	0.7	141
338	Molecular Structures of Quiescently Grown and Brain-Derived Polymorphic Fibrils of the Alzheimer Amyloid A $\beta$ 29-40 Peptide: A Comparison to Agitated Fibrils. <i>PLoS Computational Biology</i> , 2010, 6, e1000693.	1.5	54
339	Targeted Hydrolysis of Beta-Amyloid with Engineered Antibody Fragments. <i>Current Alzheimer Research</i> , 2010, 7, 214-222.	0.7	10
340	Effects of the English (H6R) and Tottori (D7N) Familial Alzheimer Disease Mutations on Amyloid $\beta$ 2-Protein Assembly and Toxicity. <i>Journal of Biological Chemistry</i> , 2010, 285, 23186-23197.	1.6	131
341	Amyloid $\beta$ Oligomers Decrease Hippocampal Spontaneous Network Activity in an Age-Dependent Manner. <i>Current Alzheimer Research</i> , 2010, 7, 453-462.	0.7	23
342	Sequestration of the A $\beta$ 2 Peptide Prevents Toxicity and Promotes Degradation In Vivo. <i>PLoS Biology</i> , 2010, 8, e1000334.	2.6	70
343	Diabetes NEP-Like Endopeptidases and Alzheimers Disease. <i>Current Alzheimer Research</i> , 2010, 7, 223-229.	0.7	21
344	Globular state in the oligomers formed by A $\beta$ 2 peptides. <i>Journal of Chemical Physics</i> , 2010, 132, 225101.	1.2	7
345	Proteases and Proteolysis in Alzheimer Disease: A Multifactorial View on the Disease Process. <i>Physiological Reviews</i> , 2010, 90, 465-494.	13.1	389
346	The presence of sodium dodecyl sulphate-stable A $\beta$ 2 dimers is strongly associated with Alzheimer-type dementia. <i>Brain</i> , 2010, 133, 1328-1341.	3.7	229
347	Fibril fragmentation in amyloid assembly and cytotoxicity. <i>Prion</i> , 2010, 4, 20-25.	0.9	106
348	Nitric Oxide: Target for Therapeutic Strategies in Alzheimers Disease. <i>Current Pharmaceutical Design</i> , 2010, 16, 2837-2850.	0.9	34
349	Prolonged Exposure of Cortical Neurons to Oligomeric Amyloid- $\beta$ 2 Impairs NMDA Receptor Function Via NADPH Oxidase-Mediated ROS Production: Protective Effect of Green Tea (-)-Epigallocatechin-3-Gallate. <i>ASN Neuro</i> , 2010, 3, AN20100025.	1.5	81
350	Neuroinflammation, Oxidative Stress and the Pathogenesis of Alzheimers Disease. <i>Current Pharmaceutical Design</i> , 2010, 16, 2766-2778.	0.9	547
351	Insights from <i>Drosophila</i> models of Alzheimer's disease. <i>Biochemical Society Transactions</i> , 2010, 38, 988-992.	1.6	24
353	A $\beta$ 2-Mediated NMDA Receptor Endocytosis in Alzheimer's Disease Involves Ubiquitination of the Tyrosine Phosphatase STEP61. <i>Journal of Neuroscience</i> , 2010, 30, 5948-5957.	1.7	198

#	ARTICLE	IF	CITATIONS
354	Isolation of Low-n Amyloid $\beta$ -Protein Oligomers from Cultured Cells, CSF, and Brain. <i>Methods in Molecular Biology</i> , 2010, 670, 33-44.	0.4	54
355	APP Intracellular Domain Impairs Adult Neurogenesis in Transgenic Mice by Inducing Neuroinflammation. <i>PLoS ONE</i> , 2010, 5, e11866.	1.1	95
356	Small Molecule Microarrays Enable the Discovery of Compounds That Bind the Alzheimer's $\beta$ Peptide and Reduce its Cytotoxicity. <i>Journal of the American Chemical Society</i> , 2010, 132, 17015-17022.	6.6	80
357	Association Thermodynamics and Conformational Stability of $\beta$ -Sheet Amyloid $\beta$ (17-42) Oligomers: Effects of E22Q (Dutch) Mutation and Charge Neutralization. <i>Biophysical Journal</i> , 2010, 98, 282-296.	0.2	49
358	Intrinsic Determinants of Neurotoxic Aggregate Formation by the Amyloid $\beta$ Peptide. <i>Biophysical Journal</i> , 2010, 98, 1677-1684.	0.2	45
359	Molecular Dynamics Simulations of Anti-Aggregation Effect of Ibuprofen. <i>Biophysical Journal</i> , 2010, 98, 2662-2670.	0.2	26
360	Mapping Conformational Ensembles of $\beta$ Oligomers in Molecular Dynamics Simulations. <i>Biophysical Journal</i> , 2010, 99, 1949-1958.	0.2	41
361	Measurement of the Attachment and Assembly of Small Amyloid- $\beta$ Oligomers on Live Cell Membranes at Physiological Concentrations Using Single-Molecule Tools. <i>Biophysical Journal</i> , 2010, 99, 1969-1975.	0.2	62
362	<i>Neurovascular Unit.</i> , 2010, , 877-877.		0
363	Effects of Congo Red on $\beta$ <sub>1-40</sub> Fibril Formation Process and Morphology. <i>ACS Chemical Neuroscience</i> , 2010, 1, 315-324.	1.7	49
364	Calcium Signaling and Amyloid Toxicity in Alzheimer Disease. <i>Journal of Biological Chemistry</i> , 2010, 285, 12463-12468.	1.6	343
365	Sex- and brain region-specific acceleration of $\beta$ -amyloidogenesis following behavioral stress in a mouse model of Alzheimer's disease. <i>Molecular Brain</i> , 2010, 3, 34.	1.3	104
366	Intravenous Immunoglobulins as a Treatment for Alzheimer's Disease. <i>Drugs</i> , 2010, 70, 513-528.	4.9	101
367	A NH2 Tau Fragment Targets Neuronal Mitochondria at AD Synapses: Possible Implications for Neurodegeneration. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 445-470.	1.2	92
368	The Mitochondrial Secret(ase) of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2010, 20, S381-S400.	1.2	28
369	CNS expression of anti-inflammatory cytokine interleukin-4 attenuates Alzheimer's disease-like pathogenesis in APP+PS1 bigenic mice. <i>FASEB Journal</i> , 2010, 24, 3093-3102.	0.2	187
370	Chemical Probes That Selectively Recognize the Earliest $\beta$ Oligomers in Complex Mixtures. <i>Journal of the American Chemical Society</i> , 2010, 132, 17655-17657.	6.6	33
371	Simultaneous Single-Molecule Fluorescence and Conductivity Studies Reveal Distinct Classes of $\beta$ Species on Lipid Bilayers. <i>Biochemistry</i> , 2010, 49, 3031-3039.	1.2	49



#	ARTICLE	IF	CITATIONS
372	Biophysical Characterization of A $\beta$ <sup>242</sup> C-Terminal Fragments: Inhibitors of A $\beta$ <sup>242</sup> Neurotoxicity. <i>Biochemistry</i> , 2010, 49, 1259-1267.	1.2	49
373	Memory Impairment in Transgenic Alzheimer Mice Requires Cellular Prion Protein. <i>Journal of Neuroscience</i> , 2010, 30, 6367-6374.	1.7	374
374	Nonsteroidal Anti-inflammatory Drug Naproxen Destabilizes A $\beta$ <sup>2</sup> Amyloid Fibrils: A Molecular Dynamics Investigation. <i>Journal of Physical Chemistry B</i> , 2010, 114, 15394-15402.	1.2	24
375	Can Alzheimer disease be prevented by amyloid- $\beta$ <sup>2</sup> immunotherapy?. <i>Nature Reviews Neurology</i> , 2010, 6, 108-119.	4.9	329
376	Amyloid- $\beta$ <sup>242</sup> Oligomer Structures from Fibrils: A Systematic Molecular Dynamics Study. <i>Journal of Physical Chemistry B</i> , 2010, 114, 2219-2226.	1.2	49
377	Lead-induced accumulation of $\beta$ -amyloid in the choroid plexus: Role of low density lipoprotein receptor protein-1 and protein kinase C. <i>NeuroToxicology</i> , 2010, 31, 524-532.	1.4	35
378	Neurogenesis in mouse models of Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2010, 1802, 872-880.	1.8	84
379	In-vivo visualization of key molecular processes involved in Alzheimer's disease pathogenesis: Insights from neuroimaging research in humans and rodent models. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2010, 1802, 373-388.	1.8	20
380	Murine models of Alzheimer's disease and their use in developing immunotherapies. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2010, 1802, 847-859.	1.8	71
381	New insights into the role of mitochondrial dysfunction and protein aggregation in Parkinson's disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2010, 1802, 935-941.	1.8	54
382	Surface-induced phase separation of a sphingomyelin/cholesterol/ganglioside GM1-planar bilayer on mica surfaces and microdomain molecular conformation that accelerates A $\beta$ <sup>2</sup> oligomerization. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2010, 1798, 1090-1099.	1.4	45
383	RS-0406 Arrests Amyloid- $\beta$ <sup>2</sup> Oligomer-Induced Behavioural Deterioration In Vivo. <i>Behavioural Brain Research</i> , 2010, 210, 32-37.	1.2	17
384	Rapamycin promotes $\beta$ -amyloid production via ADAM-10 inhibition. <i>Biochemical and Biophysical Research Communications</i> , 2010, 398, 337-341.	1.0	56
385	Amyloid formation and disaggregation of $\beta$ <sup>1±</sup> -synuclein and its tandem repeat ( $\beta$ <sup>1±</sup> -TR). <i>Biochemical and Biophysical Research Communications</i> , 2010, 400, 531-536.	1.0	36
386	Dendritic Function of Tau Mediates Amyloid- $\beta$ <sup>2</sup> Toxicity in Alzheimer's Disease Mouse Models. <i>Cell</i> , 2010, 142, 387-397.	13.5	1,563
387	Communication breaks-Down: From neurodevelopment defects to cognitive disabilities in Down syndrome. <i>Progress in Neurobiology</i> , 2010, 91, 1-22.	2.8	109
388	Group 1 mGluR-Dependent Synaptic Long-Term Depression: Mechanisms and Implications for Circuitry and Disease. <i>Neuron</i> , 2010, 65, 445-459.	3.8	529
389	Deleterious Effects of Amyloid $\beta$ <sup>2</sup> Oligomers Acting as an Extracellular Scaffold for mGluR5. <i>Neuron</i> , 2010, 66, 739-754.	3.8	413



#	ARTICLE	IF	CITATIONS
390	Probing the Biology of Alzheimer's Disease in Mice. <i>Neuron</i> , 2010, 66, 631-645.	3.8	382
391	Fibrinogen and $\beta$ -Amyloid Association Alters Thrombosis and Fibrinolysis: A Possible Contributing Factor to Alzheimer's Disease. <i>Neuron</i> , 2010, 66, 695-709.	3.8	283
392	Transsynaptic Progression of Amyloid- $\beta$ -Induced Neuronal Dysfunction within the Entorhinal-Hippocampal Network. <i>Neuron</i> , 2010, 68, 428-441.	3.8	279
393	The functional neurophysiology of the amyloid precursor protein (APP) processing pathway. <i>Neuropharmacology</i> , 2010, 59, 243-267.	2.0	56
394	ADDLs and the signaling web that leads to Alzheimer's disease. <i>Neuropharmacology</i> , 2010, 59, 230-242.	2.0	96
395	Valproic acid enhances microglial phagocytosis of amyloid- $\beta$ 42. <i>Neuroscience</i> , 2010, 169, 505-515.	1.1	49
396	Size-dependent neurotoxicity of $\beta$ -amyloid oligomers. <i>Archives of Biochemistry and Biophysics</i> , 2010, 496, 84-92.	1.4	157
397	Brain Atrophy in Healthy Aging Is Related to CSF Levels of $\beta$ 1-42. <i>Cerebral Cortex</i> , 2010, 20, 2069-2079.	1.6	102
398	Blood-Borne Amyloid- $\beta$ Dimer Correlates with Clinical Markers of Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2010, 30, 6315-6322.	1.7	70
399	Probing the Nucleus Model for Oligomer Formation during Insulin Amyloid Fibrillogenesis. <i>Biophysical Journal</i> , 2010, 99, 3979-3985.	0.2	53
400	REVIEW: $\beta$ -Secretase Inhibitors for the Treatment of Alzheimer's Disease: The Current State. <i>CNS Neuroscience and Therapeutics</i> , 2010, 16, 272-284.	1.9	63
401	$\beta$ 42 Detection in CSF of Alzheimer's disease is influenced by temperature: Indication of reversible $\beta$ 42 aggregation?. <i>Experimental Neurology</i> , 2010, 223, 371-376.	2.0	44
402	Targeting $\beta$ and tau in Alzheimer's disease, an early interim report. <i>Experimental Neurology</i> , 2010, 223, 252-266.	2.0	80
403	$\beta$ exacerbates the neuronal dysfunction caused by human tau expression in a <i>Drosophila</i> model of Alzheimer's disease. <i>Experimental Neurology</i> , 2010, 223, 401-409.	2.0	81
404	Influence of the Solvent on the Self-Assembly of a Modified Amyloid Beta Peptide Fragment. II. NMR and Computer Simulation Investigation. <i>Journal of Physical Chemistry B</i> , 2010, 114, 940-951.	1.2	77
405	Simulation of Two-Dimensional Ultraviolet Spectroscopy of Amyloid Fibrils. <i>Journal of Physical Chemistry B</i> , 2010, 114, 12150-12156.	1.2	20
406	Lipoprotein receptors – an evolutionarily ancient multifunctional receptor family. <i>Biological Chemistry</i> , 2010, 391, 1341-63.	1.2	103
407	Amyloid- $\beta$ and Mitochondria in Aging and Alzheimer's Disease: Implications for Synaptic Damage and Cognitive Decline. <i>Journal of Alzheimer's Disease</i> , 2010, 20, S499-S512.	1.2	203

#	ARTICLE	IF	CITATIONS
408	PKC and Insulin Pathways in Memory Storage: Targets for Synaptogenesis, Anti-apoptosis, and the Treatment of AD. <i>Research and Perspectives in Alzheimer's Disease</i> , 2010, , 153-182.	0.1	2
409	Diabetes, Insulin and Alzheimer's Disease. <i>Research and Perspectives in Alzheimer's Disease</i> , 2010, , .	0.1	7
410	Mechanisms of Synapse and Dendrite Maintenance and Their Disruption in Psychiatric and Neurodegenerative Disorders. <i>Annual Review of Neuroscience</i> , 2010, 33, 349-378.	5.0	217
411	The Pathological Cross Talk Between Apolipoprotein E and Amyloid- $\beta$ Peptide in Alzheimer's Disease: Emerging Gene-Based Therapeutic Approaches. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 35-48.	1.2	14
412	Ocular Biomarkers for Early Detection of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2010, 22, 1-16.	1.2	101
413	Progressive Age-Related Impairment of the Late Long-Term Potentiation in Alzheimer's Disease Presenilin-1 Mutant Knock-in Mice. <i>Journal of Alzheimer's Disease</i> , 2010, 19, 1021-1033.	1.2	44
414	LPYFDa Neutralizes Amyloid- $\beta$ -Induced Memory Impairment and Toxicity. <i>Journal of Alzheimer's Disease</i> , 2010, 19, 991-1005.	1.2	29
415	The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: oligomer size or conformation?. <i>Alzheimer's Research and Therapy</i> , 2010, 2, 12.	3.0	131
416	Differently Selected $\alpha$ -Enantiomeric Peptides Act on Different $A\beta$ Species. <i>Rejuvenation Research</i> , 2010, 13, 202-205.	0.9	22
417	Detecting $A\beta^{*56}$ Oligomers in Brain Tissues. <i>Methods in Molecular Biology</i> , 2010, 670, 45-56.	0.4	35
418	Amyloid $\beta$ Induces the Morphological Neurodegenerative Triad of Spine Loss, Dendritic Simplification, and Neuritic Dystrophies through Calcineurin Activation. <i>Journal of Neuroscience</i> , 2010, 30, 2636-2649.	1.7	328
419	Design of small molecules that target metal- $A\beta$ species and regulate metal-induced $A\beta$ aggregation and neurotoxicity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 21990-21995.	3.3	253
420	Substrate-Controlled and Organocatalytic Asymmetric Synthesis of Carbocyclic Amino Acid Dipeptide Mimetics. <i>Journal of Organic Chemistry</i> , 2010, 75, 2861-2876.	1.7	23
421	Causes versus effects: the increasing complexities of Alzheimer's disease pathogenesis. <i>Expert Review of Neurotherapeutics</i> , 2010, 10, 683-691.	1.4	61
422	Soluble amyloid $\beta$ -protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 5819-5824.	3.3	770
423	Exploring the Reactions of $\beta$ -Amyloid ( $A\beta$ ) Peptide 1-28 with AlIII and FeIII Ions. <i>Inorganic Chemistry</i> , 2011, 50, 6865-6867.	1.9	42
424	A statistical mechanical approach to protein aggregation. <i>Journal of Chemical Physics</i> , 2011, 135, 235102.	1.2	9
425	Dissociation between the Processivity and Total Activity of $\beta$ -Secretase: Implications for the Mechanism of Alzheimer's Disease-Causing Presenilin Mutations. <i>Biochemistry</i> , 2011, 50, 9023-9035.	1.2	110

#	ARTICLE	IF	CITATIONS
426	Macrocyclic $\beta$ -Sheet Peptides That Inhibit the Aggregation of a Tau-Protein-Derived Hexapeptide. <i>Journal of the American Chemical Society</i> , 2011, 133, 3144-3157.	6.6	114
427	Curcuminoid Binds to Amyloid- $\beta$ 1-42 Oligomer and Fibril. <i>Journal of Alzheimer's Disease</i> , 2011, 24, 33-42.	1.2	80
428	Fluoroalcohol-Induced Modulation of the Pathway of Amyloid Protofibril Formation by Barstar. <i>Biochemistry</i> , 2011, 50, 805-819.	1.2	12
429	Neuropathological Alterations in Alzheimer Disease. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2011, 1, a006189-a006189.	2.9	2,365
430	Characterizing the Structural Behavior of Selected A $\beta$ 1-42 Monomers with Different Solubilities. <i>Journal of Physical Chemistry B</i> , 2011, 115, 4900-4910.	1.2	45
431	Single-Molecule Atomic Force Microscopy Force Spectroscopy Study of A $\beta$ 1-40 Interactions. <i>Biochemistry</i> , 2011, 50, 5154-5162.	1.2	82
432	Discovery of BIIB042, a Potent, Selective, and Orally Bioavailable $\beta$ -Secretase Modulator. <i>ACS Medicinal Chemistry Letters</i> , 2011, 2, 786-791.	1.3	25
433	Conformer-Specific Hydrogen Exchange Analysis of A $\beta$ 1-42 Oligomers by Top-Down Electron Capture Dissociation Mass Spectrometry. <i>Analytical Chemistry</i> , 2011, 83, 5386-5393.	3.2	62
434	Molecular Engineering of a Secreted, Highly Homogeneous, and Neurotoxic A $\beta$ Dimer. <i>ACS Chemical Neuroscience</i> , 2011, 2, 242-248.	1.7	27
435	Probing Amyloid Fibril Growth by Two-Dimensional Near-Ultraviolet Spectroscopy. <i>Journal of Physical Chemistry B</i> , 2011, 115, 6321-6328.	1.2	12
436	FLAsH illuminates A $\beta$ aggregation. <i>Nature Chemical Biology</i> , 2011, 7, 581-582.	3.9	6
437	Distinct Morphologies for Amyloid Beta Protein Monomer: A $\beta$ 1-40, A $\beta$ 1-42, and A $\beta$ 1-40(D23N). <i>Journal of Chemical Theory and Computation</i> , 2011, 7, 2584-2592.	2.3	77
439	Positron Emission Tomography Radiopharmaceuticals for Imaging Brain Beta-Amyloid. <i>Seminars in Nuclear Medicine</i> , 2011, 41, 283-299.	2.5	76
440	Biphasic Effects of Insulin on Islet Amyloid Polypeptide Membrane Disruption. <i>Biophysical Journal</i> , 2011, 100, 685-692.	0.2	88
441	Naproxen Interferes with the Assembly of A $\beta$ Oligomers Implicated in Alzheimer's Disease. <i>Biophysical Journal</i> , 2011, 100, 2024-2032.	0.2	23
442	Soluble A $\beta$ Oligomers Inhibit Long-Term Potentiation through a Mechanism Involving Excessive Activation of Extrasynaptic NR2B-Containing NMDA Receptors. <i>Journal of Neuroscience</i> , 2011, 31, 6627-6638.	1.7	530
443	Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: The Present and the Future. <i>Neurodegenerative Diseases</i> , 2011, 8, 413-420.	0.8	40
444	Therapeutic intervention for Alzheimer's disease with $\beta$ -secretase inhibitors: still a viable option?. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 325-341.	1.9	86

#	ARTICLE	IF	CITATIONS
445	Amyloid Precursor Protein Processing and Alzheimer's Disease. Annual Review of Neuroscience, 2011, 34, 185-204.	5.0	1,455
446	Generalization of the Prion Hypothesis to Other Neurodegenerative Diseases: An Imperfect Fit. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2011, 74, 1433-1459.	1.1	63
447	Amyloid- $\beta$ forms fibrils by nucleated conformational conversion of oligomers. Nature Chemical Biology, 2011, 7, 602-609.	3.9	352
448	Endothelin receptor antagonists: Potential in Alzheimer's disease. Pharmacological Research, 2011, 63, 525-531.	3.1	40
449	A spoonful of sugar: the application of glycopolymers in therapeutics. Polymer Chemistry, 2011, 2, 60-68.	1.9	156
450	The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nature Reviews Drug Discovery, 2011, 10, 698-712.	21.5	1,766
451	Role of Serotonin in Alzheimer's Disease. CNS Drugs, 2011, 25, 765-781.	2.7	89
452	Alterations in the Testis and Epididymis Associated With Loss of Function of the Cystatin-Related Epididymal Spermatogenic (CRES) Protein. Journal of Andrology, 2011, 32, 444-463.	2.0	22
453	Current and Emerging Drug Treatment Options for Alzheimer's Disease. Drugs, 2011, 71, 2031-2065.	4.9	196
454	Peptidyl-prolyl cis-trans isomerase Pin1 in ageing, cancer and Alzheimer disease. Expert Reviews in Molecular Medicine, 2011, 13, e21.	1.6	169
455	Extracellular and intraneuronal HMW-A $\beta$ Os represent a molecular basis of memory loss in Alzheimer's disease model mouse. Molecular Neurodegeneration, 2011, 6, 20.	4.4	32
456	Increased CSF-BACE1 Activity Associated with Decreased Hippocampus Volume in Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 25, 373-381.	1.2	50
457	Amyloid- $\beta$ Protein Oligomer at Low Nanomolar Concentrations Activates Microglia and Induces Microglial Neurotoxicity. Journal of Biological Chemistry, 2011, 286, 3693-3706.	1.6	234
458	Resolving controversies on the path to Alzheimer's therapeutics. Nature Medicine, 2011, 17, 1060-1065.	15.2	434
459	Mitochondrial $\beta$ -secretase participates in the metabolism of mitochondria-associated amyloid precursor protein. FASEB Journal, 2011, 25, 78-88.	0.2	104
460	A Universal Method for Detection of Amyloidogenic Misfolded Proteins. Biochemistry, 2011, 50, 4322-4329.	1.2	34
461	Pharmacologists and Alzheimer disease therapy: to boldly go where no scientist has gone before. Expert Opinion on Investigational Drugs, 2011, 20, 1243-1261.	1.9	44
462	Alzheimer's Disease and Frontotemporal Dementia. Methods in Molecular Biology, 2011, , .	0.4	5

#	ARTICLE	IF	CITATIONS
463	Hippocampal synaptic plasticity in Alzheimer's disease: what have we learned so far from transgenic models?. <i>Reviews in the Neurosciences</i> , 2011, 22, 373-402.	1.4	108
464	Development of Bifunctional Stilbene Derivatives for Targeting and Modulating Metal-Amyloid- $\beta$ Species. <i>Inorganic Chemistry</i> , 2011, 50, 10724-10734.	1.9	75
465	Black Tea Theaflavins Inhibit Formation of Toxic Amyloid- $\beta$ and $\alpha$ -Synuclein Fibrils. <i>Biochemistry</i> , 2011, 50, 10624-10636.	1.2	112
466	Arc/Arg3.1 Regulates an Endosomal Pathway Essential for Activity-Dependent $\beta$ -Amyloid Generation. <i>Cell</i> , 2011, 147, 615-628.	13.5	183
467	Altered dopamine modulation of LTD-like plasticity in Alzheimer's disease patients. <i>Clinical Neurophysiology</i> , 2011, 122, 703-707.	0.7	43
468	Aluminum, copper, iron and zinc differentially alter amyloid- $\beta$ 1-42 aggregation and toxicity. <i>International Journal of Biochemistry and Cell Biology</i> , 2011, 43, 877-885.	1.2	147
469	Submicromolar $\beta$ 1-42 reduces hippocampal glutamate receptors and presynaptic markers in an aggregation-dependent manner. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2011, 1812, 1664-1674.	1.8	18
470	Role of ubiquitin-proteasome-mediated proteolysis in nervous system disease. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2011, 1809, 128-140.	0.9	87
471	Soluble $\beta$ 1-42 levels correlate with cognitive deficits in the 12-month-old APPswe/PS1dE9 mouse model of Alzheimer's disease. <i>Behavioural Brain Research</i> , 2011, 222, 342-350.	1.2	88
472	Behavioural and cellular effects of exogenous amyloid- $\beta$ peptides in rodents. <i>Behavioural Brain Research</i> , 2011, 225, 623-641.	1.2	45
473	A partially folded structure of amyloid-beta(1-40) in an aqueous environment. <i>Biochemical and Biophysical Research Communications</i> , 2011, 411, 312-316.	1.0	376
474	Endoplasmic reticulum stress enhances $\beta$ 1-42-secretase activity. <i>Biochemical and Biophysical Research Communications</i> , 2011, 416, 362-366.	1.0	45
475	Nano-enabled biomarker discovery and detection. <i>Biomarkers in Medicine</i> , 2011, 5, 387-396.	0.6	18
476	Purified high molecular weight synthetic $\beta$ 1-42 and biological $\beta$ oligomers are equipotent in rapidly inducing MTT formazan exocytosis. <i>Neuroscience Letters</i> , 2011, 497, 1-5.	1.0	5
477	A three-step model for the synaptic recruitment of AMPA receptors. <i>Molecular and Cellular Neurosciences</i> , 2011, 46, 1-8.	1.0	153
478	Monte Carlo Study of the Formation and Conformational Properties of Dimers of $\beta$ 1-42 Variants. <i>Journal of Molecular Biology</i> , 2011, 410, 357-367.	2.0	50
479	Functional Links Between $\beta$ Toxicity, Endocytic Trafficking, and Alzheimer's Disease Risk Factors in Yeast. <i>Science</i> , 2011, 334, 1241-1245.	6.0	345
480	Diet and Alzheimer's disease risk factors or prevention: the current evidence. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 677-708.	1.4	231

#	ARTICLE	IF	CITATIONS
481	Routes, destinations and delays: recent advances in AMPA receptor trafficking. Trends in Neurosciences, 2011, 34, 258-268.	4.2	147
482	Presenilin mouse and zebrafish models for dementia: Focus on neurogenesis. Progress in Neurobiology, 2011, 93, 149-164.	2.8	34
483	Autoimmune and inflammatory mechanisms of CNS damage. Progress in Neurobiology, 2011, 95, 301-333.	2.8	62
484	Protection against A $\beta$ -mediated rapid disruption of synaptic plasticity and memory by memantine. Neurobiology of Aging, 2011, 32, 614-623.	1.5	65
485	Maturation of BRI2 generates a specific inhibitor that reduces APP processing at the plasma membrane and in endocytic vesicles. Neurobiology of Aging, 2011, 32, 1400-1408.	1.5	79
486	Alzheimer's disease as homeostatic responses to age-related myelin breakdown. Neurobiology of Aging, 2011, 32, 1341-1371.	1.5	454
487	Cognitive effects of cell-derived and synthetically derived A $\beta$ oligomers. Neurobiology of Aging, 2011, 32, 1784-1794.	1.5	124
488	A $\beta$ oligomers inhibit synapse remodelling necessary for memory consolidation. Neurobiology of Aging, 2011, 32, 2211-2218.	1.5	74
489	Early neuronal dysfunction by amyloid $\beta$ oligomers depends on activation of NR2B-containing NMDA receptors. Neurobiology of Aging, 2011, 32, 2219-2228.	1.5	223
490	Carvedilol as a potential novel agent for the treatment of Alzheimer's disease. Neurobiology of Aging, 2011, 32, 2321.e1-2321.e12.	1.5	54
491	Early Functional Impairment of Sensory-Motor Connectivity in a Mouse Model of Spinal Muscular Atrophy. Neuron, 2011, 69, 453-467.	3.8	320
492	The Many Faces of Tau. Neuron, 2011, 70, 410-426.	3.8	734
493	Ethanol protects cultured neurons against amyloid- $\beta$ and $\beta$ -synuclein-induced synapse damage. Neuropharmacology, 2011, 61, 1406-1412.	2.0	29
494	Hippocampal tauopathy in tau transgenic mice coincides with impaired hippocampus-dependent learning and memory, and attenuated late-phase long-term depression of synaptic transmission. Neurobiology of Learning and Memory, 2011, 95, 296-304.	1.0	93
495	The A $\beta$ oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease. Neurobiology of Learning and Memory, 2011, 96, 529-543.	1.0	386
496	Amyloid beta 1-42 in cerebrospinal fluid is associated with cognitive plasticity. Psychiatry Research, 2011, 190, 132-136.	1.7	2
497	Misfolded protein aggregates: Mechanisms, structures and potential for disease transmission. Seminars in Cell and Developmental Biology, 2011, 22, 482-487.	2.3	180
498	The synapse and brain function. Seminars in Cell and Developmental Biology, 2011, 22, 488-491.	2.3	1

#	ARTICLE	IF	CITATIONS
499	Isolating Toxic Insulin Amyloid Reactive Species that Lack $\beta$ -Sheets and Have Wide pH Stability. <i>Biophysical Journal</i> , 2011, 100, 2792-2800.	0.2	21
500	Synthesis and characterization of IMPY derivatives that regulate metal-induced amyloid- $\beta$ aggregation. <i>Metallomics</i> , 2011, 3, 284.	1.0	36
501	Insight into Amyloid Structure Using Chemical Probes. <i>Chemical Biology and Drug Design</i> , 2011, 77, 399-411.	1.5	139
502	Amyloid $\beta$ -Peptide Oligomers Stimulate RyR-Mediated $Ca^{2+}$ Release Inducing Mitochondrial Fragmentation in Hippocampal Neurons and Prevent RyR-Mediated Dendritic Spine Remodeling Produced by BDNF. <i>Antioxidants and Redox Signaling</i> , 2011, 14, 1209-1223.	2.5	118
503	Effects of sex hormones on Alzheimer's disease-associated $\beta$ -amyloid oligomer formation in vitro. <i>Experimental Neurology</i> , 2011, 228, 298-302.	2.0	29
504	Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging's Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2011, 7, 280-292.	0.4	5,550
505	When Will Alzheimer's Disease be Cured? A Pharmaceutical Perspective. <i>Journal of Alzheimer's Disease</i> , 2011, 24, 43-52.	1.2	17
506	CSF Tau Levels Influence Cortical Plasticity in Alzheimer's Disease Patients. <i>Journal of Alzheimer's Disease</i> , 2011, 26, 181-186.	1.2	38
507	Passive (Amyloid- $\beta$ ) Immunotherapy Attenuates Monoaminergic Axonal Degeneration in the $A\beta$ PPswe/PS1dE9 Mice. <i>Journal of Alzheimer's Disease</i> , 2011, 23, 271-279.	1.2	16
508	Hypothesis: Soluble $A\beta$ Oligomers in Association with Redox-Active Metal Ions Are the Optimal Generators of Reactive Oxygen Species in Alzheimer's Disease. <i>International Journal of Alzheimer's Disease</i> , 2011, 2011, 1-6.	1.1	30
509	A Comparative Study of Five Mouse Models of Alzheimer's Disease: Cell Cycle Events Reveal New Insights into Neurons at Risk for Death. <i>International Journal of Alzheimer's Disease</i> , 2011, 2011, 1-10.	1.1	39
512	A multi nutrient concept to enhance synapse formation and function: science behind a medical food for Alzheimer's disease. <i>Oleagineux Corps Gras Lipides</i> , 2011, 18, 267-270.	0.2	4
515	Formation of the 42-mer Amyloid Radical and the Therapeutic Role of Superoxide Dismutase in Alzheimer's Disease. <i>Journal of Amino Acids</i> , 2011, 2011, 1-10.	5.8	13
516	Structure and Toxicity of the Prefibrillar Aggregation States of Beta Peptides in Alzheimer's Disease. , 2011, , .		0
517	Structural and Toxic Properties of Protein Aggregates: Towards a Molecular Understanding of Alzheimer's Disease. , 0, , .		0
518	Redox Proteomics Analysis of Brains from Subjects with Amnesic Mild Cognitive Impairment Compared to Brains from Subjects with Preclinical Alzheimer's Disease: Insights into Memory Loss in MCI. <i>Journal of Alzheimer's Disease</i> , 2011, 23, 257-269.	1.2	85
519	A Longitudinal Study of Behavioral Deficits in an $A\beta$ PP Transgenic Mouse Model of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 25, 231-243.	1.2	54
520	E22 $\Delta$ Mutation in Amyloid- $\beta$ -Protein Promotes $\beta$ -Sheet Transformation, Radical Production, and Synaptotoxicity, But Not Neurotoxicity. <i>International Journal of Alzheimer's Disease</i> , 2011, 2011, 1-8.	1.1	15



#	ARTICLE	IF	CITATIONS
521	Soluble A $\beta$ <sup>1-40</sup> Peptide Increases Excitatory Neurotransmission and Induces Epileptiform Activity in Hippocampal Neurons. <i>Journal of Alzheimer's Disease</i> , 2011, 23, 673-687.	1.2	30
522	Detection of Soluble Amyloid- $\beta$ Oligomers and Insoluble High-Molecular-Weight Particles in CSF: Development of Methods with Potential for Diagnosis and Therapy Monitoring of Alzheimer's Disease. <i>International Journal of Alzheimer's Disease</i> , 2011, 2011, 1-8.	1.1	17
523	Recent Development of Bifunctional Small Molecules to Study Metal-Amyloid- $\beta$ Species in Alzheimer's Disease. <i>International Journal of Alzheimer's Disease</i> , 2011, 2011, 1-9.	1.1	35
524	Homeostatic Disinhibition in the Aging Brain and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 24, 15-24.	1.2	49
525	Lipid Rafts: Linking Alzheimer's Amyloid- $\beta$ Production, Aggregation, and Toxicity at Neuronal Membranes. <i>International Journal of Alzheimer's Disease</i> , 2011, 2011, 1-14.	1.1	156
526	Long-Term Potentiation at CA3-CA1 Hippocampal Synapses with Special Emphasis on Aging, Disease, and Stress. <i>Frontiers in Aging Neuroscience</i> , 2011, 3, 7.	1.7	115
527	The Role of Striatal-Enriched Protein Tyrosine Phosphatase (STEP) in Cognition. <i>Frontiers in Neuroanatomy</i> , 2011, 5, 47.	0.9	37
528	Amyloid- $\beta$ -Induced Amyloid- $\beta$ Secretion: A Possible Feed-Forward Mechanism in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 24, 681-691.	1.2	30
529	Amyloid Oligomer Neurotoxicity, Calcium Dysregulation, and Lipid Rafts. <i>International Journal of Alzheimer's Disease</i> , 2011, 2011, 1-17.	1.1	34
530	The Influence of Chronic Cerebral Hypoperfusion on Cognitive Function and Amyloid $\beta$ Metabolism in APP Overexpressing Mice. <i>PLoS ONE</i> , 2011, 6, e16567.	1.1	68
531	Peripheral Delivery of a CNS Targeted, Metallo-Protease Reduces A $\beta$ Toxicity in a Mouse Model of Alzheimer's Disease. <i>PLoS ONE</i> , 2011, 6, e16575.	1.1	60
532	Chronic Delivery of Antibody Fragments Using Immunoisolated Cell Implants as a Passive Vaccination Tool. <i>PLoS ONE</i> , 2011, 6, e18268.	1.1	7
533	Chronic Intranasal Treatment with an Anti-A $\beta$ <sup>1-40</sup> scFv Antibody Ameliorates Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease. <i>PLoS ONE</i> , 2011, 6, e18296.	1.1	65
534	CDK5 Is Essential for Soluble Amyloid $\beta$ -Induced Degradation of GKAP and Remodeling of the Synaptic Actin Cytoskeleton. <i>PLoS ONE</i> , 2011, 6, e23097.	1.1	35
535	Direct Observation of Single Amyloid- $\beta$ (1-40) Oligomers on Live Cells: Binding and Growth at Physiological Concentrations. <i>PLoS ONE</i> , 2011, 6, e23970.	1.1	41
536	Intrinsic Determinants of A $\beta$ <sup>1-40</sup> pH-Dependent Self-Assembly Revealed by Combined Computational and Experimental Studies. <i>PLoS ONE</i> , 2011, 6, e24329.	1.1	26
537	Grape Seed Polyphenolic Extract Specifically Decreases A $\beta$ <sup>1-40</sup> in the Brains of Tg2576 Mice. <i>Journal of Alzheimer's Disease</i> , 2011, 26, 657-666.	1.2	49
538	&#947;-Secretase Substrates and their Implications for Drug Development in Alzheimer's Disease. <i>Current Topics in Medicinal Chemistry</i> , 2011, 11, 1513-1527.	1.0	43

#	ARTICLE	IF	CITATIONS
539	&#947;-Secretase Inhibitors and Modulators for the Treatment of Alzheimer's Disease: Disappointments and Hopes. <i>Current Topics in Medicinal Chemistry</i> , 2011, 11, 1555-1570.	1.0	168
540	Immunotherapy for Alzheimer's Disease: Rational Basis in Ongoing Clinical Trials. <i>Current Pharmaceutical Design</i> , 2011, 17, 508-520.	0.9	50
541	Solution NMR Studies of A&#946; Monomer Dynamics. <i>Protein and Peptide Letters</i> , 2011, 18, 354-361.	0.4	8
542	Brain Oligomeric $\hat{1}^2$ -Amyloid but Not Total Amyloid Plaque Burden Correlates With Neuronal Loss and Astrocyte Inflammatory Response in Amyloid Precursor Protein/Tau Transgenic Mice. <i>Journal of Neuropathology and Experimental Neurology</i> , 2011, 70, 360-376.	0.9	111
543	Aggregation State and Neurotoxic Properties of Alzheimer &#946;-Amyloid Peptide. <i>Current Protein and Peptide Science</i> , 2011, 12, 235-257.	0.7	20
544	$\hat{1}^2$ -Degrading Enzymes: Potential for Treatment of Alzheimer Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2011, 70, 944-959.	0.9	228
545	Intraneuronal $\hat{1}^2$ as a trigger for neuron loss: can this be translated into human pathology?. <i>Biochemical Society Transactions</i> , 2011, 39, 857-861.	1.6	33
546	Protective Effects of Positive Lysosomal Modulation in Alzheimer's Disease Transgenic Mouse Models. <i>PLoS ONE</i> , 2011, 6, e20501.	1.1	77
547	Age-Related Macular Degeneration (AMD): Alzheimer's Disease in the Eye?. <i>Journal of Alzheimer's Disease</i> , 2011, 24, 615-631.	1.2	211
548	Dendritic Cells Regulate Amyloid- $\hat{1}^2$ -Specific T-Cell Entry into the Brain: The Role of Perivascular Amyloid- $\hat{1}^2$ . <i>Journal of Alzheimer's Disease</i> , 2011, 27, 99-111.	1.2	25
549	Caspase-12 Activation is Involved in Amyloid- $\hat{1}^2$ Protein-Induced Synaptic Toxicity. <i>Journal of Alzheimer's Disease</i> , 2011, 26, 467-476.	1.2	29
550	Low $\hat{1}^2$ oligomers as therapeutic targets of Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2011, 117, 19-28.	2.1	80
551	A monoclonal antibody against synthetic $\hat{1}^2$ dimer assemblies neutralizes brain-derived synaptic plasticity-disrupting $\hat{1}^2$ . <i>Journal of Neurochemistry</i> , 2011, 119, 189-201.	2.1	28
552	Chronic psychosocial stress enhances long-term depression in a subthreshold amyloid- $\hat{1}^2$ rat model of Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2011, 119, 408-416.	2.1	21
553	Dysregulated phosphorylation of Ca <sup>2+</sup> /calmodulin-dependent protein kinase II $\hat{1}$ in the hippocampus of subjects with mild cognitive impairment and Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2011, 119, 791-804.	2.1	91
554	Reduced levels of the tyrosine phosphatase STEP block beta amyloid-mediated GluA1/GluA2 receptor internalization. <i>Journal of Neurochemistry</i> , 2011, 119, 664-672.	2.1	49
555	Phenylbutyric acid reduces amyloid plaques and rescues cognitive behavior in AD transgenic mice. <i>Aging Cell</i> , 2011, 10, 418-428.	3.0	91
556	Protein engineering to stabilize soluble amyloid $\hat{1}^2$ -protein aggregates for structural and functional studies. <i>FEBS Journal</i> , 2011, 278, 3884-3892.	2.2	35

#	ARTICLE	IF	CITATIONS
557	Caspase activation without apoptosis: insight into A $\beta$ initiation of neurodegeneration. <i>Nature Neuroscience</i> , 2011, 14, 5-6.	7.1	38
558	Orphan nuclear receptors control neuronal remodeling during fly metamorphosis. <i>Nature Neuroscience</i> , 2011, 14, 6-7.	7.1	11
559	Amyloid- $\beta$ and tau "a toxic pas de deux in Alzheimer's disease. <i>Nature Reviews Neuroscience</i> , 2011, 12, 67-72.	4.9	1,147
560	Extracellular phosphorylation of the amyloid $\beta$ -peptide promotes formation of toxic aggregates during the pathogenesis of Alzheimer's disease. <i>EMBO Journal</i> , 2011, 30, 2255-2265.	3.5	160
561	Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. <i>Nature</i> , 2011, 469, 47-52.	13.7	371
562	Mechanism mediating oligomeric A $\beta$ clearance by na $\beta$ -ve primary microglia. <i>Neurobiology of Disease</i> , 2011, 42, 221-230.	2.1	110
563	Preventive and therapeutic types of environmental enrichment counteract beta amyloid pathology by different molecular mechanisms. <i>Neurobiology of Disease</i> , 2011, 42, 530-538.	2.1	50
564	Structural preferences of A $\beta$ fragments in different micellar environments. <i>Neuropeptides</i> , 2011, 45, 369-376.	0.9	12
565	A mimotope peptide of A $\beta$ <sub>242</sub> fibril-specific antibodies with A $\beta$ <sub>242</sub> fibrillation inhibitory activity induces anti-A $\beta$ <sub>242</sub> conformer antibody response by a displayed form on an M13 phage in mice. <i>Journal of Neuroimmunology</i> , 2011, 236, 27-38.	1.1	12
566	Coarse-grained models for protein aggregation. <i>Current Opinion in Structural Biology</i> , 2011, 21, 209-220.	2.6	170
567	Transthyretin and the brain re-visited: Is neuronal synthesis of transthyretin protective in Alzheimer's disease?. <i>Molecular Neurodegeneration</i> , 2011, 6, 79.	4.4	84
568	Utility of imaging for nutritional intervention studies in Alzheimer's disease. <i>European Journal of Pharmacology</i> , 2011, 668, S59-S69.	1.7	16
569	Countering neurodegeneration by reducing the activity of the insulin/IGF signaling pathway: Current knowledge and future prospects. <i>Experimental Gerontology</i> , 2011, 46, 124-128.	1.2	11
570	Noninvasive brain stimulation in Alzheimer's disease: Systematic review and perspectives for the future. <i>Experimental Gerontology</i> , 2011, 46, 611-27.	1.2	128
571	Developing predictive CSF biomarkers" A challenge critical to success in Alzheimer's disease and neuropsychiatric translational medicine. <i>Biochemical Pharmacology</i> , 2011, 81, 1422-1434.	2.0	41
572	Estrogen-induced signaling attenuates soluble A $\beta$ peptide-mediated dysfunction of pathways in synaptic plasticity. <i>Brain Research</i> , 2011, 1383, 1-12.	1.1	22
573	Decreased dendritic spine density and abnormal spine morphology in Fyn knockout mice. <i>Brain Research</i> , 2011, 1415, 96-102.	1.1	34
574	Aggregation of amyloids in a cellular context: modelling and experiment. <i>Biochemical Journal</i> , 2011, 438, 415-426.	1.7	47

#	ARTICLE	IF	CITATIONS
575	A $\beta$ 1-42 inhibition of LTP is mediated by a signaling pathway involving caspase-3, Akt1 and GSK-3 $\beta$ . <i>Nature Neuroscience</i> , 2011, 14, 545-547.	7.1	273
576	Does amino acid sequence determine the properties of A $\beta$ 2 dimer?. <i>Journal of Chemical Physics</i> , 2011, 135, 035103.	1.2	3
577	Testing the Therapeutic Potential of Doxycycline in a <i>Drosophila melanogaster</i> Model of Alzheimer Disease. <i>Journal of Biological Chemistry</i> , 2011, 286, 41647-41655.	1.6	63
578	Possible role for Ca <sup>2+</sup> in the pathophysiology of the prion protein?. <i>BioFactors</i> , 2011, 37, 241-249.	2.6	21
579	Zinc-induced dimerization of the amyloid- $\beta$ 2 metal-binding domain 1-16 is mediated by residues 11-14. <i>Molecular BioSystems</i> , 2011, 7, 1053.	2.9	72
580	Functional Interactions of Fibrillar and Oligomeric Amyloid- $\beta$ 2 with Alpha7 Nicotinic Receptors in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 23, 335-347.	1.2	51
581	High Throughput Monitoring of Amyloid- $\beta$ 242 Assembly into Soluble Oligomers Achieved by Sensitive Conformation State-Dependent Immunoassays. <i>Journal of Alzheimer's Disease</i> , 2011, 25, 655-669.	1.2	2
582	Alzheimer's Disease: The Challenge of the Second Century. <i>Science Translational Medicine</i> , 2011, 3, 77sr1.	5.8	1,109
583	DNA Immunization Against Amyloid beta 42 has High Potential as Safe Therapy for Alzheimer's Disease as it Diminishes Antigen-Specific Th1 and Th17 Cell Proliferation. <i>Cellular and Molecular Neurobiology</i> , 2011, 31, 867-74.	1.7	47
584	A $\beta$ 2 Oligomer-Induced Synapse Degeneration in Alzheimer's Disease. <i>Cellular and Molecular Neurobiology</i> , 2011, 31, 939-948.	1.7	144
585	Tau, prions and A $\beta$ 2: the triad of neurodegeneration. <i>Acta Neuropathologica</i> , 2011, 121, 5-20.	3.9	84
586	In vivo multiphoton imaging reveals gradual growth of newborn amyloid plaques over weeks. <i>Acta Neuropathologica</i> , 2011, 121, 327-335.	3.9	86
587	RAGE: The Beneficial and Deleterious Effects by Diverse Mechanisms of Actions. <i>Molecules and Cells</i> , 2011, 31, 91-98.	1.0	97
588	Amyloid- $\beta$ 2 protein modulates the perivascular clearance of neuronal apolipoprotein E in mouse models of Alzheimer's disease. <i>Journal of Neural Transmission</i> , 2011, 118, 699-712.	1.4	30
589	In vivo changes in microglial activation and amyloid deposits in brain regions with hypometabolism in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 343-351.	3.3	143
590	Transformation of amyloid $\beta$ 2 (1-40) oligomers into fibrils is characterized by a major change in secondary structure. <i>Cellular and Molecular Life Sciences</i> , 2011, 68, 1429-1438.	2.4	129
591	Modes of A $\beta$ 2 toxicity in Alzheimer's disease. <i>Cellular and Molecular Life Sciences</i> , 2011, 68, 3359-3375.	2.4	78
592	The potential of microelectrode arrays and microelectronics for biomedical research and diagnostics. <i>Analytical and Bioanalytical Chemistry</i> , 2011, 399, 2313-2329.	1.9	98

#	ARTICLE	IF	CITATIONS
593	APP Transgenic Mice: Their Use and Limitations. <i>NeuroMolecular Medicine</i> , 2011, 13, 117-137.	1.8	69
594	Mechanisms of Neural and Behavioral Dysfunction in Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2011, 43, 163-179.	1.9	15
595	Early calcium dysregulation in Alzheimer's disease: setting the stage for synaptic dysfunction. <i>Science China Life Sciences</i> , 2011, 54, 752-762.	2.3	59
596	Amyloid beta dimers/trimers potently induce cofilin-actin rods that are inhibited by maintaining cofilin-phosphorylation. <i>Molecular Neurodegeneration</i> , 2011, 6, 10.	4.4	77
597	Alzheimer's disease: synapses gone cold. <i>Molecular Neurodegeneration</i> , 2011, 6, 63.	4.4	250
598	Preclinical study of dimebon on $\beta$ -amyloid-mediated neuropathology in Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2011, 6, 7.	4.4	32
599	Coordinated increase of $\beta$ -secretase reaction products in the plasma of some female Japanese sporadic Alzheimer's disease patients: quantitative analysis of p3-Alc $\beta$ with a new ELISA system. <i>Molecular Neurodegeneration</i> , 2011, 6, 76.	4.4	10
600	1,25-Dihydroxyvitamin D3 enhances cerebral clearance of human amyloid- $\beta$ peptide(1-40) from mouse brain across the blood-brain barrier. <i>Fluids and Barriers of the CNS</i> , 2011, 8, 20.	2.4	85
601	BACE-1 inhibition prevents the $\beta$ -secretase inhibitor evoked A $\beta$ rise in human neuroblastoma SH-SY5Y cells. <i>Journal of Biomedical Science</i> , 2011, 18, 76.	2.6	26
602	Asymmetric amyloid fibril elongation: A new perspective on a symmetric world. <i>Proteins: Structure, Function and Bioinformatics</i> , 2011, 79, 92-98.	1.5	28
603	Dissociation of $\beta$ -amyloid from lipoprotein in cerebrospinal fluid from Alzheimer's disease accelerates $\beta$ -amyloid-42 assembly. <i>Journal of Neuroscience Research</i> , 2011, 89, 815-821.	1.3	10
604	Endogenous amyloid- $\beta$ is necessary for hippocampal synaptic plasticity and memory. <i>Annals of Neurology</i> , 2011, 69, 819-830.	2.8	248
605	Amyloid- $\beta$ associated cortical thinning in clinically normal elderly. <i>Annals of Neurology</i> , 2011, 69, 1032-1042.	2.8	306
606	Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. <i>Annals of Neurology</i> , 2011, 70, 532-540.	2.8	536
607	Layer-specific alterations to CA1 dendritic spines in a mouse model of Alzheimer's disease. <i>Hippocampus</i> , 2011, 21, 1037-1044.	0.9	53
608	HomoFRET Fluorescence Anisotropy Imaging as a Tool to Study Molecular Self-Assembly in Live Cells. <i>ChemPhysChem</i> , 2011, 12, 500-509.	1.0	95
610	Rapid Formation of a Preoligomeric Peptide-Metal-Peptide Complex Following Copper(II) Binding to Amyloid $\beta$ -Peptides. <i>Angewandte Chemie - International Edition</i> , 2011, 50, 2532-2535.	7.2	69
611	Polyphenolic Glycosides and Aglycones Utilize Opposing Pathways To Selectively Remodel and Inactivate Toxic Oligomers of Amyloid $\beta$ . <i>ChemBioChem</i> , 2011, 12, 1749-1758.	1.3	51

#	ARTICLE	IF	CITATIONS
612	Context-Based Identification of Protein-Protein Interfaces and "Hot-Spot" Residues. <i>Chemistry and Biology</i> , 2011, 18, 344-353.	6.2	63
613	2-Arylimidazo[2,1-b]benzothiazoles: A new family of amyloid binding agents with potential for PET and SPECT imaging of Alzheimer's brain. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 2966-2968.	1.0	46
614	Binding studies of truncated variants of the A $\beta$ peptide to the V-domain of the RAGE receptor reveal A $\beta$ residues responsible for binding. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2011, 1814, 592-609.	1.1	30
615	Structural and mechanistic commonalities of amyloid- $\beta$ and the prion protein. <i>Prion</i> , 2011, 5, 126-137.	0.9	25
616	$\beta$ -Adrenergic Receptor, Amyloid $\beta$ -Peptide, and Alzheimer's Disease. <i>Current Topics in Membranes</i> , 2011, 67, 205-228.	0.5	6
617	Chronic Stress and Alzheimers Disease-Like Pathogenesis in a Rat Model: Prevention by Nicotine. <i>Current Neuropharmacology</i> , 2011, 9, 587-597.	1.4	15
618	Therapeutic potential of vaccines for Alzheimer's disease. <i>Immunotherapy</i> , 2011, 3, 287-298.	1.0	15
619	Anti- $\beta$ -Amyloid Immunotherapy for Alzheimers Disease: Focus on Bapineuzumab. <i>Current Alzheimer Research</i> , 2011, 8, 808-817.	0.7	51
620	Exploiting the Diversity of the Heat-Shock Protein Family for Primary and Secondary Tauopathy Therapeutics. <i>Current Neuropharmacology</i> , 2011, 9, 623-631.	1.4	25
621	c-Jun N-terminal Kinase Regulates Soluble A $\beta$ Oligomers and Cognitive Impairment in AD Mouse Model. <i>Journal of Biological Chemistry</i> , 2011, 286, 43871-43880.	1.6	74
622	Interacting with $\beta$ -Secretase for Treating Alzheimer's Disease: From Inhibition to Modulation. <i>Current Medicinal Chemistry</i> , 2011, 18, 5430-5447.	1.2	26
623	A $\beta$ ; Monomers, Oligomers and Fibrils: Structural Features. <i>Current Bioactive Compounds</i> , 2011, 7, 198-213.	0.2	7
624	Genetics of Dementia. <i>Seminars in Neurology</i> , 2011, 31, 449-460.	0.5	48
625	Oxidative Stress and Cell Membranes in the Pathogenesis of Alzheimer's Disease. <i>Physiology</i> , 2011, 26, 54-69.	1.6	123
626	Sequestration of Toxic Oligomers by HspB1 as a Cytoprotective Mechanism. <i>Molecular and Cellular Biology</i> , 2011, 31, 3146-3157.	1.1	83
627	Ageing and protein aggregation-mediated disorders: from invertebrates to mammals. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2011, 366, 94-98.	1.8	54
628	Targeting Oligomers in Neurodegenerative Disorders: Lessons from $\beta$ -Synuclein, Tau, and Amyloid- $\beta$ Peptide. <i>Journal of Alzheimer's Disease</i> , 2011, 24, 223-232.	1.2	95
629	CD45 Deficiency Drives Amyloid- $\beta$ Peptide Oligomers and Neuronal Loss in Alzheimer's Disease Mice. <i>Journal of Neuroscience</i> , 2011, 31, 1355-1365.	1.7	74



#	ARTICLE	IF	CITATIONS
630	Amyloid $\beta$ -Mediated Cell Death of Cultured Hippocampal Neurons Reveals Extensive Tau Fragmentation without Increased Full-length Tau Phosphorylation. <i>Journal of Biological Chemistry</i> , 2011, 286, 20797-20811.	1.6	72
631	Young coconut juice, a potential therapeutic agent that could significantly reduce some pathologies associated with Alzheimer's disease: novel findings. <i>British Journal of Nutrition</i> , 2011, 105, 738-746.	1.2	21
632	$\beta$ -secretase inhibitors for treating Alzheimer's disease: rationale and clinical data. <i>Clinical Investigation</i> , 2011, 1, 1175-1194.	0.0	2
633	Sequence-independent Control of Peptide Conformation in Liposomal Vaccines for Targeting Protein Misfolding Diseases. <i>Journal of Biological Chemistry</i> , 2011, 286, 13966-13976.	1.6	67
634	Beta-amyloid oligomers: recent developments. <i>Biomolecular Concepts</i> , 2011, 2, 211-222.	1.0	8
635	Naturally Occurring Autoantibodies against $\beta$ -Amyloid: Investigating Their Role in Transgenic Animal and <i>In Vitro</i> Models of Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2011, 31, 5847-5854.	1.7	111
636	Alzheimer's Disease. <i>Cold Spring Harbor Perspectives in Biology</i> , 2011, 3, a004457-a004457.	2.3	348
637	Nature of the Amyloid- $\beta$ Monomer and the Monomer-Oligomer Equilibrium. <i>Journal of Biological Chemistry</i> , 2011, 286, 13827-13833.	1.6	155
638	Development and validation of a yeast high-throughput screen for inhibitors of $A\beta_{42}$ oligomerization. <i>DMM Disease Models and Mechanisms</i> , 2011, 4, 822-831.	1.2	43
639	A Novel Mouse Model of Alzheimer's Disease with Chronic Estrogen Deficiency Leads to Glial Cell Activation and Hypertrophy. <i>Journal of Aging Research</i> , 2011, 2011, 1-12.	0.4	21
640	Crystal Structure of the Amyloid- $\beta$ p3 Fragment Provides a Model for Oligomer Formation in Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2011, 31, 1419-1426.	1.7	99
641	Tau-Induced Defects in Synaptic Plasticity, Learning, and Memory Are Reversible in Transgenic Mice after Switching Off the Toxic Tau Mutant. <i>Journal of Neuroscience</i> , 2011, 31, 2511-2525.	1.7	252
642	Amyloid $\beta$ -Induced Impairments in Hippocampal Synaptic Plasticity Are Rescued by Decreasing Mitochondrial Superoxide. <i>Journal of Neuroscience</i> , 2011, 31, 5589-5595.	1.7	132
643	Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer's disease: implications for neuronal damage. <i>Human Molecular Genetics</i> , 2011, 20, 2495-2509.	1.4	644
644	High ability of apolipoprotein E4 to stabilize amyloid- $\beta$ peptide oligomers, the pathological entities responsible for Alzheimer's disease. <i>FASEB Journal</i> , 2011, 25, 1585-1595.	0.2	83
645	ADP ribosylation factor 6 (ARF6) controls amyloid precursor protein (APP) processing by mediating the endosomal sorting of BACE1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, E559-68.	3.3	221
646	Cysteine Oxidation within N-terminal Mutant Huntingtin Promotes Oligomerization and Delays Clearance of Soluble Protein. <i>Journal of Biological Chemistry</i> , 2011, 286, 18320-18330.	1.6	54
647	Soluble Oligomers of Amyloid- $\beta$ Peptide Disrupt Membrane Trafficking of $\beta$ -Amino-3-hydroxy-5-methylisoxazole-4-propionic Acid Receptor Contributing to Early Synapse Dysfunction. <i>Journal of Biological Chemistry</i> , 2011, 286, 27311-27321.	1.6	89



#	ARTICLE	IF	CITATIONS
648	Characterization of Oligomer Formation of Amyloid- $\beta^2$ Peptide Using a Split-luciferase Complementation Assay. <i>Journal of Biological Chemistry</i> , 2011, 286, 27081-27091.	1.6	65
649	Amyloid $\beta^2$ (A $\beta^2$ ) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 367-374.	1.4	62
650	Effects of Estrogen on Beta-Amyloid-Induced Cholinergic Cell Death in the Nucleus Basalis Magnocellularis. <i>Neuroendocrinology</i> , 2011, 93, 90-105.	1.2	20
651	$\beta^2$ -amyloid oligomers and prion protein. <i>Prion</i> , 2011, 5, 10-15.	0.9	22
652	Alzheimers Disease: Pathological Mechanisms and Recent Insights. <i>Current Neuropharmacology</i> , 2011, 9, 674-684.	1.4	46
653	Glaucoma and Alzheimer's disease in the elderly. <i>Aging Health</i> , 2011, 7, 719-733.	0.3	12
654	SOD1 (Copper/Zinc Superoxide Dismutase) Deficiency Drives Amyloid $\beta^2$ Protein Oligomerization and Memory Loss in Mouse Model of Alzheimer Disease. <i>Journal of Biological Chemistry</i> , 2011, 286, 44557-44568.	1.6	202
655	Tissue Transglutaminase-mediated Glutamine Deamidation of $\beta^2$ -Amyloid Peptide Increases Peptide Solubility, Whereas Enzymatic Cross-linking and Peptide Fragmentation May Serve as Molecular Triggers for Rapid Peptide Aggregation. <i>Journal of Biological Chemistry</i> , 2011, 286, 12172-12188.	1.6	32
656	Activation of D1/D5 Dopamine Receptors Protects Neurons from Synapse Dysfunction Induced by Amyloid- $\beta^2$ Oligomers. <i>Journal of Biological Chemistry</i> , 2011, 286, 3270-3276.	1.6	77
657	Amyloid- $\beta^2$ -induced Synapse Damage Is Mediated via Cross-linkage of Cellular Prion Proteins. <i>Journal of Biological Chemistry</i> , 2011, 286, 37955-37963.	1.6	82
658	Cu(II) Mediates Kinetically Distinct, Non-amyloidogenic Aggregation of Amyloid- $\beta^2$ Peptides. <i>Journal of Biological Chemistry</i> , 2011, 286, 26952-26963.	1.6	114
659	Dynamic Analysis of Amyloid $\beta^2$ -Protein in Behaving Mice Reveals Opposing Changes in ISF versus Parenchymal A $\beta^2$ during Age-Related Plaque Formation. <i>Journal of Neuroscience</i> , 2011, 31, 15861-15869.	1.7	95
660	Interaction between prion protein and toxic amyloid $\beta^2$ assemblies can be therapeutically targeted at multiple sites. <i>Nature Communications</i> , 2011, 2, 336.	5.8	263
661	Two Distinct Amyloid $\beta^2$ -Protein (A $\beta^2$ ) Assembly Pathways Leading to Oligomers and Fibrils Identified by Combined Fluorescence Correlation Spectroscopy, Morphology, and Toxicity Analyses. <i>Journal of Biological Chemistry</i> , 2011, 286, 11555-11562.	1.6	102
662	Harnessing neuroplasticity for clinical applications. <i>Brain</i> , 2011, 134, 1591-1609.	3.7	907
663	Impaired $\beta^2$ -Amyloid Secretion in Alzheimer's Disease Pathogenesis. <i>Journal of Neuroscience</i> , 2011, 31, 15384-15390.	1.7	35
664	Ablation of Cellular Prion Protein Does Not Ameliorate Abnormal Neural Network Activity or Cognitive Dysfunction in the J20 Line of Human Amyloid Precursor Protein Transgenic Mice. <i>Journal of Neuroscience</i> , 2011, 31, 10427-10431.	1.7	115
665	Alzheimer's Disease Brain-Derived Amyloid- $\beta^2$ -Mediated Inhibition of LTP <i>In Vivo</i> Is Prevented by Immunotargeting Cellular Prion Protein. <i>Journal of Neuroscience</i> , 2011, 31, 7259-7263.	1.7	215

#	ARTICLE	IF	CITATIONS
666	Single-channel Ca <sup>2+</sup> imaging implicates A $\beta$ 42 amyloid pores in Alzheimer's disease pathology. <i>Journal of Cell Biology</i> , 2011, 195, 515-524.	2.3	151
667	Nature-inspired total synthesis. <i>Nature Chemical Biology</i> , 2011, 7, 582-583.	3.9	6
668	Tetrahydroperforin prevents cognitive deficit, A $\beta$ deposition, tau phosphorylation and synaptotoxicity in the APP <sup>swE</sup> /PSEN1 <sup>E9</sup> model of Alzheimer's disease: a possible effect on APP processing. <i>Translational Psychiatry</i> , 2011, 1, e20-e20.	2.4	62
669	Paving the way for Alzheimer disease drug development. <i>Nature Reviews Neurology</i> , 2011, 7, 65-66.	4.9	7
670	A Window into the Heterogeneity of Human Cerebrospinal Fluid A $\beta$ Peptides. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-9.	3.0	14
671	Longitudinal modeling of frontal cognition in APOE $\epsilon$ 4 homozygotes, heterozygotes, and noncarriers. <i>Neurology</i> , 2011, 76, 1383-1388.	1.5	83
672	Fiber Tracts Anomalies in APPxPS1 Transgenic Mice Modeling Alzheimer's Disease. <i>Journal of Aging Research</i> , 2011, 2011, 1-12.	0.4	10
673	Cognitive and Cortical Plasticity Deficits Correlate with Altered Amyloid- $\beta$ CSF Levels in Multiple Sclerosis. <i>Neuropsychopharmacology</i> , 2011, 36, 559-568.	2.8	95
674	New Tools for the Study of Alzheimer's Disease. <i>Neuroscientist</i> , 2011, 17, 592-605.	2.6	12
675	A Multiscale Approach to Characterize the Early Aggregation Steps of the Amyloid-Forming Peptide GNNQQNY from the Yeast Prion Sup-35. <i>PLoS Computational Biology</i> , 2011, 7, e1002051.	1.5	80
676	Neutralization of Soluble, Synaptotoxic Amyloid $\beta$ Species by Antibodies Is Epitope Specific. <i>Journal of Neuroscience</i> , 2012, 32, 2696-2702.	1.7	66
677	Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid- $\beta$ peptide and $\beta$ , levels: target engagement, tolerability and pharmacokinetics in humans. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 894-902.	0.9	66
678	Role of APP and A $\beta$ in Synaptic Physiology. <i>Current Alzheimer Research</i> , 2012, 9, 217-226.	0.7	42
679	Ginsenoside Rg1 Attenuates Oligomeric A $\beta$ 1-42-Induced Mitochondrial Dysfunction. <i>Current Alzheimer Research</i> , 2012, 9, 388-395.	0.7	39
680	Is the Amyloid Hypothesis of Alzheimer's disease therapeutically relevant?. <i>Biochemical Journal</i> , 2012, 446, 165-177.	1.7	89
681	Synapses and Alzheimer's Disease. <i>Cold Spring Harbor Perspectives in Biology</i> , 2012, 4, a005777-a005777.	2.3	340
682	Apolipoprotein E and Apolipoprotein E Receptors: Normal Biology and Roles in Alzheimer Disease. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012, 2, a006312-a006312.	2.9	637
683	Biochemistry of Amyloid $\beta$ -Protein and Amyloid Deposits in Alzheimer Disease. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012, 2, a006262-a006262.	2.9	451

#	ARTICLE	IF	CITATIONS
684	Structural Basis for Increased Toxicity of Pathological A $\beta$ <sub>42</sub> :A $\beta$ <sub>40</sub> Ratios in Alzheimer Disease. <i>Journal of Biological Chemistry</i> , 2012, 287, 5650-5660.	1.6	201
685	Intra-membrane Oligomerization and Extra-membrane Oligomerization of Amyloid- $\beta$ Peptide Are Competing Processes as a Result of Distinct Patterns of Motif Interplay. <i>Journal of Biological Chemistry</i> , 2012, 287, 748-756.	1.6	38
686	Nanomechanics of Proteins, Both Folded and Disordered. , 2012, , 1-47.		0
687	Postmortem Pittsburgh Compound B (PiB) Binding Increases with Alzheimer's Disease Progression. <i>Journal of Alzheimer's Disease</i> , 2012, 32, 127-138.	1.2	18
688	Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid- $\beta$ . <i>Brain</i> , 2012, 135, 2155-2168.	3.7	268
689	Synaptic Plasticity Defect Following Visual Deprivation in Alzheimer's Disease Model Transgenic Mice. <i>Journal of Neuroscience</i> , 2012, 32, 8004-8011.	1.7	52
690	Neurotoxicity and Memory Deficits Induced by Soluble Low-Molecular-Weight Amyloid- $\beta$ <sub>1-42</sub> Oligomers Are Revealed In Vivo by Using a Novel Animal Model. <i>Journal of Neuroscience</i> , 2012, 32, 7852-7861.	1.7	156
691	Amyloid-Beta Peptide 1-42 Causes Microtubule Deregulation through N-methyl-D-aspartate Receptors in Mature Hippocampal Cultures. <i>Current Alzheimer Research</i> , 2012, 9, 844-856.	0.7	30
692	The Animal Models of Dementia and Alzheimer's Disease for Pre-Clinical Testing and Clinical Translation. <i>Current Alzheimer Research</i> , 2012, 9, 1010-1029.	0.7	34
693	C-terminal fragment of N-cadherin accelerates synapse destabilization by amyloid- $\beta$ . <i>Brain</i> , 2012, 135, 2140-2154.	3.7	45
694	False recognition in a mouse model of Alzheimer's disease: rescue with sensory restriction and memantine. <i>Brain</i> , 2012, 135, 2103-2114.	3.7	49
695	Intraneuronally injected amyloid beta inhibits long-term potentiation in rat hippocampal slices. <i>Journal of Neurophysiology</i> , 2012, 107, 2526-2531.	0.9	23
696	Transgenic Expression of Intraneuronal A $\beta$ <sub>42</sub> But Not A $\beta$ <sub>40</sub> Leads to Cellular A $\beta$ <sub>2</sub> Lesions, Degeneration, and Functional Impairment without Typical Alzheimer's Disease Pathology. <i>Journal of Neuroscience</i> , 2012, 32, 1273-1283.	1.7	44
697	Molecular Pathology in Neurodegenerative Diseases. <i>Current Drug Targets</i> , 2012, 13, 1548-1559.	1.0	31
698	Memory Enhancement and Deep-Brain Stimulation of the Entorhinal Area. <i>New England Journal of Medicine</i> , 2012, 366, 1945-1946.	13.9	11
699	Early Impairment of Long-Term Depression in the Perirhinal Cortex of a Mouse Model of Alzheimer's Disease. <i>Rejuvenation Research</i> , 2012, 15, 231-234.	0.9	21
700	AFM investigation of the aggregation behavior of Alzheimer's disease A $\beta$ peptides. , 2012, , .		2
701	Striatal-Enriched Protein Tyrosine Phosphatase in Alzheimer's Disease. <i>Advances in Pharmacology</i> , 2012, 64, 303-325.	1.2	20

#	ARTICLE	IF	CITATIONS
702	Focused ultrasound disruption of the blood-brain barrier: a new frontier for therapeutic delivery in molecular neurooncology. <i>Neurosurgical Focus</i> , 2012, 32, E3.	1.0	118
703	Antihypertensives for combating dementia? A perspective on candidate molecular mechanisms and population-based prevention. <i>Translational Psychiatry</i> , 2012, 2, e107-e107.	2.4	22
704	Î±-Secretase-derived Fragment of Cellular Prion, N1, Protects against Monomeric and Oligomeric Amyloid Î² (AÎ²)-associated Cell Death. <i>Journal of Biological Chemistry</i> , 2012, 287, 5021-5032.	1.6	84
705	Cdk5 Protein Inhibition and AÎ²42 Increase BACE1 Protein Level in Primary Neurons by a Post-transcriptional Mechanism. <i>Journal of Biological Chemistry</i> , 2012, 287, 7224-7235.	1.6	56
706	Glucagon-Like Peptide-1 Cleavage Product GLP-1(9-36) Amide Rescues Synaptic Plasticity and Memory Deficits in Alzheimer's Disease Model Mice. <i>Journal of Neuroscience</i> , 2012, 32, 13701-13708.	1.7	97
707	Identification of Small Molecule Inhibitors of Neurite Loss Induced by AÎ² peptide using High Content Screening. <i>Journal of Biological Chemistry</i> , 2012, 287, 8714-8723.	1.6	20
708	Immunotherapy for Alzheimer's disease: from anti-Î²-amyloid to tau-based immunization strategies. <i>Immunotherapy</i> , 2012, 4, 213-238.	1.0	121
709	Treatment Strategies Targeting Amyloid A-Protein. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012, 2, a006387-a006387.	2.9	96
710	Solid-support Electron Paramagnetic Resonance (EPR) Studies of AÎ²40 Monomers Reveal a Structured State with Three Ordered Segments. <i>Journal of Biological Chemistry</i> , 2012, 287, 9081-9089.	1.6	15
711	Epidermal growth factor receptor is a preferred target for treating Amyloid-Î²-induced memory loss. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 16743-16748.	3.3	154
712	Retention in Endoplasmic Reticulum 1 (RER1) Modulates Amyloid-Î² (AÎ²) Production by Altering Trafficking of Î³-Secretase and Amyloid Precursor Protein (APP). <i>Journal of Biological Chemistry</i> , 2012, 287, 40629-40640.	1.6	29
713	Preparation of Stable Amyloid Î²-Protein Oligomers of Defined Assembly Order. <i>Methods in Molecular Biology</i> , 2012, 849, 23-31.	0.4	19
714	The Load of Amyloid-Î² Oligomers is Decreased in the Cerebrospinal Fluid of Alzheimer's Disease Patients. <i>Journal of Alzheimer's Disease</i> , 2012, 31, 865-878.	1.2	31
715	Soluble A-Synuclein Is a Novel Modulator of Alzheimer's Disease Pathophysiology. <i>Journal of Neuroscience</i> , 2012, 32, 10253-10266.	1.7	107
716	Aging, Protein Aggregation, Chaperones and Neurodegenerative Disorders: Mechanisms of Coupling and Therapeutic Opportunities. <i>Rambam Maimonides Medical Journal</i> , 2012, 3, e0021.	0.4	13
717	Impaired Short-Term Plasticity in Mossy Fiber Synapses Caused by Mitochondrial Dysfunction of Dentate Granule Cells Is the Earliest Synaptic Deficit in a Mouse Model of Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2012, 32, 5953-5963.	1.7	71
718	Molecular basis of Î²-amyloid oligomer recognition with a conformational antibody fragment. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 12503-12508.	3.3	76
719	Second Generation Î³-Secretase Modulators Exhibit Different Modulation of Notch Î² and AÎ² Production. <i>Journal of Biological Chemistry</i> , 2012, 287, 32640-32650.	1.6	18

#	ARTICLE	IF	CITATIONS
720	Effect of Immunotherapy With Bapineuzumab on Cerebrospinal Fluid Biomarker Levels in Patients With Mild to Moderate Alzheimer Disease. <i>Archives of Neurology</i> , 2012, 69, 1002.	4.9	215
721	Synthesis, Characterization and Potential Applications of Multifunctional PEO-PPOPEO- Magnetic Drug Delivery System. <i>Current Medicinal Chemistry</i> , 2012, 19, 5199-5204.	1.2	14
722	Aquaporin-4 deficiency exacerbates brain oxidative damage and memory deficits induced by long-term ovarian hormone deprivation and D-galactose injection. <i>International Journal of Neuropsychopharmacology</i> , 2012, 15, 55-68.	1.0	45
723	Stable Size Distribution of Amyloid Plaques Over the Course of Alzheimer Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2012, 71, 694-701.	0.9	41
724	Peptides for Therapy and Diagnosis of Alzheimer's Disease. <i>Current Pharmaceutical Design</i> , 2012, 18, 755-767.	0.9	102
725	Cerebellar Amyloid- $\beta$ Plaques: Disturbed Cortical Circuitry in A $\beta$ PP/PS1 Transgenic Mice as a Model of Familial Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 31, 285-300.	1.2	23
726	Evidence for Premature Lipid Raft Aging in APP/PS1 Double-Transgenic Mice, a Model of Familial Alzheimer Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2012, 71, 868-881.	0.9	69
727	Therapeutic Targeting of the Endoplasmic Reticulum in Alzheimers Disease. <i>Current Alzheimer Research</i> , 2012, 9, 110-119.	0.7	30
728	In Vivo Uptake of $\beta$ -Amyloid by Non-Plaque Associated Microglia. <i>Current Alzheimer Research</i> , 2012, 9, 890-901.	0.7	15
729	Endothelin-1 is Elevated in Alzheimer's Disease and Upregulated by Amyloid- $\beta$ . <i>Journal of Alzheimer's Disease</i> , 2012, 29, 853-861.	1.2	95
732	Antibody 9D5 Recognizes Oligomeric Pyroglutamate Amyloid- $\beta$ in a Fraction of Amyloid- $\beta$ Deposits in Alzheimer's Disease without Cross-Reactivity with other Protein Aggregates. <i>Journal of Alzheimer's Disease</i> , 2012, 29, 361-371.	1.2	17
734	Neuropathological Basis of Alzheimer's Disease and Alzheimer's Disease Diagnosis. <i>Advances in Biological Psychiatry</i> , 2012, , 49-70.	0.2	1
735	Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature. <i>Journal of Neuropathology and Experimental Neurology</i> , 2012, 71, 362-381.	0.9	1,599
736	Amyloid and Alzheimer's Disease: Inside and Out. <i>Canadian Journal of Neurological Sciences</i> , 2012, 39, 286-298.	0.3	56
737	Role of Aluminum and Other Metal Ions in the Pathogenesis of Alzheimer's Disease. , 2012, , 233-260.		0
738	Visualization of co-localization in A $\beta$ <sup>242</sup> -administered neuroblastoma cells reveals lysosome damage and autophagosome accumulation related to cell death. <i>Biochemical Journal</i> , 2012, 441, 579-590.	1.7	59
739	A Possible Key Role for Redox-Active Metal Ions and Soluble Oligomers in Neurodegenerative Disease. , 2012, , 23-44.		0
740	Drug Treatments in Development for Alzheimer's Disease. <i>Journal of Pharmacy Practice and Research</i> , 2012, 42, 58-65.	0.5	7

#	ARTICLE	IF	CITATIONS
741	The Complex PrP <sup>c</sup> -Fyn Couples Human Oligomeric A $\beta$ with Pathological Tau Changes in Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2012, 32, 16857-16871.	1.7	254
742	A $\beta$ oligomer toxicity inhibitor protects memory in models of synaptic toxicity. <i>British Journal of Pharmacology</i> , 2012, 167, 383-392.	2.7	15
743	Alzheimer's disease, A $\beta$ -amyloid, glutamate, NMDA receptors and memantine – searching for the connections. <i>British Journal of Pharmacology</i> , 2012, 167, 324-352.	2.7	396
744	Postsynaptic dysfunction is associated with spatial and object recognition memory loss in a natural model of Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 13835-13840.	3.3	113
745	Copper and Oxidative Stress in the Pathogenesis of Alzheimer's Disease. <i>Biochemistry</i> , 2012, 51, 6289-6311.	1.2	237
746	Deregulated Cdk5 Activity Is Involved in Inducing Alzheimer's Disease. <i>Archives of Medical Research</i> , 2012, 43, 655-662.	1.5	139
747	Role of Tau Protein in Neuronal Damage in Alzheimer's Disease and Down Syndrome. <i>Archives of Medical Research</i> , 2012, 43, 645-654.	1.5	54
748	A Mass Spectrometric Approach for Characterization of Amyloid- $\beta$ Aggregates and Identification of Their Post-Translational Modifications. <i>Biochemistry</i> , 2012, 51, 3759-3766.	1.2	9
749	Role of Water in Protein Aggregation and Amyloid Polymorphism. <i>Accounts of Chemical Research</i> , 2012, 45, 83-92.	7.6	301
750	Integrating Cytosolic Phospholipase A2 with Oxidative/Nitrosative Signaling Pathways in Neurons: A Novel Therapeutic Strategy for AD. <i>Molecular Neurobiology</i> , 2012, 46, 85-95.	1.9	40
751	A pivotal role of GSK-3 in synaptic plasticity. <i>Frontiers in Molecular Neuroscience</i> , 2012, 5, 13.	1.4	149
752	Thermodynamics of peptide dimer formation. <i>Journal of Chemical Physics</i> , 2012, 136, 245102.	1.2	13
753	Advances in the identification of $\beta$ -secretase inhibitors for the treatment of Alzheimer's disease. <i>Expert Opinion on Drug Discovery</i> , 2012, 7, 19-37.	2.5	45
754	Alzheimer's Disease and Amyloid: Culprit or Coincidence?. <i>International Review of Neurobiology</i> , 2012, 102, 277-316.	0.9	67
755	Structural polymorphism and possible pathways of amyloid fibril formation on the example of insulin protein. <i>Biochemistry (Moscow)</i> , 2012, 77, 1237-1247.	0.7	29
756	Protection of primary neurons and mouse brain from Alzheimer's pathology by molecular tweezers. <i>Brain</i> , 2012, 135, 3735-3748.	3.7	86
757	Amyloid plaque formation precedes dendritic spine loss. <i>Acta Neuropathologica</i> , 2012, 124, 797-807.	3.9	77
759	Synapse-Binding Subpopulations of A $\beta$ Oligomers Sensitive to Peptide Assembly Blockers and scFv Antibodies. <i>ACS Chemical Neuroscience</i> , 2012, 3, 972-981.	1.7	45



#	ARTICLE	IF	CITATIONS
760	An N-Heterocyclic Amine Chelate Capable of Antioxidant Capacity and Amyloid Disaggregation. ACS Chemical Neuroscience, 2012, 3, 919-927.	1.7	49
761	Familial Alzheimer's Disease Mutations Differentially Alter Amyloid- $\beta$ -Protein Oligomerization. ACS Chemical Neuroscience, 2012, 3, 909-918.	1.7	80
762	The Natural Product Betulinic Acid Rapidly Promotes Amyloid- $\beta$ Fibril Formation at the Expense of Soluble Oligomers. ACS Chemical Neuroscience, 2012, 3, 900-908.	1.7	29
763	Safety, tolerability, and antibody response of active A $\beta$ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurology, The, 2012, 11, 597-604.	4.9	261
764	NMDA Receptor-Dependent Long-Term Potentiation and Long-Term Depression (LTP/LTD). Cold Spring Harbor Perspectives in Biology, 2012, 4, a005710-a005710.	2.3	720
765	Pittsburgh compound B and the postmortem diagnosis of alzheimer disease. Annals of Neurology, 2012, 72, 564-570.	2.8	31
766	A Bioinorganic View of Alzheimer's Disease: When Misplaced Metal Ions (Re)direct the Electrons to the Wrong Target. Chemistry - A European Journal, 2012, 18, 15910-15920.	1.7	84
767	APP mutations in the A $\beta$ coding region are associated with abundant cerebral deposition of A $\beta$ 38. Acta Neuropathologica, 2012, 124, 809-821.	3.9	34
768	The levels of water-soluble and triton-soluble A $\beta$ are increased in Alzheimer's disease brain. Brain Research, 2012, 1450, 138-147.	1.1	47
769	Monoacylglycerol Lipase Is a Therapeutic Target for Alzheimer's Disease. Cell Reports, 2012, 2, 1329-1339.	2.9	219
770	A plant cell-based system that predicts A $\beta$ 42 misfolding: Potential as a drug discovery tool for Alzheimer's disease. Molecular Genetics and Metabolism, 2012, 107, 571-579.	0.5	15
771	Neurotoxicity of Amyloid A-Protein: Synaptic and Network Dysfunction. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a006338-a006338.	2.9	844
773	Expression in Drosophila of Tandem Amyloid $\beta$ Peptides Provides Insights into Links between Aggregation and Neurotoxicity. Journal of Biological Chemistry, 2012, 287, 20748-20754.	1.6	40
774	Inhibiting, promoting, and preserving stability of functional proteinfibrils. Soft Matter, 2012, 8, 876-895.	1.2	122
775	Atomic-level investigations on the amyloid- $\beta$ dimerization process and its driving forces in water. Physical Chemistry Chemical Physics, 2012, 14, 1573-1575.	1.3	38
776	Erythrocytic Stage-dependent Regulation of Oligomerization of Plasmodium Ribosomal Protein P2. Journal of Biological Chemistry, 2012, 287, 41499-41513.	1.6	10
777	Computational Insights into Dynamics of Protein Aggregation and Enzyme-Substrate Interactions. Journal of Physical Chemistry Letters, 2012, 3, 3460-3469.	2.1	5
778	Explicit Solvent Molecular Dynamics Simulations of A $\beta$ Peptide Interacting with Ibuprofen Ligands. Journal of Physical Chemistry B, 2012, 116, 12922-12932.	1.2	33



#	ARTICLE	IF	CITATIONS
779	A Butyrolactone Derivative 3BDO Alleviates Memory Deficits and Reduces Amyloid- $\beta$ Deposition in an A $\beta$ PP/PS1 Transgenic Mouse Model. <i>Journal of Alzheimer's Disease</i> , 2012, 30, 531-543.	1.2	17
780	Dimerization of the Full-Length Alzheimer Amyloid $\beta$ -Peptide (A $\beta$ 42) in Explicit Aqueous Solution: A Molecular Dynamics Study. <i>Journal of Physical Chemistry B</i> , 2012, 116, 4405-4416.	1.2	51
781	Cognition, glucose metabolism and amyloid burden in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2012, 33, 215-225.	1.5	122
782	Molecular changes in brain aging and Alzheimer's disease are mirrored in experimentally silenced cortical neuron networks. <i>Neurobiology of Aging</i> , 2012, 33, 205.e1-205.e18.	1.5	33
783	SAP97-mediated local trafficking is altered in Alzheimer disease patients' hippocampus. <i>Neurobiology of Aging</i> , 2012, 33, 422.e1-422.e10.	1.5	46
784	Nanobody specific for oligomeric beta-amyloid stabilizes nontoxic form. <i>Neurobiology of Aging</i> , 2012, 33, 1320-1328.	1.5	32
785	Assessment of activation of the plasma kallikrein-kinin system in frontal and temporal cortex in Alzheimer's disease and vascular dementia. <i>Neurobiology of Aging</i> , 2012, 33, 1345-1355.	1.5	35
786	Changes in the physiology of CA1 hippocampal pyramidal neurons in preplaque CRND8 mice. <i>Neurobiology of Aging</i> , 2012, 33, 1609-1623.	1.5	29
787	Different $\beta$ -amyloid oligomer assemblies in Alzheimer brains correlate with age of disease onset and impaired cholinergic activity. <i>Neurobiology of Aging</i> , 2012, 33, 825.e1-825.e13.	1.5	86
788	AD synapses contain abundant A $\beta$ monomer and multiple soluble oligomers, including a 56-kDa assembly. <i>Neurobiology of Aging</i> , 2012, 33, 1545-1555.	1.5	54
789	Medial septal dysfunction by A $\beta$ -induced KCNQ channel-block in glutamatergic neurons. <i>Neurobiology of Aging</i> , 2012, 33, 2046-2061.	1.5	33
790	Synaptic protein deficits are associated with dementia irrespective of extreme old age. <i>Neurobiology of Aging</i> , 2012, 33, 1125.e1-1125.e8.	1.5	26
791	Amyloid- $\beta$ oligomers stimulate microglia through a tyrosine kinase dependent mechanism. <i>Neurobiology of Aging</i> , 2012, 33, 2247-2261.	1.5	93
792	Environmental enrichment ameliorated high-fat diet-induced A $\beta$ deposition and memory deficit in APP transgenic mice. <i>Neurobiology of Aging</i> , 2012, 33, 1011.e11-1011.e23.	1.5	84
793	Critical role of cPLA2 in A $\beta$ oligomer-induced neurodegeneration and memory deficit. <i>Neurobiology of Aging</i> , 2012, 33, 1123.e17-1123.e29.	1.5	48
794	Influence of functional connectivity and structural MRI measures on episodic memory. <i>Neurobiology of Aging</i> , 2012, 33, 2612-2620.	1.5	54
795	Dispersible amyloid $\beta$ -protein oligomers, protofibrils, and fibrils represent diffusible but not soluble aggregates: their role in neurodegeneration in amyloid precursor protein (APP) transgenic mice. <i>Neurobiology of Aging</i> , 2012, 33, 2641-2660.	1.5	50
796	$\beta$ -Amyloid 42/40 ratio and kalirin expression in Alzheimer disease with psychosis. <i>Neurobiology of Aging</i> , 2012, 33, 2807-2816.	1.5	40

#	ARTICLE	IF	CITATIONS
797	Defining Alzheimer as a common age-related neurodegenerative process not inevitably leading to dementia. <i>Progress in Neurobiology</i> , 2012, 97, 38-51.	2.8	153
798	Extracellular Alpha-Synuclein Oligomers Modulate Synaptic Transmission and Impair LTP Via NMDA-Receptor Activation. <i>Journal of Neuroscience</i> , 2012, 32, 11750-11762.	1.7	228
799	Effects of Polyphenols on Brain Ageing and Alzheimer's Disease: Focus on Mitochondria. <i>Molecular Neurobiology</i> , 2012, 46, 161-178.	1.9	107
800	Amyloid- $\beta$ Peptide: Dr. Jekyll or Mr. Hyde?. <i>Journal of Alzheimer's Disease</i> , 2012, 33, S111-S120.	1.2	91
801	Alzheimer amyloid- $\beta$ oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. <i>Nature Neuroscience</i> , 2012, 15, 1227-1235.	7.1	572
802	Targeting Synaptic Dysfunction in Alzheimer's Disease Therapy. <i>Molecular Neurobiology</i> , 2012, 46, 572-587.	1.9	80
803	Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders. <i>British Journal of Pharmacology</i> , 2012, 166, 1586-1599.	2.7	200
804	$A\beta$ alters the connectivity of olfactory neurons in the absence of amyloid plaques in vivo. <i>Nature Communications</i> , 2012, 3, 1009.	5.8	71
805	Structure and Dynamics of Small Soluble $A\beta(1-40)$ Oligomers Studied by Top-Down Hydrogen Exchange Mass Spectrometry. <i>Biochemistry</i> , 2012, 51, 3694-3703.	1.2	64
806	Exercise Is More Effective than Diet Control in Preventing High Fat Diet-induced $\beta$ -Amyloid Deposition and Memory Deficit in Amyloid Precursor Protein Transgenic Mice. <i>Journal of Biological Chemistry</i> , 2012, 287, 23024-23033.	1.6	122
807	The Effect of Curcumin on the Stability of $A\beta$ Dimers. <i>Journal of Physical Chemistry B</i> , 2012, 116, 7428-7435.	1.2	92
808	Soluble amyloid precursor protein- $\beta$ modulates $\beta$ -secretase activity and amyloid- $\beta$ generation. <i>Nature Communications</i> , 2012, 3, 777.	5.8	140
809	3,6-Dithiothalidomide, a new TNF- $\alpha$ synthesis inhibitor, attenuates the effect of $A\beta_{1-42}$ intracerebroventricular injection on hippocampal neurogenesis and memory deficit. <i>Journal of Neurochemistry</i> , 2012, 122, 1181-1192.	2.1	61
810	A synthetic amino acid substitution of Tyr10 in $A\beta$ peptide sequence yields a dominant negative variant in amyloidogenesis. <i>Aging Cell</i> , 2012, 11, 530-541.	3.0	8
811	The toxic $A\beta$ oligomer and Alzheimer's disease: an emperor in need of clothes. <i>Nature Neuroscience</i> , 2012, 15, 349-357.	7.1	1,690
812	Label-free electrochemical detection of Amyloid beta aggregation in the presence of iron, copper and zinc. <i>Journal of Electroanalytical Chemistry</i> , 2012, 681, 89-95.	1.9	49
813	Molecular Interactions of Alzheimer's $A\beta$ Protofilaments with Lipid Membranes. <i>Journal of Molecular Biology</i> , 2012, 421, 572-586.	2.0	64
814	Oligomeric Intermediates in Amyloid Formation: Structure Determination and Mechanisms of Toxicity. <i>Journal of Molecular Biology</i> , 2012, 421, 427-440.	2.0	301

#	ARTICLE	IF	CITATIONS
815	Chemical Strategies for Controlling Protein Folding and Elucidating the Molecular Mechanisms of Amyloid Formation and Toxicity. <i>Journal of Molecular Biology</i> , 2012, 421, 204-236.	2.0	27
816	Synthesis, characterization and distinct butyrylcholinesterase activities of transition metal complexes of 2-[(E)-(quinolin-3-ylimino)methyl]phenol. <i>Inorganica Chimica Acta</i> , 2012, 390, 210-216.	1.2	20
817	Natural substances and Alzheimer's disease: From preclinical studies to evidence based medicine. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2012, 1822, 616-624.	1.8	72
818	Prolonged elevation in hippocampal A $\beta$ and cognitive deficits following repeated endotoxin exposure in the mouse. <i>Behavioural Brain Research</i> , 2012, 229, 176-184.	1.2	144
819	The metabotropic glutamate 2/3 receptor antagonist LY341495 differentially affects recognition memory in rats. <i>Behavioural Brain Research</i> , 2012, 230, 374-379.	1.2	20
820	Utilization of a multiple antigenic peptide as a calibration standard in the BAN50 single antibody sandwich ELISA for A $\beta$ oligomers. <i>Biochemical and Biophysical Research Communications</i> , 2012, 422, 375-380.	1.0	10
821	Plasma amyloid- $\beta$ oligomers level is a biomarker for Alzheimer's disease diagnosis. <i>Biochemical and Biophysical Research Communications</i> , 2012, 423, 697-702.	1.0	53
822	Metal binding sites in amyloid oligomers: Complexes and mechanisms. <i>Coordination Chemistry Reviews</i> , 2012, 256, 2245-2252.	9.5	95
823	Metal compounds as inhibitors of $\beta$ -amyloid aggregation. Perspectives for an innovative metallotherapeutics on Alzheimer's disease. <i>Coordination Chemistry Reviews</i> , 2012, 256, 2357-2366.	9.5	65
824	The rich electrochemistry and redox reactions of the copper sites in the cellular prion protein. <i>Coordination Chemistry Reviews</i> , 2012, 256, 2285-2296.	9.5	39
825	The Amyloid State of Proteins in Human Diseases. <i>Cell</i> , 2012, 148, 1188-1203.	13.5	1,496
826	Bryostatin-1 vs. TPPB: Dose-Dependent APP Processing and PKC- $\delta$ , - $\epsilon$ , and - $\mu$ Isoform Activation in SH-SY5Y Neuronal Cells. <i>Journal of Molecular Neuroscience</i> , 2012, 48, 234-244.	1.1	19
827	Lithium Reduces BACE1 Overexpression, Beta Amyloid Accumulation, and Spatial Learning Deficits in Mice with Traumatic Brain Injury. <i>Journal of Neurotrauma</i> , 2012, 29, 2342-2351.	1.7	89
828	Alzheimer's Disease: Redox Dysregulation As a Common Denominator for Diverse Pathogenic Mechanisms. <i>Antioxidants and Redox Signaling</i> , 2012, 16, 974-1031.	2.5	163
829	Neuronal receptors as targets for the action of amyloid-beta protein (A $\beta$ ) in the brain. <i>Expert Reviews in Molecular Medicine</i> , 2012, 14, e2.	1.6	46
830	Apolipoprotein E, Especially Apolipoprotein E4, Increases the Oligomerization of Amyloid $\beta$ Peptide. <i>Journal of Neuroscience</i> , 2012, 32, 15181-15192.	1.7	219
831	Tumor necrosis factor- $\alpha$ synthesis inhibitor 3,6-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer's disease. <i>Journal of Neuroinflammation</i> , 2012, 9, 106.	3.1	179
832	Preventive immunization of aged and juvenile non-human primates to beta-amyloid. <i>Journal of Neuroinflammation</i> , 2012, 9, 84.	3.1	22

#	ARTICLE	IF	CITATIONS
833	Alzheimer's disease A $\beta$ assemblies mediating rapid disruption of synaptic plasticity and memory. <i>Molecular Brain</i> , 2012, 5, 25.	1.3	82
834	Alzheimer's Disease and the Amyloid $\beta$ -Protein. <i>Progress in Molecular Biology and Translational Science</i> , 2012, 107, 101-124.	0.9	106
835	Orchestrated experience-driven Arc responses are disrupted in a mouse model of Alzheimer's disease. <i>Nature Neuroscience</i> , 2012, 15, 1422-1429.	7.1	108
836	N-terminal pyroglutamate formation of A $\beta$ <sub>38</sub> and A $\beta$ <sub>40</sub> enforces oligomer formation and potency to disrupt hippocampal long-term potentiation. <i>Journal of Neurochemistry</i> , 2012, 121, 774-784.	2.1	76
837	Solanezumab for the treatment of mild-to-moderate Alzheimer's disease. <i>Expert Review of Clinical Immunology</i> , 2012, 8, 135-149.	1.3	79
838	NMDA receptors and BAX are essential for A $\beta$ impairment of LTP. <i>Scientific Reports</i> , 2012, 2, 225.	1.6	38
839	Large Aggregates Are the Major Soluble A $\beta$ Species in AD Brain Fractionated with Density Gradient Ultracentrifugation. <i>PLoS ONE</i> , 2012, 7, e32014.	1.1	85
840	Staged decline of neuronal function in vivo in an animal model of Alzheimer's disease. <i>Nature Communications</i> , 2012, 3, 774.	5.8	116
841	Investigating How Peptide Length and a Pathogenic Mutation Modify the Structural Ensemble of Amyloid Beta Monomer. <i>Biophysical Journal</i> , 2012, 102, 315-324.	0.2	114
842	A Variational Model for Oligomer-Formation Process of GNNQQNY Peptide from Yeast Prion Protein Sup35. <i>Biophysical Journal</i> , 2012, 102, 597-605.	0.2	9
843	$\beta$ -Amyloid (1-40) Peptide Interactions with Supported Phospholipid Membranes: A Single-Molecule Study. <i>Biophysical Journal</i> , 2012, 103, 1500-1509.	0.2	56
844	The vascular factor in Alzheimer's disease: A study in Golgi technique and electron microscopy. <i>Journal of the Neurological Sciences</i> , 2012, 322, 117-121.	0.3	117
845	Sortilin is required for toxic action of A $\beta$ oligomers (A $\beta$ Os): Extracellular A $\beta$ Os trigger apoptosis, and intraneuronal A $\beta$ Os impair degradation pathways. <i>Life Sciences</i> , 2012, 91, 1177-1186.	2.0	28
846	New and emerging treatments for Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 535-543.	1.4	50
847	Immunotherapy for Alzheimer disease—the challenge of adverse effects. <i>Nature Reviews Neurology</i> , 2012, 8, 465-469.	4.9	107
848	Synaptic Dysfunction in Alzheimer's Disease. <i>Advances in Experimental Medicine and Biology</i> , 2012, 970, 573-601.	0.8	94
849	Efficacy of a Therapeutic Vaccine Using Mutated $\beta$ -amyloid Sensitized Dendritic Cells in Alzheimer's Mice. <i>Journal of Neuroimmune Pharmacology</i> , 2012, 7, 640-655.	2.1	13
850	DENN/MADD/IG20 Alternative Splicing Changes and Cell Death in Alzheimer's Disease. <i>Journal of Molecular Neuroscience</i> , 2012, 48, 97-110.	1.1	5

#	ARTICLE	IF	CITATIONS
851	Computational modeling of the relationship between amyloid and disease. <i>Biophysical Reviews</i> , 2012, 4, 205-222.	1.5	29
852	Molecular Interactions of Alzheimer's Biomarker FDDNP with A $\beta$ Peptide. <i>Biophysical Journal</i> , 2012, 103, 2341-2351.	0.2	15
853	Cognitive reserve, presynaptic proteins and dementia in the elderly. <i>Translational Psychiatry</i> , 2012, 2, e114-e114.	2.4	88
854	Interrelations between CSF Soluble A $\beta$ PP $\beta$ , Amyloid- $\beta$ 1-42, SORL1, and Tau Levels in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 28, 543-552.	1.2	21
855	Methods for Analysis of Amyloid- $\beta$ Aggregates. <i>Journal of Alzheimer's Disease</i> , 2012, 28, 735-758.	1.2	62
856	The N-Methylated Peptide SEN304 Powerfully Inhibits A $\beta$ (1-42) Toxicity by Perturbing Oligomer Formation. <i>Biochemistry</i> , 2012, 51, 8338-8352.	1.2	61
857	Impaired LTP- but not LTD-Like Cortical Plasticity in Alzheimer's Disease Patients. <i>Journal of Alzheimer's Disease</i> , 2012, 31, 593-599.	1.2	127
858	Modulating metals as a therapeutic strategy for Alzheimer's disease. <i>Future Medicinal Chemistry</i> , 2012, 4, 955-969.	1.1	16
859	Alzheimer's Disease-Related Loss of Pin1 Function Influences the Intracellular Localization and the Processing of A $\beta$ PP. <i>Journal of Alzheimer's Disease</i> , 2012, 30, 277-297.	1.2	36
860	Laser-Induced Liquid Bead Ion Desorption Mass Spectrometry: An Approach to Precisely Monitor the Oligomerization of the $\beta$ -Amyloid Peptide. <i>Analytical Chemistry</i> , 2012, 84, 5276-5284.	3.2	30
861	Clearance of amyloid- $\beta$ peptides by microglia and macrophages: the issue of what, when and where. <i>Future Neurology</i> , 2012, 7, 165-176.	0.9	129
862	Functional $\alpha 7$ nicotinic acetylcholine receptors expressed in hippocampal interneurons exhibit high sensitivity to pathological level of amyloid $\beta$ peptides. <i>BMC Neuroscience</i> , 2012, 13, 155.	0.8	61
863	The Synaptic Accumulation of Hyperphosphorylated Tau Oligomers in Alzheimer Disease Is Associated With Dysfunction of the Ubiquitin-Proteasome System. <i>American Journal of Pathology</i> , 2012, 181, 1426-1435.	1.9	369
864	Utility of an improved model of amyloid-beta (A $\beta$ 1-42) toxicity in <i>Caenorhabditis elegans</i> for drug screening for Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2012, 7, 57.	4.4	188
865	Aggregation, impaired degradation and immunization targeting of amyloid-beta dimers in Alzheimer's disease: a stochastic modelling approach. <i>Molecular Neurodegeneration</i> , 2012, 7, 32.	4.4	25
866	Absence of amyloid $\beta$ oligomers at the postsynapse and regulated synaptic Zn $^{2+}$ in cognitively intact aged individuals with Alzheimer's disease neuropathology. <i>Molecular Neurodegeneration</i> , 2012, 7, 23.	4.4	72
867	PathNet: a tool for pathway analysis using topological information. <i>Source Code for Biology and Medicine</i> , 2012, 7, 10.	1.7	67
868	Overlapping profiles of A $\beta$ peptides in the Alzheimer's disease and pathological aging brains. <i>Alzheimer's Research and Therapy</i> , 2012, 4, 18.	3.0	92

#	ARTICLE	IF	CITATIONS
869	A Preclinical Assessment of Neural Stem Cells as Delivery Vehicles for Anti-Amyloid Therapeutics. PLoS ONE, 2012, 7, e34097.	1.1	24
870	Cell Line Specific Modulation of Extracellular A $\beta$ 42 by Hsp40. PLoS ONE, 2012, 7, e37755.	1.1	7
871	A Foldamer-Dendrimer Conjugate Neutralizes Synaptotoxic $\beta$ 2-Amyloid Oligomers. PLoS ONE, 2012, 7, e39485.	1.1	39
872	Astrocyte Senescence as a Component of Alzheimer's Disease. PLoS ONE, 2012, 7, e45069.	1.1	393
873	Multivariate Analyses of Amyloid-Beta Oligomer Populations Indicate a Connection between Pore Formation and Cytotoxicity. PLoS ONE, 2012, 7, e47261.	1.1	79
874	Protein Fragments: Functional and Structural Roles of Their Coevolution Networks. PLoS ONE, 2012, 7, e48124.	1.1	22
875	Modeling Amyloid-Beta as Homogeneous Dodecamers and in Complex with Cellular Prion Protein. PLoS ONE, 2012, 7, e49375.	1.1	11
876	Human Anti-A $\beta$ 2 IgGs Target Conformational Epitopes on Synthetic Dimer Assemblies and the AD Brain-Derived Peptide. PLoS ONE, 2012, 7, e50317.	1.1	13
877	Adiponectin is Protective against Oxidative Stress Induced Cytotoxicity in Amyloid-Beta Neurotoxicity. PLoS ONE, 2012, 7, e52354.	1.1	119
878	Translational Concepts of mGluR5 in Synaptic Diseases of the Brain. Frontiers in Pharmacology, 2012, 3, 199.	1.6	66
879	Microglial KCa3.1 Channels as a Potential Therapeutic Target for Alzheimer's Disease. International Journal of Alzheimer's Disease, 2012, 2012, 1-8.	1.1	53
880	Selective Impairment of Some Forms of Synaptic Plasticity by Oligomeric Amyloid- $\beta$ 2 Peptide in the Mouse Hippocampus: Implication of Extrasynaptic NMDA Receptors. Journal of Alzheimer's Disease, 2012, 32, 183-196.	1.2	37
881	Oxidative Stress in Alzheimer's and Parkinson's Diseases: Insights from the Yeast <i>Saccharomyces cerevisiae</i> . Oxidative Medicine and Cellular Longevity, 2012, 2012, 1-9.	1.9	64
882	Cholesterol and Synaptic Compensatory Mechanisms in Alzheimer's Disease Mice Brain During Aging. Journal of Alzheimer's Disease, 2012, 31, 813-826.	1.2	25
883	Chronic psychosocial stress exposes Alzheimer's disease phenotype in a novel at-risk model. Frontiers in Bioscience - Elite, 2012, E4, 214-229.	0.9	13
884	Age-related changes in synaptic markers and monocyte subsets link the cognitive decline of APPSwe/PS1 mice. Frontiers in Cellular Neuroscience, 2012, 6, 51.	1.8	33
885	The role of neuronal calcium sensors in balancing synaptic plasticity and synaptic dysfunction. Frontiers in Molecular Neuroscience, 2012, 5, 57.	1.4	12
886	Molecular Mechanisms in Synaptic Plasticity. , 0, , .		4



#	ARTICLE	IF	CITATIONS
887	The Dying of the Light: Mitochondrial Failure in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 28, 771-781.	1.2	35
888	Hematopoietic CC-Chemokine Receptor 2 (CCR2) Competent Cells Are Protective for the Cognitive Impairments and Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease. <i>Molecular Medicine</i> , 2012, 18, 297-313.	1.9	61
892	Indomethacin-loaded lipid-core nanocapsules reduce the damage triggered by A $\beta$ 1-42 in Alzheimer's disease models. <i>International Journal of Nanomedicine</i> , 2012, 7, 4927.	3.3	73
893	The Biphasic Role of Microglia in Alzheimer's Disease. <i>International Journal of Alzheimer's Disease</i> , 2012, 2012, 1-9.	1.1	47
894	Phenolic Compounds Prevent Amyloid $\beta$ -Protein Oligomerization and Synaptic Dysfunction by Site-specific Binding. <i>Journal of Biological Chemistry</i> , 2012, 287, 14631-14643.	1.6	208
895	Inhibition of the NFAT Pathway Alleviates Amyloid Beta Neurotoxicity in a Mouse Model of Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2012, 32, 3176-3192.	1.7	92
896	Impact of chemical heterogeneity on protein self-assembly in water. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 7636-7641.	3.3	109
897	Rapid oligomer formation of human muscle acylphosphatase induced by heparan sulfate. <i>Nature Structural and Molecular Biology</i> , 2012, 19, 547-554.	3.6	28
898	Distinct Dimerization for Various Alloforms of the Amyloid-Beta Protein: A $\beta$ <sub>1-40</sub> , A $\beta$ <sub>1-42</sub> , and A $\beta$ <sub>1-40</sub> (D23N). <i>Journal of Physical Chemistry B</i> , 2012, 116, 4043-4055.	1.2	102
899	Purified and synthetic Alzheimer's amyloid beta (A $\beta$ ) prions. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 11025-11030.	3.3	327
900	Discovery of an Orally Available, Brain Penetrant BACE1 Inhibitor That Affords Robust CNS A $\beta$ Reduction. <i>ACS Medicinal Chemistry Letters</i> , 2012, 3, 897-902.	1.3	97
901	Reversal of Paralysis and Reduced Inflammation from Peripheral Administration of $\beta$ -Amyloid in T <sub>H</sub> 1 and T <sub>H</sub> 17 Versions of Experimental Autoimmune Encephalomyelitis. <i>Science Translational Medicine</i> , 2012, 4, 145ra105.	5.8	83
902	Complement component C3 and complement receptor type 3 contribute to the phagocytosis and clearance of fibrillar A $\beta$ by microglia. <i>Glia</i> , 2012, 60, 993-1003.	2.5	136
903	Tannic Acid Is a Natural $\beta$ -Secretase Inhibitor That Prevents Cognitive Impairment and Mitigates Alzheimer-like Pathology in Transgenic Mice. <i>Journal of Biological Chemistry</i> , 2012, 287, 6912-6927.	1.6	156
904	Adsorption and Disruption of Lipid Bilayers by Nanoscale Protein Aggregates. <i>Langmuir</i> , 2012, 28, 3887-3895.	1.6	32
905	Apoptotic and non-apoptotic roles of caspases in neuronal physiology and pathophysiology. <i>Nature Reviews Neuroscience</i> , 2012, 13, 395-406.	4.9	218
906	Mitochondrial Importance in Alzheimer's, Huntington's and Parkinson's Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2012, 724, 205-221.	0.8	57
907	Mitochondrial Dysfunction: A Pharmacological Target in Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2012, 46, 136-150.	1.9	115



#	ARTICLE	IF	CITATIONS
908	Protein oxidation in Huntington disease. <i>BioFactors</i> , 2012, 38, 173-185.	2.6	42
909	Deconstructing signal transduction pathways that regulate the actin cytoskeleton in dendritic spines. <i>Cytoskeleton</i> , 2012, 69, 426-441.	1.0	51
910	<i>Withania somnifera</i> reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 3510-3515.	3.3	304
911	Interaction between pathogenic proteins in neurodegenerative disorders. <i>Journal of Cellular and Molecular Medicine</i> , 2012, 16, 1166-1183.	1.6	104
912	Specific Soluble Oligomers of Amyloid- $\beta$ Peptide Undergo Replication and Form Non-fibrillar Aggregates in Interfacial Environments. <i>Journal of Biological Chemistry</i> , 2012, 287, 21253-21264.	1.6	41
913	New and emerging treatments for Alzheimer's disease. <i>Expert Opinion on Emerging Drugs</i> , 2012, 17, 147-156.	1.0	25
914	Prion propagation, toxicity and degradation. <i>Nature Neuroscience</i> , 2012, 15, 936-939.	7.1	105
915	Critical role of soluble amyloid- $\beta$ for early hippocampal hyperactivity in a mouse model of Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 8740-8745.	3.3	541
916	Small-molecule BACE1 inhibitors: a patent literature review (2006 - 2011). <i>Expert Opinion on Therapeutic Patents</i> , 2012, 22, 511-540.	2.4	77
917	Aberrant Dendritic Excitability: A Common Pathophysiology in CNS Disorders Affecting Memory?. <i>Molecular Neurobiology</i> , 2012, 45, 478-487.	1.9	18
918	Cerebrospinal fluid levels of A $\beta$ 42 relationship with cholinergic cortical activity in Alzheimer's disease patients. <i>Journal of Neural Transmission</i> , 2012, 119, 771-778.	1.4	31
919	A novel ARC gene polymorphism is associated with reduced risk of Alzheimer's disease. <i>Journal of Neural Transmission</i> , 2012, 119, 833-842.	1.4	27
920	Soluble A $\beta$ oligomer production and toxicity. <i>Journal of Neurochemistry</i> , 2012, 120, 125-139.	2.1	312
921	The role of metallobiology and amyloid- $\beta$ peptides in Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2012, 120, 149-166.	2.1	233
922	Amyloid $\beta$ : linking synaptic plasticity failure to memory disruption in Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2012, 120, 140-148.	2.1	110
923	Autoreactive A $\beta$ antibodies promote APP $\beta$ -secretase processing. <i>Journal of Neurochemistry</i> , 2012, 120, 732-740.	2.1	25
924	Eph receptors at synapses: Implications in neurodegenerative diseases. <i>Cellular Signalling</i> , 2012, 24, 606-611.	1.7	69
925	Protein Misfolded Oligomers: Experimental Approaches, Mechanism of Formation, and Structure-Toxicity Relationships. <i>Chemistry and Biology</i> , 2012, 19, 315-327.	6.2	239

#	ARTICLE	IF	CITATIONS
926	Probucol, a lipid-lowering drug, prevents cognitive and hippocampal synaptic impairments induced by amyloid $\beta$ peptide in mice. <i>Experimental Neurology</i> , 2012, 233, 767-775.	2.0	70
927	Amyloid oligomer detection by immobilized molecular chaperone. <i>Biochemical Engineering Journal</i> , 2012, 61, 28-33.	1.8	6
928	Chemical modulators working at pharmacological interface of target proteins. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 1893-1901.	1.4	12
929	Probing the efficacy of peptide-based inhibitors against acid- and zinc-promoted oligomerization of amyloid- $\beta$ peptide via single-oligomer spectroscopy. <i>Biophysical Chemistry</i> , 2012, 160, 12-19.	1.5	8
930	Intranasal administration of nerve growth factor ameliorate $\beta$ -amyloid deposition after traumatic brain injury in rats. <i>Brain Research</i> , 2012, 1440, 47-55.	1.1	70
931	Insulin signaling, glucose metabolism and mitochondria: Major players in Alzheimer's disease and diabetes interrelation. <i>Brain Research</i> , 2012, 1441, 64-78.	1.1	164
932	Quality Control Compartments Coming of Age. <i>Traffic</i> , 2012, 13, 635-642.	1.3	30
933	Early and Selective Impairments in Axonal Transport Kinetics of Synaptic Cargoes Induced by Soluble Amyloid $\beta$ -Protein Oligomers. <i>Traffic</i> , 2012, 13, 681-693.	1.3	50
934	High-molecular weight $A\beta$ oligomers and protofibrils are the predominant $A\beta$ species in the native soluble protein fraction of the AD brain. <i>Journal of Cellular and Molecular Medicine</i> , 2012, 16, 287-295.	1.6	58
935	Active $A\beta$ vaccination fails to enhance amyloid clearance in a mouse model of Alzheimer's disease with $A\beta$ 42-driven pathology. <i>Journal of Neuroimmunology</i> , 2012, 247, 95-99.	1.1	7
936	Herpes simplex virus type 1-based amplicon vectors for fundamental research in neurosciences and gene therapy of neurological diseases. <i>Journal of Physiology (Paris)</i> , 2012, 106, 2-11.	2.1	18
937	Preferential accumulation of amyloid-beta in presynaptic glutamatergic terminals (VGlut1 and VGlut2) in Alzheimer's disease cortex. <i>Neurobiology of Disease</i> , 2012, 45, 381-387.	2.1	72
938	Activation of glycogen synthase kinase-3 beta mediates $\beta$ -amyloid induced neuritic damage in Alzheimer's disease. <i>Neurobiology of Disease</i> , 2012, 45, 425-437.	2.1	145
939	Vitamin A and Alzheimer's disease. <i>Geriatrics and Gerontology International</i> , 2012, 12, 180-188.	0.7	99
940	AMPA receptors as drug targets in neurological disease – advantages, caveats, and future outlook. <i>European Journal of Neuroscience</i> , 2012, 35, 1908-1916.	1.2	133
941	Proteinopathies, neurodegenerative disorders with protein aggregation-based pathology. <i>Molecular Biology</i> , 2012, 46, 362-374.	0.4	54
942	Modeling the interactions of Alzheimer-related genes from the whole brain microarray data and diffusion tensor images of human brain. <i>BMC Bioinformatics</i> , 2012, 13, S10.	1.2	14
943	Huperzine A alleviates synaptic deficits and modulates amyloidogenic and nonamyloidogenic pathways in APP <sup>swE</sup> /PS1 <sup>dE9</sup> transgenic mice. <i>Journal of Neuroscience Research</i> , 2012, 90, 508-517.	1.3	47

#	ARTICLE	IF	CITATIONS
944	Preparation of true solutions of monomeric amyloidogenic protein/peptide: A critical prerequisite for aggregation kinetic study. <i>Science China Chemistry</i> , 2012, 55, 118-124.	4.2	6
945	A $\beta$ Imaging: feasible, pertinent, and vital to progress in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 209-219.	3.3	55
946	Effect of Phenolic Compounds Against A $\beta$ Aggregation and A $\beta$ -Induced Toxicity in Transgenic <i>C. elegans</i> . <i>Neurochemical Research</i> , 2012, 37, 40-48.	1.6	44
947	Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets?. <i>Immunity and Ageing</i> , 2013, 10, 18.	1.8	97
948	Fluid biomarkers in Alzheimer's disease – current concepts. <i>Molecular Neurodegeneration</i> , 2013, 8, 20.	4.4	180
949	Effects of antiparkinsonian agents on A $\beta$ -amyloid and $\alpha$ -synuclein oligomer formation in vitro. <i>Journal of Neuroscience Research</i> , 2013, 91, 1371-1381.	1.3	22
950	SnapShot: Pathobiology of Alzheimer's Disease. <i>Cell</i> , 2013, 154, 468-468.e1.	13.5	42
951	Metal dyshomeostasis and oxidative stress in Alzheimer's disease. <i>Neurochemistry International</i> , 2013, 62, 540-555.	1.9	376
952	The case for soluble A $\beta$ oligomers as a drug target in Alzheimer's disease. <i>Trends in Pharmacological Sciences</i> , 2013, 34, 261-266.	4.0	102
953	Granulocyte colony stimulating factor (GCSF) improves memory and neurobehavior in an amyloid- $\beta$ induced experimental model of Alzheimer's disease. <i>Pharmacology Biochemistry and Behavior</i> , 2013, 110, 46-57.	1.3	63
954	The neurodegeneration in Alzheimer disease and the prion protein. <i>Prion</i> , 2013, 7, 60-65.	0.9	12
955	Delayed dendritic development in newly generated dentate granule cells by cell-autonomous expression of the amyloid precursor protein. <i>Molecular and Cellular Neurosciences</i> , 2013, 56, 298-306.	1.0	8
956	Molecular links between Alzheimer's disease and diabetes mellitus. <i>Neuroscience</i> , 2013, 250, 140-150.	1.1	173
957	Single-molecule Studies of Proteins. , 2013, , .		7
958	Effects of corticosterone and amyloid-beta on proteins essential for synaptic function: Implications for depression and Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2013, 1832, 2245-2256.	1.8	35
959	Structures of Oligomers of a Peptide from A $\beta$ -Amyloid. <i>Journal of the American Chemical Society</i> , 2013, 135, 12460-12467.	6.6	50
960	Neurotoxic Saboteurs: Straws that Break the Hippocampus Back Drive Cognitive Impairment and Alzheimer's Disease. <i>Neurotoxicity Research</i> , 2013, 24, 407-459.	1.3	47
961	A $\beta$ Monomers Transiently Sample Oligomer and Fibril-Like Configurations: Ensemble Characterization Using a Combined MD/NMR Approach. <i>Journal of Molecular Biology</i> , 2013, 425, 3338-3359.	2.0	198

#	ARTICLE	IF	CITATIONS
962	3H-Deprenyl and 3H-PIB autoradiography show different laminar distributions of astroglia and fibrillar $A\beta$ -amyloid in Alzheimer brain. <i>Journal of Neuroinflammation</i> , 2013, 10, 90.	3.1	54
963	The therapeutics of Alzheimer's disease: Where we stand and where we are heading. <i>Annals of Neurology</i> , 2013, 74, 328-336.	2.8	101
964	Cognitive-enhancing and antioxidant activities of inhaled coriander volatile oil in amyloid $A\beta$ (1-42) rat model of Alzheimer's disease. <i>Physiology and Behavior</i> , 2013, 120, 193-202.	1.0	104
965	Analysis of Amino-Terminal Variants of Amyloid- $A\beta$ Peptides by Capillary Isoelectric Focusing Immunoassay. <i>Analytical Chemistry</i> , 2013, 85, 8142-8149.	3.2	34
966	Nicotine Prevents Synaptic Impairment Induced by Amyloid- $A\beta$ Oligomers Through $\alpha 7$ -Nicotinic Acetylcholine Receptor Activation. <i>NeuroMolecular Medicine</i> , 2013, 15, 549-569.	1.8	77
967	Nuclear calcium signalling in the regulation of brain function. <i>Nature Reviews Neuroscience</i> , 2013, 14, 593-608.	4.9	295
968	Biological function of Presenilin and its role in AD pathogenesis. <i>Translational Neurodegeneration</i> , 2013, 2, 15.	3.6	68
969	N-truncated amyloid $A\beta$ ( $A\beta$ ) 4-42 forms stable aggregates and induces acute and long-lasting behavioral deficits. <i>Acta Neuropathologica</i> , 2013, 126, 189-205.	3.9	153
970	Metabotropic Glutamate Receptor 5 Is a Coreceptor for Alzheimer $A\beta$ Oligomer Bound to Cellular Prion Protein. <i>Neuron</i> , 2013, 79, 887-902.	3.8	485
971	Neuropharmacological Review of the Nootropic Herb <i>Bacopa monnieri</i> . <i>Rejuvenation Research</i> , 2013, 16, 313-326.	0.9	198
972	Revealing Hidden Helix Propensity in $A\beta$ Peptides by Molecular Dynamics Simulations. <i>Journal of Physical Chemistry B</i> , 2013, 117, 12030-12038.	1.2	7
973	Binding to the lipid monolayer induces conformational transition in $A\beta$ monomer. <i>Journal of Molecular Modeling</i> , 2013, 19, 737-750.	0.8	9
974	Dissecting phenotypic traits linked to human resilience to Alzheimer's pathology. <i>Brain</i> , 2013, 136, 2510-2526.	3.7	294
975	The role of phosphodiesterases in hippocampal synaptic plasticity. <i>Neuropharmacology</i> , 2013, 74, 86-95.	2.0	44
976	Microcontact printing of Alzheimer's $A\beta$ -amyloid monomers and fibrils. <i>European Polymer Journal</i> , 2013, 49, 3052-3059.	2.6	1
977	Neuronal activity and secreted amyloid $A\beta$ lead to altered amyloid $A\beta$ precursor protein and presenilin 1 interactions. <i>Neurobiology of Disease</i> , 2013, 50, 127-134.	2.1	32
978	Fibrillar seeds alleviate amyloid- $A\beta$ cytotoxicity by omitting formation of higher-molecular-weight oligomers. <i>Biochemical and Biophysical Research Communications</i> , 2013, 439, 321-326.	1.0	13
979	Structural Insights into $A\beta$ 42 Oligomers Using Site-directed Spin Labeling. <i>Journal of Biological Chemistry</i> , 2013, 288, 18673-18683.	1.6	70

#	ARTICLE	IF	CITATIONS
980	The effects of ferulic acid on $\beta$ -amyloid fibrillar structures investigated through experimental and computational techniques. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2013, 1830, 2924-2937.	1.1	23
981	Protective effects of EphB2 on $A\beta_{1-42}$ oligomer-induced neurotoxicity and synaptic NMDA receptor signaling in hippocampal neurons. <i>Neurochemistry International</i> , 2013, 63, 283-290.	1.9	27
982	Pathology of clinical and preclinical Alzheimer's disease. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013, 263, 137-145.	1.8	51
983	Design and Synthesis of Curcumin Analogues for in Vivo Fluorescence Imaging and Inhibiting Copper-Induced Cross-Linking of Amyloid Beta Species in Alzheimer's Disease. <i>Journal of the American Chemical Society</i> , 2013, 135, 16397-16409.	6.6	286
984	Brain amyloid- $\beta$ oligomers in ageing and Alzheimer's disease. <i>Brain</i> , 2013, 136, 1383-1398.	3.7	384
985	Current and Emerging Therapies for Alzheimer's Disease. <i>Clinical Therapeutics</i> , 2013, 35, 1480-1489.	1.1	28
986	The BRICHOS Domain, Amyloid Fibril Formation, and Their Relationship. <i>Biochemistry</i> , 2013, 52, 7523-7531.	1.2	70
987	Alzheimer's Amyloid- $\beta$ Oligomers Rescue Cellular Prion Protein Induced Tau Reduction via the Fyn Pathway. <i>ACS Chemical Neuroscience</i> , 2013, 4, 1287-1296.	1.7	26
988	Glyconanoparticle Aided Detection of $\beta$ -Amyloid by Magnetic Resonance Imaging and Attenuation of $\beta$ -Amyloid Induced Cytotoxicity. <i>ACS Chemical Neuroscience</i> , 2013, 4, 575-584.	1.7	60
989	Heme prevents amyloid beta peptide aggregation through hydrophobic interaction based on molecular dynamics simulation. <i>Physical Chemistry Chemical Physics</i> , 2013, 15, 14098-14106.	1.3	18
990	APP/PS1 mice overexpressing SREBP-2 exhibit combined $A\beta$ accumulation and tau pathology underlying Alzheimer's disease. <i>Human Molecular Genetics</i> , 2013, 22, 3460-3476.	1.4	98
991	Synaptic changes in Alzheimer's disease and its models. <i>Neuroscience</i> , 2013, 251, 51-65.	1.1	257
992	Personalized medicine strategies for managing patients with Parkinsonism and cognitive deficits. <i>Metabolism: Clinical and Experimental</i> , 2013, 62, S27-S29.	1.5	8
993	Single-Molecule Imaging Reveals $A\beta_{42}$ : $A\beta_{40}$ Ratio-Dependent Oligomer Growth on Neuronal Processes. <i>Biophysical Journal</i> , 2013, 104, 894-903.	0.2	29
994	CD4 T cells in immunity and immunotherapy of Alzheimer's disease. <i>Immunology</i> , 2013, 139, 438-446.	2.0	56
995	Orally bioavailable small molecule drug protects memory in Alzheimer's disease models. <i>Neurobiology of Aging</i> , 2013, 34, 1116-1125.	1.5	16
996	The cell biology of prion-like spread of protein aggregates: mechanisms and implication in neurodegeneration. <i>Biochemical Journal</i> , 2013, 452, 1-17.	1.7	126
997	Combination therapy in a transgenic model of Alzheimer's disease. <i>Experimental Neurology</i> , 2013, 250, 228-238.	2.0	29

#	ARTICLE	IF	CITATIONS
998	Modeling Alzheimer's disease in transgenic rats. <i>Molecular Neurodegeneration</i> , 2013, 8, 37.	4.4	144
999	The systemic iron-regulatory proteins hepcidin and ferroportin are reduced in the brain in Alzheimer's disease. <i>Acta Neuropathologica Communications</i> , 2013, 1, 55.	2.4	152
1000	Tau pathology induces loss of GABAergic interneurons leading to altered synaptic plasticity and behavioral impairments. <i>Acta Neuropathologica Communications</i> , 2013, 1, 34.	2.4	98
1001	A central role for dityrosine crosslinking of Amyloid- $\beta$ in Alzheimer's disease. <i>Acta Neuropathologica Communications</i> , 2013, 1, 83.	2.4	150
1002	The type of $A\beta$ -related neuronal degeneration differs between amyloid precursor protein (APP23) and amyloid $\beta$ -peptide (APP48) transgenic mice. <i>Acta Neuropathologica Communications</i> , 2013, 1, 77.	2.4	12
1003	Dysregulation of synaptic and extrasynaptic N-methyl-D-aspartate receptors induced by amyloid- $\beta$ . <i>Neuroscience Bulletin</i> , 2013, 29, 752-760.	1.5	42
1004	SUMO and Alzheimer's Disease. <i>NeuroMolecular Medicine</i> , 2013, 15, 720-736.	1.8	82
1005	Targeting the neural extracellular matrix in neurological disorders. <i>Neuroscience</i> , 2013, 253, 194-213.	1.1	198
1006	Human LILRB2 Is a $\beta$ -Amyloid Receptor and Its Murine Homolog PirB Regulates Synaptic Plasticity in an Alzheimer's Model. <i>Science</i> , 2013, 341, 1399-1404.	6.0	335
1007	Synthetic dityrosine-linked $\beta$ -amyloid dimers form stable, soluble, neurotoxic oligomers. <i>Chemical Science</i> , 2013, 4, 4449.	3.7	44
1008	Copper ligation to soluble oligomers of the English mutant of the amyloid- $\beta$ peptide yields a linear Cu(I) site that is resistant to O <sub>2</sub> oxidation. <i>Chemical Communications</i> , 2013, 49, 4797.	2.2	12
1009	Early Molecular Changes in Alzheimer Disease: Can We Catch the Disease in its Presymptomatic Phase?. <i>Journal of Alzheimer's Disease</i> , 2013, 38, 719-740.	1.2	40
1010	Statistical Mechanical Treatments of Protein Amyloid Formation. <i>International Journal of Molecular Sciences</i> , 2013, 14, 17420-17452.	1.8	4
1011	Synthesis of quinoline derivatives: Discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer's disease. <i>European Journal of Medicinal Chemistry</i> , 2013, 60, 285-294.	2.6	96
1012	Structural insights into the interaction of platinum-based inhibitors with the Alzheimer's disease amyloid- $\beta$ peptide. <i>Chemical Communications</i> , 2013, 49, 11364.	2.2	38
1013	S100A9 induces aggregation-prone conformation in A $\beta$ peptides: a combined experimental and simulation study. <i>RSC Advances</i> , 2013, 3, 24081.	1.7	9
1014	Tauroursodeoxycholic acid suppresses amyloid $\beta$ -induced synaptic toxicity in vitro and in APP/PS1 mice. <i>Neurobiology of Aging</i> , 2013, 34, 551-561.	1.5	44
1015	Amyloid deposition detected with florbetapir F 18 (18F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. <i>Neurobiology of Aging</i> , 2013, 34, 822-831.	1.5	118

#	ARTICLE	IF	CITATIONS
1016	Leptin prevents hippocampal synaptic disruption and neuronal cell death induced by amyloid $\beta$ . <i>Neurobiology of Aging</i> , 2013, 34, 226-237.	1.5	98
1017	Alzheimer's Disease Modeling: Ups, Downs, and Perspectives for Human Induced Pluripotent Stem Cells. <i>Journal of Alzheimer's Disease</i> , 2013, 34, 563-588.	1.2	34
1018	Extracellular Amyloid- $\beta$ Protein Dynamics in Alzheimer's Disease. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2013, , 163-178.	0.2	2
1019	Critique of the use of fluorescence-based reporters in <i>Escherichia coli</i> as a screening tool for the identification of peptide inhibitors of A $\beta$ 42 aggregation. <i>Journal of Peptide Science</i> , 2013, 19, 74-83.	0.8	4
1020	Structural networks in Alzheimer's disease. <i>European Neuropsychopharmacology</i> , 2013, 23, 63-77.	0.3	87
1021	Recombinant DNA vaccine against neurite outgrowth inhibitors attenuates behavioral deficits and decreases Abeta in an Alzheimer's disease mouse model. <i>Neuropharmacology</i> , 2013, 70, 200-210.	2.0	15
1022	Reducing HDAC6 ameliorates cognitive deficits in a mouse model for Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2013, 5, 52-63.	3.3	270
1023	CCL2 affects $\beta$ -amyloidosis and progressive neurocognitive dysfunction in a mouse model of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2013, 34, 1060-1068.	1.5	67
1024	Enhancement of long-term depression by soluble amyloid $\beta$ protein in rat hippocampus is mediated by metabotropic glutamate receptor and involves activation of p38MAPK, STEP and caspase-3. <i>Neuroscience</i> , 2013, 253, 435-443.	1.1	75
1025	Synthesis and distinct urease enzyme inhibitory activities of metal complexes of Schiff-base ligands: Kinetic and thermodynamic parameters evaluation from TG-DTA analysis. <i>Thermochimica Acta</i> , 2013, 555, 72-80.	1.2	18
1026	Biomarker evidence for uncoupling of amyloid build-up and toxicity in Alzheimer's disease. , 2013, 9, 459-462.		13
1027	From a cell's viewpoint: targeting mitochondria in Alzheimer's disease. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2013, 10, e91-e98.	0.5	4
1028	The role of $\beta$ -secretase in hippocampal synaptic transmission and activity-dependent synaptic plasticity. <i>Neuroscience Letters</i> , 2013, 554, 16-21.	1.0	6
1029	Age-dependent alterations in the presynaptic active zone in a <i>Drosophila</i> model of Alzheimer's Disease. <i>Neurobiology of Disease</i> , 2013, 51, 161-167.	2.1	35
1030	Alzheimer brain-derived amyloid $\beta$ -protein impairs synaptic remodeling and memory consolidation. <i>Neurobiology of Aging</i> , 2013, 34, 1315-1327.	1.5	54
1031	Amyloid beta 25-35 impairs reconsolidation of object recognition memory in rats and this effect is prevented by lithium carbonate. <i>Neuroscience Letters</i> , 2013, 548, 79-83.	1.0	10
1032	R-flurbiprofen improves tau, but not A $\beta$ pathology in a triple transgenic model of Alzheimer's disease. <i>Brain Research</i> , 2013, 1541, 115-127.	1.1	30
1033	Glycyrrhiza and Uncaria Hook contribute to protective effect of traditional Japanese medicine yokukansan against amyloid $\beta$ oligomer-induced neuronal death. <i>Journal of Ethnopharmacology</i> , 2013, 149, 360-370.	2.0	28



#	ARTICLE	IF	CITATIONS
1034	Combination of A $\beta$ clearance and neurotrophic factors as a potential treatment for Alzheimer's disease. <i>Neuroscience Bulletin</i> , 2013, 29, 111-120.	1.5	9
1035	Metabotropic NMDA receptor function is required for $\beta$ -amyloid-induced synaptic depression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 4033-4038.	3.3	154
1036	Modeling Alzheimer's Disease with iPSCs Reveals Stress Phenotypes Associated with Intracellular A $\beta$ and Differential Drug Responsiveness. <i>Cell Stem Cell</i> , 2013, 12, 487-496.	5.2	652
1037	Untangling Amyloid- $\beta$ , Tau, and Metals in Alzheimer's Disease. <i>ACS Chemical Biology</i> , 2013, 8, 856-865.	1.6	329
1038	Immunogenicity, Efficacy, Safety, and Mechanism of Action of Epitope Vaccine (Lu AF20513) for Alzheimer's Disease: Prelude to a Clinical Trial. <i>Journal of Neuroscience</i> , 2013, 33, 4923-4934.	1.7	100
1039	Environmental Novelty Activates $\beta$ -Adrenergic Signaling to Prevent the Impairment of Hippocampal LTP by A $\beta$ Oligomers. <i>Neuron</i> , 2013, 77, 929-941.	3.8	152
1040	Advances with RNA interference in Alzheimer's disease research. <i>Drug Design, Development and Therapy</i> , 2013, 7, 117.	2.0	20
1041	Amyloid- $\beta$ induced signaling by cellular prion protein and Fyn kinase in Alzheimer disease. <i>Prion</i> , 2013, 7, 37-41.	0.9	114
1042	Triazolopyrimidinones as $\beta$ -secretase modulators: structure-activity relationship, modulator profile, and in vivo profiling. <i>MedChemComm</i> , 2013, 4, 422.	3.5	10
1043	Omega-3 fatty acids in neurodegenerative diseases: Focus on mitochondria. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2013, 88, 105-114.	1.0	85
1044	Quantitative analysis of the time course of A $\beta$ oligomerization and subsequent growth steps using tetramethylrhodamine-labeled A $\beta$ . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 3321-3326.	3.3	126
1045	Aggregation and neurotoxicity of recombinant $\beta$ -synuclein aggregates initiated by dimerization. <i>Molecular Neurodegeneration</i> , 2013, 8, 5.	4.4	71
1046	A $\beta$ <sub>42</sub> -Binding Peptoids as Amyloid Aggregation Inhibitors and Detection Ligands. <i>ACS Chemical Neuroscience</i> , 2013, 4, 952-962.	1.7	44
1047	The missing link in the amyloid cascade of Alzheimer's disease - Metal ions. <i>Neurochemistry International</i> , 2013, 62, 367-378.	1.9	72
1048	The intersection of amyloid beta and tau in glutamatergic synaptic dysfunction and collapse in Alzheimer's disease. <i>Ageing Research Reviews</i> , 2013, 12, 757-763.	5.0	130
1049	The CAMKK2-AMPK Kinase Pathway Mediates the Synaptotoxic Effects of A $\beta$ Oligomers through Tau Phosphorylation. <i>Neuron</i> , 2013, 78, 94-108.	3.8	300
1050	The Alzheimer's Amyloid- $\beta$ (1-42) Peptide Forms Off-Pathway Oligomers and Fibrils That Are Distinguished Structurally by Intermolecular Organization. <i>Journal of Molecular Biology</i> , 2013, 425, 2494-2508.	2.0	95
1051	Oligomers, fact or artefact? SDS-PAGE induces dimerization of $\beta$ -amyloid in human brain samples. <i>Acta Neuropathologica</i> , 2013, 125, 549-564.	3.9	74

#	ARTICLE	IF	CITATIONS
1052	A Transgenic Alzheimer Rat with Plaques, Tau Pathology, Behavioral Impairment, Oligomeric A $\beta$ , and Frank Neuronal Loss. <i>Journal of Neuroscience</i> , 2013, 33, 6245-6256.	1.7	376
1054	Amyloidogenesis, Neurogenesis, Learning, and Memory in Alzheimer's Disease: Lessons from Transgenic Mouse Models. <i>Molecular Medicine and Biotechnology</i> , 2013, 23, 157-186.	0.4	0
1055	New ELISAs with high specificity for soluble oligomers of amyloid $\beta$ protein detect natural A $\beta$ oligomers in human brain but not CSF. <i>Alzheimer's and Dementia</i> , 2013, 9, 99-112.	0.4	103
1056	A Novel Nicotinic Mechanism Underlies $\beta$ -Amyloid-Induced Neuronal Hyperexcitation. <i>Journal of Neuroscience</i> , 2013, 33, 7253-7263.	1.7	50
1058	Alzheimer's Disease Biomarkers: More Than Molecular Diagnostics. <i>Drug Development and Industrial Pharmacy</i> , 2013, 39, 92-111.	1.4	6
1059	Alzheimer disease. <i>Prion</i> , 2013, 7, 14-19.	0.9	108
1060	Brain interstitial oligomeric amyloid $\beta$ increases with age and is resistant to clearance from brain in a mouse model of Alzheimer's disease. <i>FASEB Journal</i> , 2013, 27, 3239-3248.	0.2	57
1061	MER5101, a Novel A $\beta$ 1-15:DT Conjugate Vaccine, Generates a Robust Anti-A $\beta$ Antibody Response and Attenuates A $\beta$ Pathology and Cognitive Deficits in APPsw/PS1 $\Delta$ E9 Transgenic Mice. <i>Journal of Neuroscience</i> , 2013, 33, 7027-7037.	1.7	50
1062	Wnt signaling: Role in LTP, neural networks and memory. <i>Ageing Research Reviews</i> , 2013, 12, 786-800.	5.0	76
1063	Evolutionary, Physicochemical, and Functional Mechanisms of Protein Homooligomerization. <i>Progress in Molecular Biology and Translational Science</i> , 2013, 117, 3-24.	0.9	34
1064	Amyloid beta and the longest-lived rodent: the naked mole-rat as a model for natural protection from Alzheimer's disease. <i>Neurobiology of Aging</i> , 2013, 34, 2352-2360.	1.5	76
1065	Mechanistic and environmental control of the prevalence and lifetime of amyloid oligomers. <i>Nature Communications</i> , 2013, 4, 1891.	5.8	36
1066	Conformational altered p53 affects neuronal function: relevance for the response to toxic insult and growth-associated protein 43 expression. <i>Cell Death and Disease</i> , 2013, 4, e484-e484.	2.7	30
1067	Natural Compounds May Open New Routes to Treatment of Amyloid Diseases. <i>Neurotherapeutics</i> , 2013, 10, 429-439.	2.1	75
1068	Alzheimer's Disease, Dementia, Mild Cognitive Impairment and the Menopause: A "Window of Opportunity"? <i>Women's Health</i> , 2013, 9, 279-290.	0.7	26
1069	Trifluoromethylphenol Reduces BACE1 Activity and Mitigates Amyloidosis via the AGE/RAGE/NF- $\kappa$ B Pathway in a Transgenic Mouse Model of Alzheimer's Disease. <i>Antioxidants and Redox Signaling</i> , 2013, 19, 2024-2039.	2.5	50
1070	Deregulation of excitatory neurotransmission underlying synapse failure in Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2013, 126, 191-202.	2.1	145
1071	Effects of small interfering RNA targeting sphingosine kinase-1 gene on the animal model of Alzheimer's disease. <i>Journal of Huazhong University of Science and Technology [Medical Sciences]</i> , 2013, 33, 427-432.	1.0	15

#	ARTICLE	IF	CITATIONS
1072	pH-Dependent Conformational Ensemble and Polymorphism of Amyloid- $\beta$ Core Fragment. <i>Journal of Physical Chemistry B</i> , 2013, 117, 8392-8399.	1.2	13
1073	Brain regional correlation of amyloid- $\beta$ with synapses and apolipoprotein E in non-demented individuals: potential mechanisms underlying regional vulnerability to amyloid- $\beta$ accumulation. <i>Acta Neuropathologica</i> , 2013, 125, 535-547.	3.9	51
1074	BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases. <i>Nature Reviews Neuroscience</i> , 2013, 14, 401-416.	4.9	601
1075	The Elevated Copper Binding Strength of Amyloid- $\beta$ Aggregates Allows the Sequestration of Copper from Albumin: A Pathway to Accumulation of Copper in Senile Plaques. <i>Biochemistry</i> , 2013, 52, 547-556.	1.2	54
1076	The Role of HSP70 in the Protection of: (A) The Brain in Alzheimer's Disease and (B) The Heart in Cardiac Surgery. <i>SpringerBriefs in Biochemistry and Molecular Biology</i> , 2013, , 113-139.	0.3	2
1077	The effect of fulvic acid on pre- and postaggregation state of A $\beta$ 17-42: Molecular dynamics simulation studies. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2013, 1834, 24-33.	1.1	13
1078	Single Molecule Characterization of the Interactions between Amyloid- $\beta$ Peptides and the Membranes of Hippocampal Cells. <i>Journal of the American Chemical Society</i> , 2013, 135, 1491-1498.	6.6	75
1079	Exosomes neutralize synaptic-plasticity-disrupting activity of A $\beta$ assemblies in vivo. <i>Molecular Brain</i> , 2013, 6, 47.	1.3	155
1080	On the subject of rigor in the study of amyloid $\beta$ -protein assembly. <i>Alzheimer's Research and Therapy</i> , 2013, 5, 39.	3.0	64
1081	Amyloid $\beta$ -protein oligomers and Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2013, 5, 60.	3.0	209
1082	Fine Mapping of the Amyloid $\beta$ -Protein Binding Site on Myelin Basic Protein. <i>Biochemistry</i> , 2013, 52, 2565-2573.	1.2	15
1083	NMDA Receptor as a Newly Identified Member of the Metabotropic Glutamate Receptor Family: Clinical Implications for Neurodegenerative Diseases. <i>Molecules and Cells</i> , 2013, 36, 99-104.	1.0	21
1084	Positron Emission Tomography Imaging of Fibrillar Parenchymal and Vascular Amyloid- $\beta$ in TgCRND8 Mice. <i>ACS Chemical Neuroscience</i> , 2013, 4, 613-623.	1.7	21
1085	Glycogen synthase kinase-3 $\beta$ (GSK3 $\beta$ ) expression in a mouse model of Alzheimer's disease: A light and electron microscopy study. <i>Synapse</i> , 2013, 67, 313-327.	0.6	21
1086	The role of amyloid $\beta$ in the pathogenesis of Alzheimer's disease. <i>Journal of Clinical Pathology</i> , 2013, 66, 362-366.	1.0	97
1087	Neurodegeneration, $\beta$ -amyloid and mood disorders: state of the art and future perspectives. <i>International Journal of Geriatric Psychiatry</i> , 2013, 28, 661-671.	1.3	12
1088	Overlapped Metabolic and Therapeutic Links between Alzheimer and Diabetes. <i>Molecular Neurobiology</i> , 2013, 47, 399-424.	1.9	71
1089	Cerebrospinal Fluid A $\beta$ 42, Phosphorylated Tau <sub>181</sub> , and Resting-State Functional Connectivity. <i>JAMA Neurology</i> , 2013, 70, 1242-8.	4.5	89

#	ARTICLE	IF	CITATIONS
1090	Hypothalamic-Pituitary-Thyroid Axis in Patients with Alzheimer Disease (AD). <i>Journal of Investigative Medicine</i> , 2013, 61, 578-581.	0.7	25
1091	Tackling the Elusive Challenges Relevant to Conquering the 100-Plus Year Old Problem of Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2013, 10, 108-116.	0.7	5
1092	The Association of ACT -17 A/T Polymorphism with Alzheimer's Disease: A Meta-Analysis. <i>Current Alzheimer Research</i> , 2013, 10, 63-71.	0.7	4
1093	Hypersensitivity of the hippocampal CA3 region to stress-induced neurodegeneration and amyloidogenesis in a rat model of surgical menopause. <i>Brain</i> , 2013, 136, 1432-1445.	3.7	44
1094	Amyloid- $\beta$ oligomers regulate the properties of human neural stem cells through GSK-3 $\beta$ signaling. <i>Experimental and Molecular Medicine</i> , 2013, 45, e60-e60.	3.2	58
1095	Targeting Synaptic Dysfunction in Alzheimer's Disease by Administering a Specific Nutrient Combination. <i>Journal of Alzheimer's Disease</i> , 2013, 38, 459-479.	1.2	96
1096	Conformational Stability of Fibrillar Amyloid-Beta Oligomers via Protofilament Pair Formation – A Systematic Computational Study. <i>PLoS ONE</i> , 2013, 8, e70521.	1.1	64
1097	Glutamate system, amyloid $\beta$ peptides and tau protein: functional interrelationships and relevance to Alzheimer disease pathology. <i>Journal of Psychiatry and Neuroscience</i> , 2013, 38, 6-23.	1.4	247
1098	Breaking the Code of Amyloid- $\beta$ Oligomers. <i>International Journal of Cell Biology</i> , 2013, 2013, 1-6.	1.0	25
1099	The effect of PN-1, a Traditional Chinese Prescription, on the Learning and Memory in a Transgenic Mouse Model of Alzheimer's Disease. <i>Evidence-based Complementary and Alternative Medicine</i> , 2013, 2013, 1-12.	0.5	13
1100	Thermodynamically stable amyloid- $\beta$ monomers have much lower membrane affinity than the small oligomers. <i>Frontiers in Physiology</i> , 2013, 4, 84.	1.3	47
1101	Naringin Enhances CaMKII Activity and Improves Long-Term Memory in a Mouse Model of Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2013, 14, 5576-5586.	1.8	91
1102	Prion Protein-mediated Toxicity of Amyloid- $\beta$ Oligomers Requires Lipid Rafts and the Transmembrane LRP1. <i>Journal of Biological Chemistry</i> , 2013, 288, 8935-8951.	1.6	131
1103	Examination of the Clinicopathologic Continuum of Alzheimer Disease in the Autopsy Cohort of the National Alzheimer Coordinating Center. <i>Journal of Neuropathology and Experimental Neurology</i> , 2013, 72, 1182-1192.	0.9	89
1104	Pharmacokinetics and Pharmacodynamics of CHF5074 After Short-term Administration in Healthy Subjects. <i>Alzheimer Disease and Associated Disorders</i> , 2013, 27, 278-286.	0.6	34
1105	Dendritic Spine Density, Morphology, and Fibrillar Actin Content Surrounding Amyloid- $\beta$ Plaques in a Mouse Model of Amyloid- $\beta$ Deposition. <i>Journal of Neuropathology and Experimental Neurology</i> , 2013, 72, 791-800.	0.9	33
1106	Changes in Plasticity Across the Lifespan. <i>Progress in Brain Research</i> , 2013, 207, 91-120.	0.9	102
1107	Possible contributions of a novel form of synaptic plasticity in <i>Aplysia</i> to reward, memory, and their dysfunctions in mammalian brain. <i>Learning and Memory</i> , 2013, 20, 580-591.	0.5	16

#	ARTICLE	IF	CITATIONS
1108	A $\beta$ 2 induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E2518-27.	3.3	495
1110	Unintended Effects of Cardiovascular Drugs on the Pathogenesis of Alzheimer's Disease. PLoS ONE, 2013, 8, e65232.	1.1	26
1111	Electrochemical Detection of Amyloid-Beta Aggregation in the Presence of Resveratrol. Journal of the Electrochemical Society, 2013, 160, G3097-G3101.	1.3	18
1112	Cerebrospinal fluid biomarkers for pathological processes in Alzheimer's disease. Current Opinion in Psychiatry, 2013, 26, 276-282.	3.1	20
1113	Insulin/IGF Signaling-Related Gene Expression in the Brain of a Sporadic Alzheimer's Disease Monkey Model Induced by Intracerebroventricular Injection of Streptozotocin. Journal of Alzheimer's Disease, 2013, 38, 251-267.	1.2	42
1114	Design, Synthesis, and Evaluation of Bioactive Small Molecules. Chemical Record, 2013, 13, 60-69.	2.9	3
1115	Isolation and characterization of antibody fragments selective for specific protein morphologies from nanogram antigen samples. Biotechnology Progress, 2013, 29, 463-471.	1.3	23
1116	CHF5074 restores visual memory ability and pre-synaptic cortical acetylcholine release in plaque Tg2576 mice. Journal of Neurochemistry, 2013, 124, 613-620.	2.1	16
1117	An Epidermal MicroRNA Regulates Neuronal Migration Through Control of the Cellular Glycosylation State. Science, 2013, 341, 1404-1408.	6.0	73
1118	Structural studies of the tethered N-terminus of the Alzheimer's disease amyloid- $\beta$ 2 peptide. Proteins: Structure, Function and Bioinformatics, 2013, 81, 1748-1758.	1.5	22
1119	Clinical correlates in an experimental model of repetitive mild brain injury. Annals of Neurology, 2013, 74, 65-75.	2.8	141
1120	The Catalytically Active Copper-Amyloid $\beta$ State: Coordination Site Responsible for Reactive Oxygen Species Production. Angewandte Chemie - International Edition, 2013, 52, 11110-11113.	7.2	105
1121	Prions and Diseases. , 2013, , .		0
1122	Amyloid $\beta$ oligomerization in Alzheimer dementia versus high $\beta$ pathology controls. Annals of Neurology, 2013, 73, 104-119.	2.8	244
1123	Amyloid- $\beta$ 2 nanotubes are associated with prion protein-dependent synaptotoxicity. Nature Communications, 2013, 4, 2416.	5.8	112
1124	How structure shapes (dys)function. Prion, 2013, 7, 291-293.	0.9	3
1125	A fast and reproducible method for albumin isolation and depletion from serum and cerebrospinal fluid. Proteomics, 2013, 13, 743-750.	1.3	35
1126	Enhanced Proteolytic Clearance of Plasma A $\beta$ 2 by Peripherally Administered Neprilysin Does Not Result in Reduced Levels of Brain A $\beta$ 2 in Mice. Journal of Neuroscience, 2013, 33, 2457-2464.	1.7	53

#	ARTICLE	IF	CITATIONS
1127	Deletion of <i>Abca7</i> Increases Cerebral Amyloid- $\beta$ Accumulation in the J20 Mouse Model of Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2013, 33, 4387-4394.	1.7	165
1128	Memantine Rescues Transient Cognitive Impairment Caused by High-Molecular-Weight A $\beta$ Oligomers But Not the Persistent Impairment Induced by Low-Molecular-Weight Oligomers. <i>Journal of Neuroscience</i> , 2013, 33, 9626-9634.	1.7	160
1129	Genomic background-related activation of microglia and reduced $\beta$ -amyloidosis in a mouse model of Alzheimer's disease. <i>European Journal of Microbiology and Immunology</i> , 2013, 3, 21-27.	1.5	14
1130	Mass Transfer and Computational Fluid-dynamics in Bioreactors. , 2013, , 460-486.		0
1131	Optimized Protocol for Amyloid- $\beta$ Extraction from the Brain. <i>Journal of Alzheimer's Disease</i> , 2013, 34, 835-839.	1.2	14
1132	The Amyloid- $\beta$ Oligomer Count in Cerebrospinal Fluid is a Biomarker for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2013, 34, 985-994.	1.2	60
1134	Differential Relationships of Reactive Astrocytes and Microglia to Fibrillar Amyloid Deposits in Alzheimer Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2013, 72, 462-471.	0.9	163
1135	Nano-Chaperones: Nanoparticles Acting as Artificial Chaperones. <i>Regenerative Medicine, Artificial Cells and Nanomedicine</i> , 2013, , 449-480.	0.7	1
1137	FIB/SEM Technology and Alzheimer's Disease: Three-Dimensional Analysis of Human Cortical Synapses. <i>Journal of Alzheimer's Disease</i> , 2013, 34, 995-1013.	1.2	52
1138	Effects of Anesthetic Isoflurane and Desflurane on Human Cerebrospinal Fluid A $\beta$ and $\tau$ Level. <i>Anesthesiology</i> , 2013, 119, 52-60.	1.3	61
1139	Anti-amyloid-beta to tau-based immunization: developments in immunotherapy for Alzheimer's disease. <i>ImmunoTargets and Therapy</i> , 2013, 2013, 105.	2.7	32
1140	Molecular Mechanism Underlying A $\beta$ Immunotherapy: Implications for the Toxic Action of A $\beta$ Oligomers. <i>Journal of Gerontology &amp; Geriatric Research</i> , 2013, 02, .	0.1	1
1141	In Vivo and Ex Vivo Imaging of Amyloid- $\beta$ Cascade Aggregates with a Pronucleon $\beta$ Peptide. <i>Journal of Alzheimer's Disease</i> , 2013, 34, 957-967.	1.2	13
1143	The Proton-Pump Inhibitor Lansoprazole Enhances Amyloid Beta Production. <i>PLoS ONE</i> , 2013, 8, e58837.	1.1	122
1144	The Intracellular Domain of Sortilin Interacts with Amyloid Precursor Protein and Regulates Its Lysosomal and Lipid Raft Trafficking. <i>PLoS ONE</i> , 2013, 8, e63049.	1.1	29
1145	A Luminex Assay Detects Amyloid $\beta$ Oligomers in Alzheimer's Disease Cerebrospinal Fluid. <i>PLoS ONE</i> , 2013, 8, e67898.	1.1	59
1146	Anti-Aggregating Effect of the Naturally Occurring Dipeptide Carnosine on A $\beta$ <sup>1-42</sup> Fibril Formation. <i>PLoS ONE</i> , 2013, 8, e68159.	1.1	58
1147	Age-Dependent Modulation of Synaptic Plasticity and Insulin Mimetic Effect of Lipoic Acid on a Mouse Model of Alzheimer's Disease. <i>PLoS ONE</i> , 2013, 8, e69830.	1.1	80



#	ARTICLE	IF	CITATIONS
1148	A Microliter-Scale High-throughput Screening System with Quantum-Dot Nanoprobes for Amyloid- $\beta^2$ Aggregation Inhibitors. PLoS ONE, 2013, 8, e72992.	1.1	28
1149	Novel Neuroprotective Function of Apical-Basal Polarity Gene Crumbs in Amyloid Beta 42 ( $A\beta^{42}$ ) Mediated Neurodegeneration. PLoS ONE, 2013, 8, e78717.	1.1	26
1150	Synergistic Interactions between Alzheimer's $A\beta^{40}$ and $A\beta^{42}$ on the Surface of Primary Neurons Revealed by Single Molecule Microscopy. PLoS ONE, 2013, 8, e82139.	1.1	22
1151	Modeling Alzheimer's disease: from past to future. Frontiers in Pharmacology, 2013, 4, 77.	1.6	40
1152	Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review. Frontiers in Aging Neuroscience, 2013, 5, 25.	1.7	12
1153	$\beta^2$ -Amyloid oligomers in aging and Alzheimer's disease. Frontiers in Aging Neuroscience, 2013, 5, 28.	1.7	54
1154	Multiple effects of $\beta^2$ -amyloid on single excitatory synaptic connections in the PFC. Frontiers in Cellular Neuroscience, 2013, 7, 129.	1.8	16
1155	Amyloidosis in Alzheimer's Disease: The Toxicity of Amyloid Beta ( $A\beta$ ), Mechanisms of Its Accumulation and Implications of Medicinal Plants for Therapy. Evidence-based Complementary and Alternative Medicine, 2013, 2013, 1-10.	0.5	63
1156	The Beta-Amyloid Protein of Alzheimer's Disease: Communication Breakdown by Modifying the Neuronal Cytoskeleton. International Journal of Alzheimer's Disease, 2013, 2013, 1-15.	1.1	45
1157	Alzheimer's Disease and Prion Protein. Intractable and Rare Diseases Research, 2013, 2, 35-44.	0.3	15
1158	A Lifespan Observation of a Novel Mouse Model: In Vivo Evidence Supports $A\beta$ Oligomer Hypothesis. PLoS ONE, 2014, 9, e85885.	1.1	35
1159	RNA Aptamer Probes as Optical Imaging Agents for the Detection of Amyloid Plaques. PLoS ONE, 2014, 9, e89901.	1.1	37
1160	Soluble Beta-Amyloid Peptides, but Not Insoluble Fibrils, Have Specific Effect on Neuronal MicroRNA Expression. PLoS ONE, 2014, 9, e90770.	1.1	52
1161	Intracellular Cleavage of Amyloid $\beta^2$ by a Viral Protease N1a Prevents Amyloid $\beta^2$ -Mediated Cytotoxicity. PLoS ONE, 2014, 9, e98650.	1.1	5
1162	Mechanisms of U87 Astrocytoma Cell Uptake and Trafficking of Monomeric versus Protofibril Alzheimer's Disease Amyloid- $\beta^2$ Proteins. PLoS ONE, 2014, 9, e99939.	1.1	37
1163	Disruption of Axonal Transport Perturbs Bone Morphogenetic Protein (BMP) - Signaling and Contributes to Synaptic Abnormalities in Two Neurodegenerative Diseases. PLoS ONE, 2014, 9, e104617.	1.1	27
1164	Smart Soup, a Traditional Chinese Medicine Formula, Ameliorates Amyloid Pathology and Related Cognitive Deficits. PLoS ONE, 2014, 9, e111215.	1.1	39
1165	Heat Shock Protein 70 in Alzheimer's Disease. BioMed Research International, 2014, 2014, 1-8.	0.9	59



#	ARTICLE	IF	CITATIONS
1166	Heat Shock Proteins at the Crossroads between Cancer and Alzheimer's Disease. BioMed Research International, 2014, 2014, 1-9.	0.9	19
1167	Diverse Molecular Targets for Therapeutic Strategies in Alzheimer's Disease. Journal of Korean Medical Science, 2014, 29, 893.	1.1	21
1168	Memory loss in Alzheimer's disease: are the alterations in the UPR network involved in the cognitive impairment?. Frontiers in Aging Neuroscience, 2014, 6, 8.	1.7	34
1169	Differential spatio-temporal regulation of MMPs in the 5xFAD mouse model of Alzheimer's disease: evidence for a pro-amyloidogenic role of MT1-MMP. Frontiers in Aging Neuroscience, 2014, 6, 247.	1.7	60
1170	Homotaurine Induces Measurable Changes of Short Latency Afferent Inhibition in a Group of Mild Cognitive Impairment Individuals. Frontiers in Aging Neuroscience, 2014, 6, 254.	1.7	34
1171	Super-resolution 2-photon microscopy reveals that the morphology of each dendritic spine correlates with diffusive but not synaptic properties. Frontiers in Neuroanatomy, 2014, 8, 29.	0.9	43
1172	GABAergic neurotransmission and new strategies of neuromodulation to compensate synaptic dysfunction in early stages of Alzheimer's disease. Frontiers in Cellular Neuroscience, 2014, 8, 167.	1.8	88
1173	Chronochemistry in neurodegeneration. Frontiers in Molecular Neuroscience, 2014, 7, 20.	1.4	7
1174	Pathological Reorganization of NMDA Receptors Subunits and Postsynaptic Protein PSD-95 Distribution in Alzheimer's Disease. Current Alzheimer Research, 2014, 11, 86-96.	0.7	31
1175	Cerebrovascular Pathology and Amyloid Plaque Formation in Alzheimer's Disease. Current Alzheimer Research, 2014, 11, 4-10.	0.7	26
1176	Alzheimer Disease: The Role of A $\beta$ in the Glutamatergic System. , 0, , .		10
1177	Operationalization of Global Alzheimer's Disease Trials. , 2014, , 159-177.		2
1178	The central molecular clock is robust in the face of behavioural arrhythmia in a <i>Drosophila</i> model of Alzheimer's disease. DMM Disease Models and Mechanisms, 2014, 7, 445-58.	1.2	44
1179	ECM in brain aging and dementia. Progress in Brain Research, 2014, 214, 207-227.	0.9	69
1180	Prion-like activity of Cu/Zn superoxide dismutase. Prion, 2014, 8, 33-41.	0.9	57
1181	A $\beta$ -Microglobulin Amyloid Fibrils Are Nanoparticles That Disrupt Lysosomal Membrane Protein Trafficking and Inhibit Protein Degradation by Lysosomes. Journal of Biological Chemistry, 2014, 289, 35781-35794.	1.6	31
1182	Long-term depression-inducing stimuli promote cleavage of the synaptic adhesion molecule NGL-3 through NMDA receptors, matrix metalloproteinases and presenilin-1-secretase. Philosophical Transactions of the Royal Society B: Biological Sciences, 2014, 369, 20130158.	1.8	29
1183	Peripheral Administration of a Humanized Anti-PrP Antibody Blocks Alzheimer's Disease A $\beta$ Synaptotoxicity. Journal of Neuroscience, 2014, 34, 6140-6145.	1.7	68

#	ARTICLE	IF	CITATIONS
1184	Oligomeric A $\beta$ -induced synaptic dysfunction in Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2014, 9, 48.	4.4	424
1185	Blockade of EphA4 signaling ameliorates hippocampal synaptic dysfunctions in mouse models of Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 9959-9964.	3.3	162
1186	Inconsistencies and Controversies Surrounding the Amyloid Hypothesis of Alzheimer's Disease. <i>Acta Neuropathologica Communications</i> , 2014, 2, 135.	2.4	246
1187	Chronic $\beta$ -secretase inhibition reduces amyloid plaque-associated instability of pre- and postsynaptic structures. <i>Molecular Psychiatry</i> , 2014, 19, 937-946.	4.1	38
1188	Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 405-419.	1.3	86
1189	Amyloid Beta, TNF $\alpha$ and FAIM-L; Approaching New Therapeutic Strategies for AD. <i>Frontiers in Neurology</i> , 2014, 5, 276.	1.1	5
1190	Computational identification of potential multitarget treatments for ameliorating the adverse effects of amyloid- $\beta$ on synaptic plasticity. <i>Frontiers in Pharmacology</i> , 2014, 5, 85.	1.6	17
1191	New Functions of Old Drugs: Aureolic Acid Group of Anti-Cancer Antibiotics and Non-Steroidal Anti-Inflammatory Drugs. , 2014, , 3-55.		4
1192	Challenges in Designing Therapeutic Agents for Treating Alzheimer's Disease-from Serendipity to Rationality. , 2014, , 40-141.		10
1193	Enzyme Inhibitors Involved in the Treatment of Alzheimer's Disease. , 2014, , 142-198.		1
1194	Protective Effects of <i>Borago officinalis</i> Extract on Amyloid- $\beta$ -Peptide(25-35)-Induced Memory Impairment in Male Rats: A Behavioral Study. <i>BioMed Research International</i> , 2014, 2014, 1-8.	0.9	42
1195	Successful therapies for Alzheimer's disease: why so many in animal models and none in humans?. <i>Frontiers in Pharmacology</i> , 2014, 5, 146.	1.6	138
1196	Epidemic Spreading Model to Characterize Misfolded Proteins Propagation in Aging and Associated Neurodegenerative Disorders. <i>PLoS Computational Biology</i> , 2014, 10, e1003956.	1.5	151
1197	Use of <i>Caenorhabditis elegans</i> as a model to study Alzheimer's disease and other neurodegenerative diseases. <i>Frontiers in Genetics</i> , 2014, 5, 279.	1.1	242
1199	Differential splicing and glycosylation of Apoer2 alters synaptic plasticity and fear learning. <i>Science Signaling</i> , 2014, 7, ra113.	1.6	46
1200	Axonal tract tracing for delineating interacting brain regions: implications for Alzheimer's disease-associated memory. <i>Future Neurology</i> , 2014, 9, 89-98.	0.9	3
1201	Stability and cytotoxicity of crystallin amyloid nanofibrils. <i>Nanoscale</i> , 2014, 6, 13169-13178.	2.8	21
1202	Decrease of ERK/MAPK Overactivation in Prefrontal Cortex Reverses Early Memory Deficit in a Mouse Model of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 40, 69-82.	1.2	59

#	ARTICLE	IF	CITATIONS
1203	Crucial role of nonspecific interactions in amyloid nucleation. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 17869-17874.	3.3	157
1204	An improved capillary electrophoresis method for in vitro monitoring of the challenging early steps of A $\beta$ <sub>42</sub> peptide oligomerization: Application to anti-Alzheimer's drug discovery. Electrophoresis, 2014, 35, 3302-3309.	1.3	28
1205	Safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel $\beta$ -secretase modulator, E2212, in healthy human subjects. Journal of Clinical Pharmacology, 2014, 54, 528-536.	1.0	32
1206	Elucidating Molecular Mass and Shape of a Neurotoxic A $\beta$ Oligomer. ACS Chemical Neuroscience, 2014, 5, 1238-1245.	1.7	24
1207	Apolipoprotein E receptor pathways in Alzheimer disease. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2014, 6, 255-270.	6.6	9
1208	Imaging of Amyloid- $\beta$ Aggregation Using a Novel Quantum dot Nanoprobe and its Advanced Applications. , 2014, , 121-131.		2
1209	Capping of A $\beta$ <sub>42</sub> Oligomers by Small Molecule Inhibitors. Biochemistry, 2014, 53, 7893-7903.	1.2	70
1210	RAGE Inhibition in Microglia Prevents Ischemia-Dependent Synaptic Dysfunction in an Amyloid-Enriched Environment. Journal of Neuroscience, 2014, 34, 8749-8760.	1.7	47
1211	SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease. Molecular Neurodegeneration, 2014, 9, 53.	4.4	216
1212	Intracellular A $\beta$ pathology and early cognitive impairments in a transgenic rat overexpressing human amyloid precursor protein: a multidimensional study. Acta Neuropathologica Communications, 2014, 2, 61.	2.4	84
1213	Platelet-activating factor antagonists enhance intracellular degradation of amyloid- $\beta$ <sub>42</sub> in neurons via regulation of cholesterol ester hydrolases. Alzheimer's Research and Therapy, 2014, 6, 15.	3.0	13
1214	Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?. Current Opinion in Psychiatry, 2014, 27, 128-137.	3.1	86
1215	The role of AMPA receptors in postsynaptic mechanisms of synaptic plasticity. Frontiers in Cellular Neuroscience, 2014, 8, 401.	1.8	243
1216	Nutritional Approaches for Healthy Aging of the Brain and the Prevention of Neurodegenerative Diseases. AAPS Advances in the Pharmaceutical Sciences Series, 2014, , 457-479.	0.2	4
1217	Brain Intraventricular Injection of Amyloid- $\beta$ in Zebrafish Embryo Impairs Cognition and Increases Tau Phosphorylation, Effects Reversed by Lithium. PLoS ONE, 2014, 9, e105862.	1.1	64
1218	A $\beta$ <sub>(1-42)</sub> Enhances Neuronal Excitability in the CA1 via NR2B Subunit-Containing NMDA Receptors. Neural Plasticity, 2014, 2014, 1-12.	1.0	17
1219	The Role of Wnt Signaling in the Development of Alzheimer's Disease: A Potential Therapeutic Target?. BioMed Research International, 2014, 2014, 1-9.	0.9	61
1220	mGlu5 receptors and cellular prion protein mediate amyloid- $\beta$ -facilitated synaptic long-term depression in vivo. Nature Communications, 2014, 5, 3374.	5.8	157

#	ARTICLE	IF	CITATIONS
1221	A Sensitive A $\beta$ 2 Oligomer Assay Discriminates Alzheimer's and Aged Control Cerebrospinal Fluid. <i>Journal of Neuroscience</i> , 2014, 34, 2884-2897.	1.7	138
1222	Structural Diversity of Alzheimer's Disease Amyloid- $\beta$ 2 Dimers and Their Role in Oligomerization and Fibril Formation. <i>Journal of Alzheimer's Disease</i> , 2014, 39, 583-600.	1.2	26
1223	Enhancement of $\beta$ 2-amyloid oligomer accumulation after intracerebroventricular injection of streptozotocin, which involves central insulin signaling in a transgenic mouse model. <i>NeuroReport</i> , 2014, 25, 1289-1295.	0.6	17
1224	A $\beta$ 2 induces its own prion protein N-terminal fragment (PrPN1)-mediated neutralization in amorphous aggregates. <i>Neurobiology of Aging</i> , 2014, 35, 1537-1548.	1.5	34
1225	Spreading of amyloid- $\beta$ 2 peptides via neuritic cell-to-cell transfer is dependent on insufficient cellular clearance. <i>Neurobiology of Disease</i> , 2014, 65, 82-92.	2.1	135
1226	Taurine and central nervous system disorders. <i>Amino Acids</i> , 2014, 46, 31-46.	1.2	121
1227	Protein aggregation and prionopathies. <i>Pathologie Et Biologie</i> , 2014, 62, 162-168.	2.2	23
1228	Detection and structural characterization of insulin prefibrillar oligomers using surface enhanced Raman spectroscopy. <i>Biotechnology Progress</i> , 2014, 30, 488-495.	1.3	23
1229	The role of synaptic activity in the regulation of amyloid beta levels in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2014, 35, 1217-1232.	1.5	36
1230	Behavioral assays with mouse models of Alzheimer's disease: Practical considerations and guidelines. <i>Biochemical Pharmacology</i> , 2014, 88, 450-467.	2.0	151
1231	Green tea extract enhances parieto-frontal connectivity during working memory processing. <i>Psychopharmacology</i> , 2014, 231, 3879-3888.	1.5	44
1232	Novel lipid signaling pathways in Alzheimer's disease pathogenesis. <i>Biochemical Pharmacology</i> , 2014, 88, 560-564.	2.0	33
1233	Immunotherapy for Alzheimer's disease. <i>Biochemical Pharmacology</i> , 2014, 88, 499-507.	2.0	90
1234	Republished: The role of amyloid $\beta$ 2 in the pathogenesis of Alzheimer's disease. <i>Postgraduate Medical Journal</i> , 2014, 90, 113-117.	0.9	15
1235	The Impact of Surgery and Anesthesia on Post-Operative Cognitive Decline and Alzheimer's Disease Development: Biomarkers and Preventive Strategies. <i>Journal of Alzheimer's Disease</i> , 2014, 41, 1-13.	1.2	71
1236	Rare Individual Amyloid- $\beta$ 2 Oligomers Act on Astrocytes to Initiate Neuronal Damage. <i>Biochemistry</i> , 2014, 53, 2442-2453.	1.2	83
1237	Involvement of "stress" response-kinase pathways in Alzheimer's disease progression. <i>Current Opinion in Neurobiology</i> , 2014, 27, 110-117.	2.0	12
1238	Activity-independent release of the amyloid $\beta$ 2-peptide from rat brain nerve terminals. <i>Neuroscience Letters</i> , 2014, 566, 125-130.	1.0	16

#	ARTICLE	IF	CITATIONS
1239	Chemical kinetics for drug discovery to combat protein aggregation diseases. Trends in Pharmacological Sciences, 2014, 35, 127-135.	4.0	191
1240	Tau acts as a mediator for $\alpha$ -Amyloid-related synaptic deficits. European Journal of Neuroscience, 2014, 39, 1202-1213.	1.2	43
1241	Tau phosphorylation and tau mislocalization mediate soluble $A\beta$ oligomer-induced AMPA glutamate receptor signaling deficits. European Journal of Neuroscience, 2014, 39, 1214-1224.	1.2	100
1242	Nanoprobng of misfolding and interactions of amyloid $A\beta$ 42 protein. Nanomedicine: Nanotechnology, Biology, and Medicine, 2014, 10, 871-878.	1.7	22
1243	Mechanism of cholesterol-assisted oligomeric channel formation by a short Alzheimer $A\beta$ amyloid peptide. Journal of Neurochemistry, 2014, 128, 186-195.	2.1	79
1244	A label-free electrical impedimetric biosensor for the specific detection of Alzheimer's amyloid-beta oligomers. Biosensors and Bioelectronics, 2014, 56, 83-90.	5.3	166
1245	Long-term depression: a cell biological view. Philosophical Transactions of the Royal Society B: Biological Sciences, 2014, 369, 20130138.	1.8	33
1246	Understanding Amyloid Fibril Nucleation and $A\beta$ Oligomer/Drug Interactions from Computer Simulations. Accounts of Chemical Research, 2014, 47, 603-611.	7.6	118
1247	Active and passive immunization strategies based on the SDPM1 peptide demonstrate pre-clinical efficacy in the APP <sup>swe</sup> PSEN1 <sup>DE9</sup> mouse model for Alzheimer's disease. Neurobiology of Disease, 2014, 62, 31-43.	2.1	5
1248	Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease. New England Journal of Medicine, 2014, 370, 322-333.	13.9	1,613
1249	Why Alzheimer trials fail: removing soluble oligomeric beta amyloid is essential, inconsistent, and difficult. Neurobiology of Aging, 2014, 35, 969-974.	1.5	119
1250	Rational Design of a Structural Framework with Potential Use to Develop Chemical Reagents That Target and Modulate Multiple Facets of Alzheimer's Disease. Journal of the American Chemical Society, 2014, 136, 299-310.	6.6	166
1251	Environment and Brain Plasticity: Towards an Endogenous Pharmacotherapy. Physiological Reviews, 2014, 94, 189-234.	13.1	340
1252	Atomic and Dynamic Insights into the Beneficial Effect of the 1,4-Naphthoquinon-2-yl-L-tryptophan Inhibitor on Alzheimer's $A\beta$ 42 Dimer in Terms of Aggregation and Toxicity. ACS Chemical Neuroscience, 2014, 5, 148-159.	1.7	66
1253	Experimental Traumatic Brain Injury Induces Rapid Aggregation and Oligomerization of Amyloid-Beta in an Alzheimer's Disease Mouse Model. Journal of Neurotrauma, 2014, 31, 125-134.	1.7	90
1254	Amyloid beta receptors responsible for neurotoxicity and cellular defects in Alzheimer's disease. Cellular and Molecular Life Sciences, 2014, 71, 4803-4813.	2.4	42
1255	Structure-activity relationships of sugar-based peptidomimetics as modulators of amyloid $A\beta$ -peptide early oligomerization and fibrillization. European Journal of Medicinal Chemistry, 2014, 86, 752-758.	2.6	24
1256	The Evolution of Preclinical Alzheimer's Disease: Implications for Prevention Trials. Neuron, 2014, 84, 608-622.	3.8	568

#	ARTICLE	IF	CITATIONS
1257	Estimation of phosphorylation level of amyloid-beta isolated from human blood plasma: Ultrahigh-resolution mass spectrometry. <i>Molecular Biology</i> , 2014, 48, 607-614.	0.4	8
1258	Regulation of Neuronal Gene Expression and Survival by Basal NMDA Receptor Activity: A Role for Histone Deacetylase 4. <i>Journal of Neuroscience</i> , 2014, 34, 15327-15339.	1.7	28
1259	Methylene Blue Modulates $\beta$ -Secretase, Reverses Cerebral Amyloidosis, and Improves Cognition in Transgenic Mice. <i>Journal of Biological Chemistry</i> , 2014, 289, 30303-30317.	1.6	43
1260	Inhibiting ACAT1/SOAT1 in Microglia Stimulates Autophagy-Mediated Lysosomal Proteolysis and Increases $A\beta$ 42 Clearance. <i>Journal of Neuroscience</i> , 2014, 34, 14484-14501.	1.7	86
1261	Highly potent soluble amyloid- $\beta$ seeds in human Alzheimer brain but not cerebrospinal fluid. <i>Brain</i> , 2014, 137, 2909-2915.	3.7	61
1262	Fluorinated beta-sheet breaker peptides. <i>Journal of Materials Chemistry B</i> , 2014, 2, 2259-2264.	2.9	44
1263	Identification of peptide products from enzymatic degradation of amyloid beta. <i>Biochimie</i> , 2014, 105, 216-220.	1.3	14
1264	$A\beta$ dimers differ from monomers in structural propensity, aggregation paths and population of synaptotoxic assemblies. <i>Biochemical Journal</i> , 2014, 461, 413-426.	1.7	71
1265	Platinoid complexes to target monomeric disordered peptides: a forthcoming solution against amyloid diseases?. <i>Dalton Transactions</i> , 2014, 43, 4233.	1.6	20
1266	Dopaminergic Modulation of Cortical Plasticity in Alzheimer's Disease Patients. <i>Neuropsychopharmacology</i> , 2014, 39, 2654-2661.	2.8	121
1267	Alteration of epigenetic program to recover memory and alleviate neurodegeneration: prospects of multi-target molecules. <i>Biomaterials Science</i> , 2014, 2, 1043-1056.	2.6	10
1268	Dendritic spinopathy in transgenic mice expressing ALS/dementia-linked mutant <i>UBQLN2</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 14524-14529.	3.3	68
1269	More than Cholesterol Transporters: Lipoprotein Receptors in CNS Function and Neurodegeneration. <i>Neuron</i> , 2014, 83, 771-787.	3.8	127
1270	Golgi Apparatus and Protein Trafficking in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 42, S153-S162.	1.2	37
1271	Genomic and genetic aspects of autism spectrum disorder. <i>Biochemical and Biophysical Research Communications</i> , 2014, 452, 244-253.	1.0	81
1272	Dominance of misfolded intermediates in the dynamics of $\beta$ -helix folding. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 14424-14429.	3.3	17
1273	Turn Plasticity Distinguishes Different Modes of Amyloid- $\beta$ Aggregation. <i>Journal of the American Chemical Society</i> , 2014, 136, 4913-4919.	6.6	39
1274	Deficiency in LRP6-Mediated Wnt Signaling Contributes to Synaptic Abnormalities and Amyloid Pathology in Alzheimer's Disease. <i>Neuron</i> , 2014, 84, 63-77.	3.8	168



#	ARTICLE	IF	CITATIONS
1275	X-ray Crystallographic Structures of Trimers and Higher-Order Oligomeric Assemblies of a Peptide Derived from A $\beta$ 1-36. <i>Journal of the American Chemical Society</i> , 2014, 136, 5595-5598.	6.6	85
1276	CSF in Alzheimer's Disease. <i>Advances in Clinical Chemistry</i> , 2014, 65, 143-172.	1.8	19
1277	Nuclear Translocation Uncovers the Amyloid Peptide A $\beta$ 242 as a Regulator of Gene Transcription*. <i>Journal of Biological Chemistry</i> , 2014, 289, 20182-20191.	1.6	65
1278	Amyloid- $\beta$ -Induced Action Potential Desynchronization and Degradation of Hippocampal Gamma Oscillations Is Prevented by Interference with Peptide Conformation Change and Aggregation. <i>Journal of Neuroscience</i> , 2014, 34, 11416-11425.	1.7	91
1279	Leptin gene therapy attenuates neuronal damages evoked by amyloid- $\beta$ and rescues memory deficits in APP/PS1 mice. <i>Gene Therapy</i> , 2014, 21, 298-308.	2.3	64
1280	Synaptic plasticity in multiple sclerosis and in experimental autoimmune encephalomyelitis. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2014, 369, 20130162.	1.8	43
1281	Alzheimer's A $\beta$ 1-40 Peptide Binds and Penetrates DMPC Bilayer: An Isobaric-Isothermal Replica Exchange Molecular Dynamics Study. <i>Journal of Physical Chemistry B</i> , 2014, 118, 2638-2648.	1.2	45
1282	Insights into the Oxygen-Based Ligand of the Low pH Component of the Cu <sup>2+</sup> -Amyloid- $\beta$ Complex. <i>Journal of Physical Chemistry B</i> , 2014, 118, 10052-10064.	1.2	10
1283	Fyn kinase inhibition as a novel therapy for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 8.	3.0	160
1284	Is pathological aging a successful resistance against amyloid-beta or preclinical Alzheimer's disease?. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 24.	3.0	35
1285	Dietary regulation of PI3K/AKT/GSK-3 $\beta$ pathway in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 35.	3.0	148
1286	Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer's disease immunotherapeutics. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 42.	3.0	140
1287	Blocking the apoE/A $\beta$ interaction ameliorates A $\beta$ -related pathology in APOE $\mu$ 2 and $\mu$ 4 targeted replacement Alzheimer model mice. <i>Acta Neuropathologica Communications</i> , 2014, 2, 75.	2.4	42
1288	The Conformational Stability of Nonfibrillar Amyloid- $\beta$ Peptide Oligomers Critically Depends on the C-Terminal Peptide Length. <i>ACS Chemical Neuroscience</i> , 2014, 5, 161-167.	1.7	21
1289	Conformation-specific antibodies to target amyloid $\beta$ oligomers and their application to immunotherapy for Alzheimer's disease. <i>Bioscience, Biotechnology and Biochemistry</i> , 2014, 78, 1293-1305.	0.6	37
1290	Leptin regulation of hippocampal synaptic function in health and disease. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2014, 369, 20130155.	1.8	98
1291	Peptides Containing $\beta$ -Amino Acid Patterns: Challenges and Successes in Medicinal Chemistry. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 9718-9739.	2.9	249
1292	Secreted Amyloid $\beta$ -Proteins in a Cell Culture Model Include N-Terminally Extended Peptides That Impair Synaptic Plasticity. <i>Biochemistry</i> , 2014, 53, 3908-3921.	1.2	85



#	ARTICLE	IF	CITATIONS
1293	Dimerization Process of Amyloid- $\beta$ (29-42) Studied by the Hamiltonian Replica-Permutation Molecular Dynamics Simulations. <i>Journal of Physical Chemistry B</i> , 2014, 118, 11428-11436.	1.2	44
1294	Cocoa Extracts Reduce Oligomerization of Amyloid- $\beta$ : Implications for Cognitive Improvement in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 41, 643-650.	1.2	58
1295	Transient dynamics of A $\beta$ contribute to toxicity in Alzheimer's disease. <i>Cellular and Molecular Life Sciences</i> , 2014, 71, 3507-3521.	2.4	76
1296	Immunomodulation and AD "Down But Not Out. <i>Journal of Clinical Immunology</i> , 2014, 34, 70-73.	2.0	11
1297	Effects of acidic oligosaccharide sugar chain on amyloid oligomer-induced impairment of synaptic plasticity in rats. <i>Metabolic Brain Disease</i> , 2014, 29, 683-690.	1.4	1
1298	Diagnostic effectiveness of quantitative [18F]flutemetamol PET imaging for detection of fibrillar amyloid $\beta$ using cortical biopsy histopathology as the standard of truth in subjects with idiopathic normal pressure hydrocephalus. <i>Acta Neuropathologica Communications</i> , 2014, 2, 46.	2.4	19
1299	Biochemical stages of amyloid- $\beta$ peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically preclinical Alzheimer's disease. <i>Brain</i> , 2014, 137, 887-903.	3.7	136
1300	Nucleic acid oxidation: an early feature of Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2014, 128, 294-304.	2.1	88
1301	Structural evolution and membrane interactions of Alzheimer's amyloid- $\beta$ peptide oligomers: New knowledge from single-molecule fluorescence studies. <i>Protein Science</i> , 2014, 23, 869-883.	3.1	27
1302	c-Jun N-terminal kinase has a key role in Alzheimer disease synaptic dysfunction in vivo. <i>Cell Death and Disease</i> , 2014, 5, e1019-e1019.	2.7	88
1303	Soluble A $\beta$ Oligomers Are Rapidly Sequestered from Brain ISF In Vivo and Bind GM1 Ganglioside on Cellular Membranes. <i>Neuron</i> , 2014, 82, 308-319.	3.8	174
1304	Reelin delays amyloid-beta fibril formation and rescues cognitive deficits in a model of Alzheimer's disease. <i>Nature Communications</i> , 2014, 5, 3443.	5.8	108
1305	The Potential Role of Rho GTPases in Alzheimer's Disease Pathogenesis. <i>Molecular Neurobiology</i> , 2014, 50, 406-422.	1.9	36
1306	Amyloid- $\beta$ and Tau. <i>JAMA Neurology</i> , 2014, 71, 505.	4.5	1,416
1307	Differential Changes in A $\beta$ 42 and A $\beta$ 40 with Age. <i>Journal of Alzheimer's Disease</i> , 2014, 40, 727-735.	1.2	26
1308	ERP abnormalities elicited by word repetition in fragile X-associated tremor/ataxia syndrome (FXTAS) and amnesic MCI. <i>Neuropsychologia</i> , 2014, 63, 34-42.	0.7	21
1309	Neuronal SUMOylation: Mechanisms, Physiology, and Roles in Neuronal Dysfunction. <i>Physiological Reviews</i> , 2014, 94, 1249-1285.	13.1	157
1310	Hesperidin Alleviates Cognitive Impairment, Mitochondrial Dysfunction and Oxidative Stress in a Mouse Model of Alzheimer's Disease. <i>Cellular and Molecular Neurobiology</i> , 2014, 34, 1209-1221.	1.7	80

#	ARTICLE	IF	CITATIONS
1311	Neurotransmitter receptor and time dependence of the synaptic plasticity disrupting actions of Alzheimer's disease A $\beta$ <i>in vivo</i>. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2014, 369, 20130147.	1.8	23
1312	Antiparallel Triple-strand Architecture for Prefibrillar A $\beta$ 42 Oligomers. <i>Journal of Biological Chemistry</i> , 2014, 289, 27300-27313.	1.6	60
1313	Interactions between A $\beta$ oligomers and presynaptic cholinergic signaling: Age-dependent effects on attentional capacities. <i>Behavioural Brain Research</i> , 2014, 274, 30-42.	1.2	24
1314	Therapeutic Molecules and Endogenous Ligands Regulate the Interaction between Brain Cellular Prion Protein (PrPC) and Metabotropic Glutamate Receptor 5 (mGluR5). <i>Journal of Biological Chemistry</i> , 2014, 289, 28460-28477.	1.6	70
1315	Effects of the neurotrophic agent T-817MA on oligomeric amyloid- $\beta$ -induced deficits in long-term potentiation in the hippocampal CA1 subfield. <i>Neurobiology of Aging</i> , 2014, 35, 532-536.	1.5	21
1316	Simultaneous measurement of a range of particle sizes during A $\beta$ 1-42 fibrillogenesis quantified using fluorescence correlation spectroscopy. <i>Biochemical and Biophysical Research Communications</i> , 2014, 448, 195-199.	1.0	25
1317	Sleep deficits in mild cognitive impairment are related to increased levels of plasma amyloid- $\beta$ and cortical thinning. <i>NeuroImage</i> , 2014, 98, 395-404.	2.1	50
1318	Changes in the brain and plasma A $\beta$ peptide levels with age and its relationship with cognitive impairment in the APPswe/PS1dE9 mouse model of Alzheimer's disease. <i>Neuroscience</i> , 2014, 263, 269-279.	1.1	32
1319	APP Homodimers Transduce an Amyloid- $\beta$ -Mediated Increase in Release Probability at Excitatory Synapses. <i>Cell Reports</i> , 2014, 7, 1560-1576.	2.9	109
1320	Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: Targets for disease modification?. <i>Progress in Neurobiology</i> , 2014, 118, 1-18.	2.8	185
1321	High-fat diet-induced memory impairment in triple-transgenic Alzheimer's disease (3xTgAD) mice is independent of changes in amyloid and tau pathology. <i>Neurobiology of Aging</i> , 2014, 35, 1821-1832.	1.5	189
1322	Changed membrane integration and catalytic site conformation are two mechanisms behind the increased A $\beta$ 42/A $\beta$ 40 ratio by presenilin 1 familial Alzheimer-linked mutations. <i>FEBS Open Bio</i> , 2014, 4, 393-406.	1.0	12
1323	Memory Deficits in Aging and Neurological Diseases. <i>Progress in Molecular Biology and Translational Science</i> , 2014, 122, 1-29.	0.9	29
1324	Polymorphism of Oligomers of a Peptide from $\beta$ -Amyloid. <i>Journal of the American Chemical Society</i> , 2014, 136, 5432-5442.	6.6	24
1325	Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). <i>The Cochrane Library</i> , 2014, , CD008782.	1.5	88
1326	Tonic inhibition in dentate gyrus impairs long-term potentiation and memory in an Alzheimer's disease model. <i>Nature Communications</i> , 2014, 5, 4159.	5.8	215
1327	Resting microglia react to A $\beta$ 42 fibrils but do not detect oligomers or oligomer-induced neuronal damage. <i>Neurobiology of Aging</i> , 2014, 35, 2444-2457.	1.5	32
1328	The Intersection of Amyloid Beta and Tau at Synapses in Alzheimer's Disease. <i>Neuron</i> , 2014, 82, 756-771.	3.8	862

#	ARTICLE	IF	CITATIONS
1329	Factors Influencing Compactâ€“Extended Structure Equilibrium in Oligomers of A $\beta$ 1-40 Peptideâ€“An Ion Mobility Mass Spectrometry Study. <i>Journal of Molecular Biology</i> , 2014, 426, 2871-2885.	2.0	37
1330	A review of A $\beta$ -amyloid neuroimaging in Alzheimer's disease. <i>Frontiers in Neuroscience</i> , 2014, 8, 327.	1.4	76
1331	Memantine prevents memory consolidation failure induced by soluble beta amyloid in rats. <i>Frontiers in Behavioral Neuroscience</i> , 2014, 8, 332.	1.0	38
1332	Andrographolide reduces cognitive impairment in young and mature A $\beta$ PPswe/PS-1 mice. <i>Molecular Neurodegeneration</i> , 2014, 9, 61.	4.4	95
1334	Amyloid Plaque-Independent Deficit of Early Postnatal Visual Cortical Plasticity in the 5XFAD Transgenic Model of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 42, 103-107.	1.2	10
1335	Tissue Transglutaminase in Alzheimer's Disease: Involvement in Pathogenesis and its Potential as a Therapeutic Target. <i>Journal of Alzheimer's Disease</i> , 2014, 42, S289-S303.	1.2	27
1336	Clinical Trials and Drug Development. <i>Cancer Control</i> , 2014, 21, 188-189.	0.7	1
1337	Use of Magnetization Transfer Contrast MRI to Detect Early Molecular Pathology in Alzheimer's Disease. <i>Magnetic Resonance in Medicine</i> , 2014, 71, 333-338.	1.9	23
1338	Novel 5-aryloxypyrimidine SEN1576 as a candidate for the treatment of Alzheimer's disease. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 117-126.	1.0	13
1339	Caspase-dependent degradation of MDMx/MDM4 cell cycle regulatory protein in amyloid $\beta$ -induced neuronal damage. <i>Neuroscience Letters</i> , 2015, 609, 182-188.	1.0	5
1341	Food and Beverages Fortified with Phytonutrients. <i>Nutraceuticals</i> , 2015, , 173-238.	0.0	0
1342	Traumatic Brain Injury, Chronic Traumatic Encephalopathy, and Alzheimer's Disease: Common Pathologies Potentiated by Altered Zinc Homeostasis. <i>Journal of Alzheimer's Disease</i> , 2015, 46, 297-311.	1.2	24
1343	Potential Therapeutic Implications of Gelsolin in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 44, 13-25.	1.2	12
1344	Can oral infection be a risk factor for Alzheimer's disease?. <i>Journal of Oral Microbiology</i> , 2015, 7, 29143.	1.2	144
1345	Tomoregulin (TMEFF2) Binds Alzheimer's Disease Amyloid- $\beta$ (A $\beta$ ) Oligomer and A $\beta$ PP and Protects Neurons from A $\beta$ -Induced Toxicity. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 731-743.	1.2	17
1347	Tau and Amyloid- $\beta$ Cerebrospinal Fluid Biomarkers have Differential Relationships with Cognition in Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 965-975.	1.2	18
1348	Plaque-associated lipids in Alzheimer's diseased brain tissue visualized by nonlinear microscopy. <i>Scientific Reports</i> , 2015, 5, 13489.	1.6	86
1349	Yeast Model of Amyloid- $\beta$ and Tau Aggregation in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 9-16.	1.2	16

#	ARTICLE	IF	CITATIONS
1350	Molecular Signaling Mechanisms of Natural and Synthetic Retinoids for Inhibition of Pathogenesis in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 335-352.	1.2	42
1351	Synthesis and characterization of the amyloid A <sub>240</sub> dimer model with a linker at position 30 adjacent to the intermolecular $\beta$ -sheet region. <i>Biochemical and Biophysical Research Communications</i> , 2015, 466, 463-467.	1.0	6
1352	An N-terminal antibody promotes the transformation of amyloid fibrils into oligomers and enhances the neurotoxicity of amyloid-beta: the dust-raising effect. <i>Journal of Neuroinflammation</i> , 2015, 12, 153.	3.1	29
1353	Human neural stem cells alleviate Alzheimer-like pathology in a mouse model. <i>Molecular Neurodegeneration</i> , 2015, 10, 38.	4.4	120
1354	Calcium/calmodulin-dependent kinase II and Alzheimer's disease. <i>Molecular Brain</i> , 2015, 8, 78.	1.3	138
1355	ADAM10 and BACE1 are localized to synaptic vesicles. <i>Journal of Neurochemistry</i> , 2015, 135, 606-615.	2.1	65
1356	Sucrose prevents protein fibrillation through compaction of the tertiary structure but hardly affects the secondary structure. <i>Proteins: Structure, Function and Bioinformatics</i> , 2015, 83, 2039-2051.	1.5	18
1357	Reduced Incidence of Dementia in Solid Organ Transplant Patients Treated with Calcineurin Inhibitors. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 329-333.	1.2	63
1358	Translation of Pre-Clinical Studies into Successful Clinical Trials for Alzheimer's Disease: What are the Roadblocks and How Can They Be Overcome?1. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 815-843.	1.2	84
1359	Melatonin regulates the transcription of $\beta$ APP-cleaving secretases mediated through melatonin receptors in human neuroblastoma SH-SY5Y cells. <i>Journal of Pineal Research</i> , 2015, 59, 308-320.	3.4	47
1360	Dextran sulfate sodium inhibits amyloid A <sub>2</sub> oligomer binding to cellular prion protein. <i>Journal of Neurochemistry</i> , 2015, 134, 611-617.	2.1	11
1361	Cerebrospinal Fluid A <sub>42</sub> Levels: When Physiological Become Pathological State. <i>CNS Neuroscience and Therapeutics</i> , 2015, 21, 921-925.	1.9	41
1362	A Naturally Occurring $\beta$ -Secretase Modulator, Tannic Acid, Improves Behavioral Impairment and Mitigates Alzheimer-Like Pathology. , 2015, , 1069-1079.		0
1363	The elusive nature and diagnostics of misfolded A <sub>2</sub> oligomers. <i>Frontiers in Chemistry</i> , 2015, 3, 17.	1.8	24
1364	cAMP-Inhibits Cytoplasmic Phospholipase A2 and Protects Neurons against Amyloid- $\beta$ -Induced Synapse Damage. <i>Biology</i> , 2015, 4, 591-606.	1.3	17
1365	Neurodegeneration and microtubule dynamics: death by a thousand cuts. <i>Frontiers in Cellular Neuroscience</i> , 2015, 9, 343.	1.8	133
1366	Altered intrinsic excitability of hippocampal CA1 pyramidal neurons in aged PDAPP mice. <i>Frontiers in Cellular Neuroscience</i> , 2015, 9, 372.	1.8	46
1367	The prion protein constitutively controls neuronal store-operated Ca <sup>2+</sup> entry through Fyn kinase. <i>Frontiers in Cellular Neuroscience</i> , 2015, 9, 416.	1.8	24

#	ARTICLE	IF	CITATIONS
1368	Cerebrospinal Fluid P-Tau181P: Biomarker for Improved Differential Dementia Diagnosis. <i>Frontiers in Neurology</i> , 2015, 6, 138.	1.1	44
1369	Therapeutic potential of mGluR5 targeting in Alzheimer's disease. <i>Frontiers in Neuroscience</i> , 2015, 9, 215.	1.4	66
1370	Synaptic activity and Alzheimer's disease: a critical update. <i>Frontiers in Neuroscience</i> , 2015, 9, 423.	1.4	97
1371	Neurobiology of Alzheimer's Disease: Integrated Molecular, Physiological, Anatomical, Biomarker, and Cognitive Dimensions. <i>Current Alzheimer Research</i> , 2015, 12, 712-722.	0.7	134
1372	A $\beta$ -Secretase Inhibitor, but Not a $\beta$ -Secretase Modulator, Induced Defects in BDNF Axonal Trafficking and Signaling: Evidence for a Role for APP. <i>PLoS ONE</i> , 2015, 10, e0118379.	1.1	37
1373	Genetics of Autism Spectrum Disorder: Current Status and Possible Clinical Applications. <i>Experimental Neurobiology</i> , 2015, 24, 257-272.	0.7	133
1374	Neural Plasticity in Multiple Sclerosis: The Functional and Molecular Background. <i>Neural Plasticity</i> , 2015, 2015, 1-11.	1.0	54
1375	The Role of Oxidative Stress-Induced Epigenetic Alterations in Amyloid- $\beta$ Production in Alzheimer's Disease. <i>Oxidative Medicine and Cellular Longevity</i> , 2015, 2015, 1-13.	1.9	98
1376	PET Imaging of Epigenetic Influences on Alzheimer's Disease. <i>International Journal of Alzheimer's Disease</i> , 2015, 2015, 1-11.	1.1	13
1377	Prion-Protein-interacting Amyloid- $\beta$ Oligomers of High Molecular Weight Are Tightly Correlated with Memory Impairment in Multiple Alzheimer Mouse Models. <i>Journal of Biological Chemistry</i> , 2015, 290, 17415-17438.	1.6	104
1378	Coupling of Zinc-Binding and Secondary Structure in Nonfibrillar A $\beta$ 240 Peptide Oligomerization. <i>Journal of Chemical Information and Modeling</i> , 2015, 55, 1218-1230.	2.5	16
1379	Proteotoxicity and Cardiac Dysfunction. <i>Circulation Research</i> , 2015, 116, 1863-1882.	2.0	80
1380	Alzheimer Disease. , 2015, , 753-768.		6
1381	Amyloid misfolding, aggregation, and the early onset of protein deposition diseases: insights from AFM experiments and computational analyses. <i>AIMS Molecular Science</i> , 2015, 2, 190-210.	0.3	16
1382	Therapeutic effects of glatiramer acetate and grafted CD115 <sup>+</sup> monocytes in a mouse model of Alzheimer's disease. <i>Brain</i> , 2015, 138, 2399-2422.	3.7	122
1383	Synthesis of chemically-tethered amyloid- $\beta$ segment trimer possessing amyloidogenic properties. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 2976-2979.	1.0	16
1384	Effects of A $\beta$ exposure on long-term associative memory and its neuronal mechanisms in a defined neuronal network. <i>Scientific Reports</i> , 2015, 5, 10614.	1.6	27
1385	Glutamate transporter EAAT2: regulation, function, and potential as a therapeutic target for neurological and psychiatric disease. <i>Cellular and Molecular Life Sciences</i> , 2015, 72, 3489-3506.	2.4	130

#	ARTICLE	IF	CITATIONS
1386	Effects of noninvasive brain stimulation on cognitive function in healthy aging and Alzheimer's disease: a systematic review and meta-analysis. <i>Neurobiology of Aging</i> , 2015, 36, 2348-2359.	1.5	268
1387	Antiparallel $\beta$ -Sheet Structure within the C-Terminal Region of 42-Residue Alzheimer's Amyloid- $\beta$ Peptides When They Form 150-kDa Oligomers. <i>Journal of Molecular Biology</i> , 2015, 427, 2319-2328.	2.0	69
1388	The case for rejecting the amyloid cascade hypothesis. <i>Nature Neuroscience</i> , 2015, 18, 794-799.	7.1	613
1389	Three dimensions of the amyloid hypothesis: time, space and 'wingmen'. <i>Nature Neuroscience</i> , 2015, 18, 800-806.	7.1	582
1390	Brazilin inhibits amyloid $\beta$ -protein fibrillogenesis, remodels amyloid fibrils and reduces amyloid cytotoxicity. <i>Scientific Reports</i> , 2015, 5, 7992.	1.6	134
1391	Systematic analysis of time-dependent neural effects of soluble amyloid $\beta$ oligomers in culture and in vivo: Prevention by scyllo-inositol. <i>Neurobiology of Disease</i> , 2015, 82, 152-163.	2.1	43
1392	The Transient Receptor Potential Melastatin 2 (TRPM2) Channel Contributes to $\beta$ -Amyloid Oligomer-Related Neurotoxicity and Memory Impairment. <i>Journal of Neuroscience</i> , 2015, 35, 15157-15169.	1.7	110
1393	Dietary DHA supplementation in an APP/PS1 transgenic rat model of AD reduces behavioral and $A\beta$ pathology and modulates $A\beta$ oligomerization. <i>Neurobiology of Disease</i> , 2015, 82, 552-560.	2.1	48
1394	What has electron microscopy contributed to Alzheimer's research?. <i>Future Neurology</i> , 2015, 10, 515-527.	0.9	3
1395	EPPS rescues hippocampus-dependent cognitive deficits in APP/PS1 mice by disaggregation of amyloid- $\beta$ oligomers and plaques. <i>Nature Communications</i> , 2015, 6, 8997.	5.8	96
1396	ACAT1/SOAT1 as a therapeutic target for Alzheimer's disease. <i>Future Medicinal Chemistry</i> , 2015, 7, 2451-2467.	1.1	82
1397	New Views on the Misconstrued: Executioner Caspases and Their Diverse Non-apoptotic Roles. <i>Neuron</i> , 2015, 88, 461-474.	3.8	71
1398	Glycogen Synthase Kinase $\beta$ -mediated Phosphorylation in the Most C-terminal Region of Protein Interacting with C Kinase 1 (PICK1) Regulates the Binding of PICK1 to Glutamate Receptor Subunit GluA2. <i>Journal of Biological Chemistry</i> , 2015, 290, 29438-29448.	1.6	30
1399	Beta-Amyloid and Tau-Protein: Structure, Interaction, and Prion-Like Properties. <i>Biochemistry (Moscow)</i> , 2015, 80, 1800-1819.	0.7	31
1400	Blocking IGF Signaling in Adult Neurons Alleviates Alzheimer's Disease Pathology through Amyloid- $\beta$ Clearance. <i>Journal of Neuroscience</i> , 2015, 35, 11500-11513.	1.7	124
1401	Quaternary Structure Defines a Large Class of Amyloid- $\beta$ Oligomers Neutralized by Sequestration. <i>Cell Reports</i> , 2015, 11, 1760-1771.	2.9	141
1402	The Roles of Cellular and Organismal Aging in the Development of Late-Onset Maladies. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2015, 10, 1-23.	9.6	31
1403	Strong Inhibition of Beta-Amyloid Peptide Aggregation Realized by Two Steps Evolved Peptides. <i>Chemical Biology and Drug Design</i> , 2015, 85, 356-368.	1.5	6



#	ARTICLE	IF	CITATIONS
1404	The $\text{Ca}^{2+}$ channel inhibitor 2-APB reverses $\text{A}\beta$ -induced LTP deficit in hippocampus by blocking BAX and caspase-3 hyperactivation. <i>British Journal of Pharmacology</i> , 2015, 172, 2273-2285.	2.7	16
1405	The N-terminal region of myelin basic protein reduces fibrillar amyloid- $\beta$ deposition in Tg-5xFAD mice. <i>Neurobiology of Aging</i> , 2015, 36, 801-811.	1.5	10
1406	MRZ-99030: A novel modulator of $\text{A}\beta$ aggregation: II: Reversal of $\text{A}\beta$ oligomer-induced deficits in long-term potentiation (LTP) and cognitive performance in rats and mice. <i>Neuropharmacology</i> , 2015, 92, 170-182.	2.0	23
1407	Long-term treatment with Ginkgo biloba extract EGb 761 improves symptoms and pathology in a transgenic mouse model of Alzheimer's disease. <i>Brain, Behavior, and Immunity</i> , 2015, 46, 121-131.	2.0	110
1408	Neurotoxicity and synaptic plasticity impairment of N-acetylglucosamine polymers: implications for Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015, 36, 1780-1791.	1.5	17
1409	Erythropoietin improves synaptic plasticity and memory deficits by decrease of the neurotransmitter release probability in the rat model of Alzheimer's disease. <i>Pharmacology Biochemistry and Behavior</i> , 2015, 130, 15-21.	1.3	72
1410	Calcium Signaling, Excitability, and Synaptic Plasticity Defects in a Mouse Model of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 561-580.	1.2	61
1411	Binding and Dissociation of Biomarkers for Alzheimer's Disease on Biosensor Surfaces. , 2015, , 377-486.		0
1412	Posttraumatic Stress Disorder-Like Induction Elevates $\beta$ -Amyloid Levels, Which Directly Activates Corticotropin-Releasing Factor Neurons to Exacerbate Stress Responses. <i>Journal of Neuroscience</i> , 2015, 35, 2612-2623.	1.7	64
1413	Tripchlorolide improves cognitive deficits by reducing amyloid $\beta$ and upregulating synapse-related proteins in a transgenic model of Alzheimer's Disease. <i>Journal of Neurochemistry</i> , 2015, 133, 38-52.	2.1	49
1414	Cerebrospinal Fluid in Clinical Neurology. , 2015, , .		16
1415	The metabolism hypothesis of Alzheimer's disease: from the concept of central insulin resistance and associated consequences to insulin therapy. <i>Journal of Neural Transmission</i> , 2015, 122, 499-504.	1.4	33
1416	Compromised MAPK signaling in human diseases: an update. <i>Archives of Toxicology</i> , 2015, 89, 867-882.	1.9	782
1417	The protective effect of <i>Borago Officinalis</i> extract on amyloid $\beta$ (25-35)-induced long term potentiation disruption in the dentate gyrus of male rats. <i>Metabolic Brain Disease</i> , 2015, 30, 151-156.	1.4	17
1418	Subchronic Glucocorticoid Receptor Inhibition Rescues Early Episodic Memory and Synaptic Plasticity Deficits in a Mouse Model of Alzheimer's Disease. <i>Neuropsychopharmacology</i> , 2015, 40, 1772-1781.	2.8	63
1419	Telencephalic neurocircuitry and synaptic plasticity in rodent spatial learning and memory. <i>Brain Research</i> , 2015, 1621, 294-308.	1.1	14
1420	A Food and Drug Administration-approved Asthma Therapeutic Agent Impacts Amyloid $\beta$ in the Brain in a Transgenic Model of Alzheimer Disease. <i>Journal of Biological Chemistry</i> , 2015, 290, 1966-1978.	1.6	65
1421	Energetic contributions of residues to the formation of early amyloid- $\beta$ oligomers. <i>Physical Chemistry Chemical Physics</i> , 2015, 17, 2823-2837.	1.3	10



#	ARTICLE	IF	CITATIONS
1422	High Order W <sup>02</sup> -Reactive Stable Oligomers of Amyloid- $\beta^2$ are Produced in vivo and in vitro via Dialysis and Filtration of Synthetic Amyloid- $\beta^2$ Monomer. <i>Journal of Alzheimer's Disease</i> , 2015, 44, 69-78.	1.2	2
1423	Stabilization of Nontoxic A $\beta$ -Oligomers: Insights into the Mechanism of Action of Hydroxyquinolines in Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2015, 35, 2871-2884.	1.7	67
1424	Evaluation of the effects of amyloid $\beta^2$ aggregation from seaweed extracts by a microliter-scale high-throughput screening system with a quantum dot nanoprobe. <i>Journal of Bioscience and Bioengineering</i> , 2015, 120, 45-50.	1.1	16
1425	On the lag phase in amyloid fibril formation. <i>Physical Chemistry Chemical Physics</i> , 2015, 17, 7606-7618.	1.3	590
1426	Restored glial glutamate transporter EAAT2 function as a potential therapeutic approach for Alzheimer's disease. <i>Journal of Experimental Medicine</i> , 2015, 212, 319-332.	4.2	120
1427	BDNF prevents amyloid-dependent impairment of LTP in the entorhinal cortex by attenuating p38 MAPK phosphorylation. <i>Neurobiology of Aging</i> , 2015, 36, 1303-1309.	1.5	64
1428	Donepezil attenuates A $\beta^2$ -associated mitochondrial dysfunction and reduces mitochondrial A $\beta^2$ accumulation in vivo and in vitro. <i>Neuropharmacology</i> , 2015, 95, 29-36.	2.0	61
1429	From molecule to molecule and cell to cell: Prion-like mechanisms in amyotrophic lateral sclerosis. <i>Neurobiology of Disease</i> , 2015, 77, 257-265.	2.1	74
1430	syn inhibition rescues established memory and synapse loss in Alzheimer mice. <i>Annals of Neurology</i> , 2015, 77, 953-971.	2.8	282
1431	New progress in active immunotherapy targeting to amyloid beta. <i>Science China Chemistry</i> , 2015, 58, 383-389.	4.2	1
1432	Soluble amyloid- $\beta^2$ oligomers as synaptotoxins leading to cognitive impairment in Alzheimer's disease. <i>Frontiers in Cellular Neuroscience</i> , 2015, 9, 191.	1.8	284
1433	Toxic species in amyloid disorders: Oligomers or mature fibrils. <i>Annals of Indian Academy of Neurology</i> , 2015, 18, 138.	0.2	168
1434	Geldanamycin Reduces A $\beta^2$ -Associated Anxiety and Depression, Concurrent with Autophagy Provocation. <i>Journal of Molecular Neuroscience</i> , 2015, 57, 317-324.	1.1	25
1435	Na, K-ATPase $\beta^3$ is a death target of Alzheimer patient amyloid- $\beta^2$ assembly. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E4465-74.	3.3	112
1436	Structure-based drug design identifies polythiophenes as anti-prion compounds. <i>Science Translational Medicine</i> , 2015, 7, 299ra123.	5.8	130
1437	Increased GADD34 in oligodendrocytes in Alzheimer's disease. <i>Neuroscience Letters</i> , 2015, 602, 50-55.	1.0	19
1438	HDAC6 and RhoA are novel players in A $\beta$ -driven disruption of neuronal polarity. <i>Nature Communications</i> , 2015, 6, 7781.	5.8	52
1439	Near-infrared fluorescence molecular imaging of amyloid beta species and monitoring therapy in animal models of Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 9734-9739.	3.3	187

#	ARTICLE	IF	CITATIONS
1440	Intraperitoneal injection of the pancreatic peptide amylin potently reduces behavioral impairment and brain amyloid pathology in murine models of Alzheimer's disease. <i>Molecular Psychiatry</i> , 2015, 20, 252-262.	4.1	83
1441	Contribution of N-methyl-D-aspartate receptors to attention and episodic spatial memory during senescence. <i>Neurobiology of Learning and Memory</i> , 2015, 125, 36-46.	1.0	25
1442	Age-dependent impairment of glucose tolerance in the 3xTg-AD mouse model of Alzheimer's disease. <i>FASEB Journal</i> , 2015, 29, 4273-4284.	0.2	84
1443	GIRK Channels. <i>International Review of Neurobiology</i> , 2015, 123, 239-277.	0.9	13
1444	SORL1 gene polymorphism association with late-onset Alzheimer's disease. <i>Neuroscience Letters</i> , 2015, 584, 382-389.	1.0	21
1445	Fluphenazine-HCl and Epigallocatechin Gallate Modulate the Rate of Formation and Structural Properties of Apolipoprotein C-II Amyloid Fibrils. <i>Biochemistry</i> , 2015, 54, 3831-3838.	1.2	8
1446	Structural, morphological, and functional diversity of amyloid oligomers. <i>FEBS Letters</i> , 2015, 589, 2640-2648.	1.3	150
1447	PPAR- $\delta$ agonist regulates amyloid- $\beta$ generation via inhibiting BACE-1 activity in human neuroblastoma SH-SY5Y cells transfected with APP <sup>swe</sup> gene. <i>Molecular and Cellular Biochemistry</i> , 2015, 408, 37-46.	1.4	18
1448	Regulation of extracellular Zn <sup>2+</sup> homeostasis in the hippocampus as a therapeutic target for Alzheimer's disease. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 1051-1058.	1.5	9
1449	A theoretical study on the molecular determinants of the affibody protein Z <sub>3</sub> bound to an amyloid $\beta$ peptide. <i>Physical Chemistry Chemical Physics</i> , 2015, 17, 16886-16893.	1.3	4
1450	Amyloid Tracers. , 2015, , 633-639.		0
1451	The aqueous phase of Alzheimer's disease brain contains assemblies built from $\sim$ 4 and $\sim$ 7 kDa A $\beta$ species. <i>Alzheimer's and Dementia</i> , 2015, 11, 1286-1305.	0.4	54
1452	Astrocyte physiopathology: At the crossroads of intercellular networking, inflammation and cell death. <i>Progress in Neurobiology</i> , 2015, 130, 86-120.	2.8	157
1453	Animal models for prion-like diseases. <i>Virus Research</i> , 2015, 207, 5-24.	1.1	10
1454	Immunotherapeutic Approaches for Alzheimer's Disease. <i>Neuron</i> , 2015, 85, 1162-1176.	3.8	241
1455	Roles of zinc ions and structural polymorphism of $\beta$ -amyloid in the development of Alzheimer's disease. <i>Molecular Biology</i> , 2015, 49, 217-230.	0.4	27
1456	A highly sensitive novel immunoassay specifically detects low levels of soluble A $\beta$ oligomers in human cerebrospinal fluid. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 14.	3.0	78
1457	The Role of the Tripartite Glutamatergic Synapse in the Pathophysiology of Alzheimer's Disease. , 2015, 6, 131.		114

#	ARTICLE	IF	CITATIONS
1458	Fluid biomarkers in multiple system atrophy: A review of the MSA Biomarker Initiative. <i>Neurobiology of Disease</i> , 2015, 80, 29-41.	2.1	71
1460	Centrally Delivered BACE1 Inhibitor Activates Microglia, and Reverses Amyloid Pathology and Cognitive Deficit in Aged Tg2576 Mice. <i>Journal of Neuroscience</i> , 2015, 35, 6931-6936.	1.7	29
1461	Amyloid-Beta: A Crucial Factor in Alzheimer's Disease. <i>Medical Principles and Practice</i> , 2015, 24, 1-10.	1.1	344
1462	Oxidation as an important factor of protein damage: Implications for Maillard reaction. <i>Journal of Biosciences</i> , 2015, 40, 419-439.	0.5	31
1463	Tau Immunotherapy Modulates Both Pathological Tau and Upstream Amyloid Pathology in an Alzheimer's Disease Mouse Model. <i>Journal of Neuroscience</i> , 2015, 35, 4857-4868.	1.7	122
1464	Is interaction of amyloid $\beta$ -peptides with metals involved in cognitive activity?. <i>Metallomics</i> , 2015, 7, 1205-1212.	1.0	18
1465	Small angle X-ray scattering analysis of Cu <sup>2+</sup> -induced oligomers of the Alzheimer's amyloid $\beta$ peptide. <i>Metallomics</i> , 2015, 7, 536-543.	1.0	25
1466	Electrically pulsatile responsive drug delivery platform for treatment of Alzheimer's disease. <i>Nano Research</i> , 2015, 8, 2400-2414.	5.8	35
1467	Structural Insight into an Alzheimer's Brain-Derived Spherical Assembly of Amyloid $\beta$ by Solid-State NMR. <i>Journal of the American Chemical Society</i> , 2015, 137, 6480-6483.	6.6	54
1468	Amyloid Polymorphism: Structural Basis and Neurobiological Relevance. <i>Neuron</i> , 2015, 86, 632-645.	3.8	347
1469	Olfactory dysfunction: its early temporal relationship and neural correlates in the pathogenesis of Alzheimer's disease. <i>Journal of Neural Transmission</i> , 2015, 122, 1475-1497.	1.4	52
1470	Amyloid $\beta$ -Protein Assembly: The Effect of Molecular Tweezers CLR01 and CLR03. <i>Journal of Physical Chemistry B</i> , 2015, 119, 4831-4841.	1.2	69
1471	Nobiletin, a citrus flavonoid, improves cognitive impairment and reduces soluble $A\beta$ levels in a triple transgenic mouse model of Alzheimer's disease (3XTg-AD). <i>Behavioural Brain Research</i> , 2015, 289, 69-77.	1.2	111
1472	Neuroinflammatory Signals in Alzheimer Disease and APP/PS1 Transgenic Mice. <i>Journal of Neuropathology and Experimental Neurology</i> , 2015, 74, 319-344.	0.9	105
1473	Role of amyloid- $\beta$ CSF levels in cognitive deficit in MS. <i>Clinica Chimica Acta</i> , 2015, 449, 23-30.	0.5	27
1474	Alzheimer's Disease and Mechanism-Based Attempts to Enhance Cognition. , 2015, , 193-231.		0
1475	Amyloid $\beta$ Protein and Alzheimer's Disease: When Computer Simulations Complement Experimental Studies. <i>Chemical Reviews</i> , 2015, 115, 3518-3563.	23.0	530
1476	Cosolute Effects on Amyloid Aggregation in a Nondiffusion Limited Regime: Intrinsic Osmolyte Properties and the Volume Exclusion Principle. <i>Langmuir</i> , 2015, 31, 4246-4254.	1.6	19

#	ARTICLE	IF	CITATIONS
1477	Distinct Role of Hydration Water in Protein Misfolding and Aggregation Revealed by Fluctuating Thermodynamics Analysis. <i>Accounts of Chemical Research</i> , 2015, 48, 956-965.	7.6	68
1478	Stability of Osaka Mutant and Wild-Type Fibril Models. <i>Journal of Physical Chemistry B</i> , 2015, 119, 13063-13070.	1.2	20
1479	Autoregulated paracellular clearance of amyloid- $\beta^2$ across the blood-brain barrier. <i>Science Advances</i> , 2015, 1, e1500472.	4.7	113
1480	Peptide dimer structure in an A $\beta^2$ (1-42) fibril visualized with cryo-EM. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 11858-11863.	3.3	196
1481	Intracellular amyloid $\beta^2$ oligomers impair organelle transport and induce dendritic spine loss in primary neurons. <i>Acta Neuropathologica Communications</i> , 2015, 3, 51.	2.4	52
1482	A Human Monoclonal IgG That Binds A $\beta^2$ Assemblies and Diverse Amyloids Exhibits Anti-Amyloid Activities <i>In Vitro</i> and <i>In Vivo</i> . <i>Journal of Neuroscience</i> , 2015, 35, 6265-6276.	1.7	23
1483	Two macrocyclic polyamines as modulators of metal-mediated A $\beta^2$ aggregation. <i>Integrative Biology (United Kingdom)</i> , 2015, 7, 655-662.	0.6	21
1484	Cross-Seeding Interaction between $\beta^2$ -Amyloid and Human Islet Amyloid Polypeptide. <i>ACS Chemical Neuroscience</i> , 2015, 6, 1759-1768.	1.7	78
1485	Soluble Prion Protein Binds Isolated Low Molecular Weight Amyloid- $\beta^2$ Oligomers Causing Cytotoxicity Inhibition. <i>ACS Chemical Neuroscience</i> , 2015, 6, 1972-1980.	1.7	19
1486	High Membrane Curvature Enhances Binding, Conformational Changes, and Fibrillation of Amyloid- $\beta^2$ on Lipid Bilayer Surfaces. <i>Langmuir</i> , 2015, 31, 11549-11557.	1.6	50
1487	Direct Correlation of Cell Toxicity to Conformational Ensembles of Genetic A $\beta^2$ Variants. <i>ACS Chemical Neuroscience</i> , 2015, 6, 1990-1996.	1.7	16
1489	Amyloid- $\beta^2$ Oligomers May Impair SNARE-Mediated Exocytosis by Direct Binding to Syntaxin 1a. <i>Cell Reports</i> , 2015, 12, 1244-1251.	2.9	54
1490	Breaking immune tolerance by targeting Foxp3+ regulatory T cells mitigates Alzheimer's disease pathology. <i>Nature Communications</i> , 2015, 6, 7967.	5.8	366
1491	$\beta$ -Secretase processing of APP inhibits neuronal activity in the hippocampus. <i>Nature</i> , 2015, 526, 443-447.	13.7	308
1492	Calcium flux-independent NMDA receptor activity is required for A $\beta^2$ oligomer-induced synaptic loss. <i>Cell Death and Disease</i> , 2015, 6, e1791-e1791.	2.7	71
1493	The binding of small carbazole derivative (P7C3) to protofibrils of the Alzheimer's disease and $\beta^2$ -secretase: Molecular dynamics simulation studies. <i>Chemical Physics</i> , 2015, 459, 31-39.	0.9	11
1494	Association between variant amyloid deposits and motor deficits in FAD-associated presenilin-1 mutations: A systematic review. <i>Neuroscience and Biobehavioral Reviews</i> , 2015, 56, 180-192.	2.9	11
1495	The keystone of Alzheimer pathogenesis might be sought in A $\beta^2$ physiology. <i>Neuroscience</i> , 2015, 307, 26-36.	1.1	98

#	ARTICLE	IF	CITATIONS
1496	Protective spin-labeled fluorenes maintain amyloid beta peptide in small oligomers and limit transitions in secondary structure. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2015, 1854, 1860-1870.	1.1	10
1497	Novel zinc-targeted therapeutic options for cognitive decline. <i>Future Neurology</i> , 2015, 10, 537-546.	0.9	1
1498	Low concentrations of ethanol protect against synaptotoxicity induced by A $\beta$ in hippocampal neurons. <i>Neurobiology of Aging</i> , 2015, 36, 845-856.	1.5	29
1499	Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 83-105.	1.4	64
1500	Neuropathology and biochemistry of A $\beta$ and its aggregates in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2015, 129, 167-182.	3.9	224
1501	Combining an amyloid-beta (A $\beta$ ) cleaving enzyme inhibitor with a $\beta$ -secretase modulator results in an additive reduction of A $\beta$ production. <i>FEBS Journal</i> , 2015, 282, 65-73.	2.2	18
1502	Rescue of impaired late-phase long-term depression in a tau transgenic mouse model. <i>Neurobiology of Aging</i> , 2015, 36, 730-739.	1.5	37
1503	Intraneuronal A $\beta$ accumulation induces hippocampal neuron hyperexcitability through A-type K <sup>+</sup> current inhibition mediated by activation of caspases and GSK-3. <i>Neurobiology of Aging</i> , 2015, 36, 886-900.	1.5	78
1504	WASP-1, a canonical Wnt signaling potentiator, rescues hippocampal synaptic impairments induced by A $\beta$ oligomers. <i>Experimental Neurology</i> , 2015, 264, 14-25.	2.0	29
1505	Childhood and adolescent obesity and long-term cognitive consequences during aging. <i>Journal of Comparative Neurology</i> , 2015, 523, 757-768.	0.9	43
1506	Parallel age-associated changes in brain and plasma neuronal pentraxin receptor levels in a transgenic APP/PS1 rat model of Alzheimer's disease. <i>Neurobiology of Disease</i> , 2015, 74, 32-40.	2.1	4
1508	The green tea polyphenol (epigallocatechin gallate) prevents the aggregation of tau protein into toxic oligomers at substoichiometric ratios. <i>FEBS Letters</i> , 2015, 589, 77-83.	1.3	172
1509	Effect of active A $\beta$ immunotherapy on neurons in human Alzheimer's disease. <i>Journal of Pathology</i> , 2015, 235, 721-730.	2.1	31
1510	Chronic Neurodegeneration After Traumatic Brain Injury: Alzheimer Disease, Chronic Traumatic Encephalopathy, or Persistent Neuroinflammation?. <i>Neurotherapeutics</i> , 2015, 12, 143-150.	2.1	199
1511	The Role of Cholesterol Metabolism in Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2015, 51, 947-965.	1.9	62
1512	Cognitive Reserve and Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2015, 51, 187-208.	1.9	86
1513	Application of human induced pluripotent stem cells for modeling and treating neurodegenerative diseases. <i>New Biotechnology</i> , 2015, 32, 212-228.	2.4	34
1514	Ultrasonic force microscopy for nanomechanical characterization of early and late-stage amyloid- $\beta$ peptide aggregation. <i>Scientific Reports</i> , 2014, 4, 4004.	1.6	27

#	ARTICLE	IF	CITATIONS
1515	Biometals and Their Therapeutic Implications in Alzheimer's Disease. <i>Neurotherapeutics</i> , 2015, 12, 109-120.	2.1	109
1516	Molecular structure of the NQTrp inhibitor with the Alzheimer A $\beta$ 1-28 monomer. <i>European Journal of Medicinal Chemistry</i> , 2015, 91, 43-50.	2.6	32
1517	Small A $\beta$ <sup>42</sup> oligomer-induced membrane depolarization of neuronal and microglial cells: Role of N-methyl-D-aspartate receptors. <i>Journal of Neuroscience Research</i> , 2015, 93, 475-486.	1.3	27
1518	Eph receptors: New players in Alzheimer's disease pathogenesis. <i>Neurobiology of Disease</i> , 2015, 73, 137-149.	2.1	34
1519	The multifaceted nature of amyloid precursor protein and its proteolytic fragments: friends and foes. <i>Acta Neuropathologica</i> , 2015, 129, 1-19.	3.9	184
1520	Omega-3 fatty acid obtained from <i>Nannochloropsis oceanica</i> cultures grown under low urea protect against A $\beta$ -induced neural damage. <i>Journal of Food Science and Technology</i> , 2015, 52, 2982-2989.	1.4	13
1521	Insulin and Lispro Insulin: What is Common and Different in their Behavior?. <i>Current Protein and Peptide Science</i> , 2016, 18, 57-64.	0.7	14
1522	Insulin Resistance is Associated with Increased Levels of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Reduced Memory Function in At-Risk Healthy Middle-Aged Adults. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 1373-1383.	1.2	51
1523	Is the Combination/Multi-target Therapy a New Promise for Alzheimer's Disease?. , 2016, 06, .		1
1524	A Link Between Nerve Growth Factor Metabolic Deregulation and Amyloid- $\beta$ -Driven Inflammation in Down Syndrome. <i>CNS and Neurological Disorders - Drug Targets</i> , 2016, 15, 434-447.	0.8	24
1525	Stress and Cognitive Reserve as independent factors of neuropsychological performance in healthy elderly. <i>Ciencia E Saude Coletiva</i> , 2016, 21, 3499-3508.	0.1	14
1526	PSEN1 L226F mutation in a patient with early-onset Alzheimer's disease in Korea. <i>Clinical Interventions in Aging</i> , 2016, Volume 11, 1433-1440.	1.3	13
1527	AFM-Based Single Molecule Techniques: Unraveling the Amyloid Pathogenic Species. <i>Current Pharmaceutical Design</i> , 2016, 22, 3950-3970.	0.9	75
1528	Soluble Amyloid- $\beta$ <sup>42</sup> Stimulates Glutamate Release through Activation of the $\alpha$ 7 Nicotinic Acetylcholine Receptor. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 337-347.	1.2	40
1529	The Transcription Factor XBP1 in Memory and Cognition: implications in Alzheimer's Disease. <i>Molecular Medicine</i> , 2016, 22, 905-917.	1.9	27
1530	Emerging Link between Alzheimer's Disease and Homeostatic Synaptic Plasticity. <i>Neural Plasticity</i> , 2016, 2016, 1-19.	1.0	67
1531	Erythropoietin Restores Long-Term Neurocognitive Function Involving Mechanisms of Neuronal Plasticity in a Model of Hyperoxia-Induced Preterm Brain Injury. <i>Oxidative Medicine and Cellular Longevity</i> , 2016, 2016, 1-13.	1.9	29
1532	Overview of Alzheimer's Disease and Some Therapeutic Approaches Targeting A $\beta$ by Using Several Synthetic and Herbal Compounds. <i>Oxidative Medicine and Cellular Longevity</i> , 2016, 2016, 1-22.	1.9	126

#	ARTICLE	IF	CITATIONS
1533	Amyloid- $\beta$ -Induced Dysregulation of AMPA Receptor Trafficking. <i>Neural Plasticity</i> , 2016, 2016, 1-12.	1.0	83
1534	Biomaterials for the Treatment of Alzheimer's Disease. <i>Frontiers in Bioengineering and Biotechnology</i> , 2016, 4, 49.	2.0	41
1535	Regulation of the Postsynaptic Compartment of Excitatory Synapses by the Actin Cytoskeleton in Health and Its Disruption in Disease. <i>Neural Plasticity</i> , 2016, 2016, 1-19.	1.0	20
1536	Hippocampal Injections of Oligomeric Amyloid $\beta$ -peptide (1-42) Induce Selective Working Memory Deficits and Long-lasting Alterations of ERK Signaling Pathway. <i>Frontiers in Aging Neuroscience</i> , 2015, 7, 245.	1.7	84
1537	Altered Cortical Synaptic Plasticity in Response to 5-Hz Repetitive Transcranial Magnetic Stimulation as a New Electrophysiological Finding in Amnesic Mild Cognitive Impairment Converting to Alzheimer's Disease: Results from a 4-year Prospective Cohort Study. <i>Frontiers in Aging Neuroscience</i> , 2015, 7, 253.	1.7	25
1538	Effect of Presenilin Mutations on APP Cleavage; Insights into the Pathogenesis of FAD. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 51.	1.7	44
1539	Human Neural Stem Cell Transplantation Rescues Cognitive Defects in APP/PS1 Model of Alzheimer's Disease by Enhancing Neuronal Connectivity and Metabolic Activity. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 282.	1.7	43
1540	Early Impairment of Synaptic and Intrinsic Excitability in Mice Expressing ALS/Dementia-Linked Mutant UBQLN2. <i>Frontiers in Cellular Neuroscience</i> , 2016, 10, 216.	1.8	23
1541	Amyloidosis in Retinal Neurodegenerative Diseases. <i>Frontiers in Neurology</i> , 2016, 7, 127.	1.1	34
1542	Alzheimer Disease: Crosstalk between the Canonical Wnt/Beta-Catenin Pathway and PPARs Alpha and Gamma. <i>Frontiers in Neuroscience</i> , 2016, 10, 459.	1.4	110
1543	Neuronal Gene Targets of NF- $\kappa$ B and Their Dysregulation in Alzheimer's Disease. <i>Frontiers in Molecular Neuroscience</i> , 2016, 9, 118.	1.4	116
1544	The Emergence of NMDA Receptor Metabotropic Function: Insights from Imaging. <i>Frontiers in Synaptic Neuroscience</i> , 2016, 8, 20.	1.3	64
1545	Diabetes Mellitus Induces Alzheimer's Disease Pathology: Histopathological Evidence from Animal Models. <i>International Journal of Molecular Sciences</i> , 2016, 17, 503.	1.8	88
1546	Tocotrienol Affects Oxidative Stress, Cholesterol Homeostasis and the Amyloidogenic Pathway in Neuroblastoma Cells: Consequences for Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1809.	1.8	35
1547	The Rationale for Insulin Therapy in Alzheimer's Disease. <i>Molecules</i> , 2016, 21, 689.	1.7	14
1548	Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps. <i>Journal of Visualized Experiments</i> , 2016, .	0.2	4
1549	Competitive Mirror Image Phage Display Derived Peptide Modulates Amyloid Beta Aggregation and Toxicity. <i>PLoS ONE</i> , 2016, 11, e0147470.	1.1	12
1550	Assessing the Effects of Acute Amyloid $\beta$ Oligomer Exposure in the Rat. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1390.	1.8	13



#	ARTICLE	IF	CITATIONS
1551	Methods for the Specific Detection and Quantitation of Amyloid- $\beta$ Oligomers in Cerebrospinal Fluid. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 53-67.	1.2	26
1552	Alzheimer's Disease and the Aggregation of Amyloid $\beta$ . <i>Springer Theses</i> , 2016, , 31-52.	0.0	0
1553	Overcoming translational barriers impeding development of Alzheimer's disease modifying therapies. <i>Journal of Neurochemistry</i> , 2016, 139, 224-236.	2.1	17
1554	Protein aggregation as an antibiotic design strategy. <i>Molecular Microbiology</i> , 2016, 99, 849-865.	1.2	44
1555	A2T and A2V A $\beta$ peptides exhibit different aggregation kinetics, primary nucleation, morphology, structure, and LTP inhibition. <i>Proteins: Structure, Function and Bioinformatics</i> , 2016, 84, 488-500.	1.5	30
1557	Early Activation of Experience-Independent Dendritic Spine Turnover in a Mouse Model of Alzheimer's Disease. <i>Cerebral Cortex</i> , 2016, 27, 3660-3674.	1.6	20
1558	Peripheral Interventions Enhancing Brain Glutamate Homeostasis Relieve Amyloid $\beta$ - and TNF $\alpha$ - Mediated Synaptic Plasticity Disruption in the Rat Hippocampus. <i>Cerebral Cortex</i> , 2017, 27, 3724-3735.	1.6	17
1559	Long-term potentiation-like cortical plasticity is disrupted in Alzheimer's disease patients independently from age of onset. <i>Annals of Neurology</i> , 2016, 80, 202-210.	2.8	79
1560	Calcium channel blockade attenuates abnormal synaptic transmission in the dentate gyrus elicited by entorhinal amyloidopathy. <i>Synapse</i> , 2016, 70, 408-417.	0.6	17
1561	Nanoscale Imaging and Characterisation of Amyloid- $\beta$ . <i>Springer Theses</i> , 2016, , .	0.0	0
1562	Uncovering the Binding and Specificity of $\beta$ -Wrapins for Amyloid- $\beta$ and $\alpha$ -Synuclein. <i>Journal of Physical Chemistry B</i> , 2016, 120, 12781-12794.	1.2	22
1563	Exendin-4 antagonizes A $\beta$ 1-42-induced attenuation of spatial learning and memory ability. <i>Experimental and Therapeutic Medicine</i> , 2016, 12, 2885-2892.	0.8	23
1564	Involvement of hippocampal excitability in amyloid $\beta$ -induced behavioral and psychological symptoms of dementia. <i>Journal of Toxicological Sciences</i> , 2016, 41, 449-457.	0.7	20
1565	Tackling amyloidogenesis in Alzheimer's disease with A2V variants of Amyloid- $\beta$ . <i>Scientific Reports</i> , 2016, 6, 20949.	1.6	26
1566	Presumed LRP1-targeting transport peptide delivers $\beta$ -secretase inhibitor to neurons in vitro with limited efficiency. <i>Scientific Reports</i> , 2016, 6, 34297.	1.6	9
1567	RPS23RC1 reduces A $\beta$ oligomer-induced synaptic and cognitive deficits. <i>Scientific Reports</i> , 2016, 6, 18668.	1.6	10
1568	Fingolimod modulates multiple neuroinflammatory markers in a mouse model of Alzheimer's disease. <i>Scientific Reports</i> , 2016, 6, 24939.	1.6	92
1569	Amyloid structure exhibits polymorphism on multiple length scales in human brain tissue. <i>Scientific Reports</i> , 2016, 6, 33079.	1.6	48

#	ARTICLE	IF	CITATIONS
1570	Modeling neurological disease processes using process algebra. <i>Drug Discovery Today: Disease Models</i> , 2016, 19, 43-49.	1.2	2
1571	Soluble Amyloid-beta Aggregates from Human Alzheimer's Disease Brains. <i>Scientific Reports</i> , 2016, 6, 38187.	1.6	119
1572	Targets and Strategies Toward the Development of Alzheimer Therapeutics. <i>Topics in Medicinal Chemistry</i> , 2016, , 1-25.	0.4	0
1573	Reversal of LTP-Like Cortical Plasticity in Alzheimer's Disease Patients with Tau-Related Faster Clinical Progression. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 605-616.	1.2	51
1574	Monophosphoryl Lipid-A: A Promising Tool for Alzheimer's Disease Toll. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 1189-1202.	1.2	11
1575	Isomerization of Asp7 increases the toxic effects of amyloid $\beta^2$ and its phosphorylated form in SH-SY5Y neuroblastoma cells. <i>Molecular Biology</i> , 2016, 50, 762-767.	0.4	8
1576	Aberrant Co-localization of Synaptic Proteins Promoted by Alzheimer's Disease Amyloid- $\beta^2$ Peptides: Protective Effect of Human Serum Albumin. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 171-182.	1.2	18
1577	Kinetics of spontaneous filament nucleation via oligomers: Insights from theory and simulation. <i>Journal of Chemical Physics</i> , 2016, 145, 211926.	1.2	73
1578	Viscoelastic response of neural cells governed by the deposition of amyloid- $\beta^2$ peptides ( $A\beta^2$ ). <i>Journal of Applied Physics</i> , 2016, 119, .	1.1	13
1579	The UPR and synaptic dysfunction in neurodegeneration. <i>Brain Research</i> , 2016, 1648, 530-537.	1.1	62
1580	The inhibitory mechanism of a fullerene derivative against amyloid- $\beta^2$ peptide aggregation: an atomistic simulation study. <i>Physical Chemistry Chemical Physics</i> , 2016, 18, 12582-12591.	1.3	67
1581	Rifampicin is a candidate preventive medicine against amyloid- $\beta^2$ and tau oligomers. <i>Brain</i> , 2016, 139, 1568-1586.	3.7	96
1582	The flavonoid baicalein rescues synaptic plasticity and memory deficits in a mouse model of Alzheimer's disease. <i>Behavioural Brain Research</i> , 2016, 311, 309-321.	1.2	78
1583	Original Research: Influence of okadaic acid on hyperphosphorylation of tau and nicotinic acetylcholine receptors in primary neurons. <i>Experimental Biology and Medicine</i> , 2016, 241, 1825-1833.	1.1	10
1584	Modelling bidirectional modulations in synaptic plasticity: A biochemical pathway model to understand the emergence of long term potentiation (LTP) and long term depression (LTD). <i>Journal of Theoretical Biology</i> , 2016, 403, 159-177.	0.8	14
1585	Icariside II, a novel phosphodiesterase-5 inhibitor, attenuates streptozotocin-induced cognitive deficits in rats. <i>Neuroscience</i> , 2016, 328, 69-79.	1.1	47
1586	Inhibiting BACE1 to reverse synaptic dysfunctions in Alzheimer's disease. <i>Neuroscience and Biobehavioral Reviews</i> , 2016, 65, 326-340.	2.9	58
1587	Identification of approved drugs that inhibit the binding of amyloid $\beta^2$ oligomers to ephrin type B receptor 2. <i>FEBS Open Bio</i> , 2016, 6, 461-468.	1.0	13

#	ARTICLE	IF	CITATIONS
1588	Inhibition of the Motor Protein Eg5/Kinesin-5 in Amyloid $\beta$ -Mediated Impairment of Hippocampal Long-Term Potentiation and Dendritic Spine Loss. <i>Molecular Pharmacology</i> , 2016, 89, 552-559.	1.0	22
1589	Repression of the eIF2 $\alpha$ kinase PERK alleviates mGluR-LTD impairments in a mouse model of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2016, 41, 19-24.	1.5	70
1590	Synaptic AMPA receptor composition in development, plasticity and disease. <i>Nature Reviews Neuroscience</i> , 2016, 17, 337-350.	4.9	403
1591	Increasing the Receptor Tyrosine Kinase EphB2 Prevents Amyloid- $\beta$ -induced Depletion of Cell Surface Glutamate Receptors by a Mechanism That Requires the PDZ-binding Motif of EphB2 and Neuronal Activity. <i>Journal of Biological Chemistry</i> , 2016, 291, 1719-1734.	1.6	27
1592	Cerebrospinal Fluid Biomarkers in Alzheimer's Disease. <i>Methods in Pharmacology and Toxicology</i> , 2016, , 153-179.	0.1	0
1593	Interaction of the N-Acetyl(13 $\alpha$ - <sup>23</sup> )NH <sub>2</sub> segment of the beta amyloid peptide with beta-sheet-blocking peptides: site and edge specificity. <i>Canadian Journal of Chemistry</i> , 2016, 94, 583-592.	0.6	5
1594	Amyloid- $\beta$ oligomerization is associated with the generation of a typical peptide fragment fingerprint. <i>Alzheimer's and Dementia</i> , 2016, 12, 996-1013.	0.4	17
1595	Gene therapy to target ER stress in brain diseases. <i>Brain Research</i> , 2016, 1648, 561-570.	1.1	31
1596	Early pathologic amyloid induces hypersynchrony of BOLD resting-state networks in transgenic mice and provides an early therapeutic window before amyloid plaque deposition. <i>Alzheimer's and Dementia</i> , 2016, 12, 964-976.	0.4	76
1597	Synaptic pathology: A shared mechanism in neurological disease. <i>Ageing Research Reviews</i> , 2016, 28, 72-84.	5.0	122
1598	SEPT8 modulates $\beta$ -amyloidogenic processing of APP via affecting the sorting and accumulation of BACE1. <i>Journal of Cell Science</i> , 2016, 129, 2224-38.	1.2	15
1599	Dietary arachidonic acid as a risk factor for age-associated neurodegenerative diseases: Potential mechanisms. <i>Biochimie</i> , 2016, 130, 168-177.	1.3	30
1600	Molecular Dynamics Simulations of Amyloid $\beta$ -Peptide (1-42): Tetramer Formation and Membrane Interactions. <i>Biophysical Journal</i> , 2016, 111, 937-949.	0.2	84
1601	Learning to classify neural activity from a mouse model of Alzheimer's disease amyloidosis versus controls. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 2, 39-48.	1.2	2
1602	Self-assembly of the full-length amyloid A $\beta$ 42 protein in dimers. <i>Nanoscale</i> , 2016, 8, 18928-18937.	2.8	47
1603	Computational principles of synaptic memory consolidation. <i>Nature Neuroscience</i> , 2016, 19, 1697-1706.	7.1	156
1604	$\alpha$ 7-Nicotinic Acetylcholine Receptors and $\beta$ -Amyloid Peptides in Alzheimer's Disease. <i>Neuromethods</i> , 2016, , 171-205.	0.2	2
1605	Amyloid- $\beta$ effects on synapses and memory require AMPA receptor subunit GluA3. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E6526-E6534.	3.3	100

#	ARTICLE	IF	CITATIONS
1606	Monomer Dynamics of Alzheimer Peptides and Kinetic Control of Early Aggregation in Alzheimer's Disease. <i>ChemPhysChem</i> , 2016, 17, 3470-3479.	1.0	20
1607	Amyloid- $\beta^2$ containing isoaspartate 7 as potential biomarker and drug target in Alzheimer's disease. <i>Mendelevov Communications</i> , 2016, 26, 269-275.	0.6	33
1608	Functions of the Alzheimer's Disease Protease BACE1 at the Synapse in the Central Nervous System. <i>Journal of Molecular Neuroscience</i> , 2016, 60, 305-315.	1.1	48
1609	Nanostructured Antagonist of Extrasynaptic NMDA Receptors. <i>Nano Letters</i> , 2016, 16, 5495-5502.	4.5	26
1610	Hippocampal A $\beta^2$ expression, but not phosphorylated tau, predicts cognitive deficits following repeated peripheral poly I:C administration. <i>Behavioural Brain Research</i> , 2016, 313, 219-225.	1.2	4
1611	Molecular tweezers for lysine and arginine – powerful inhibitors of pathologic protein aggregation. <i>Chemical Communications</i> , 2016, 52, 11318-11334.	2.2	115
1612	The antibody aducanumab reduces A $\beta^2$ plaques in Alzheimer's disease. <i>Nature</i> , 2016, 537, 50-56.	13.7	2,179
1613	Environmental Enrichment Potently Prevents Microglia-Mediated Neuroinflammation by Human Amyloid A-Protein Oligomers. <i>Journal of Neuroscience</i> , 2016, 36, 9041-9056.	1.7	93
1614	The amyloid hypothesis of Alzheimer's disease at 25 years. <i>EMBO Molecular Medicine</i> , 2016, 8, 595-608.	3.3	4,226
1615	Monascin from <i>Monascus</i> -Fermented Products Reduces Oxidative Stress and Amyloid- $\beta^2$ Toxicity via DAF-16/FOXO in <i>Caenorhabditis elegans</i> . <i>Journal of Agricultural and Food Chemistry</i> , 2016, 64, 7114-7120.	2.4	35
1616	Pathogenic mechanisms of prion protein, amyloid- $\beta^2$ and $\alpha$ -synuclein misfolding: the prion concept and neurotoxicity of protein oligomers. <i>Journal of Neurochemistry</i> , 2016, 139, 162-180.	2.1	77
1617	Heat- and pH-induced BSA conformational changes, hydrogel formation and application as 3D cell scaffold. <i>Archives of Biochemistry and Biophysics</i> , 2016, 606, 134-142.	1.4	41
1618	An Interesting Link. , 2016, , 139-151.		0
1619	82-kDa choline acetyltransferase and SATB1 localize to $\beta^2$ -amyloid induced matrix attachment regions. <i>Scientific Reports</i> , 2016, 6, 23914.	1.6	10
1620	Store-Operated Calcium Channel Complex in Postsynaptic Spines: A New Therapeutic Target for Alzheimer's Disease Treatment. <i>Journal of Neuroscience</i> , 2016, 36, 11837-11850.	1.7	103
1621	Blocking the Interaction between EphB2 and ADDLs by a Small Peptide Rescues Impaired Synaptic Plasticity and Memory Deficits in a Mouse Model of Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2016, 36, 11959-11973.	1.7	44
1622	Non-Fibrillar Oligomeric Amyloid- $\beta^2$ within Synapses. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 787-800.	1.2	65
1623	Soluble Conformers of A $\beta^2$ and Tau Alter Selective Proteins Governing Axonal Transport. <i>Journal of Neuroscience</i> , 2016, 36, 9647-9658.	1.7	47

#	ARTICLE	IF	CITATIONS
1624	Tau and tauopathies. <i>Brain Research Bulletin</i> , 2016, 126, 238-292.	1.4	444
1625	Synaptopathies: synaptic dysfunction in neurological disorders – A review from students to students. <i>Journal of Neurochemistry</i> , 2016, 138, 785-805.	2.1	244
1626	Trifluoroethanol modulates $\beta$ -synuclein amyloid-like aggregate formation, stability and dissolution. <i>Biophysical Chemistry</i> , 2016, 216, 23-30.	1.5	9
1627	Alzheimer's disease like pathology induced six weeks after aggregated amyloid-beta injection in rats: increased oxidative stress and impaired long-term memory with anxiety-like behavior. <i>Neurological Research</i> , 2016, 38, 838-850.	0.6	71
1628	3-N-butylphthalide Rescues Hippocampal Synaptic Failure and Attenuates Neuropathology in Aged $\beta$ -APP/PS1 Mouse Model of Alzheimer's Disease. <i>CNS Neuroscience and Therapeutics</i> , 2016, 22, 979-987.	1.9	43
1629	Characterizing the Effect of Multivalent Conjugates Composed of $A\beta$ -Specific Ligands and Metal Nanoparticles on Neurotoxic Fibrillar Aggregation. <i>ACS Nano</i> , 2016, 10, 7582-7597.	7.3	46
1630	A Study of $A\beta$ Oligomers in the Temporal Cortex and Cerebellum of Patients with Neuropathologically Confirmed Alzheimer's Disease Compared to Aged Controls. <i>Neurodegenerative Diseases</i> , 2016, 16, 398-406.	0.8	14
1631	Glycoprotein quality control-related proteins effectively inhibit fibrillation of amyloid beta 1-42. <i>Biochemical and Biophysical Research Communications</i> , 2016, 481, 227-231.	1.0	6
1632	Amyloid- $\beta$ Peptide Nitrotyrosination Stabilizes Oligomers and Enhances NMDAR-Mediated Toxicity. <i>Journal of Neuroscience</i> , 2016, 36, 11693-11703.	1.7	50
1633	Local and Use-Dependent Effects of $\beta$ -Amyloid Oligomers on NMDA Receptor Function Revealed by Optical Quantal Analysis. <i>Journal of Neuroscience</i> , 2016, 36, 11532-11543.	1.7	46
1634	High-Affinity Binding of Monomeric but Not Oligomeric Amyloid- $\beta$ to Ganglioside GM1 Containing Nanodiscs. <i>Biochemistry</i> , 2016, 55, 6662-6672.	1.2	26
1635	Network abnormalities and interneuron dysfunction in Alzheimer disease. <i>Nature Reviews Neuroscience</i> , 2016, 17, 777-792.	4.9	685
1636	Monoclonal antibody with conformational specificity for a toxic conformer of amyloid $\beta$ 242 and its application toward the Alzheimer's disease diagnosis. <i>Scientific Reports</i> , 2016, 6, 29038.	1.6	50
1637	BMS-708163 and Nilotinib restore synaptic dysfunction in human embryonic stem cell-derived Alzheimer's disease models. <i>Scientific Reports</i> , 2016, 6, 33427.	1.6	22
1638	Inhibition of Wnt signaling induces amyloidogenic processing of amyloid precursor protein and the production and aggregation of Amyloid- $\beta$ ( $A\beta$ ) <sub>42</sub> peptides. <i>Journal of Neurochemistry</i> , 2016, 139, 1175-1191.	2.1	62
1639	Depletion of TDP-43 decreases fibril and plaque $\beta$ -amyloid and exacerbates neurodegeneration in an Alzheimer's mouse model. <i>Acta Neuropathologica</i> , 2016, 132, 859-873.	3.9	43
1640	HMGB1, a pathogenic molecule that induces neurite degeneration via TLR4-MARCKS, is a potential therapeutic target for Alzheimer's disease. <i>Scientific Reports</i> , 2016, 6, 31895.	1.6	111
1641	Individual aggregates of amyloid beta induce temporary calcium influx through the cell membrane of neuronal cells. <i>Scientific Reports</i> , 2016, 6, 31910.	1.6	42

#	ARTICLE	IF	CITATIONS
1642	Physiological regulation of the heat shock response by glutamine: implications for chronic low-grade inflammatory diseases in age-related conditions. <i>Nutrire</i> , 2016, 41, .	0.3	27
1643	Amyloid Cascade into Clarity. <i>Immunity</i> , 2016, 45, 717-718.	6.6	15
1644	The Aggregation Paths and Products of A $\beta$ 242 Dimers Are Distinct from Those of the A $\beta$ 242 Monomer. <i>Biochemistry</i> , 2016, 55, 6150-6161.	1.2	22
1645	Human tau increases amyloid $\beta$ 2 plaque size but not amyloid $\beta$ 2-mediated synapse loss in a novel mouse model of Alzheimer's disease. <i>European Journal of Neuroscience</i> , 2016, 44, 3056-3066.	1.2	81
1646	Persistent activation of microglia and NADPH oxidase drive hippocampal dysfunction in experimental multiple sclerosis. <i>Scientific Reports</i> , 2016, 6, 20926.	1.6	68
1647	A critical role for the self-assembly of Amyloid- $\beta$ 1-42 in neurodegeneration. <i>Scientific Reports</i> , 2016, 6, 30182.	1.6	63
1648	Strain-dependent profile of misfolded prion protein aggregates. <i>Scientific Reports</i> , 2016, 6, 20526.	1.6	35
1649	The reemergence of long-term potentiation in aged Alzheimer's disease mouse model. <i>Scientific Reports</i> , 2016, 6, 29152.	1.6	32
1650	Integrins in synapse regulation. <i>Nature Reviews Neuroscience</i> , 2016, 17, 745-756.	4.9	133
1651	Presenilin 1 transgene addition to amyloid precursor protein overexpressing transgenic rats increases amyloid beta 42 levels and results in loss of memory retention. <i>BMC Neuroscience</i> , 2016, 17, 46.	0.8	14
1652	Biomarker Exposure-Response Analysis in Mild-To-Moderate Alzheimer's Disease Trials of Bapineuzumab. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 535-546.	1.2	4
1653	Mitochondrial Dysfunction in Neurodegenerative Disorders. , 2016, , .		3
1654	The Complex Pathways to Mechanism-Based Therapeutics in Alzheimer's Disease. , 2016, , 1-22.		0
1655	Targeting A $\beta$ 2 Receptors to Modify Alzheimer's Disease Progression. , 2016, , 227-250.		0
1656	Fluid Biomarkers and Diagnostics. , 2016, , 565-587.		0
1657	Prospects and Challenges for Alzheimer Therapeutics. , 2016, , 605-637.		2
1658	Active Immunization Against the Amyloid- $\beta$ 2 Peptide. <i>Methods in Pharmacology and Toxicology</i> , 2016, , 19-35.	0.1	0
1659	The modeling of Alzheimer's disease by the overexpression of mutant Presenilin 1 in human embryonic stem cells. <i>Biochemical and Biophysical Research Communications</i> , 2016, 469, 587-592.	1.0	14

#	ARTICLE	IF	CITATIONS
1660	Chronic Pharmacological mGluR5 Inhibition Prevents Cognitive Impairment and Reduces Pathogenesis in an Alzheimer Disease Mouse Model. <i>Cell Reports</i> , 2016, 15, 1859-1865.	2.9	95
1661	Evolution of Alzheimer's disease pathogenesis conception. <i>Moscow University Biological Sciences Bulletin</i> , 2016, 71, 4-10.	0.1	4
1662	Mitochondria, the Synapse, and Neurodegeneration. , 2016, , 219-239.		1
1663	Oligomer Formation of Amyloid- $\beta$ (29-42) from Its Monomers Using the Hamiltonian Replica-Permutation Molecular Dynamics Simulation. <i>Journal of Physical Chemistry B</i> , 2016, 120, 6555-6561.	1.2	36
1664	Experience-dependent reduction of soluble $\beta$ -amyloid oligomers and rescue of cognitive abilities in middle-age Ts65Dn mice, a model of Down syndrome. <i>Experimental Neurology</i> , 2016, 283, 49-56.	2.0	26
1665	Hippocampal metabotropic glutamate receptor long-term depression in health and disease: focus on mitogen-activated protein kinase pathways. <i>Journal of Neurochemistry</i> , 2016, 139, 200-214.	2.1	55
1666	Safflower yellow ameliorates cognition deficits and reduces tau phosphorylation in APP/PS1 transgenic mice. <i>Metabolic Brain Disease</i> , 2016, 31, 1133-1142.	1.4	11
1667	Oligomers of Amyloid $\beta$ Prevent Physiological Activation of the Cellular Prion Protein-Metabotropic Glutamate Receptor 5 Complex by Glutamate in Alzheimer Disease. <i>Journal of Biological Chemistry</i> , 2016, 291, 17112-17121.	1.6	65
1668	The Binding Receptors of $A\beta$ : an Alternative Therapeutic Target for Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2016, 53, 455-471.	1.9	41
1669	Estradiol prevents $A\beta$ 25-35-inhibited long-term potentiation induction through enhancing survival of newborn neurons in the dentate gyrus. <i>International Journal of Neuroscience</i> , 2016, 126, 154-162.	0.8	2
1670	Voluntary Running Attenuates Memory Loss, Decreases Neuropathological Changes and Induces Neurogenesis in a Mouse Model of Alzheimer's Disease. <i>Brain Pathology</i> , 2016, 26, 62-74.	2.1	128
1671	A Place at the Table. <i>Neuroscientist</i> , 2016, 22, 359-371.	2.6	54
1672	Molecular dynamics study of the monomers and dimers of N-Ac $\beta$ (1-23)NH <sub>2</sub> : on the effect of pH on the aggregation of the amyloid beta peptide of Alzheimer's disease. <i>Canadian Journal of Chemistry</i> , 2016, 94, 273-281.	0.6	9
1673	Microtubule Dynamics in Neuronal Development, Plasticity, and Neurodegeneration. <i>International Review of Cell and Molecular Biology</i> , 2016, 321, 89-169.	1.6	79
1674	1,25-Dihydroxyvitamin D3 regulates expression of LRP1 and RAGE in vitro and in vivo, enhancing $A\beta$ 1-40 brain-to-blood efflux and peripheral uptake transport. <i>Neuroscience</i> , 2016, 322, 28-38.	1.1	68
1675	The Role of Ephs and Ephrins in Memory Formation. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pyv106.	1.0	36
1676	Designed Glycopeptidomimetics Disrupt Protein-Protein Interactions Mediating Amyloid $\beta$ -Peptide Aggregation and Restore Neuroblastoma Cell Viability. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 2025-2040.	2.9	37
1677	Amyloid Plaque-Associated Oxidative Degradation of Uniformly Radiolabeled Arachidonic Acid. <i>ACS Chemical Neuroscience</i> , 2016, 7, 367-377.	1.7	22



#	ARTICLE	IF	CITATIONS
1678	A $\beta$ -mediated spine changes in the hippocampus are microtubule-dependent and can be reversed by a subnanomolar concentration of the microtubule-stabilizing agent epothilone D. <i>Neuropharmacology</i> , 2016, 105, 84-95.	2.0	48
1679	PTEN recruitment controls synaptic and cognitive function in Alzheimer's models. <i>Nature Neuroscience</i> , 2016, 19, 443-453.	7.1	118
1680	Vascular mTOR-dependent mechanisms linking the control of aging to Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016, 1862, 992-1007.	1.8	28
1681	Cassia obtusifolia seed ameliorates amyloid $\beta$ -induced synaptic dysfunction through anti-inflammatory and Akt/GSK-3 $\beta$ pathways. <i>Journal of Ethnopharmacology</i> , 2016, 178, 50-57.	2.0	40
1682	Broad neutralization of calcium-permeable amyloid pore channels with a chimeric Alzheimer/Parkinson peptide targeting brain gangliosides. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016, 1862, 213-222.	1.8	19
1683	Metabotropic glutamate receptor 5 couples cellular prion protein to intracellular signalling in Alzheimer's disease. <i>Brain</i> , 2016, 139, 526-546.	3.7	110
1684	Validation and Characterization of a Novel Peptide That Binds Monomeric and Aggregated $\beta$ -Amyloid and Inhibits the Formation of Neurotoxic Oligomers. <i>Journal of Biological Chemistry</i> , 2016, 291, 547-559.	1.6	15
1685	Relationship of regional brain $\beta$ -amyloid to gait speed. <i>Neurology</i> , 2016, 86, 36-43.	1.5	119
1686	Amyloid- $\beta$ dimers in the absence of plaque pathology impair learning and synaptic plasticity. <i>Brain</i> , 2016, 139, 509-525.	3.7	74
1687	Anthocyanin suppresses the toxicity of $\beta$ deposits through diversion of molecular forms in <i>in vitro</i> and <i>in vivo</i> models of Alzheimer's disease. <i>Nutritional Neuroscience</i> , 2016, 19, 32-42.	1.5	57
1688	Methionine sulfoxide reductase A affects $\beta$ -amyloid solubility and mitochondrial function in a mouse model of Alzheimer's disease. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2016, 310, E388-E393.	1.8	26
1689	Dopamine agonists rescue $\beta$ -induced LTP impairment by Src-family tyrosine kinases. <i>Neurobiology of Aging</i> , 2016, 40, 98-102.	1.5	26
1690	A critical appraisal of the pathogenic protein spread hypothesis of neurodegeneration. <i>Nature Reviews Neuroscience</i> , 2016, 17, 251-260.	4.9	251
1691	Actin dynamics and cofilin-actin rods in alzheimer disease. <i>Cytoskeleton</i> , 2016, 73, 477-497.	1.0	132
1692	Conformational Dynamics of Specific $\beta$ Oligomers Govern Their Ability To Replicate and Induce Neuronal Apoptosis. <i>Biochemistry</i> , 2016, 55, 2238-2250.	1.2	26
1693	One of the possible mechanisms of amyloid fibrils formation based on the sizes of primary and secondary folding nuclei of $\beta$ 40 and $\beta$ 42. <i>Journal of Structural Biology</i> , 2016, 194, 404-414.	1.3	37
1694	Investigation of the effect of erythrosine B on amyloid beta peptide using molecular modeling. <i>Journal of Molecular Modeling</i> , 2016, 22, 92.	0.8	14
1695	A Novel Multifunctional Compound Camellikaempferoside B Decreases $\beta$ Production, Interferes with $\beta$ Aggregation, and Prohibits $\beta$ -Mediated Neurotoxicity and Neuroinflammation. <i>ACS Chemical Neuroscience</i> , 2016, 7, 505-518.	1.7	29

#	ARTICLE	IF	CITATIONS
1696	Metabolic changes may precede proteostatic dysfunction in <i>Drosophila</i> model of amyloid beta peptide toxicity. <i>Neurobiology of Aging</i> , 2016, 41, 39-52.	1.5	14
1697	Conformational transition of A $\beta$ 42 inhibited by a mimetic peptide. A molecular modeling study using QM/MM calculations and QAIM analysis. <i>Computational and Theoretical Chemistry</i> , 2016, 1080, 56-65.	1.1	23
1698	An anticancer drug suppresses the primary nucleation reaction that initiates the production of the toxic A $\beta$ 242 aggregates linked with Alzheimer's disease. <i>Science Advances</i> , 2016, 2, e1501244.	4.7	180
1699	Neurotrophic activity of jiadifenolide on neuronal precursor cells derived from human induced pluripotent stem cells. <i>Biochemical and Biophysical Research Communications</i> , 2016, 470, 798-803.	1.0	16
1700	Antibody-based PET imaging of amyloid beta in mouse models of Alzheimer's disease. <i>Nature Communications</i> , 2016, 7, 10759.	5.8	155
1701	The structure of chromophore-grafted amyloid- $\beta$ 28 dimers in the gas-phase: FRET-experiment guided modelling. <i>Physical Chemistry Chemical Physics</i> , 2016, 18, 9061-9069.	1.3	12
1702	DL-3-n-butylphthalide-induced upregulation of antioxidant defense is involved in the enhancement of cross talk between CREB and Nrf2 in an Alzheimer's disease mouse model. <i>Neurobiology of Aging</i> , 2016, 38, 32-46.	1.5	75
1703	Blockade of Astrocytic Calcineurin/NFAT Signaling Helps to Normalize Hippocampal Synaptic Function and Plasticity in a Rat Model of Traumatic Brain Injury. <i>Journal of Neuroscience</i> , 2016, 36, 1502-1515.	1.7	65
1704	A $\beta$ 2-Induced Synaptic Alterations Require the E3 Ubiquitin Ligase Nedd4-1. <i>Journal of Neuroscience</i> , 2016, 36, 1590-1595.	1.7	54
1705	Caspase-3 is Involved in Aluminum-Induced Impairment of Long-Term Potentiation in Rats Through the Akt/GSK-3 $\beta$ Pathway. <i>Neurotoxicity Research</i> , 2016, 29, 484-494.	1.3	34
1706	Defeating Alzheimer's disease and other dementias: a priority for European science and society. <i>Lancet Neurology</i> , The, 2016, 15, 455-532.	4.9	1,242
1707	The Luminescent Oligothiophene p-FTAA Converts Toxic A $\beta$ 1-42 Species into Nontoxic Amyloid Fibers with Altered Properties. <i>Journal of Biological Chemistry</i> , 2016, 291, 9233-9243.	1.6	17
1708	Alzheimer's Disease and the Sleep-Wake Cycle. , 2016, , 295-317.		0
1709	Dopaminergic neurotransmission dysfunction induced by amyloid- $\beta$ 2 transforms cortical long-term potentiation into long-term depression and produces memory impairment. <i>Neurobiology of Aging</i> , 2016, 41, 187-199.	1.5	66
1710	X-ray Crystallographic Structures of a Trimer, Dodecamer, and Annular Pore Formed by an A $\beta$ 1-36 $\beta$ -Hairpin. <i>Journal of the American Chemical Society</i> , 2016, 138, 4634-4642.	6.6	69
1711	Oxidative stress and hippocampal synaptic protein levels in elderly cognitively intact individuals with Alzheimer's disease pathology. <i>Neurobiology of Aging</i> , 2016, 42, 1-12.	1.5	69
1712	Neurogranin restores amyloid $\beta$ -mediated synaptic transmission and long-term potentiation deficits. <i>Experimental Neurology</i> , 2016, 277, 115-123.	2.0	22
1713	Amyloid- $\beta$ 2 Receptors: The Good, the Bad, and the Prion Protein. <i>Journal of Biological Chemistry</i> , 2016, 291, 3174-3183.	1.6	201

#	ARTICLE	IF	CITATIONS
1714	Pycnogenol protects CA3-CA1 synaptic function in a rat model of traumatic brain injury. <i>Experimental Neurology</i> , 2016, 276, 5-12.	2.0	17
1715	Beta-amyloid deposition and cognitive function in patients with major depressive disorder with different subtypes of mild cognitive impairment: 18F-florbetapir (AV-45/Amyvid) PET study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1067-1076.	3.3	31
1716	Glimepiride protects neurons against amyloid- $\beta^2$ -induced synapse damage. <i>Neuropharmacology</i> , 2016, 101, 225-236.	2.0	37
1717	Viral gene transfer of APPs $\Delta$ rescues synaptic failure in an Alzheimer's disease mouse model. <i>Acta Neuropathologica</i> , 2016, 131, 247-266.	3.9	131
1718	Neuroregeneration: Disease Modeling and Therapeutic Strategies for Alzheimer's and Parkinson's Diseases. <i>Biosystems and Biorobotics</i> , 2016, , 293-325.	0.2	2
1719	MT5-MMP is a new pro-amyloidogenic proteinase that promotes amyloid pathology and cognitive decline in a transgenic mouse model of Alzheimer's disease. <i>Cellular and Molecular Life Sciences</i> , 2016, 73, 217-236.	2.4	96
1720	No difference in paired associative stimulation induced cortical neuroplasticity between patients with mild cognitive impairment and elderly controls. <i>Clinical Neurophysiology</i> , 2016, 127, 1254-1260.	0.7	19
1722	Anti-amyloid Aggregation Activity of Natural Compounds: Implications for Alzheimer's Drug Discovery. <i>Molecular Neurobiology</i> , 2016, 53, 3565-3575.	1.9	73
1723	An in vitro model for synaptic loss in neurodegenerative diseases suggests a neuroprotective role for valproic acid via inhibition of cPLA2 dependent signalling. <i>Neuropharmacology</i> , 2016, 101, 566-575.	2.0	22
1724	The Essential Role of Soluble A $\beta^2$ Oligomers in Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2016, 53, 1905-1924.	1.9	73
1725	Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies. <i>Progress in Neurobiology</i> , 2017, 155, 171-193.	2.8	137
1726	Physiological and Pathophysiological Implications of Synaptic Tau. <i>Neuroscientist</i> , 2017, 23, 137-151.	2.6	53
1727	Long-term Ameliorative Effects of the Antidepressant Fluoxetine Exposure on Cognitive Deficits in 3xTg-AD Mice. <i>Molecular Neurobiology</i> , 2017, 54, 4160-4171.	1.9	35
1728	Synaptic degeneration and neurogranin in the pathophysiology of Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 47-57.	1.4	65
1729	Hippocampal proteomics defines pathways associated with memory decline and resilience in normal aging and Alzheimer's disease mouse models. <i>Behavioural Brain Research</i> , 2017, 322, 288-298.	1.2	72
1730	Progressive Neuronal Pathology and Synaptic Loss Induced by Prediabetes and Type 2 Diabetes in a Mouse Model of Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2017, 54, 3428-3438.	1.9	50
1731	Central role for NMDA receptors in redox mediated impairment of synaptic function during aging and Alzheimer's disease. <i>Behavioural Brain Research</i> , 2017, 322, 223-232.	1.2	86
1732	Phosphoinositides: Two-Path Signaling in Neuronal Response to Oligomeric Amyloid $\beta^2$ Peptide. <i>Molecular Neurobiology</i> , 2017, 54, 3236-3252.	1.9	14

#	ARTICLE	IF	CITATIONS
1733	Prokineticin system modulation as a new target to counteract the amyloid beta toxicity induced by glutamatergic alterations in an <i>in vitro</i> model of Alzheimer's disease. <i>Neuropharmacology</i> , 2017, 116, 82-97.	2.0	21
1734	Neural plasticity and network remodeling: From concepts to pathology. <i>Neuroscience</i> , 2017, 344, 326-345.	1.1	30
1735	Antibody Therapeutics Targeting A $\beta$ and Tau. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2017, 7, a024331.	2.9	39
1737	Comparison of Efficacy of Preventive and Therapeutic Vaccines Targeting the N Terminus of $\beta$ -Amyloid in an Animal Model of Alzheimer's Disease. <i>Molecular Therapy</i> , 2017, 25, 153-164.	3.7	13
1738	Modulation of BDNF cleavage by plasminogen-activator inhibitor-1 contributes to Alzheimer's neuropathology and cognitive deficits. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2017, 1863, 991-1001.	1.8	69
1739	Real-Time Analysis of Binding Events between Different A $\beta$ <sup>42</sup> Species and Human Lirb2 by Dual Polarization Interferometry. <i>Analytical Chemistry</i> , 2017, 89, 2606-2612.	3.2	21
1740	Stress-Induced Synaptic Dysfunction and Neurotransmitter Release in Alzheimer's Disease: Can Neurotransmitters and Neuromodulators be Potential Therapeutic Targets?. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 1017-1039.	1.2	24
1741	Randomized trial on the effects of a combined physical/cognitive training in aged MCI subjects: the Train the Brain study. <i>Scientific Reports</i> , 2017, 7, 39471.	1.6	108
1742	Subclinical Doses of ATP-Sensitive Potassium Channel Modulators Prevent Alterations in Memory and Synaptic Plasticity Induced by Amyloid- $\beta$ . <i>Journal of Alzheimer's Disease</i> , 2017, 57, 205-226.	1.2	26
1743	Meta-Analysis of Parkinson's Disease and Alzheimer's Disease Revealed Commonly Impaired Pathways and Dysregulation of NRF2-Dependent Genes. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 1525-1539.	1.2	77
1744	Clearance of cerebral A $\beta$ in Alzheimer's disease: reassessing the role of microglia and monocytes. <i>Cellular and Molecular Life Sciences</i> , 2017, 74, 2167-2201.	2.4	199
1745	Entorhinal Cortex dysfunction can be rescued by inhibition of microglial RAGE in an Alzheimer's disease mouse model. <i>Scientific Reports</i> , 2017, 7, 42370.	1.6	64
1746	Amyloid- $\beta$ Oligomers Interact with Neurexin and Diminish Neurexin-mediated Excitatory Presynaptic Organization. <i>Scientific Reports</i> , 2017, 7, 42548.	1.6	29
1747	Potassium channel expression and function in microglia: Plasticity and possible species variations. <i>Channels</i> , 2017, 11, 305-315.	1.5	44
1748	Islet amyloid polypeptide: Another key molecule in Alzheimer's pathogenesis?. <i>Progress in Neurobiology</i> , 2017, 153, 100-120.	2.8	64
1749	Amyloid plaque structure and cell surface interactions of $\beta$ -amyloid fibrils revealed by electron tomography. <i>Scientific Reports</i> , 2017, 7, 43577.	1.6	67
1750	Flexible N-Termini of Amyloid $\beta$ -Protein Oligomers: A Link between Structure and Activity?. <i>Israel Journal of Chemistry</i> , 2017, 57, 651-664.	1.0	8
1751	Psychosocial stress on neuroinflammation and cognitive dysfunctions in Alzheimer's disease: the emerging role for microglia?. <i>Neuroscience and Biobehavioral Reviews</i> , 2017, 77, 148-164.	2.9	101

#	ARTICLE	IF	CITATIONS
1752	Memantine reduces the production of amyloid- $\beta$ peptides through modulation of amyloid precursor protein trafficking. <i>European Journal of Pharmacology</i> , 2017, 798, 16-25.	1.7	31
1753	Involvement of GluN2B subunit containing N-methyl- d -aspartate (NMDA) receptors in mediating the acute and chronic synaptotoxic effects of oligomeric amyloid-beta ( $A\beta$ ) in murine models of Alzheimer's disease (AD). <i>Neuropharmacology</i> , 2017, 123, 100-115.	2.0	29
1754	The thermodynamics of protein aggregation reactions may underpin the enhanced metabolic efficiency associated with heterosis, some balancing selection, and the evolution of ploidy levels. <i>Progress in Biophysics and Molecular Biology</i> , 2017, 126, 1-21.	1.4	8
1755	Polo-like kinase 2 phosphorylation of amyloid precursor protein regulates activity-dependent amyloidogenic processing. <i>Neuropharmacology</i> , 2017, 117, 387-400.	2.0	21
1756	Emerging biomarkers and screening for cognitive frailty. <i>Aging Clinical and Experimental Research</i> , 2017, 29, 1075-1086.	1.4	39
1757	Tongxinluo improves cognition by decreasing $\beta$ -amyloid in spontaneous hypertensive rats. <i>Brain Research</i> , 2017, 1663, 151-160.	1.1	5
1758	Potential of GPCRs to modulate MAPK and mTOR pathways in Alzheimer's disease. <i>Progress in Neurobiology</i> , 2017, 149-150, 21-38.	2.8	42
1759	Natural product-based amyloid inhibitors. <i>Biochemical Pharmacology</i> , 2017, 139, 40-55.	2.0	155
1760	Targeting glutamatergic and cellular prion protein mechanisms of amyloid $\beta$ -mediated persistent synaptic plasticity disruption: Longitudinal studies. <i>Neuropharmacology</i> , 2017, 121, 231-246.	2.0	26
1761	Understanding Alzheimer's disease by global quantification of protein phosphorylation and sialylated N-linked glycosylation profiles: A chance for new biomarkers in neuroproteomics?. <i>Journal of Proteomics</i> , 2017, 161, 11-25.	1.2	23
1762	Early neurovascular dysfunction in a transgenic rat model of Alzheimer's disease. <i>Scientific Reports</i> , 2017, 7, 46427.	1.6	83
1763	A preclinical screen to evaluate pharmacotherapies for the treatment of agitation in dementia. <i>Behavioural Pharmacology</i> , 2017, 28, 199-206.	0.8	0
1765	Neural changes in Alzheimer's disease from circuit to molecule: Perspective of optogenetics. <i>Neuroscience and Biobehavioral Reviews</i> , 2017, 79, 110-118.	2.9	12
1766	The Anti-Amyloid- $\beta$ and Neuroprotective Properties of a Novel Tricyclic Pyrone Molecule. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 559-574.	1.2	10
1767	Secondary nucleation of monomers on fibril surface dominates $\beta$ -synuclein aggregation and provides autocatalytic amyloid amplification. <i>Quarterly Reviews of Biophysics</i> , 2017, 50, e6.	2.4	183
1768	Metaplasticity mechanisms restore plasticity and associativity in an animal model of Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 5527-5532.	3.3	48
1769	The amyloid- $\beta$ oligomer $A\beta^{25-56}$ induces specific alterations in neuronal signaling that lead to tau phosphorylation and aggregation. <i>Science Signaling</i> , 2017, 10, .	1.6	90
1770	Dysregulated Metabolism of the Amyloid- $\beta$ Protein and Therapeutic Approaches in Alzheimer Disease. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 4183-4190.	1.2	34

#	ARTICLE	IF	CITATIONS
1771	Leveraging symmetry to predict self-assembly of multiple polymers. <i>Chemical Physics Letters</i> , 2017, 683, 347-351.	1.2	2
1772	Effects of phenothiazine-structured compounds on APP processing in Alzheimer's disease cellular model. <i>Biochimie</i> , 2017, 138, 82-89.	1.3	17
1773	Astrocyte dysfunction in Alzheimer disease. <i>Journal of Neuroscience Research</i> , 2017, 95, 2430-2447.	1.3	189
1774	UBA311, a novel UBTH <sup>1</sup> amyloid $\beta^2$ peptide vaccine for mild Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 262-272.	1.8	104
1775	Glutaminy Cyclase Inhibitor PQ912 Improves Cognition in Mouse Models of Alzheimer's Disease—Studies on Relation to Effective Target Occupancy. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2017, 362, 119-130.	1.3	50
1776	Characterization and Identification of Dityrosine Cross-Linked Peptides Using Tandem Mass Spectrometry. <i>Analytical Chemistry</i> , 2017, 89, 6136-6145.	3.2	70
1777	Revisiting the flip side: Long-term depression of synaptic efficacy in the hippocampus. <i>Neuroscience and Biobehavioral Reviews</i> , 2017, 80, 394-413.	2.9	47
1778	Bapineuzumab for mild to moderate Alzheimer's disease: a meta-analysis of randomized controlled trials. <i>BMC Neurology</i> , 2017, 17, 66.	0.8	60
1779	Synaptic dysfunction in Alzheimer's disease: From the role of amyloid $\beta^2$ -peptide to the $\beta$ -secretase ADAM10. <i>European Journal of Pharmacology</i> , 2017, 817, 30-37.	1.7	29
1780	Immunization of Tg-APP <sup>swe</sup> /PSEN1 <sup>dE9</sup> mice with A $\beta$ <sup>23-10</sup> -KLH vaccine prevents synaptic deficits of Alzheimer's disease. <i>Behavioural Brain Research</i> , 2017, 332, 64-70.	1.2	5
1783	Combination therapy with octyl gallate and ferulic acid improves cognition and neurodegeneration in a transgenic mouse model of Alzheimer's disease. <i>Journal of Biological Chemistry</i> , 2017, 292, 11310-11325.	1.6	44
1784	TRPC Channels and Alzheimer's Disease. <i>Advances in Experimental Medicine and Biology</i> , 2017, 976, 73-83.	0.8	12
1785	Alzheimer's disease: How metal ions define $\beta$ -amyloid function. <i>Coordination Chemistry Reviews</i> , 2017, 351, 127-159.	9.5	120
1786	Alzheimer's Disease and ncRNAs. <i>Advances in Experimental Medicine and Biology</i> , 2017, 978, 337-361.	0.8	64
1787	Omega-3 fatty acids, lipids, and apoE lipidation in Alzheimer's disease: a rationale for multi-nutrient dementia prevention. <i>Journal of Lipid Research</i> , 2017, 58, 2083-2101.	2.0	65
1788	Inhibition of amyloid oligomerization into different supramolecular architectures by small molecules: mechanistic insights and design rules. <i>Future Medicinal Chemistry</i> , 2017, 9, 797-810.	1.1	42
1789	Cholinergic neuron gene expression differences captured by translational profiling in a mouse model of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017, 57, 104-119.	1.5	24
1790	Metformin – a Future Therapy for Neurodegenerative Diseases. <i>Pharmaceutical Research</i> , 2017, 34, 2614-2627.	1.7	187



#	ARTICLE	IF	CITATIONS
1791	A Molecular Tweezer Ameliorates Motor Deficits in Mice Overexpressing $\beta$ -Synuclein. <i>Neurotherapeutics</i> , 2017, 14, 1107-1119.	2.1	49
1792	Probing amylin fibrillation at an early stage via a tetracysteine-recognising fluorophore. <i>Talanta</i> , 2017, 173, 44-50.	2.9	12
1793	Influence of Hyperglycemic Conditions on Self-Association of the Alzheimer's Amyloid $\beta$ ( $\beta$ 42) Peptide. <i>ACS Omega</i> , 2017, 2, 2134-2147.	1.6	15
1794	Fermented <i>Citrus reticulata</i> (ponkan) fruit squeezed draff that contains a large amount of 4-demethylnobiletin prevents MK801-induced memory impairment. <i>Journal of Natural Medicines</i> , 2017, 71, 617-631.	1.1	8
1795	Diphenylalanine as a Reductionist Model for the Mechanistic Characterization of $\beta$ -Amyloid Modulators. <i>ACS Nano</i> , 2017, 11, 5960-5969.	7.3	62
1796	The double faced role of copper in $\beta$ homeostasis: A survey on the interrelationship between metal dyshomeostasis, UPS functioning and autophagy in neurodegeneration. <i>Coordination Chemistry Reviews</i> , 2017, 347, 1-22.	9.5	39
1797	Hydrogen Bond Networks and Hydrophobic Effects in the Amyloid $\beta$ 35 Chain in Water: A Molecular Dynamics Study. <i>Journal of Chemical Information and Modeling</i> , 2017, 57, 1548-1562.	2.5	24
1798	High affinity binding of amyloid $\beta$ -peptide to calmodulin: Structural and functional implications. <i>Biochemical and Biophysical Research Communications</i> , 2017, 486, 992-997.	1.0	37
1799	Lithium and memantine improve spatial memory impairment and neuroinflammation induced by $\beta$ -amyloid 1-42 oligomers in rats. <i>Neurobiology of Learning and Memory</i> , 2017, 141, 84-92.	1.0	33
1800	Soluble oligomeric amyloid- $\beta$ induces calcium dyshomeostasis that precedes synapse loss in the living mouse brain. <i>Molecular Neurodegeneration</i> , 2017, 12, 27.	4.4	120
1801	Inclusion of lipopeptides into the DMPC lipid bilayers prevents $\beta$ peptide insertion. <i>Physical Chemistry Chemical Physics</i> , 2017, 19, 10087-10098.	1.3	6
1802	A molecular dynamics investigation of the effects of mutation on prefoldin nano actuator in inhibiting amyloid $\beta$ 42-dimer. <i>Sensors and Actuators B: Chemical</i> , 2017, 248, 536-544.	4.0	6
1803	GluA1 subunit ubiquitination mediates amyloid- $\beta$ -induced loss of surface $\beta$ -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. <i>Journal of Biological Chemistry</i> , 2017, 292, 8186-8194.	1.6	53
1804	Structure-dependent effects of amyloid- $\beta$ on long-term memory in <i>Lymnaea stagnalis</i> . <i>FEBS Letters</i> , 2017, 591, 1236-1246.	1.3	12
1805	IRE1 signaling exacerbates Alzheimer's disease pathogenesis. <i>Acta Neuropathologica</i> , 2017, 134, 489-506.	3.9	147
1806	Modulation of $\beta$ PP and GSK3 $\beta$ by Endoplasmic Reticulum Stress and Involvement in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 1157-1170.	1.2	13
1807	Role of amyloid $\beta$ protein receptors in mediating synaptic plasticity. <i>Biomedical Reports</i> , 2017, 6, 379-386.	0.9	7
1808	Synthesis and Characterization of Hairpin Mimics that Modulate the Early Oligomerization and Fibrillization of Amyloid $\beta$ -Peptide. <i>European Journal of Organic Chemistry</i> , 2017, 2017, 2971-2980.	1.2	12



#	ARTICLE	IF	CITATIONS
1809	Not just amyloid: physiological functions of the amyloid precursor protein family. <i>Nature Reviews Neuroscience</i> , 2017, 18, 281-298.	4.9	434
1810	Preclinical to phase II amyloid beta (A $\beta$ ) peptide modulators under investigation for Alzheimer's disease. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 579-592.	1.9	23
1811	Unmodified and pyroglutamylated amyloid $\beta$ peptides form hypertoxic hetero-oligomers of unique secondary structure. <i>FEBS Journal</i> , 2017, 284, 1355-1369.	2.2	15
1812	Protein misfolding in neurodegenerative diseases: implications and strategies. <i>Translational Neurodegeneration</i> , 2017, 6, 6.	3.6	424
1813	Identification of an RNA Polymerase III Regulator Linked to Disease-Associated Protein Aggregation. <i>Molecular Cell</i> , 2017, 65, 1096-1108.e6.	4.5	14
1814	The Effects of Gene Mutations on Default Mode Network in Familial Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 327-334.	1.2	8
1815	Amyloid-Beta and Phosphorylated Tau Accumulations Cause Abnormalities at Synapses of Alzheimer's disease Neurons. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 975-999.	1.2	294
1816	Synthetic Models of Quasi-Stable Amyloid $\beta$ 40 Oligomers with Significant Neurotoxicity. <i>ACS Chemical Neuroscience</i> , 2017, 8, 807-816.	1.7	28
1817	Neurophysiological assessment of neural network plasticity and connectivity: Progress towards early functional biomarkers for disease interception therapies in Alzheimer's disease. <i>Neuroscience and Biobehavioral Reviews</i> , 2017, 73, 340-358.	2.9	30
1818	Decreasing amyloid toxicity through an increased rate of aggregation. <i>Physical Chemistry Chemical Physics</i> , 2017, 19, 1458-1465.	1.3	22
1819	The synergistic effect between KLVFF and self-assembly chaperones on both disaggregation of beta-amyloid fibrils and reducing consequent toxicity. <i>Chemical Communications</i> , 2017, 53, 1289-1292.	2.2	34
1820	Stabilization, Assembly, and Toxicity of Trimers Derived from A $\beta$ 2. <i>Journal of the American Chemical Society</i> , 2017, 139, 966-975.	6.6	68
1821	Binding Sites for Amyloid- $\beta$ Oligomers and Synaptic Toxicity. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2017, 7, a024075.	2.9	76
1822	Structural Characteristics of $\beta$ -Synuclein Oligomers. <i>International Review of Cell and Molecular Biology</i> , 2017, 329, 79-143.	1.6	95
1823	In vitro monitoring of amyloid $\beta$ -peptide oligomerization by Electrospray differential mobility analysis: An alternative tool to evaluate Alzheimer's disease drug candidates. <i>Talanta</i> , 2017, 165, 84-91.	2.9	12
1824	Activity-dependent proteolytic cleavage of cell adhesion molecules regulates excitatory synaptic development and function. <i>Neuroscience Research</i> , 2017, 116, 60-69.	1.0	29
1825	Using transcranial direct current stimulation to treat symptoms in mild cognitive impairment and Alzheimer's disease. <i>Neurodegenerative Disease Management</i> , 2017, 7, 317-329.	1.2	30
1826	Prion-like Protein Seeding and the Pathobiology of Alzheimer's Disease. , 2017, , 57-82.		0

#	ARTICLE	IF	CITATIONS
1827	The Role of 5-HTR6 in Mossy Fiber Sprouting: Activating Fyn and p-ERK1/2 in Pilocarpine-Induced Chronic Epileptic Rats. <i>Cellular Physiology and Biochemistry</i> , 2017, 42, 231-241.	1.1	6
1828	The vascular facet of late-onset Alzheimer's disease: an essential factor in a complex multifactorial disorder. <i>Current Opinion in Neurology</i> , 2017, 30, 623-629.	1.8	14
1829	Genetic underpinnings in Alzheimer's disease – a review. <i>Reviews in the Neurosciences</i> , 2017, 29, 21-38.	1.4	25
1830	Self-Assembly Pathways of $\beta$ -Sheet-Rich Amyloid- $\beta$ (1-40) Dimers: Markov State Model Analysis on Millisecond Hybrid-Resolution Simulations. <i>Journal of Chemical Theory and Computation</i> , 2017, 13, 5731-5744.	2.3	45
1831	Amyloid Beta Peptides Block New Synapse Assembly by Nogo Receptor-Mediated Inhibition of T-Type Calcium Channels. <i>Neuron</i> , 2017, 96, 355-372.e6.	3.8	40
1832	How accurate are your simulations? Effects of confined aqueous volume and AMBER FF99SB and CHARMM22/CMAP force field parameters on structural ensembles of intrinsically disordered proteins: Amyloid- $\beta$ <sub>42</sub> in water. <i>Intrinsically Disordered Proteins</i> , 2017, 5, e1377813.	1.9	37
1833	A Hexamer of a Peptide Derived from A $\beta$ <sub>16-36</sub> . <i>Biochemistry</i> , 2017, 56, 6061-6071.	1.2	23
1834	The current agonists and positive allosteric modulators of $\beta$ 7 nAChR for CNS indications in clinical trials. <i>Acta Pharmaceutica Sinica B</i> , 2017, 7, 611-622.	5.7	87
1835	Overexpression of Kinesin Superfamily Motor Proteins in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 1511-1524.	1.2	29
1836	Cellular prion protein targets amyloid- $\beta$ fibril ends via its C-terminal domain to prevent elongation. <i>Journal of Biological Chemistry</i> , 2017, 292, 16858-16871.	1.6	32
1837	Conditional Deletion of <i>Prnp</i> Rescues Behavioral and Synaptic Deficits after Disease Onset in Transgenic Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2017, 37, 9207-9221.	1.7	45
1838	Tuning the stereo-hindrance of a curcumin scaffold for the selective imaging of the soluble forms of amyloid beta species. <i>Chemical Science</i> , 2017, 8, 7710-7717.	3.7	69
1839	Mechanisms and rates of nucleation of amyloid fibrils. <i>Journal of Chemical Physics</i> , 2017, 147, 105103.	1.2	27
1840	SEN1500, a novel oral amyloid- $\beta$ aggregation inhibitor, attenuates brain pathology in a mouse model of Alzheimer's disease. <i>Neuroscience Letters</i> , 2017, 660, 96-102.	1.0	3
1841	Cationization increases brain distribution of an amyloid-beta protofibril selective F(ab') <sub>2</sub> fragment. <i>Biochemical and Biophysical Research Communications</i> , 2017, 493, 120-125.	1.0	30
1842	Gamma rhythm low field magnetic stimulation alleviates neuropathologic changes and rescues memory and cognitive impairments in a mouse model of Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 487-497.	1.8	36
1843	A Toxic Conformer of A $\beta$ <sub>42</sub> with a Turn at 22-23 is a Novel Therapeutic Target for Alzheimer's Disease. <i>Scientific Reports</i> , 2017, 7, 11811.	1.6	23
1844	In silico studies of solvated F19W amyloid $\beta$ (11-40) trimer. <i>RSC Advances</i> , 2017, 7, 42379-42386.	1.7	15

#	ARTICLE	IF	CITATIONS
1845	Fluoxetine administration during adolescence attenuates cognitive and synaptic deficits in adult 3Å–TgAD mice. <i>Neuropharmacology</i> , 2017, 126, 200-212.	2.0	33
1846	Somatodendritic accumulation of Tau in Alzheimer's disease is promoted by Fyn-mediated local protein translation. <i>EMBO Journal</i> , 2017, 36, 3120-3138.	3.5	140
1847	Diversity of Amyloid-beta Proteoforms in the Alzheimer's Disease Brain. <i>Scientific Reports</i> , 2017, 7, 9520.	1.6	125
1848	Sialylated glycosylphosphatidylinositols suppress the production of toxic amyloid-Î² oligomers. <i>Biochemical Journal</i> , 2017, 474, 3045-3058.	1.7	3
1849	BACE inhibition-dependent repair of Alzheimer's pathophysiology. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 8631-8636.	3.3	93
1850	N-Terminal Acetylation Preserves Î±-Synuclein from Oligomerization by Blocking Intermolecular Hydrogen Bonds. <i>ACS Chemical Neuroscience</i> , 2017, 8, 2145-2151.	1.7	52
1851	Matrix Metalloproteinases, Neural Extracellular Matrix, and Central Nervous System Pathology. <i>Progress in Molecular Biology and Translational Science</i> , 2017, 148, 167-202.	0.9	30
1852	Identification of proteins that specifically recognize and bind protofibrillar aggregates of amyloid-Î². <i>Scientific Reports</i> , 2017, 7, 5949.	1.6	17
1853	The cholesterol ester cycle regulates signalling complexes and synapse damage caused by amyloid-Î². <i>Journal of Cell Science</i> , 2017, 130, 3050-3059.	1.2	8
1854	Mannich base approach to 5-methoxyisatin 3-(4-isopropylphenyl)hydrazone: A water-soluble prodrug for a multitarget inhibition of cholinesterases, beta-amyloid fibrillization and oligomer-induced cytotoxicity. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 109, 381-388.	1.9	33
1855	APP/AÎ² structural diversity and Alzheimer's disease pathogenesis. <i>Neurochemistry International</i> , 2017, 110, 1-13.	1.9	78
1856	Pharmacokinetics, biodistribution and brain retention of a bispecific antibody-based PET radioligand for imaging of amyloid-Î². <i>Scientific Reports</i> , 2017, 7, 17254.	1.6	39
1857	Inhibiting the Ca <sup>2+</sup> Influx Induced by Human CSF. <i>Cell Reports</i> , 2017, 21, 3310-3316.	2.9	20
1858	Initial Structural Models of the AÎ² <sub>42</sub> Dimer from Replica Exchange Molecular Dynamics Simulations. <i>ACS Omega</i> , 2017, 2, 7621-7636.	1.6	10
1859	Nanoscale Dynamics of Amyloid Î² <sub>42</sub> Oligomers As Revealed by High-Speed Atomic Force Microscopy. <i>ACS Nano</i> , 2017, 11, 12202-12209.	7.3	85
1860	Bidirectionality of Synaptic Pathways Related to LTP and LTD. <i>Series on Advances in Bioinformatics and Computational Biology</i> , 2017, , 169-253.	0.2	0
1861	Amyloid Accumulation Drives Proteome-wide Alterations in Mouse Models of Alzheimer's Disease-like Pathology. <i>Cell Reports</i> , 2017, 21, 2614-2627.	2.9	56
1862	Periodontitis induced by bacterial infection exacerbates features of Alzheimer's disease in transgenic mice. <i>Npj Aging and Mechanisms of Disease</i> , 2017, 3, 15.	4.5	141

#	ARTICLE	IF	CITATIONS
1863	Cell-type Dependent Alzheimer's Disease Phenotypes: Probing the Biology of Selective Neuronal Vulnerability. <i>Stem Cell Reports</i> , 2017, 9, 1868-1884.	2.3	73
1864	Role of the Microbiome in Polyphenol Metabolite-Mediated Attenuation of $\beta$ -amyloid and tau Protein Misfolding in Alzheimer's Disease. , 2017, , 281-304.		0
1865	Peptides from sesame cake reduce oxidative stress and amyloid- $\beta$ -induced toxicity by upregulation of SKN-1 in a transgenic <i>Caenorhabditis elegans</i> model of Alzheimer's disease. <i>Journal of Functional Foods</i> , 2017, 39, 287-298.	1.6	18
1866	Neuronal hyperactivity due to loss of inhibitory tone in APOE4 mice lacking Alzheimer's disease-like pathology. <i>Nature Communications</i> , 2017, 8, 1464.	5.8	122
1867	Human Brain-Derived $A\beta$ Oligomers Bind to Synapses and Disrupt Synaptic Activity in a Manner That Requires APP. <i>Journal of Neuroscience</i> , 2017, 37, 11947-11966.	1.7	108
1868	Unconventional NMDA Receptor Signaling. <i>Journal of Neuroscience</i> , 2017, 37, 10800-10807.	1.7	99
1869	EEG spectral analysis as a putative early prognostic biomarker in nondemented, amyloid positive subjects. <i>Neurobiology of Aging</i> , 2017, 57, 133-142.	1.5	91
1870	Silent Allosteric Modulation of mGluR5 Maintains Glutamate Signaling while Rescuing Alzheimer's Mouse Phenotypes. <i>Cell Reports</i> , 2017, 20, 76-88.	2.9	84
1871	Ablating ErbB4 in PV neurons attenuates synaptic and cognitive deficits in an animal model of Alzheimer's disease. <i>Neurobiology of Disease</i> , 2017, 106, 171-180.	2.1	42
1872	$A\beta$ <sub>42</sub> pentamers/hexamers are the smallest detectable oligomers in solution. <i>Scientific Reports</i> , 2017, 7, 2493.	1.6	49
1873	Neurotrophin Signaling and Stem Cells—Implications for Neurodegenerative Diseases and Stem Cell Therapy. <i>Molecular Neurobiology</i> , 2017, 54, 7401-7459.	1.9	49
1874	Alzheimer's Protective Cross-Interaction between Wild-Type and A2T Variants Alters $A\beta$ <sub>42</sub> Dimer Structure. <i>ACS Chemical Neuroscience</i> , 2017, 8, 606-618.	1.7	45
1875	Large Soluble Oligomers of Amyloid $\beta$ -Protein from Alzheimer Brain Are Far Less Neuroactive Than the Smaller Oligomers to Which They Dissociate. <i>Journal of Neuroscience</i> , 2017, 37, 152-163.	1.7	262
1876	Protein Quality Control in Health and Disease. <i>Cold Spring Harbor Perspectives in Biology</i> , 2017, 9, a023523.	2.3	68
1877	Visual system manifestations of Alzheimer's disease. <i>Acta Ophthalmologica</i> , 2017, 95, e668-e676.	0.6	48
1878	DMSO modulates CNS function in a preclinical Alzheimer's disease model. <i>Neuropharmacology</i> , 2017, 113, 434-444.	2.0	40
1880	The Effects of Astilbin on Cognitive Impairments in a Transgenic Mouse Model of Alzheimer's Disease. <i>Cellular and Molecular Neurobiology</i> , 2017, 37, 695-706.	1.7	22
1881	Neuroinflammatory challenges compromise neuronal function in the aging brain: Postoperative cognitive delirium and Alzheimer's disease. <i>Behavioural Brain Research</i> , 2017, 322, 269-279.	1.2	55

#	ARTICLE	IF	CITATIONS
1882	A Leptin Fragment Mirrors the Cognitive Enhancing and Neuroprotective Actions of Leptin. <i>Cerebral Cortex</i> , 2017, 27, 4769-4782.	1.6	29
1883	Metformin Attenuates A $\beta$ Pathology Mediated Through Levamisole Sensitive Nicotinic Acetylcholine Receptors in a <i>C. elegans</i> Model of Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2017, 54, 5427-5439.	1.9	43
1884	Is there correlation between A $\beta$ -heme peroxidase activity and the peptide aggregation state? A literature review combined with hypothesis. <i>International Journal of Biological Macromolecules</i> , 2017, 100, 18-36.	3.6	13
1885	Metabotropic glutamate receptors and neurodegenerative diseases. <i>Pharmacological Research</i> , 2017, 115, 179-191.	3.1	194
1886	Towards an understanding of amyloid- $\beta$ oligomers: characterization, toxicity mechanisms, and inhibitors. <i>Chemical Society Reviews</i> , 2017, 46, 310-323.	18.7	405
1887	Capsaicin Attenuates Amyloid- $\beta$ -Induced Synapse Loss and Cognitive Impairments in Mice. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 683-694.	1.2	40
1888	Perplexity of Amyloid $\beta$ -Protein Oligomer Formation: Relevance to Alzheimer's Disease. <i>World Scientific Lecture and Course Notes in Chemistry</i> , 2017, , 1-50.	0.2	4
1889	Neuroimmune Dynamics in Alzheimer's Disease Progression. , 0, , .		1
1890	Morphofunctional Correlation of Excitatory and Depressor Synaptic Processes in Hippocampus, Amygdala and Basal Meynert Nucleus Neurons in Dynamics of Development of Alzheimer's Disease Model Induced by A $\beta$ 25-35. , 2017, 07, .		0
1891	Can Co-Activation of Nrf2 and Neurotrophic Signaling Pathway Slow Alzheimer's Disease?. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1168.	1.8	41
1892	Bivalent Brain Shuttle Increases Antibody Uptake by Monovalent Binding to the Transferrin Receptor. <i>Theranostics</i> , 2017, 7, 308-318.	4.6	146
1893	Contribution of Nucleic Acids in the Pathogenesis of Alzheimer's Disease. , 2017, , 129-162.		0
1894	Molecular Recognition Using Foldamers. , 2017, , 511-537.		3
1895	Design, Synthesis, and Biological Evaluation of a New Series of Biphenyl/Bibenzyl Derivatives Functioning as Dual Inhibitors of Acetylcholinesterase and Butyrylcholinesterase. <i>Molecules</i> , 2017, 22, 172.	1.7	11
1896	Actions of Brain-Derived Neurotrophic Factor and Glucocorticoid Stress in Neurogenesis. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2312.	1.8	111
1897	Amyloid $\beta$ Hypothesis in the Development of Therapeutic Agents for Alzheimer's Disease. , 2017, , 109-143.		5
1898	The Emerging Roles of Early Protein Folding Events in the Secretory Pathway in the Development of Neurodegenerative Maladies. <i>Frontiers in Neuroscience</i> , 2017, 11, 48.	1.4	9
1899	Low-Frequency Repetitive Transcranial Magnetic Stimulation Ameliorates Cognitive Function and Synaptic Plasticity in APP23/PS45 Mouse Model of Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 292.	1.7	36

#	ARTICLE	IF	CITATIONS
1900	Synaptic Dysfunction in Alzheimer's Disease and Glaucoma: From Common Degenerative Mechanisms Toward Neuroprotection. <i>Frontiers in Cellular Neuroscience</i> , 2017, 11, 53.	1.8	31
1901	Analysis of Amyloid- $\beta$ Pathology Spread in Mouse Models Suggests Spread Is Driven by Spatial Proximity, Not Connectivity. <i>Frontiers in Neurology</i> , 2017, 8, 653.	1.1	20
1902	Protein Quality Control by Molecular Chaperones in Neurodegeneration. <i>Frontiers in Neuroscience</i> , 2017, 11, 185.	1.4	245
1903	G-Protein-Coupled Inwardly Rectifying Potassium (GIRK) Channel Activation by the p75 Neurotrophin Receptor Is Required for Amyloid $\beta$ Toxicity. <i>Frontiers in Neuroscience</i> , 2017, 11, 455.	1.4	19
1904	Novel Insights into the Physiological Function of the APP (Gene) Family and Its Proteolytic Fragments in Synaptic Plasticity. <i>Frontiers in Molecular Neuroscience</i> , 2016, 9, 161.	1.4	48
1905	Therapeutic Potential of Secreted Amyloid Precursor Protein APPs $\beta$ . <i>Frontiers in Molecular Neuroscience</i> , 2017, 10, 30.	1.4	91
1906	APP Function and Lipids: A Bidirectional Link. <i>Frontiers in Molecular Neuroscience</i> , 2017, 10, 63.	1.4	76
1907	Interplay of Energetics and ER Stress Exacerbates Alzheimer's Amyloid- $\beta$ ( $A\beta$ ) Toxicity in Yeast. <i>Frontiers in Molecular Neuroscience</i> , 2017, 10, 232.	1.4	28
1908	Amino-Terminal $\beta$ -Amyloid Antibody Blocks $\beta$ -Amyloid-Mediated Inhibition of the High-Affinity Choline Transporter CHT. <i>Frontiers in Molecular Neuroscience</i> , 2017, 10, 361.	1.4	14
1909	Amyloid- $\beta$ Homeostasis Bridges Inflammation, Synaptic Plasticity Deficits and Cognitive Dysfunction in Multiple Sclerosis. <i>Frontiers in Molecular Neuroscience</i> , 2017, 10, 390.	1.4	21
1910	NPTX2 and cognitive dysfunction in Alzheimer's Disease. <i>ELife</i> , 2017, 6, .	2.8	146
1911	Optimized-SopungSunkiwon, a Herbal Formula, Attenuates A $\beta$ Oligomer-Induced Neurotoxicity in Alzheimer's Disease Models. <i>Evidence-based Complementary and Alternative Medicine</i> , 2017, 2017, 1-12.	0.5	2
1912	Association between injury severity and amyloid $\beta$ protein levels in serum and cerebrospinal fluid in rats with traumatic spinal cord injury. <i>Molecular Medicine Reports</i> , 2017, 15, 2241-2246.	1.1	3
1913	Optogenetic Restoration of Disrupted Slow Oscillations Halts Amyloid Deposition and Restores Calcium Homeostasis in an Animal Model of Alzheimer's Disease. <i>PLoS ONE</i> , 2017, 12, e0170275.	1.1	75
1914	Presynaptic A $\beta$ <sub>240</sub> prevents synapse addition in the adult <i>Drosophila</i> neuromuscular junction. <i>PLoS ONE</i> , 2017, 12, e0177541.	1.1	4
1915	Study of structural stability and damaging effect on membrane for four A $\beta$ <sub>242</sub> dimers. <i>PLoS ONE</i> , 2017, 12, e0179147.	1.1	4
1916	Differential deregulation of NGF and BDNF neurotrophins in a transgenic rat model of Alzheimer's disease. <i>Neurobiology of Disease</i> , 2017, 108, 307-323.	2.1	66
1917	Abnormal dendritic calcium activity and synaptic depotentiation occur early in a mouse model of Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2017, 12, 86.	4.4	37



#	ARTICLE	IF	CITATIONS
1918	Non-canonical soluble amyloid-beta aggregates and plaque buffering: controversies and future directions for target discovery in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 62.	3.0	62
1919	Age-dependent changes in synaptic plasticity enhance tau oligomerization in the mouse hippocampus. <i>Acta Neuropathologica Communications</i> , 2017, 5, 67.	2.4	25
1920	Mechanisms of Alzheimer's Disease Pathogenesis and Prevention: The Brain, Neural Pathology, N-methyl-D-aspartate Receptors, Tau Protein and Other Risk Factors. <i>Clinical Psychopharmacology and Neuroscience</i> , 2017, 15, 1-8.	0.9	153
1921	Role of Endoplasmic Reticulum Stress in Learning and Memory Impairment and Alzheimer's Disease-Like Neuropathology in the PS19 and APP <sup>Swe</sup> Mouse Models of Tauopathy and Amyloidosis. <i>ENeuro</i> , 2017, 4, ENEURO.0025-17.2017.	0.9	40
1922	The role of PI3K/AKT pathway and its therapeutic possibility in Alzheimer's disease. <i>Hanyang Medical Reviews</i> , 2017, 37, 18.	0.4	20
1923	Molecular Mechanisms of Synaptic Plasticity and Memory and Their Dysfunction in Alzheimer's Disease <i>Acta Neuropathologica</i> , 2017, 127, 65-135.		1
1924	Activation of Ras-ERK Signaling and GSK-3 by Amyloid Precursor Protein and Amyloid Beta Facilitates Neurodegeneration in Alzheimer's Disease. <i>ENeuro</i> , 2017, 4, ENEURO.0149-16.2017.	0.9	149
1925	Calcium Dysregulation in Alzheimer's Disease: A Target for New Drug Development. <i>Journal of Alzheimer's Disease</i> , 2017, 51, 1-12.		78
1926	Molecular and Cellular Basis of Neurodegeneration in Alzheimer's Disease. <i>Molecules and Cells</i> , 2017, 40, 613-620.	1.0	131
1927	A $\beta$ -amyloid inhibits hippocampal LTP through TNFR/IKK/NF- $\kappa$ B pathway. <i>Neurological Research</i> , 2018, 40, 268-276.	0.6	24
1928	Dale Schenk One Year Anniversary: Fighting to Preserve the Memories. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1-13.	1.2	7
1929	Differential effect of amyloid beta peptides on mitochondrial axonal trafficking depends on their state of aggregation and binding to the plasma membrane. <i>Neurobiology of Disease</i> , 2018, 114, 1-16.	2.1	34
1930	Weaker N-Terminal Interactions for the Protective over the Causative A $\beta$ Peptide Dimer Mutants. <i>ACS Chemical Neuroscience</i> , 2018, 9, 1247-1253.	1.7	18
1931	Synaptic vesicle cycle and amyloid A $\beta$ : Biting the hand that feeds. <i>Alzheimer's and Dementia</i> , 2018, 14, 502-513.	0.4	40
1932	An Artificial Neural Network Integrated Pipeline for Biomarker Discovery Using Alzheimer's Disease as a Case Study. <i>Computational and Structural Biotechnology Journal</i> , 2018, 16, 77-87.	1.9	56
1933	A $\beta$ dimers induce behavioral and neurochemical deficits of relevance to early Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 69, 1-9.	1.5	14
1934	Neuroprotective Effects of Ferruginol, Jatrophone, and Junicedric Acid Against Amyloid-A $\beta$ Injury in Hippocampal Neurons. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 705-723.	1.2	8
1935	Critical review: involvement of endoplasmic reticulum stress in the aetiology of Alzheimer's disease. <i>Open Biology</i> , 2018, 8, 180024.	1.5	106



#	ARTICLE	IF	CITATIONS
1936	Diffusible, highly bioactive oligomers represent a critical minority of soluble A $\beta$ in Alzheimer's disease brain. <i>Acta Neuropathologica</i> , 2018, 136, 19-40.	3.9	100
1937	A solution NMR toolset to probe the molecular mechanisms of amyloid inhibitors. <i>Chemical Communications</i> , 2018, 54, 4644-4652.	2.2	33
1938	Synaptotoxic Signaling by Amyloid Beta Oligomers in Alzheimer's Disease Through Prion Protein and mGluR5. <i>Advances in Pharmacology</i> , 2018, 82, 293-323.	1.2	67
1939	A Rational Structured Epitope Defines a Distinct Subclass of Toxic Amyloid-beta Oligomers. <i>ACS Chemical Neuroscience</i> , 2018, 9, 1591-1606.	1.7	21
1940	Combination anti-A $\beta$ treatment maximizes cognitive recovery and rebalances mTOR signaling in APP mice. <i>Journal of Experimental Medicine</i> , 2018, 215, 1349-1364.	4.2	14
1941	Sulforaphane Inhibits the Generation of Amyloid- $\beta$ Oligomer and Promotes Spatial Learning and Memory in Alzheimer's Disease (PS1V97L) Transgenic Mice. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1803-1813.	1.2	48
1942	Covalent labeling-mass spectrometry with non-specific reagents for studying protein structure and interactions. <i>Methods</i> , 2018, 144, 79-93.	1.9	81
1943	Early alteration of distribution and activity of hippocampal type-1 cannabinoid receptor in Alzheimer's disease-like mice overexpressing the human mutant amyloid precursor protein. <i>Pharmacological Research</i> , 2018, 130, 366-373.	3.1	19
1944	Shedding light on aberrant interactions – a review of modern tools for studying protein aggregates. <i>FEBS Journal</i> , 2018, 285, 3604-3630.	2.2	10
1945	The Mechanisms of Bushen-Yizhi Formula as a Therapeutic Agent against Alzheimer's Disease. <i>Scientific Reports</i> , 2018, 8, 3104.	1.6	46
1946	Endogenous Murine Amyloid- $\beta$ Peptide Assembles into Aggregates in the Aged C57BL/6J Mouse Suggesting These Animals as a Model to Study Pathogenesis of Amyloid- $\beta$ Plaque Formation. <i>Journal of Alzheimer's Disease</i> , 2018, 61, 1425-1450.	1.2	26
1947	Verapamil Inhibits Ser202/Thr205 Phosphorylation of Tau by Blocking TXNIP/ROS/p38 MAPK Pathway. <i>Pharmaceutical Research</i> , 2018, 35, 44.	1.7	50
1948	Imbalance between firing homeostasis and synaptic plasticity drives early-phase Alzheimer's disease. <i>Nature Neuroscience</i> , 2018, 21, 463-473.	7.1	225
1949	Amyloid- $\beta$ oligomers synaptotoxicity: The emerging role of EphA4/c-Abl signaling in Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 1148-1159.	1.8	48
1950	Cerebrospinal Fluid Biomarkers are Differentially Related to Structural and Functional Changes in Dementia of the Alzheimer's Type. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 417-427.	1.2	5
1951	<sup>18</sup> F-florbetapir Positron Emission Tomography – determined Cerebral $\beta$ -Amyloid Deposition and Neurocognitive Performance after Cardiac Surgery. <i>Anesthesiology</i> , 2018, 128, 728-744.	1.3	28
1952	Characterization of a 3xTg-AD mouse model of Alzheimer's disease with the senescence accelerated mouse prone 8 (SAMP8) background. <i>Synapse</i> , 2018, 72, e22025.	0.6	16
1953	Synaptic plasticity modulation by circulating peptides and metaplasticity: Involvement in Alzheimer's disease. <i>Pharmacological Research</i> , 2018, 130, 385-401.	3.1	38

#	ARTICLE	IF	CITATIONS
1954	The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer's disease. <i>Journal of Pathology</i> , 2018, 245, 85-100.	2.1	180
1955	Revisiting the earliest signatures of amyloidogenesis: Roadmaps emerging from computational modeling and experiment. <i>Wiley Interdisciplinary Reviews: Computational Molecular Science</i> , 2018, 8, e1359.	6.2	17
1956	To Be Fibrils or To Be Nanofilms? Oligomers Are Building Blocks for Fibril and Nanofilm Formation of Fragments of A $\beta$ Peptide. <i>Langmuir</i> , 2018, 34, 2332-2343.	1.6	33
1957	Celecoxib Prevents Cognitive Impairment and Neuroinflammation in Soluble Amyloid $\beta$ -treated Rats. <i>Neuroscience</i> , 2018, 372, 58-73.	1.1	47
1958	Inhibition of $\beta$ -Amyloid Aggregation through a Designed $\beta$ -Hairpin Peptide. <i>Langmuir</i> , 2018, 34, 1591-1600.	1.6	38
1959	Cinnamon, a promising prospect towards Alzheimer's disease. <i>Pharmacological Research</i> , 2018, 130, 241-258.	3.1	67
1960	A $\beta$ mediates F-actin disassembly in dendritic spines leading to cognitive deficits in Alzheimer's disease. <i>Journal of Neuroscience</i> , 2018, 38, 1085-1099.	1.7	104
1961	Cholesterol ester hydrolase inhibitors reduce the production of synaptotoxic amyloid- $\beta$ oligomers. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 649-659.	1.8	6
1962	Monomeric amyloid- $\beta$ reduced amyloid- $\beta$ oligomer-induced synapse damage in neuronal cultures. <i>Neurobiology of Disease</i> , 2018, 111, 48-58.	2.1	20
1963	Potential for therapeutic targeting of AKAP signaling complexes in nervous system disorders. , 2018, 185, 99-121.		47
1964	Discrete Pools of Oligomeric Amyloid- $\beta$ Track with Spatial Learning Deficits in a Mouse Model of Alzheimer Amyloidosis. <i>American Journal of Pathology</i> , 2018, 188, 739-756.	1.9	16
1965	Recent developments in solution nuclear magnetic resonance (NMR)-based molecular biology. <i>Journal of Molecular Medicine</i> , 2018, 96, 1-8.	1.7	23
1966	Using Herpes Simplex Virus Type 1-Based Amplicon Vectors for Neuroscience Research and Gene Therapy of Neurologic Diseases. , 2018, , 445-477.		0
1967	The interactions of p53 with tau and A $\beta$ as potential therapeutic targets for Alzheimer's disease. <i>Progress in Neurobiology</i> , 2018, 168, 104-127.	2.8	74
1968	Supratherapeutic concentrations of cilostazol inhibits $\beta$ -amyloid oligomerization in vitro. <i>Neuroscience Letters</i> , 2018, 677, 19-25.	1.0	12
1969	Brain Inflammation Connects Cognitive and Non-Cognitive Symptoms in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S313-S327.	1.2	31
1970	Discovery of tetrahydroindazoles as a novel class of potent and in vivo efficacious gamma secretase modulators. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 3227-3241.	1.4	8
1971	Structure of APP-C991 and implications for role of extra-membrane domains in function and oligomerization. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2018, 1860, 1698-1708.	1.4	38

#	ARTICLE	IF	CITATIONS
1972	MicroRNA Expression Levels Are Altered in the Cerebrospinal Fluid of Patients with Young-Onset Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2018, 55, 8826-8841.	1.9	111
1974	Direct Evidence of the Presence of Cross-Linked A $\beta$ Dimers in the Brains of Alzheimer's Disease Patients. <i>Analytical Chemistry</i> , 2018, 90, 4552-4560.	3.2	37
1975	Brain Aging and Late-Onset Alzheimer's Disease: A Matter of Increased Amyloid or Reduced Energy?. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S397-S404.	1.2	17
1976	Time dependence of NMR observables reveals salient differences in the accumulation of early aggregated species between human islet amyloid polypeptide and amyloid- $\beta$ . <i>Physical Chemistry Chemical Physics</i> , 2018, 20, 9561-9573.	1.3	9
1977	Role of ASIC1a in A $\beta$ -induced synaptic alterations in the hippocampus. <i>Pharmacological Research</i> , 2018, 131, 61-65.	3.1	20
1978	Interactions of amyloid- $\beta$ peptides on lipid bilayer studied by single molecule imaging and tracking. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2018, 1860, 1616-1624.	1.4	26
1979	The retina as a window to early dysfunctions of Alzheimer's disease following studies with a 5xFAD mouse model. <i>Neurobiology of Aging</i> , 2018, 67, 181-188.	1.5	51
1980	The phospholipase A2 pathway controls a synaptic cholesterol ester cycle and synapse damage. <i>Journal of Cell Science</i> , 2018, 131, .	1.2	4
1981	Pin1 mediates A $\beta$ -induced dendritic spine loss. <i>Science Signaling</i> , 2018, 11, .	1.6	23
1982	The Effects of N-terminal Mutations on $\beta$ -amyloid Peptide Aggregation and Toxicity. <i>Neuroscience</i> , 2018, 379, 177-188.	1.1	20
1983	Anti-A $\beta$ drug candidates in clinical trials and plasmonic nanoparticle-based drug-screen for Alzheimer's disease. <i>Analyst</i> , 2018, 143, 2204-2212.	1.7	19
1984	Mutations in the $\beta$ -amyloid precursor protein in familial Alzheimer's disease increase A $\beta$ oligomer production in cellular models. <i>Heliyon</i> , 2018, 4, e00511.	1.4	10
1985	Studies of the Process of Amyloid Formation by A $\beta$ Peptide. <i>Biochemistry (Moscow)</i> , 2018, 83, S62-S80.	0.7	10
1986	Binding Patterns Associated A $\beta$ -HSP60 p458 Conjugate to HLA-DR-DRB Allele of Human in Alzheimer's Disease: An In Silico Approach. <i>Interdisciplinary Sciences, Computational Life Sciences</i> , 2018, 10, 93-104.	2.2	5
1987	Bridging Type 2 Diabetes and Alzheimer's Disease: Assembling the Puzzle Pieces in the Quest for the Molecules With Therapeutic and Preventive Potential. <i>Medicinal Research Reviews</i> , 2018, 38, 261-324.	5.0	55
1988	Hippocampal Proteomic Analysis Reveals Distinct Pathway Deregulation Profiles at Early and Late Stages in a Rat Model of Alzheimer's-Like Amyloid Pathology. <i>Molecular Neurobiology</i> , 2018, 55, 3451-3476.	1.9	21
1989	Injected Amyloid Beta in the Olfactory Bulb Transfers to Other Brain Regions via Neural Connections in Mice. <i>Molecular Neurobiology</i> , 2018, 55, 1703-1713.	1.9	13
1990	Targeting Fyn Kinase in Alzheimer's Disease. <i>Biological Psychiatry</i> , 2018, 83, 369-376.	0.7	108

#	ARTICLE	IF	CITATIONS
1991	Rapid amyloid- $\beta$ oligomer and protofibril accumulation in traumatic brain injury. <i>Brain Pathology</i> , 2018, 28, 451-462.	2.1	31
1992	Inhibition of Poly(ADP-ribose) Polymerase-1 Enhances Gene Expression of Selected Sirtuins and APP Cleaving Enzymes in Amyloid Beta Cytotoxicity. <i>Molecular Neurobiology</i> , 2018, 55, 4612-4623.	1.9	27
1993	The contribution of biophysical and structural studies of protein self-assembly to the design of therapeutic strategies for amyloid diseases. <i>Neurobiology of Disease</i> , 2018, 109, 178-190.	2.1	62
1994	Direct pharmacological Akt activation rescues Alzheimer's disease like memory impairments and aberrant synaptic plasticity. <i>Neuropharmacology</i> , 2018, 128, 282-292.	2.0	66
1995	Astrocytic glutamatergic transporters are involved in $A\beta$ -induced synaptic dysfunction. <i>Brain Research</i> , 2018, 1678, 129-137.	1.1	37
1996	Valproic acid and its congener propylisopropylacetic acid reduced the amount of soluble amyloid- $\beta$ oligomers released from 7PA2 cells. <i>Neuropharmacology</i> , 2018, 128, 54-62.	2.0	8
1997	Roles for Arc in metabotropic glutamate receptor-dependent LTD and synapse elimination: Implications in health and disease. <i>Seminars in Cell and Developmental Biology</i> , 2018, 77, 51-62.	2.3	46
1998	Food for thought: Leptin regulation of hippocampal function and its role in Alzheimer's disease. <i>Neuropharmacology</i> , 2018, 136, 298-306.	2.0	26
1999	A novel role for osteopontin in macrophage-mediated amyloid- $\beta$ clearance in Alzheimer's models. <i>Brain, Behavior, and Immunity</i> , 2018, 67, 163-180.	2.0	86
2000	Alzheimer's disease. <i>European Journal of Neurology</i> , 2018, 25, 59-70.	1.7	1,624
2001	Phytochemicals as inhibitors of NF- $\kappa$ B for treatment of Alzheimer's disease. <i>Pharmacological Research</i> , 2018, 129, 262-273.	3.1	192
2002	Down regulation of pro-inflammatory pathways by tanshinone IIA and cryptotanshinone in a non-genetic mouse model of Alzheimer's disease. <i>Pharmacological Research</i> , 2018, 129, 482-490.	3.1	95
2003	Seed-induced $A\beta$ deposition is modulated by microglia under environmental enrichment in a mouse model of Alzheimer's disease. <i>EMBO Journal</i> , 2018, 37, 167-182.	3.5	87
2004	Amyloid- $\beta$ and tau complexity towards improved biomarkers and targeted therapies. <i>Nature Reviews Neurology</i> , 2018, 14, 22-39.	4.9	303
2005	Wnt signaling loss accelerates the appearance of neuropathological hallmarks of Alzheimer's disease in J20-APP transgenic and wild-type mice. <i>Journal of Neurochemistry</i> , 2018, 144, 443-465.	2.1	66
2006	Discovery of novel scaffolds for $\beta$ -secretase modulators without an arylimidazole moiety. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 435-442.	1.4	14
2007	Amyloid $\beta$ oligomers ( $A\beta$ Os) in Alzheimer's disease. <i>Journal of Neural Transmission</i> , 2018, 125, 177-191.	1.4	114
2008	Prion Protein as a Toxic Acceptor of Amyloid- $\beta$ Oligomers. <i>Biological Psychiatry</i> , 2018, 83, 358-368.	0.7	66

#	ARTICLE	IF	CITATIONS
2009	The Emerging Relationship Between Interstitial Fluidâ€“Cerebrospinal Fluid Exchange, Amyloid- $\beta$ , and Sleep. <i>Biological Psychiatry</i> , 2018, 83, 328-336.	0.7	112
2010	Understanding the roles of mutations in the amyloid precursor protein in Alzheimer disease. <i>Molecular Psychiatry</i> , 2018, 23, 81-93.	4.1	74
2011	Detection of $\beta$ -Amyloid by Sialic Acid Coated Bovine Serum Albumin Magnetic Nanoparticles in a Mouse Model of Alzheimer's Disease. <i>Small</i> , 2018, 14, 1701828.	5.2	38
2012	Earlyâ€“stage attenuation of phaseâ€“amplitude coupling in the hippocampus and medial prefrontal cortex in a transgenic rat model of Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2018, 144, 669-679.	2.1	69
2013	Alzheimer's disease as oligomeropathy. <i>Neurochemistry International</i> , 2018, 119, 57-70.	1.9	90
2014	A Novel MicroRNA-124/PTPN1 Signal Pathway Mediates Synaptic and Memory Deficits in Alzheimerâ€™s Disease. <i>Biological Psychiatry</i> , 2018, 83, 395-405.	0.7	153
2015	Topological Biomarker of Alzheimerâ€™s Disease. , 0, , .		1
2017	Regulatory effects of the long nonâ€“coding RNA RP11â€“543N12.1 and microRNAâ€“324â€“3p axis on the neuronal apoptosis induced by the inflammatory reactions of microglia. <i>International Journal of Molecular Medicine</i> , 2018, 42, 1741-1755.	1.8	11
2018	Mitochondrial Complex I Deficit in the Olfactory Systems of Age-related Neurodegenerative Monkey Models: A PET Study using 18F-BCPP-EF. , 2018, 08, .		1
2019	Regulation of Hippocampal Synaptic Function by the Metabolic Hormone, Leptin: Implications for Health and Neurodegenerative Disease. <i>Frontiers in Cellular Neuroscience</i> , 2018, 12, 340.	1.8	48
2020	Royal jelly coordinately enhances hippocampal neuronal expression of somatostatin and neprilysin genes conferring neuronal protection against toxic soluble amyloid- $\beta$ oligomers implicated in Alzheimerâ€™s disease pathogenesis. <i>Journal of Functional Foods</i> , 2018, 51, 28-38.	1.6	5
2021	Possible Clues for Brain Energy Translation via Endolysosomal Trafficking of APP-CTFs in Alzheimerâ€™s Disease. <i>Oxidative Medicine and Cellular Longevity</i> , 2018, 2018, 1-11.	1.9	8
2022	Deficient Wnt Signaling and Synaptic Vulnerability in Alzheimerâ€™s Disease: Emerging Roles for the LRP6 Receptor. <i>Frontiers in Synaptic Neuroscience</i> , 2018, 10, 38.	1.3	30
2023	Decoding the synaptic dysfunction of bioactive human AD brain soluble $A\beta$ to inspire novel therapeutic avenues for Alzheimerâ€™s disease. <i>Acta Neuropathologica Communications</i> , 2018, 6, 121.	2.4	46
2024	Lessons from the Study of Covalent Dimers of the Alzheimerâ€™s Disease-Associate Amyloid $\beta$ -Protein. <i>Biochemistry &amp; Physiology</i> , 2018, 07, .	0.2	2
2025	Effects of a Dehydroevodiamine-Derivative on Synaptic Destabilization and Memory Impairment in the 5xFAD, Alzheimer's Disease Mouse Model. <i>Frontiers in Behavioral Neuroscience</i> , 2018, 12, 273.	1.0	22
2026	The Role of Glial Cells and Synapse Loss in Mouse Models of Alzheimerâ€™s Disease. <i>Frontiers in Cellular Neuroscience</i> , 2018, 12, 473.	1.8	24
2027	The Emerging Role of Altered Cerebellar Synaptic Processing in Alzheimerâ€™s Disease. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 396.	1.7	38

#	ARTICLE	IF	CITATIONS
2028	Copper Redox Cycling Inhibits A $\beta$ 2 Fibre Formation and Promotes Fibre Fragmentation, while Generating a Dityrosine A $\beta$ 2 Dimer. <i>Scientific Reports</i> , 2018, 8, 16190.	1.6	46
2029	SAR228810: an antibody for protofibrillar amyloid $\beta$ 2 peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA). <i>Alzheimer's Research and Therapy</i> , 2018, 10, 117.	3.0	14
2030	Bee venom phospholipase A2 ameliorates Alzheimer's disease pathology in A $\beta$ 2 vaccination treatment without inducing neuro-inflammation in a 3xTg-AD mouse model. <i>Scientific Reports</i> , 2018, 8, 17369.	1.6	23
2031	Dendritic spine loss caused by AlCl3 is associated with inhibition of the Rac 1/cofilin signaling pathway. <i>Environmental Pollution</i> , 2018, 243, 1689-1695.	3.7	8
2033	Motor improvement requires an increase in presynaptic protein expression and depends on exercise type and age. <i>Experimental Gerontology</i> , 2018, 113, 18-28.	1.2	3
2034	Reduced retromer function results in the accumulation of amyloid-beta oligomers. <i>Molecular and Cellular Neurosciences</i> , 2018, 93, 18-26.	1.0	12
2035	Synaptosomes. <i>Neuromethods</i> , 2018, , .	0.2	3
2036	A bispecific immunotweezer prevents soluble PrP oligomers and abolishes prion toxicity. <i>PLoS Pathogens</i> , 2018, 14, e1007335.	2.1	21
2037	Light at the End of the Amyloid Tunnel. <i>Biochemistry</i> , 2018, 57, 5921-5922.	1.2	12
2038	Nosocomial Pneumonia Elicits an Endothelial Proteinopathy: Evidence for a Source of Neurotoxic Amyloids in Critically Ill Patients. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 1575-1578.	2.5	22
2039	Soluble A $\beta$ 242 Acts as Allosteric Activator of the Core Cholinergic Enzyme Choline Acetyltransferase. <i>Frontiers in Molecular Neuroscience</i> , 2018, 11, 327.	1.4	8
2040	Endogenous amyloid- $\beta$ 2 mediates memory forgetting in the normal brain. <i>Biochemical and Biophysical Research Communications</i> , 2018, 506, 492-497.	1.0	5
2041	Cellular Prion Protein Mediates the Disruption of Hippocampal Synaptic Plasticity by Soluble Tau <i>In Vivo</i> . <i>Journal of Neuroscience</i> , 2018, 38, 10595-10606.	1.7	66
2042	Evidence of intraneuronal A $\beta$ 2 accumulation preceding tau pathology in the entorhinal cortex. <i>Acta Neuropathologica</i> , 2018, 136, 901-917.	3.9	65
2043	Liquid and Hydrogel Phases of PrPC Linked to Conformation Shifts and Triggered by Alzheimer's Amyloid- $\beta$ 2 Oligomers. <i>Molecular Cell</i> , 2018, 72, 426-443.e12.	4.5	87
2044	NMDA receptors mediate synaptic depression, but not spine loss in the dentate gyrus of adult amyloid Beta (A $\beta$ 2) overexpressing mice. <i>Acta Neuropathologica Communications</i> , 2018, 6, 110.	2.4	26
2045	Synaptotoxicity in Alzheimer's Disease Involved a Dysregulation of Actin Cytoskeleton Dynamics through Cofilin 1 Phosphorylation. <i>Journal of Neuroscience</i> , 2018, 38, 10349-10361.	1.7	80
2046	Amyloid Fibril Design: Limiting Structural Polymorphism in Alzheimer's A $\beta$ 2 Protofilaments. <i>Journal of Physical Chemistry B</i> , 2018, 122, 11535-11545.	1.2	7



#	ARTICLE	IF	CITATIONS
2047	Formation of Heterotypic Amyloids: $\beta$ -Synuclein in Co-Aggregation. <i>Proteomics</i> , 2018, 18, e1800059.	1.3	8
2048	Seasonal plasticity of cognition and related biological measures in adults with and without Alzheimer disease: Analysis of multiple cohorts. <i>PLoS Medicine</i> , 2018, 15, e1002647.	3.9	42
2049	TOM1 Regulates Neuronal Accumulation of Amyloid- $\beta$ Oligomers by Fc $\gamma$ RIIb2 Variant in Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2018, 38, 9001-9018.	1.7	21
2050	The Current Status of the Pharmaceutical Potential of Juniperus L. Metabolites. <i>Medicines (Basel)</i> , 2018, 5, 107. <small>0.784314 rgBT / Overload</small>	0.7	23
2051	Anti-amyloid Therapy of Alzheimer's Disease: Current State and Prospects. <i>Biochemistry (Moscow)</i> , 2018, 83, 1057-1067.	0.7	29
2052	A role for APP in Wnt signalling links synapse loss with $\beta$ -amyloid production. <i>Translational Psychiatry</i> , 2018, 8, 179.	2.4	74
2053	A new era for understanding amyloid structures and disease. <i>Nature Reviews Molecular Cell Biology</i> , 2018, 19, 755-773.	16.1	654
2054	Etersalate prevents the formations of A $\beta$ <sub>16-22</sub> oligomer: An in silico study. <i>PLoS ONE</i> , 2018, 13, e0204026.	1.1	11
2055	Potent PDZ-Domain PICK1 Inhibitors that Modulate Amyloid Beta-Mediated Synaptic Dysfunction. <i>Scientific Reports</i> , 2018, 8, 13438.	1.6	13
2056	Effects of NMDAR Antagonist on the Regulation of P-MARCKS Protein to A $\beta$ <sub>1-42</sub> Oligomers Induced Neurotoxicity. <i>Neurochemical Research</i> , 2018, 43, 2008-2015.	1.6	9
2057	An integrated strategy to correlate aggregation state, structure and toxicity of A $\beta$ <sub>1-42</sub> oligomers. <i>Talanta</i> , 2018, 188, 17-26.	2.9	28
2058	Melatonin in Synaptic Impairments of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 911-926.	1.2	19
2059	Tailoring Hydrophobic Interactions between Probes and Amyloid- $\beta$ Peptides for Fluorescent Monitoring of Amyloid- $\beta$ Aggregation. <i>ACS Omega</i> , 2018, 3, 5141-5154.	1.6	7
2060	Amyloid- $\beta$ /Drug Interactions from Computer Simulations and Cell-Based Assays. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S659-S672.	1.2	5
2061	Neurosteroids: non-genomic pathways in neuroplasticity and involvement in neurological diseases. , 2018, 191, 190-206.		37
2062	Adenosine Receptors in Alzheimer's Disease. , 2018, , 259-280.		5
2063	Bringing Molecular Dynamics and Ion-Mobility Spectrometry Closer Together: Shape Correlations, Structure-Based Predictors, and Dissociation. <i>Journal of Physical Chemistry B</i> , 2018, 122, 8317-8329.	1.2	16
2065	Association between Alzheimer's Disease and Oral and Gut Microbiota: Are Pore Forming Proteins the Missing Link?. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 29-46.	1.2	38



#	ARTICLE	IF	CITATIONS
2066	Systems Pharmacological Approach to Investigate the Mechanism of <i>Acori Tatarinowii Rhizoma</i> for Alzheimer's Disease. <i>Evidence-based Complementary and Alternative Medicine</i> , 2018, 2018, 1-20.	0.5	20
2067	Genesis of Neuroprotective Peptoid from A $\beta$ 30-34 Inhibits A $\beta$ Aggregation and AChE Activity. <i>ACS Chemical Neuroscience</i> , 2018, 9, 2929-2940.	1.7	13
2068	Traumatic brain injury: a platform for studies in A $\beta$ processing. <i>Brain Pathology</i> , 2018, 28, 463-465.	2.1	5
2069	Human-Induced Pluripotent Stem Cell-Derived Neurons to Model and Gain Insights into Alzheimer's Disease Pathogenesis. , 2018, , 3-12.		0
2070	Use of Peptides for the Management of Alzheimer's Disease: Diagnosis and Inhibition. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 21.	1.7	79
2071	U1 snRNP Alteration and Neuronal Cell Cycle Reentry in Alzheimer Disease. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 75.	1.7	16
2072	Reconsideration of Amyloid Hypothesis and Tau Hypothesis in Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2018, 12, 25.	1.4	591
2073	Challenges for Alzheimer's Disease Therapy: Insights from Novel Mechanisms Beyond Memory Defects. <i>Frontiers in Neuroscience</i> , 2018, 12, 37.	1.4	132
2074	Microglia Gone Rogue: Impacts on Psychiatric Disorders across the Lifespan. <i>Frontiers in Molecular Neuroscience</i> , 2017, 10, 421.	1.4	151
2075	AMPA Receptor Trafficking in Natural and Pathological Aging. <i>Frontiers in Molecular Neuroscience</i> , 2017, 10, 446.	1.4	52
2076	Chronic ghrelin administration restores hippocampal long-term potentiation and ameliorates memory impairment in rat model of Alzheimer's disease. <i>Hippocampus</i> , 2018, 28, 724-734.	0.9	44
2077	Probing Intermolecular Interactions within the Amyloid A $\beta$ Trimer Using a Tethered Polymer Nanoarray. <i>Bioconjugate Chemistry</i> , 2018, 29, 2755-2762.	1.8	8
2078	What Happens with the Circuit in Alzheimer's Disease in Mice and Humans?. <i>Annual Review of Neuroscience</i> , 2018, 41, 277-297.	5.0	154
2079	Insights into the Molecular Mechanisms of Alzheimer's and Parkinson's Diseases with Molecular Simulations: Understanding the Roles of Artificial and Pathological Missense Mutations in Intrinsically Disordered Proteins Related to Pathology. <i>International Journal of Molecular Sciences</i> , 2018, 19, 336.	1.8	51
2080	Aptamers Selected for Recognizing Amyloid A $\beta$ -Protein: A Case for Cautious Optimism. <i>International Journal of Molecular Sciences</i> , 2018, 19, 668.	1.8	14
2081	Tau-Induced Pathology in Epilepsy and Dementia: Notions from Patients and Animal Models. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1092.	1.8	49
2082	Cellular Receptors of Amyloid A $\beta$ Oligomers (A $\beta$ O $_s$ ) in Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1884.	1.8	66
2083	Peptides as Potential Therapeutics for Alzheimer's Disease. <i>Molecules</i> , 2018, 23, 283.	1.7	45

#	ARTICLE	IF	CITATIONS
2084	Insights into Structure-Activity Relationships of 3-Arylhydrazonoindolin-2-One Derivatives for Their Multitarget Activity on $\beta$ -Amyloid Aggregation and Neurotoxicity. <i>Molecules</i> , 2018, 23, 1544.	1.7	22
2085	Dietary arachidonic acid: a Janus face actor in brain and Alzheimer's disease?. <i>OCL - Oilseeds and Fats, Crops and Lipids</i> , 2018, 25, D406.	0.6	4
2086	An in vitro paradigm to assess potential anti- $\beta$ antibodies for Alzheimer's disease. <i>Nature Communications</i> , 2018, 9, 2676.	5.8	50
2087	Age-Dependent Changes in the Sarkosyl-Insoluble Proteome of APPSWE/PS1 <sup>E9</sup> Transgenic Mice Implicate Dysfunctional Mitochondria in the Pathogenesis of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 1247-1259.	1.2	23
2088	Regulation of actin dynamics during structural plasticity of dendritic spines: Signaling messengers and actin-binding proteins. <i>Molecular and Cellular Neurosciences</i> , 2018, 91, 122-130.	1.0	126
2089	Identification of an acute functional cross-talk between amyloid- $\beta$ and glucocorticoid receptors at hippocampal excitatory synapses. <i>Neurobiology of Disease</i> , 2018, 118, 117-128.	2.1	8
2090	The spectrum of preclinical Alzheimer's disease pathology and its modulation by ApoE genotype. <i>Neurobiology of Aging</i> , 2018, 71, 72-80.	1.5	42
2091	The effect of amyloid- $\beta$ peptide on synaptic plasticity and memory is influenced by different isoforms, concentrations, and aggregation status. <i>Neurobiology of Aging</i> , 2018, 71, 51-60.	1.5	55
2092	Physiological $\beta$ Concentrations Produce a More Biomimetic Representation of the Alzheimer's Disease Phenotype in iPSC Derived Human Neurons. <i>ACS Chemical Neuroscience</i> , 2018, 9, 1693-1701.	1.7	12
2093	BACE1 elevation engendered by GGA3 deletion increases $\beta$ -amyloid pathology in association with APP elevation and decreased CHL1 processing in 5XFAD mice. <i>Molecular Neurodegeneration</i> , 2018, 13, 6.	4.4	24
2094	Impact of amyloid-beta changes on cognitive outcomes in Alzheimer's disease: analysis of clinical trials using a quantitative systems pharmacology model. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 14.	3.0	27
2095	Production and Use of Recombinant $\beta$ for Aggregation Studies. <i>Methods in Molecular Biology</i> , 2018, 1777, 307-320.	0.4	5
2096	Experimental and Computational Protocols for Studies of Cross-Seeding Amyloid Assemblies. <i>Methods in Molecular Biology</i> , 2018, 1777, 429-447.	0.4	8
2097	Binding of Cytotoxic $\beta$ 25-35 Peptide to the Dimyristoylphosphatidylcholine Lipid Bilayer. <i>Journal of Chemical Information and Modeling</i> , 2018, 58, 1053-1065.	2.5	28
2098	Excitatory Dendritic Mitochondrial Calcium Toxicity: Implications for Parkinson's and Other Neurodegenerative Diseases. <i>Frontiers in Neuroscience</i> , 2018, 12, 523.	1.4	55
2099	Recent Advances by In Silico and In Vitro Studies of Amyloid- $\beta$ 1-42 Fibril Depicted a S-Shape Conformation. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2415.	1.8	21
2100	Clusterin Is Required for $\beta$ -Amyloid Toxicity in Human iPSC-Derived Neurons. <i>Frontiers in Neuroscience</i> , 2018, 12, 504.	1.4	39
2101	Side-chain moieties from the N-terminal region of $\beta$ are involved in an oligomer-stabilizing network of interactions. <i>PLoS ONE</i> , 2018, 13, e0201761.	1.1	14

#	ARTICLE	IF	CITATIONS
2102	Enriched environment enhances $\beta$ -adrenergic signaling to prevent microglia inflammation by $\text{A}\beta$ . EMBO Molecular Medicine, 2018, 10, .	3.3	50
2103	Soluble $\text{A}\beta$ Oligomers Impair Dipolar Heterodendritic Plasticity by Activation of mGluR in the Hippocampal CA1 Region. Science, 2018, 6, 138-150.	1.9	14
2104	Postsynaptic p47phox regulates long-term depression in the hippocampus. Cell Discovery, 2018, 4, 44.	3.1	7
2105	Could a Common Mechanism of Protein Degradation Impairment Underlie Many Neurodegenerative Diseases?. Journal of Experimental Neuroscience, 2018, 12, 117906951879467.	2.3	24
2106	Go with the Flow—Microfluidics Approaches for Amyloid Research. Chemistry - an Asian Journal, 2018, 13, 3437-3447.	1.7	12
2107	Importance of GPCR-Mediated Microglial Activation in Alzheimer's Disease. Frontiers in Cellular Neuroscience, 2018, 12, 258.	1.8	31
2108	Inflammasome-derived cytokine IL18 suppresses amyloid-induced seizures in Alzheimer-prone mice. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 9002-9007.	3.3	41
2109	Role of Amyloid- $\beta$ and Tau Proteins in Alzheimer's Disease: Confuting the Amyloid Cascade. Journal of Alzheimer's Disease, 2018, 64, S611-S631.	1.2	102
2110	The Amyloid- $\beta$ Oligomer Hypothesis: Beginning of the Third Decade. Journal of Alzheimer's Disease, 2018, 64, S567-S610.	1.2	572
2111	Decreased retention of olfactory predator recognition in juvenile surgeon fish exposed to pesticide. Chemosphere, 2018, 208, 469-475.	4.2	8
2112	Heme and hemoglobin suppress amyloid $\beta$ -mediated inflammatory activation of mouse astrocytes. Journal of Biological Chemistry, 2018, 293, 11358-11373.	1.6	25
2113	Neurodegenerative Diseases as Protein Folding Disorders. , 2018, , 243-267.		0
2114	Impaired $\text{AMPA}$ signaling and cytoskeletal alterations induce early synaptic dysfunction in a mouse model of Alzheimer's disease. Aging Cell, 2018, 17, e12791.	3.0	58
2115	Drug-Bearing Supramolecular MMP Inhibitor Nanofibers for Inhibition of Metastasis and Growth of Liver Cancer. Advanced Science, 2018, 5, 1700867.	5.6	45
2116	Preparation of Pure Populations of Amyloid $\beta$ -Protein Oligomers of Defined Size. Methods in Molecular Biology, 2018, 1779, 3-12.	0.4	6
2117	Molecular Aspects of Ischemic Injury. , 2018, , 41-87.		1
2118	RNP Assembly Defects in Spinal Muscular Atrophy. Advances in Neurobiology, 2018, 20, 143-171.	1.3	18
2119	Clitoria ternatea L. root extract ameliorated the cognitive and hippocampal long-term potentiation deficits induced by chronic cerebral hypoperfusion in the rat. Journal of Ethnopharmacology, 2018, 224, 381-390.	2.0	27

#	ARTICLE	IF	CITATIONS
2120	Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Bapineuzumab: A Singleâ€‘Ascendingâ€‘Dose Study in Patients With Mild to Moderate Alzheimer Disease. <i>Clinical Pharmacology in Drug Development</i> , 2019, 8, 326-335.	0.8	9
2121	Arsenic Exposure Contributes to the Bioenergetic Damage in an Alzheimerâ€™s Disease Model. <i>ACS Chemical Neuroscience</i> , 2019, 10, 323-336.	1.7	39
2122	Fecal microbiota transplantation alleviated Alzheimerâ€™s disease-like pathogenesis in APP/PS1 transgenic mice. <i>Translational Psychiatry</i> , 2019, 9, 189.	2.4	287
2123	Targeting Synaptic Plasticity in Experimental Models of Alzheimerâ€™s Disease. <i>Frontiers in Pharmacology</i> , 2019, 10, 778.	1.6	66
2124	Modulation of synaptic plasticity by exercise. <i>International Review of Neurobiology</i> , 2019, 147, 295-322.	0.9	35
2125	A vicious cycle of $\beta$ amyloidâ€‘dependent neuronal hyperactivation. <i>Science</i> , 2019, 365, 559-565.	6.0	407
2126	Comparative Study on Hyaluronic Acid Binding to Murine SAA1.1 and SAA2.2. <i>ACS Omega</i> , 2019, 4, 13388-13399.	1.6	5
2127	Biopharmaceutical Monotargeting versus â€‘Universal Targetingâ€™ of Late-Onset Alzheimerâ€™s Disease Using Mixtures of Pleiotropic Natural Compounds. <i>Journal of Alzheimer's Disease Reports</i> , 2019, 3, 219-232.	1.2	1
2128	Evaluation of Hemisphere Lateralization with Bilateral Local Field Potential Recording in Secondary Motor Cortex of Mice. <i>Journal of Visualized Experiments</i> , 2019, , .	0.2	2
2129	Trapping and Characterization of Nontoxic $A\beta_{42}$ Aggregation Intermediates. <i>ACS Chemical Neuroscience</i> , 2019, 10, 3880-3887.	1.7	25
2130	Inhibition of Histone Methyltransferases EHMT1/2 Reverses Amyloid- $\beta$ -Induced Loss of AMPAR Currents in Human Stem Cell-Derived Cortical Neurons. <i>Journal of Alzheimer's Disease</i> , 2019, 70, 1175-1185.	1.2	14
2131	Alzheimer Disease Pathogenesis: Insights From Molecular and Cellular Biology Studies of Oligomeric $A\beta$ and Tau Species. <i>Frontiers in Neuroscience</i> , 2019, 13, 659.	1.4	198
2132	Inhibition of Polo-like kinase 2 ameliorates pathogenesis in Alzheimerâ€™s disease model mice. <i>PLoS ONE</i> , 2019, 14, e0219691.	1.1	14
2133	$A\beta_{40}$ (M1â€‘40) and Wild-Type $A\beta_{40}$ Self-Assemble into Oligomers with Distinct Quaternary Structures. <i>Molecules</i> , 2019, 24, 2242.	1.7	2
2134	A Rationally Designed Humanized Antibody Selective for Amyloid Beta Oligomers in Alzheimerâ€™s Disease. <i>Scientific Reports</i> , 2019, 9, 9870.	1.6	35
2135	The Role of Eicosanoids in Alzheimerâ€™s Disease. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 2560.	1.2	46
2136	Alzheimerâ€™s Disease as a Membrane Disorder: Spatial Cross-Talk Among Beta-Amyloid Peptides, Nicotinic Acetylcholine Receptors and Lipid Rafts. <i>Frontiers in Cellular Neuroscience</i> , 2019, 13, 309.	1.8	103
2137	Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease. <i>JAMA Neurology</i> , 2019, 76, 1219.	4.5	107

#	ARTICLE	IF	CITATIONS
2138	Doxycycline for Alzheimer's Disease: Fighting $\beta$ -Amyloid Oligomers and Neuroinflammation. <i>Frontiers in Pharmacology</i> , 2019, 10, 738.	1.6	58
2139	Soluble aggregates present in cerebrospinal fluid change in size and mechanism of toxicity during Alzheimer's disease progression. <i>Acta Neuropathologica Communications</i> , 2019, 7, 120.	2.4	64
2140	The molecular lifecycle of amyloid $\beta$ — Mechanism of assembly, mesoscopic organisation, polymorphism, suprastructures, and biological consequences. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2019, 1867, 140257.	1.1	35
2141	Acute restraint stress reverses impaired LTP in the hippocampal CA1 region in mouse models of Alzheimer's disease. <i>Scientific Reports</i> , 2019, 9, 10955.	1.6	14
2142	A soluble truncated tau species related to cognitive dysfunction and caspase-2 is elevated in the brain of Huntington's disease patients. <i>Acta Neuropathologica Communications</i> , 2019, 7, 111.	2.4	29
2143	Mechanistic Insights into the Early Events in the Aggregation of Immunoglobulin Light Chains. <i>Biochemistry</i> , 2019, 58, 3155-3168.	1.2	20
2144	Classic Prescription, Kai-Xin-San, Ameliorates Alzheimer's Disease as an Effective Multitarget Treatment: From Neurotransmitter to Protein Signaling Pathway. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-14.	1.9	15
2145	Effects of the Pentapeptide P33 on Memory and Synaptic Plasticity in APP/PS1 Transgenic Mice: A Novel Mechanism Presenting the Protein Fe65 as a Target. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3050.	1.8	10
2146	Effect of ceftriaxone on paired-pulse response and long-term potentiation of hippocampal dentate gyrus neurons in rats with Alzheimer-like disease. <i>Life Sciences</i> , 2019, 238, 116969.	2.0	20
2147	Bexarotene therapy ameliorates behavioral deficits and induces functional and molecular changes in very-old Triple Transgenic Mice model of Alzheimer's disease. <i>PLoS ONE</i> , 2019, 14, e0223578.	1.1	22
2148	Biological, Diagnostic and Therapeutic Advances in Alzheimer's Disease. , 2019, , .		6
2149	Isoflurane mediated neuropathological and cognitive impairments in the triple transgenic Alzheimer's mouse model are associated with hippocampal synaptic deficits in an age-dependent manner. <i>PLoS ONE</i> , 2019, 14, e0223509.	1.1	7
2150	Exploration of the optimized parameters for bioactive prodigiosin mass production and its biomedical applications in vitro as well as in silico. <i>Biocatalysis and Agricultural Biotechnology</i> , 2019, 22, 101385.	1.5	26
2151	Temporal dynamics of learning-promoted synaptic diversity in CA1 pyramidal neurons. <i>FASEB Journal</i> , 2019, 33, 14382-14393.	0.2	7
2152	Copper, dityrosine cross-links and amyloid- $\beta$ aggregation. <i>Journal of Biological Inorganic Chemistry</i> , 2019, 24, 1217-1229.	1.1	19
2153	Identifying Phlorofucofuroeckol-A as a Dual Inhibitor of Amyloid- $\beta$ 25-35 Self-Aggregation and Insulin Glycation: Elucidation of the Molecular Mechanism of Action. <i>Marine Drugs</i> , 2019, 17, 600.	2.2	27
2154	Long-term cognitive impairment after acute respiratory distress syndrome: a review of clinical impact and pathophysiological mechanisms. <i>Critical Care</i> , 2019, 23, 352.	2.5	235
2155	Intra- and extracellular $\beta$ -amyloid overexpression via adeno-associated virus-mediated gene transfer impairs memory and synaptic plasticity in the hippocampus. <i>Scientific Reports</i> , 2019, 9, 15936.	1.6	12

#	ARTICLE	IF	CITATIONS
2156	The Tripeptide RER Mimics Secreted Amyloid Precursor Protein-Alpha in Upregulating LTP. <i>Frontiers in Cellular Neuroscience</i> , 2019, 13, 459.	1.8	2
2157	Association between increased levels of amyloid- $\beta$ oligomers in plasma and episodic memory loss in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 89.	3.0	41
2158	A $\beta$ Seeding as a Tool to Study Cerebral Amyloidosis and Associated Pathology. <i>Frontiers in Molecular Neuroscience</i> , 2019, 12, 233.	1.4	32
2159	Molecular Mechanism and Kinetics of Amyloid- $\beta$ Aggregate Formation: A Simulation Study. <i>ACS Chemical Neuroscience</i> , 2019, 10, 4643-4658.	1.7	13
2160	Disease-directed engineering for physiology-driven treatment interventions in neurological disorders. <i>APL Bioengineering</i> , 2019, 3, 040901.	3.3	14
2161	Molecular Lysine Tweezers Counteract Aberrant Protein Aggregation. <i>Frontiers in Chemistry</i> , 2019, 7, 657.	1.8	17
2162	Gene expression modulation by the linker of nucleoskeleton and cytoskeleton complex contributes to proteostasis. <i>Aging Cell</i> , 2019, 18, e13047.	3.0	8
2163	A Brief Ischemic Postconditioning Protects Against Amyloid- $\beta$ Peptide Neurotoxicity by Downregulating MLK3-MKK3/6-P38MAPK Signal in Rat Hippocampus. <i>Journal of Alzheimer's Disease</i> , 2019, 71, 671-684.	1.2	7
2164	Unravelling Alzheimer's Disease: It's Not the Whole Story, but A $\beta$ Still Matters. <i>FASEB Journal</i> , 2019, 33, 9701-9705.	0.2	5
2165	Multifunctional multi-shank neural probe for investigating and modulating long-range neural circuits in vivo. <i>Nature Communications</i> , 2019, 10, 3777.	5.8	101
2166	Intracerebroventricular microinjection of kaempferol on memory retention of passive avoidance learning in rats: involvement of cholinergic mechanism(s). <i>International Journal of Neuroscience</i> , 2019, 129, 1203-1212.	0.8	21
2167	Preparation and characterization of a highly soluble A $\beta$ 1-42 peptide variant. <i>Protein Expression and Purification</i> , 2019, 164, 105480.	0.6	5
2168	High-Fat Diet Increases Amylin Accumulation in the Hippocampus and Accelerates Brain Aging in hIAPP Transgenic Mice. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 225.	1.7	15
2169	Amyloid $\beta$ -Induced Upregulation of Nav1.6 Underlies Neuronal Hyperactivity in Tg2576 Alzheimer's Disease Mouse Model. <i>Scientific Reports</i> , 2019, 9, 13592.	1.6	49
2170	Distinct Primary Nucleation of Polymorphic A $\beta$ Dimers Yields to Distinguished Fibrillation Pathways. <i>ACS Chemical Neuroscience</i> , 2019, 10, 4407-4413.	1.7	13
2171	The Link of the Prion Protein with Ca <sup>2+</sup> Metabolism and ROS Production, and the Possible Implication in A $\beta$ Toxicity. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4640.	1.8	12
2172	The Role of Protein Misfolding and Tau Oligomers (TauOs) in Alzheimer's Disease (AD). <i>International Journal of Molecular Sciences</i> , 2019, 20, 4661.	1.8	48
2173	Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. <i>Cell</i> , 2019, 179, 312-339.	13.5	1,675



#	ARTICLE	IF	CITATIONS
2174	Amyloid- $\beta^2$ and Synaptic Vesicle Dynamics: A Cacophonous Orchestra. <i>Journal of Alzheimer's Disease</i> , 2019, 72, 1-14.	1.2	24
2175	Functions of adiponectin signaling in regulating neural plasticity and its application as the therapeutic target to neurological and psychiatric diseases. <i>Reviews in the Neurosciences</i> , 2019, 30, 485-495.	1.4	6
2176	SNAP-25 in Serum Is Carried by Exosomes of Neuronal Origin and Is a Potential Biomarker of Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2019, 56, 5792-5798.	1.9	78
2177	Molecular Modulation of Human $\alpha 7$ Nicotinic Receptor by Amyloid- $\beta^2$ Peptides. <i>Frontiers in Cellular Neuroscience</i> , 2019, 13, 37.	1.8	39
2178	Prenatal noise stress aggravates cognitive decline and the onset and progression of beta amyloid pathology in a mouse model of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2019, 77, 66-86.	1.5	36
2179	Vibrational Approach to the Dynamics and Structure of Protein Amyloids. <i>Molecules</i> , 2019, 24, 186.	1.7	46
2180	Chronic cerebral hypoperfusion-induced memory impairment and hippocampal long-term potentiation deficits are improved by cholinergic stimulation in rats. <i>Pharmacological Reports</i> , 2019, 71, 443-448.	1.5	30
2181	Synthesis and biochemical characterization of quasi-stable trimer models of full-length amyloid $\beta^{240}$ with a toxic conformation. <i>Chemical Communications</i> , 2019, 55, 182-185.	2.2	17
2182	Infection-induced endothelial amyloids impair memory. <i>FASEB Journal</i> , 2019, 33, 10300-10314.	0.2	20
2183	Effects of MDMA on neuroplasticity, amyloid burden and phospho-tau expression in APP <sup>swe</sup> /PS1 <sup>dE9</sup> mice. <i>Journal of Psychopharmacology</i> , 2019, 33, 1170-1182.	2.0	7
2184	Amyloid Beta-Related Alterations to Glutamate Signaling Dynamics During Alzheimer's Disease Progression. <i>ASN Neuro</i> , 2019, 11, 175909141985554.	1.5	77
2185	Clinical utility of serum hepcidin and iron profile measurements in Alzheimer's disease. <i>Journal of the Neurological Sciences</i> , 2019, 403, 85-91.	0.3	18
2186	A BODIPY biosensor to detect and drive self-assembly of diphenylalanine. <i>Chemical Communications</i> , 2019, 55, 8564-8566.	2.2	9
2187	Inhibition of the Self-Assembly of $A\beta^2$ and of Tau by Polyphenols: Mechanistic Studies. <i>Molecules</i> , 2019, 24, 2316.	1.7	48
2188	Brains of rhesus monkeys display $A\beta^2$ deposits and glial pathology while lacking $A\beta^2$ dimers and other Alzheimer's pathologies. <i>Aging Cell</i> , 2019, 18, e12978.	3.0	17
2189	Oral Immunization with Soybean Storage Protein Containing Amyloid- $\beta^2$ 4 $\times$ 10 Prevents Spatial Learning Decline. <i>Journal of Alzheimer's Disease</i> , 2019, 70, 487-503.	1.2	4
2190	Adiponectin suppresses amyloid- $\beta^2$ oligomer ( $A\beta^2O$ )-induced inflammatory response of microglia via AdipoR1-AMPK-NF- $\kappa B$ signaling pathway. <i>Journal of Neuroinflammation</i> , 2019, 16, 110.	3.1	78
2191	Binary Structure of Amyloid Beta Oligomers Revealed by Dual Recognition Mapping. <i>Analytical Chemistry</i> , 2019, 91, 8422-8428.	3.2	9



#	ARTICLE	IF	CITATIONS
2192	Insulin Modulates Excitatory Synaptic Transmission and Synaptic Plasticity in the Mouse Hippocampus. <i>Neuroscience</i> , 2019, 411, 237-254.	1.1	32
2193	Extracellular Zn <sup>2+</sup> -independently attenuated LTP by human amyloid $\beta$ <sup>1-40</sup> and rat amyloid $\beta$ <sup>21-42</sup> . <i>Biochemical and Biophysical Research Communications</i> , 2019, 514, 888-892.	1.0	9
2194	Gels of Amyloid Fibers. <i>Biomolecules</i> , 2019, 9, 210.	1.8	9
2195	Target engagement in an alzheimer trial: Crenezumab lowers amyloid $\beta$ <sup>2</sup> oligomers in cerebrospinal fluid. <i>Annals of Neurology</i> , 2019, 86, 215-224.	2.8	70
2196	Force clamp approach for characterization of nano-assembly in amyloid beta 42 dimer. <i>Nanoscale</i> , 2019, 11, 12259-12265.	2.8	13
2197	Pharmacological Potential of Cilostazol for Alzheimer's Disease. <i>Frontiers in Pharmacology</i> , 2019, 10, 559.	1.6	20
2198	miR-132 regulates the expression of synaptic proteins in APP/PS1 transgenic mice through C1q. <i>European Journal of Histochemistry</i> , 2019, 63, .	0.6	29
2199	Molecular dynamics simulations reveal the mechanism of graphene oxide nanosheet inhibition of A $\beta$ <sup>1-42</sup> peptide aggregation. <i>Physical Chemistry Chemical Physics</i> , 2019, 21, 10981-10991.	1.3	48
2200	Epigenetic Modifications in Alzheimer's Neuropathology and Therapeutics. <i>Frontiers in Neuroscience</i> , 2019, 13, 476.	1.4	50
2201	De novo aggregation of Alzheimer's A $\beta$ <sup>25-35</sup> peptides in a lipid bilayer. <i>Scientific Reports</i> , 2019, 9, 7161.	1.6	21
2202	Binding between Prion Protein and A $\beta$ <sup>2</sup> Oligomers Contributes to the Pathogenesis of Alzheimer's Disease. <i>Virologica Sinica</i> , 2019, 34, 475-488.	1.2	10
2203	Exploring Amyloid- $\beta$ <sup>2</sup> Dimer Structure Using Molecular Dynamics Simulations. <i>Journal of Physical Chemistry A</i> , 2019, 123, 4658-4670.	1.1	13
2204	Label-free distribution of anti-amyloid D $\beta$ AIP in <i>Drosophila melanogaster</i> : prevention of A $\beta$ <sup>242</sup> -induced toxicity without side effects in transgenic flies. <i>Journal of Neurochemistry</i> , 2019, 150, 74-87.	2.1	7
2205	Steady, Symmetric, and Reversible Growth and Dissolution of Individual Amyloid- $\beta$ <sup>2</sup> Fibrils. <i>ACS Chemical Neuroscience</i> , 2019, 10, 2967-2976.	1.7	16
2206	Simultaneous Live Imaging of Multiple Endogenous Proteins Reveals a Mechanism for Alzheimer's-Related Plasticity Impairment. <i>Cell Reports</i> , 2019, 27, 658-665.e4.	2.9	39
2207	Association of Cortical $\beta$ <sup>2</sup> -Amyloid Protein in the Absence of Insoluble Deposits With Alzheimer Disease. <i>JAMA Neurology</i> , 2019, 76, 818.	4.5	25
2208	Use of a Stereochemical Strategy To Probe the Mechanism of Phenol-Soluble Modulin $\beta$ <sup>3</sup> Toxicity. <i>Journal of the American Chemical Society</i> , 2019, 141, 7660-7664.	6.6	32
2209	Conformational Change of Amyloid- $\beta$ <sup>2</sup> 40 in Association with Binding to GM1-Glycan Cluster. <i>Scientific Reports</i> , 2019, 9, 6853.	1.6	33

#	ARTICLE	IF	CITATIONS
2210	Identification of neurotoxic cross-linked amyloid- $\beta^2$ dimers in the Alzheimer's brain. <i>Brain</i> , 2019, 142, 1441-1457.	3.7	74
2211	The structure of amyloid- $\beta^2$ dimers in Alzheimer's disease brain: a step forward for oligomers. <i>Brain</i> , 2019, 142, 1168-1169.	3.7	3
2212	Excitatory-inhibitory imbalance in Alzheimer's disease and therapeutic significance. <i>Neurobiology of Disease</i> , 2019, 127, 605-615.	2.1	79
2213	Neuroimaging and Neurolaw: Drawing the Future of Aging. <i>Frontiers in Endocrinology</i> , 2019, 10, 217.	1.5	5
2214	Can magnesium reduce central neurodegeneration in Alzheimer's disease? Basic evidences and research needs. <i>Neurochemistry International</i> , 2019, 126, 195-202.	1.9	24
2215	Molecular chaperones biochemistry and role in neurodegenerative diseases. <i>International Journal of Biological Macromolecules</i> , 2019, 131, 396-411.	3.6	18
2216	ApoE-fragment/ $A\beta^2$ heteromers in the brain of patients with Alzheimer's disease. <i>Scientific Reports</i> , 2019, 9, 3989.	1.6	24
2217	Emergence of synaptic and cognitive impairment in a mature-onset APP mouse model of Alzheimer's disease. <i>Acta Neuropathologica Communications</i> , 2019, 7, 25.	2.4	28
2218	Dual effect of chitosan-based nanoparticles on the inhibition of $\beta^2$ -amyloid peptide aggregation and disintegration of the preformed fibrils. <i>Journal of Materials Chemistry B</i> , 2019, 7, 3362-3373.	2.9	30
2219	Amyloid $\beta^2$ oligomers suppress excitatory transmitter release via presynaptic depletion of phosphatidylinositol-4,5-bisphosphate. <i>Nature Communications</i> , 2019, 10, 1193.	5.8	92
2220	BACE1-AS prevents BACE1 mRNA degradation through the sequestration of BACE1-targeting miRNAs. <i>Journal of Chemical Neuroanatomy</i> , 2019, 98, 87-96.	1.0	50
2221	Role of hydrophobic residues for the gaseous formation of helical motifs. <i>Chemical Communications</i> , 2019, 55, 5147-5150.	2.2	3
2222	A Novel PSEN1 M139L Mutation Found in a Chinese Pedigree with Early-Onset Alzheimer's Disease Increases $A\beta^{42}/A\beta^{40}$ ratio. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 199-212.	1.2	11
2223	Astrocyte Heterogeneity: Impact to Brain Aging and Disease. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 59.	1.7	256
2224	Calcitonin native prefibrillar oligomers but not monomers induce membrane damage that triggers NMDA-mediated $Ca^{2+}$ -influx, LTP impairment and neurotoxicity. <i>Scientific Reports</i> , 2019, 9, 5144.	1.6	9
2225	Synthetic standard aided quantification and structural characterization of amyloid-beta glycopeptides enriched from cerebrospinal fluid of Alzheimer's disease patients. <i>Scientific Reports</i> , 2019, 9, 5522.	1.6	20
2226	Different soluble aggregates of $A\beta^{42}$ can give rise to cellular toxicity through different mechanisms. <i>Nature Communications</i> , 2019, 10, 1541.	5.8	140
2227	Cerebrospinal fluids from Alzheimer's disease patients exhibit neurotoxic effects on neuronal cell cultures. <i>European Journal of Neuroscience</i> , 2019, 50, 1994-2006.	1.2	3

#	ARTICLE	IF	CITATIONS
2228	An automated microliter-scale high-throughput screening system (MSHTS) for real-time monitoring of protein aggregation using quantum-dot nanoprobe. <i>Scientific Reports</i> , 2019, 9, 2587.	1.6	17
2229	Learning Promotes Subfield-Specific Synaptic Diversity in Hippocampal CA1 Neurons. <i>Cerebral Cortex</i> , 2019, 29, 2183-2195.	1.6	13
2230	Impaired Glucose Tolerance and Reduced Plasma Insulin Precede Decreased AKT Phosphorylation and GLUT3 Translocation in the Hippocampus of Old 3xTg-AD Mice. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 809-837.	1.2	30
2231	Intrinsic origin of amyloid aggregation: Behavior of histidine ( $\beta$ ) and ( $\alpha$ ) tautomer homodimers of $A\beta^{25-35}$ (1-40). <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2019, 1863, 795-801.	1.1	27
2232	Serotonin type 6 receptor antagonist attenuates the impairment of long-term potentiation and memory induced by Abeta. <i>Behavioural Brain Research</i> , 2019, 364, 205-212.	1.2	16
2233	Fully Automated Synthesis and Evaluation of [ <sup>18</sup> F]BPAM121: Potential of an AMPA Receptor Positive Allosteric Modulator as PET Radiotracer. <i>ChemMedChem</i> , 2019, 14, 788-795.	1.6	4
2234	The Amazon rain forest plant <i>Uncaria tomentosa</i> (cat's claw) and its specific proanthocyanidin constituents are potent inhibitors and reducers of both brain plaques and tangles. <i>Scientific Reports</i> , 2019, 9, 561.	1.6	42
2235	Glial Contribution to Excitatory and Inhibitory Synapse Loss in Neurodegeneration. <i>Frontiers in Cellular Neuroscience</i> , 2019, 13, 63.	1.8	99
2236	Roles of microRNAs in Parkinson's and other neurodegenerative diseases. , 2019, , 209-232.		3
2237	The amyloid cascade and Alzheimer's disease therapeutics: theory versus observation. <i>Laboratory Investigation</i> , 2019, 99, 958-970.	1.7	82
2238	Alzheimer's disease. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2019, 167, 231-255.	1.0	415
2239	Synaptic Elimination in Neurological Disorders. <i>Current Neuropharmacology</i> , 2019, 17, 1071-1095.	1.4	63
2240	Amyloid Beta Oligomers Target to Extracellular and Intracellular Neuronal Synaptic Proteins in Alzheimer's Disease. <i>Frontiers in Neurology</i> , 2019, 10, 1140.	1.1	46
2241	c-Abl Deficiency Provides Synaptic Resiliency Against $A\beta^{25-35}$ -Oligomers. <i>Frontiers in Cellular Neuroscience</i> , 2019, 13, 526.	1.8	10
2242	Do Cholesterol and Sphingomyelin Change the Mechanism of $A\beta^{25-35}$ Peptide Binding to Zwitterionic Bilayer?. <i>Journal of Chemical Information and Modeling</i> , 2019, 59, 5207-5217.	2.5	7
2243	Down syndrome. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2019, 167, 321-336.	1.0	27
2244	Optogenetic gamma stimulation rescues memory impairments in an Alzheimer's disease mouse model. <i>Nature Communications</i> , 2019, 10, 5322.	5.8	152
2245	New Alzheimer's disease model mouse specialized for analyzing the function and toxicity of intraneuronal Amyloid $A\beta^{25-35}$ oligomers. <i>Scientific Reports</i> , 2019, 9, 17368.	1.6	13

#	ARTICLE	IF	CITATIONS
2246	Synapsin 1 promotes A $\beta$ generation via BACE1 modulation. PLoS ONE, 2019, 14, e0226368.	1.1	10
2247	Neurophysiological Markers of Alzheimer's Disease: Quantitative EEG Approach. Neurology and Therapy, 2019, 8, 37-55.	1.4	60
2248	Characterization of the selective in vitro and in vivo binding properties of crenezumab to oligomeric A $\beta$ . Alzheimer's Research and Therapy, 2019, 11, 97.	3.0	22
2249	Fundamentals of cross-seeding of amyloid proteins: an introduction. Journal of Materials Chemistry B, 2019, 7, 7267-7282.	2.9	87
2250	JBPOS0101 attenuates amyloid- $\beta$ accumulation and memory loss in a mouse model of Alzheimer's disease. NeuroReport, 2019, 30, 741-747.	0.6	2
2251	The Role of Leptin and Adiponectin in Obesity-Associated Cognitive Decline and Alzheimer's Disease. Frontiers in Neuroscience, 2018, 12, 1027.	1.4	136
2252	Effects of a Hydrophilic/Hydrophobic Interface on Amyloid- $\beta$ Peptides Studied by Molecular Dynamics Simulations and NMR Experiments. Journal of Physical Chemistry B, 2019, 123, 160-169.	1.2	36
2253	Emerging roles of long non-coding RNAs in the pathogenesis of Alzheimer's disease. Ageing Research Reviews, 2019, 50, 19-26.	5.0	45
2254	Quantitative proteomics reveals distinct composition of amyloid plaques in Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 429-440.	0.4	69
2255	Norepinephrine Inhibits Alzheimer's Amyloid- $\beta$ Peptide Aggregation and Destabilizes Amyloid- $\beta$ Protofibrils: A Molecular Dynamics Simulation Study. ACS Chemical Neuroscience, 2019, 10, 1585-1594.	1.7	83
2256	Kalirin-7 prevents dendritic spine dysgenesis induced by amyloid beta-derived oligomers. European Journal of Neuroscience, 2019, 49, 1091-1101.	1.2	10
2257	Physical and toxicological profiles of human IAPP amyloids and plaques. Science Bulletin, 2019, 64, 26-35.	4.3	24
2258	Amyloid beta soluble forms and plasminogen activation system in Alzheimer's disease: Consequences on extracellular maturation of brain-derived neurotrophic factor and therapeutic implications. CNS Neuroscience and Therapeutics, 2019, 25, 303-313.	1.9	40
2259	Discovery of Neuroregenerative Peptoid from Amphibian Neuropeptide That Inhibits Amyloid- $\beta$ Toxicity and Crosses Blood-Brain Barrier. ACS Chemical Neuroscience, 2019, 10, 1355-1368.	1.7	15
2260	Susceptibility to A $\beta$ and TBOA of LTD and Extrasynaptic NMDAR-Dependent Tonic Current in the Aged Rat Hippocampus. Neurochemical Research, 2019, 44, 692-702.	1.6	4
2261	Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer's disease. Alzheimer's Research and Therapy, 2019, 11, 2.	3.0	19
2262	Photobiomodulation preconditioning prevents cognitive impairment in a neonatal rat model of hypoxia-ischemia. Journal of Biophotonics, 2019, 12, e201800359.	1.1	32
2263	Activation of mGluR1 Mediates C1q-Dependent Microglial Phagocytosis of Glutamatergic Synapses in Alzheimer's Rodent Models. Molecular Neurobiology, 2019, 56, 5568-5585.	1.9	53

#	ARTICLE	IF	CITATIONS
2264	When safeguarding goes wrong: Impact of oxidative stress on protein homeostasis in health and neurodegenerative disorders. <i>Advances in Protein Chemistry and Structural Biology</i> , 2019, 114, 221-264.	1.0	13
2265	Combined treatment with the phenolics (âˆ“)epigallocatechin-3-gallate and ferulic acid improves cognition and reduces Alzheimer-like pathology in mice. <i>Journal of Biological Chemistry</i> , 2019, 294, 2714-5444.	1.6	78
2266	Activity-Induced Amyloid-Î² Oligomers Drive Compensatory Synaptic Rearrangements in Brain Circuits Controlling Memory of Presymptomatic Alzheimer's Disease Mice. <i>Biological Psychiatry</i> , 2019, 86, 185-195.	0.7	15
2267	Candidate-based screening via gene modulation in human neurons and astrocytes implicates <i>FERMT2</i> in AÎ² and TAU proteostasis. <i>Human Molecular Genetics</i> , 2019, 28, 718-735.	1.4	33
2268	Excitation-Energy-Dependent Molecular Beacon Detects Early Stage Neurotoxic AÎ² Aggregates in the Presence of Cortical Neurons. <i>ACS Chemical Neuroscience</i> , 2019, 10, 1240-1250.	1.7	8
2269	Alzheimer's Disease Risk Factor Pyk2 Mediates Amyloid-Î²-Induced Synaptic Dysfunction and Loss. <i>Journal of Neuroscience</i> , 2019, 39, 758-772.	1.7	61
2270	Alzheimer's Disease and Dementia. , 2019, , 25-82.		2
2271	Functions and dysfunctions of nitric oxide in brain. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 1949-1967.	1.8	197
2272	Fucosterol exerts protection against amyloid Î²-induced neurotoxicity, reduces intracellular levels of amyloid Î² and enhances the mRNA expression of neuroglobin in amyloid Î²-induced SH-SY5Y cells. <i>International Journal of Biological Macromolecules</i> , 2019, 121, 207-213.	3.6	28
2273	Regulation of Neurotransmitter Release by Amyloid Precursor Protein Through Synapsin Phosphorylation. <i>Neurochemical Research</i> , 2019, 44, 683-691.	1.6	13
2274	Leptin Regulation of Synaptic Function at Hippocampal TA-CA1 and SC-CA1 Synapses: Implications for Health and Disease. <i>Neurochemical Research</i> , 2019, 44, 650-660.	1.6	32
2275	Chronic Amyloid Î² Oligomer Infusion Evokes Sustained Inflammation and Microglial Changes in the Rat Hippocampus via NLRP3. <i>Neuroscience</i> , 2019, 405, 35-46.	1.1	26
2276	Coordination of AMPA receptor trafficking by Rab GTPases. <i>Small GTPases</i> , 2019, 10, 419-432.	0.7	28
2277	Age-related shift in LTD is dependent on neuronal adenosine A2A receptors interplay with mGluR5 and NMDA receptors. <i>Molecular Psychiatry</i> , 2020, 25, 1876-1900.	4.1	129
2278	What electrophysiology tells us about Alzheimer's disease: a window into the synchronization and connectivity of brain neurons. <i>Neurobiology of Aging</i> , 2020, 85, 58-73.	1.5	150
2279	New diagnostic method for Alzheimer's disease based on the toxic conformation theory of amyloid Î². <i>Bioscience, Biotechnology and Biochemistry</i> , 2020, 84, 1-16.	0.6	32
2280	Adrenergic Receptor Complexes with the L-Type Ca <sup>2+</sup> Channel Ca <sub>v</sub> 1.2 and AMPA-Type Glutamate Receptors: Paradigms for Pharmacological Targeting of Protein Interactions. <i>Annual Review of Pharmacology and Toxicology</i> , 2020, 60, 155-174.	4.2	13
2281	Icariside II inhibits lipopolysaccharide-induced inflammation and amyloid production in rat astrocytes by regulating IKK/Î²B/NF-Î²B/BACE1 signaling pathway. <i>Acta Pharmacologica Sinica</i> , 2020, 41, 154-162.	2.8	37

#	ARTICLE	IF	CITATIONS
2282	Intraventricular murine A $\beta$ 2 infusion elicits hippocampal inflammation and disrupts the consolidation, but not retrieval, of conditioned fear in C57BL6/J mice. <i>Behavioural Brain Research</i> , 2020, 378, 112303.	1.2	3
2283	Life-Course Contribution of Prenatal Stress in Regulating the Neural Modulation Network Underlying the Prepulse Inhibition of the Acoustic Startle Reflex in Male Alzheimer's Disease Mice. <i>Cerebral Cortex</i> , 2020, 30, 311-325.	1.6	9
2284	Mathematical Models to Shed Light on Amyloid-Beta and Tau Protein Dependent Pathologies in Alzheimer's Disease. <i>Neuroscience</i> , 2020, 424, 45-57.	1.1	10
2285	Proposal of therapeutic curcumin derivatives for Alzheimer's disease based on ab initio molecular simulations. <i>Chemical Physics Letters</i> , 2020, 738, 136883.	1.2	9
2286	Neuroprotective effect of PPAR alpha and gamma agonists in a mouse model of amyloidogenesis through modulation of the Wnt/beta catenin pathway via targeting alpha- and beta-secretases. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020, 97, 109793.	2.5	31
2287	Amyloid model core peptides: Effects of hydrophobes and disulfides. <i>Protein Science</i> , 2020, 29, 527-541.	3.1	5
2288	Telmisartan ameliorates A $\beta$ 2 oligomer-induced inflammation via PPAR $\beta$ /PTEN pathway in BV2 microglial cells. <i>Biochemical Pharmacology</i> , 2020, 171, 113674.	2.0	27
2289	G protein-coupled receptors in neurodegenerative diseases. , 2020, , 335-365.		0
2290	Modulation of the MAPKs pathways affects A $\beta$ 2-induced cognitive deficits in Alzheimer's disease via activation of 7nAChR. <i>Neurobiology of Learning and Memory</i> , 2020, 168, 107154.	1.0	15
2291	Modulatory Effects of Ginkgo biloba Against Amyloid Aggregation Through Induction of Heat Shock Proteins in Aluminium Induced Neurotoxicity. <i>Neurochemical Research</i> , 2020, 45, 465-490.	1.6	19
2292	A high throughput drug screening paradigm using transgenic <i>Caenorhabditis elegans</i> model of Alzheimer's disease. <i>Translational Medicine of Aging</i> , 2020, 4, 11-21.	0.6	6
2293	PrP is a central player in toxicity mediated by soluble aggregates of neurodegeneration-causing proteins. <i>Acta Neuropathologica</i> , 2020, 139, 503-526.	3.9	110
2294	Effects of vitamin D in an animal model of Alzheimer's disease: behavioral assessment with biochemical investigation of Hippocampus and serum. <i>Metabolic Brain Disease</i> , 2020, 35, 263-274.	1.4	21
2295	Neural stem cell therapy for neurovascular injury in Alzheimer's disease. <i>Experimental Neurology</i> , 2020, 324, 113112.	2.0	60
2296	Polysaccharides from <i>Lycium barbarum</i> ameliorate amyloid pathology and cognitive functions in APP/PS1 transgenic mice. <i>International Journal of Biological Macromolecules</i> , 2020, 144, 1004-1012.	3.6	35
2297	Stabilization Mechanism for a Nonfibrillar Amyloid $\beta$ 2 Oligomer Based on Formation of a Hydrophobic Core Determined by Dissipative Particle Dynamics. <i>ACS Chemical Neuroscience</i> , 2020, 11, 385-394.	1.7	15
2298	PPAR $\delta$ serves as a new receptor of aspirin for neuroprotection. <i>Journal of Neuroscience Research</i> , 2020, 98, 626-631.	1.3	17
2299	Cell and Tissue Destruction in Selected Disorders. , 2020, , 249-287.		0



#	ARTICLE	IF	CITATIONS
2300	NMR-based site-resolved profiling of $\beta$ -amyloid misfolding reveals structural transitions from pathologically relevant spherical oligomer to fibril. <i>Journal of Biological Chemistry</i> , 2020, 295, 458-467.	1.6	21
2301	Peripherally derived angiotensin converting enzyme-enhanced macrophages alleviate Alzheimer-related disease. <i>Brain</i> , 2020, 143, 336-358.	3.7	52
2302	The Protective Effect of Exercise in Neurodegenerative Diseases: The Potential Role of Extracellular Vesicles. <i>Cells</i> , 2020, 9, 2182.	1.8	31
2303	Tanshinone IIA attenuates neuroinflammation via inhibiting RAGE/NF- $\kappa$ B signaling pathway in vivo and in vitro. <i>Journal of Neuroinflammation</i> , 2020, 17, 302.	3.1	75
2304	One or more $\beta$ -amyloid(s)? New insights into the prion-like nature of Alzheimer's disease. <i>Progress in Molecular Biology and Translational Science</i> , 2020, 175, 213-237.	0.9	1
2305	SPECT imaging of distribution and retention of a brain-penetrating bispecific amyloid- $\beta$ antibody in a mouse model of Alzheimer's disease. <i>Translational Neurodegeneration</i> , 2020, 9, 37.	3.6	32
2306	Research on Cognition Disorders. , 2020, , .		0
2307	Zinc enhances carnosine inhibitory effect against structural and functional age-related protein alterations in an albumin glycoxidation model. <i>BioMetals</i> , 2020, 33, 353-364.	1.8	4
2308	$\beta$ oligomer induced cognitive impairment and evaluation of ACU193-based MRI in rabbit. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12087.	1.8	4
2309	Parallels between retinal and brain pathology and response to immunotherapy in old, late-stage Alzheimer's disease mouse models. <i>Aging Cell</i> , 2020, 19, e13246.	3.0	32
2310	Bicine promotes rapid formation of $\beta$ -sheet-rich amyloid- $\beta$ fibrils. <i>PLoS ONE</i> , 2020, 15, e0240608.	1.1	2
2311	LTP-like plasticity is impaired in amyloid-positive amnesic MCI but independent of PET-amyloid burden. <i>Neurobiology of Aging</i> , 2020, 96, 109-116.	1.5	14
2312	The amyloid cascade hypothesis and Alzheimer's disease: A mathematical model. <i>European Journal of Applied Mathematics</i> , 2021, 32, 749-768.	1.4	10
2313	Phosphorylation Promotes $\beta$ 25-35 Peptide Aggregation within the DMPC Bilayer. <i>ACS Chemical Neuroscience</i> , 2020, 11, 3430-3441.	1.7	8
2314	Acid-responsive fibrillation and urease-assisted defibrillation of phenylalanine: a transient supramolecular hydrogel. <i>Soft Matter</i> , 2020, 16, 10115-10121.	1.2	19
2315	Caspase Activation and Caspase-Mediated Cleavage of APP Is Associated with Amyloid $\beta$ -Protein-Induced Synapse Loss in Alzheimer's Disease. <i>Cell Reports</i> , 2020, 31, 107839.	2.9	45
2316	Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2020, 15, 40.	4.4	438
2317	Toward a dissection of $\beta$ -amyloid localized effects on glutamatergic hippocampal repertoire. <i>Journal of Neurochemistry</i> , 2020, 155, 7-9.	2.1	0



#	ARTICLE	IF	CITATIONS
2318	Matriptase processing of APLP1 ectodomain alters its homodimerization. <i>Scientific Reports</i> , 2020, 10, 10091.	1.6	3
2319	Therapeutic Strategies to Reduce the Toxicity of Misfolded Protein Oligomers. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8651.	1.8	23
2320	Acetylation of AMPA Receptors Regulates Receptor Trafficking and Rescues Memory Deficits in Alzheimer's Disease. <i>IScience</i> , 2020, 23, 101465.	1.9	6
2321	TDP-43 interacts with amyloid- $\beta^2$ , inhibits fibrillization, and worsens pathology in a model of Alzheimer's disease. <i>Nature Communications</i> , 2020, 11, 5950.	5.8	45
2322	Endosomal Dysfunction Induced by Directly Overactivating Rab5 Recapitulates Prodromal and Neurodegenerative Features of Alzheimer's Disease. <i>Cell Reports</i> , 2020, 33, 108420.	2.9	58
2323	Association of Odor Identification Ability With Amyloid- $\beta^2$ and Tau Burden: A Systematic Review and Meta-Analysis. <i>Frontiers in Neuroscience</i> , 2020, 14, 586330.	1.4	13
2324	MIRRAGGE " Minimum Information Required for Reproducible AGgregation Experiments. <i>Frontiers in Molecular Neuroscience</i> , 2020, 13, 582488.	1.4	19
2325	Modulation of $\beta^2$ -Amyloid Fibril Formation in Alzheimer's Disease by Microglia and Infection. <i>Frontiers in Molecular Neuroscience</i> , 2020, 13, 609073.	1.4	35
2326	Integrating music-based interventions with Gamma-frequency stimulation: Implications for healthy ageing. <i>European Journal of Neuroscience</i> , 2022, 55, 3303-3323.	1.2	10
2327	Emergence of Barrel Motif in Amyloid- $\beta^2$ Trimer: A Computational Study. <i>Journal of Physical Chemistry B</i> , 2020, 124, 10617-10631.	1.2	12
2328	Antibody Fragments as Tools for Elucidating Structure-Toxicity Relationships and for Diagnostic/Therapeutic Targeting of Neurotoxic Amyloid Oligomers. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8920.	1.8	8
2329	Amyloid- $\beta^2$ Peptide Impact on Synaptic Function and Neuroepigenetic Gene Control Reveal New Therapeutic Strategies for Alzheimer's Disease. <i>Frontiers in Molecular Neuroscience</i> , 2020, 13, 577622.	1.4	32
2330	The Role of Mitochondrial Calcium Homeostasis in Alzheimer's and Related Diseases. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9153.	1.8	54
2331	Complex Interaction between Resident Microbiota and Misfolded Proteins: Role in Neuroinflammation and Neurodegeneration. <i>Cells</i> , 2020, 9, 2476.	1.8	31
2332	"What Doesn't Kill You Makes You Stronger" Future Applications of Amyloid Aggregates in Biomedicine. <i>Molecules</i> , 2020, 25, 5245.	1.7	20
2333	Tip60 protects against amyloid- $\beta^2$ -induced transcriptomic alterations via different modes of action in early versus late stages of neurodegeneration. <i>Molecular and Cellular Neurosciences</i> , 2020, 109, 103570.	1.0	8
2334	Impairments of Synaptic Plasticity Induction Threshold and Network Oscillatory Activity in the Hippocampus Underlie Memory Deficits in a Non-Transgenic Mouse Model of Amyloidosis. <i>Biology</i> , 2020, 9, 175.	1.3	16
2335	Signaling via the p75 neurotrophin receptor facilitates amyloid- $\beta^2$ -induced dendritic spine pathology. <i>Scientific Reports</i> , 2020, 10, 13322.	1.6	24

#	ARTICLE	IF	CITATIONS
2336	Microglia Do Not Take Up Soluble Amyloid-beta Peptides, But Partially Degrade Them by Secreting Insulin-degrading Enzyme. <i>Neuroscience</i> , 2020, 443, 30-43.	1.1	14
2337	Alzheimer's disease-related amyloid $\beta^2$ peptide causes structural disordering of lipids and changes the electric properties of a floating bilayer lipid membrane. <i>Nanoscale Advances</i> , 2020, 2, 3467-3480.	2.2	17
2338	Effects of IL-34 on Macrophage Immunological Profile in Response to Alzheimer's-Related $A\beta^{242}$ Assemblies. <i>Frontiers in Immunology</i> , 2020, 11, 1449.	2.2	15
2339	Design and synthesis of $\beta^2$ -strand-fixed peptides inhibiting aggregation of amyloid $\beta^2$ -protein. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115676.	1.4	8
2340	Effects of rosmarinic acid on nervous system disorders: an updated review. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2020, 393, 1779-1795.	1.4	53
2341	Conformation-dependent membrane permeabilization by neurotoxic PrP oligomers: The role of the H2H3 oligomerization domain. <i>Archives of Biochemistry and Biophysics</i> , 2020, 692, 108517.	1.4	1
2342	The existence of $A\beta^2$ strains and their potential for driving phenotypic heterogeneity in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2021, 142, 17-39.	3.9	35
2343	An update on potential links between type 2 diabetes mellitus and Alzheimer's disease. <i>Molecular Biology Reports</i> , 2020, 47, 6347-6356.	1.0	28
2344	Seeding and Growth of $\beta^2$ -Amyloid Aggregates upon Interaction with Neuronal Cell Membranes. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5035.	1.8	10
2345	Magnolol Ameliorates Behavioral Impairments and Neuropathology in a Transgenic Mouse Model of Alzheimer's Disease. <i>Oxidative Medicine and Cellular Longevity</i> , 2020, 2020, 1-17.	1.9	25
2346	Extracellular vesicles: where the amyloid precursor protein carboxyl-terminal fragments accumulate and amyloid $\beta^2$ oligomerizes. <i>FASEB Journal</i> , 2020, 34, 12922-12931.	0.2	32
2347	Amyloid Beta Secreted during Consolidation Prevents Memory Malleability. <i>Current Biology</i> , 2020, 30, 1934-1940.e4.	1.8	13
2348	Age-Dependent Shift of AMPA Receptors From Synapses to Intracellular Compartments in Alzheimer's Disease: Immunocytochemical Analysis of the CA1 Hippocampal Region in APP/PS1 Transgenic Mouse Model. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 577996.	1.7	18
2349	Axonal Degeneration in AD: The Contribution of $A\beta^2$ and Tau. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 581767.	1.7	28
2350	pH-bioresponsive poly( $\mu$ -caprolactone)-based polymersome for effective drug delivery in cancer and protein glycooxidation prevention. <i>Archives of Biochemistry and Biophysics</i> , 2020, 695, 108643.	1.4	12
2351	Design, synthesis and biological evaluation of novel osthole-based derivatives as potential neuroprotective agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127633.	1.0	6
2352	Co-treatment of AMPA endocytosis inhibitor and GluN2B antagonist facilitate consolidation and retrieval of memory impaired by $\beta^2$ amyloid peptide. <i>International Journal of Neuroscience</i> , 2020, , 1-10.	0.8	4
2353	The two faces of synaptic failure in AppNL-G-F knock-in mice. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 100.	3.0	25

#	ARTICLE	IF	CITATIONS
2354	Administration of Amyloid Precursor Protein Gene Deleted Mouse ESC-Derived Thymic Epithelial Progenitors Attenuates Alzheimer's Pathology. <i>Frontiers in Immunology</i> , 2020, 11, 1781.	2.2	10
2355	Internalisation and toxicity of amyloid- $\beta$ 1-42 are influenced by its conformation and assembly state rather than size. <i>FEBS Letters</i> , 2020, 594, 3490-3503.	1.3	27
2356	Two boron-containing compounds affect the cellular viability of SH-SY5Y cells in an in vitro amyloid-beta toxicity model. <i>Turkish Journal of Biology</i> , 2020, 44, 208-214.	2.1	7
2357	Neuro-Retina Might Reflect Alzheimer's Disease Stage. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1455-1468.	1.2	16
2358	Circuitry and Synaptic Dysfunction in Alzheimer's Disease: A New Tau Hypothesis. <i>Neural Plasticity</i> , 2020, 2020, 1-11.	1.0	19
2359	Impact of Four Common Hydrogels on Amyloid- $\beta$ ( $A\beta$ ) Aggregation and Cytotoxicity: Implications for 3D Models of Alzheimer's Disease. <i>ACS Omega</i> , 2020, 5, 20250-20260.	1.6	12
2360	Mechanisms of Pathogenic Tau and $A\beta$ Protein Spreading in Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 265.	1.7	78
2361	Gallic acid is a dual $\beta$ -secretase modulator that reverses cognitive impairment and remediates pathology in Alzheimer mice. <i>Journal of Biological Chemistry</i> , 2020, 295, 16251-16266.	1.6	49
2362	Early Detection of Amyloid $\beta$ Pathology in Alzheimer's Disease by Molecular MRI*. , 2020, 2020, 1100-1103.		3
2363	Organismal Protein Homeostasis Mechanisms. <i>Genetics</i> , 2020, 215, 889-901.	1.2	29
2364	The retinal toxicity profile towards assemblies of Amyloid- $\beta$ indicate the predominant pathophysiological activity of oligomeric species. <i>Scientific Reports</i> , 2020, 10, 20954.	1.6	11
2366	Degradation of FA reduces $A\beta$ neurotoxicity and Alzheimer-related phenotypes. <i>Molecular Psychiatry</i> , 2021, 26, 5578-5591.	4.1	23
2367	Targeting histone K4 trimethylation for treatment of cognitive and synaptic deficits in mouse models of Alzheimer's disease. <i>Science Advances</i> , 2020, 6, .	4.7	52
2368	Novel PET Biomarkers to Disentangle Molecular Pathways across Age-Related Neurodegenerative Diseases. <i>Cells</i> , 2020, 9, 2581.	1.8	20
2369	A Novel Optical Quantal Analysis of Miniature Events Reveals Enhanced Frequency Following Amyloid $\beta$ Exposure. <i>Frontiers in Cellular Neuroscience</i> , 2020, 14, 564081.	1.8	2
2370	Ethanol neurotoxicity is mediated by changes in expression, surface localization and functional properties of glutamate AMPA receptors. <i>Journal of Neurochemistry</i> , 2021, 157, 2106-2118.	2.1	7
2371	Dropout in Neural Networks Simulates the Paradoxical Effects of Deep Brain Stimulation on Memory. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 273.	1.7	6
2372	Mechanobiology of the brain in ageing and Alzheimer's disease. <i>European Journal of Neuroscience</i> , 2021, 53, 3851-3878.	1.2	61

#	ARTICLE	IF	CITATIONS
2373	The Role of Synaptic Dysfunction in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 49-62.	1.2	13
2374	Alzheimer's Disease, a Lipid Story: Involvement of Peroxisome Proliferator-Activated Receptor $\alpha$ . <i>Cells</i> , 2020, 9, 1215.	1.8	30
2375	Intracellular Trafficking Mechanisms of Synaptic Dysfunction in Alzheimer's Disease. <i>Frontiers in Cellular Neuroscience</i> , 2020, 14, 72.	1.8	31
2376	Clinical significance of fluid biomarkers in Alzheimer's Disease. <i>Pharmacological Reports</i> , 2020, 72, 528-542.	1.5	22
2377	MicroRNA miR-212 regulates PDCD4 to attenuate A $\beta$ <sub>25-35</sub> -induced neurotoxicity via PI3K/AKT signaling pathway in Alzheimer's disease. <i>Biotechnology Letters</i> , 2020, 42, 1789-1797.	1.1	26
2378	Microglia and Wnt Pathways: Prospects for Inflammation in Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 110.	1.7	38
2379	Versatile near-infrared fluorescent probe for in vivo detection of A $\beta$ <sub>2</sub> oligomers. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115559.	1.4	13
2380	The Role of P2X7 Receptor in Alzheimer's Disease. <i>Frontiers in Molecular Neuroscience</i> , 2020, 13, 94.	1.4	44
2381	Molecular mechanisms of forgetting. <i>European Journal of Neuroscience</i> , 2021, 54, 6912-6932.	1.2	8
2382	Molecular interactions between monoclonal oligomer-specific antibody 5E3 and its amyloid beta cognates. <i>PLoS ONE</i> , 2020, 15, e0232266.	1.1	0
2383	Integrin adhesion in brain assembly: From molecular structure to neuropsychiatric disorders. <i>European Journal of Neuroscience</i> , 2021, 53, 3831-3850.	1.2	42
2384	Progress toward Alzheimer's disease treatment: Leveraging the Achilles' heel of A $\beta$ <sub>2</sub> oligomers?. <i>Protein Science</i> , 2020, 29, 1748-1759.	3.1	45
2385	Tipping the Scales: Peptide-Dependent Dysregulation of Neural Circuit Dynamics in Alzheimer's Disease. <i>Neuron</i> , 2020, 107, 417-435.	3.8	90
2386	Neuronal Plasticity: Neuronal Organization is Associated with Neurological Disorders. <i>Journal of Molecular Neuroscience</i> , 2020, 70, 1684-1701.	1.1	11
2387	Revisiting the role of brain and peripheral A $\beta$ <sub>2</sub> in the pathogenesis of Alzheimer's disease. <i>Journal of the Neurological Sciences</i> , 2020, 416, 116974.	0.3	48
2388	Comparison of Synthetic Neuronal Model Membrane Mimics in Amyloid Aggregation at Atomic Resolution. <i>ACS Chemical Neuroscience</i> , 2020, 11, 1965-1977.	1.7	18
2389	RISK FACTORS AND CURRENT STRATEGIES TO OVERCOME ALZHEIMER'S DISEASE: A REVIEW. <i>International Journal of Research in Ayurveda and Pharmacy</i> , 2020, 11, 115-123.	0.0	0
2390	Dimerization of A $\beta$ <sub>20</sub> inside dipalmitoylphosphatidylcholine bilayer and its effect on bilayer integrity: Atomistic simulation at three temperatures. <i>Proteins: Structure, Function and Bioinformatics</i> , 2020, 88, 1540-1552.	1.5	8

#	ARTICLE	IF	CITATIONS
2391	Synaptic Loss, ER Stress and Neuro-Inflammation Emerge Late in the Lateral Temporal Cortex and Associate with Progressive Tau Pathology in Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2020, 57, 3258-3272.	1.9	33
2392	Cu(II) disrupts autophagy-mediated lysosomal degradation of oligomeric A $\beta$ 2 in microglia via mTOR-TFEB pathway. <i>Toxicology and Applied Pharmacology</i> , 2020, 401, 115090.	1.3	9
2393	Expedition into Taurine Biology: Structural Insights and Therapeutic Perspective of Taurine in Neurodegenerative Diseases. <i>Biomolecules</i> , 2020, 10, 863.	1.8	18
2394	Amyloid- $\beta$ 242/40 ratio drives tau pathology in 3D human neural cell culture models of Alzheimer's disease. <i>Nature Communications</i> , 2020, 11, 1377.	5.8	88
2395	A mechanistic hypothesis for the impairment of synaptic plasticity by soluble A $\beta$ 2 oligomers from Alzheimer's brain. <i>Journal of Neurochemistry</i> , 2020, 154, 583-597.	2.1	158
2396	The role of myelin damage in Alzheimer's disease pathology. <i>Archives of Medical Science</i> , 2020, 16, 345-341.	0.4	80
2397	The clinical promise of biomarkers of synapse damage or loss in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 21.	3.0	183
2398	&lt;p&gt;Removal of A $\beta$ 2 Oligomers from the Blood: A Potential Therapeutic System for Alzheimer's Disease&lt;/p&gt;. <i>Neuropsychiatric Disease and Treatment</i> , 2020, Volume 16, 607-627.	1.0	8
2399	Discovery of Chemicals to Either Clear or Indicate Amyloid Aggregates by Targeting Memory-Impairing Anti-Parallel A $\beta$ 2 Dimers. <i>Angewandte Chemie - International Edition</i> , 2020, 59, 11491-11500.	7.2	15
2400	Anti-Alzheimer's disease activity of secondary metabolites from <i>Xanthoceras sorbifolia</i> Bunge. <i>Food and Function</i> , 2020, 11, 2067-2079.	2.1	10
2401	Half a century of amyloids: past, present and future. <i>Chemical Society Reviews</i> , 2020, 49, 5473-5509.	18.7	345
2402	IPSC-Derived Neuronal Cultures Carrying the Alzheimer's Disease Associated TREM2 R47H Variant Enables the Construction of an A $\beta$ 2-Induced Gene Regulatory Network. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4516.	1.8	9
2403	Yeast-Based A $\beta$ 21-15 Vaccine Elicits Strong Immunogenicity and Attenuates Neuropathology and Cognitive Deficits in Alzheimer's Disease Transgenic Mice. <i>Vaccines</i> , 2020, 8, 351.	2.1	7
2404	Heavy Tau Burden with Subtle Amyloid $\beta$ 2 Accumulation in the Cerebral Cortex and Cerebellum in a Case of Familial Alzheimer's Disease with APP Osaka Mutation. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4443.	1.8	9
2405	Synthetic and biochemical studies on the effect of persulfidation on disulfide dimer models of amyloid $\beta$ 242 at position 35 in Alzheimer's etiology. <i>RSC Advances</i> , 2020, 10, 19506-19512.	1.7	3
2406	Strategies for the Molecular Imaging of Amyloid and the Value of a Multimodal Approach. <i>ACS Sensors</i> , 2020, 5, 2268-2282.	4.0	23
2407	Proximity ligation assay reveals both pre- and postsynaptic localization of the APP-processing enzymes ADAM10 and BACE1 in rat and human adult brain. <i>BMC Neuroscience</i> , 2020, 21, 6.	0.8	18
2408	Targeting Aggrephagy for the Treatment of Alzheimer's Disease. <i>Cells</i> , 2020, 9, 311.	1.8	29

#	ARTICLE	IF	CITATIONS
2409	Homeotic-Like Effects of L-Homocysteine on Synaptic Structure, Function, and A $\beta$ Aggregation. <i>Pharmaceuticals</i> , 2020, 13, 24.	1.7	11
2410	The Clustering of mApoE Anti-Amyloidogenic Peptide on Nanoparticle Surface Does Not Alter Its Performance in Controlling Beta-Amyloid Aggregation. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1066.	1.8	10
2411	APP Osaka Mutation in Familial Alzheimer's Disease—Its Discovery, Phenotypes, and Mechanism of Recessive Inheritance. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1413.	1.8	32
2412	A soluble truncated tau species related to cognitive dysfunction is elevated in the brain of cognitively impaired human individuals. <i>Scientific Reports</i> , 2020, 10, 3869.	1.6	26
2413	An inexpensive programmable optogenetic platform for controlled neuronal activation regimens in <i>C. elegans</i> . <i>APL Bioengineering</i> , 2020, 4, 016101.	3.3	7
2414	TRPV1 activation alleviates cognitive and synaptic plasticity impairments through inhibiting AMPAR endocytosis in APP23/PS45 mouse model of Alzheimer's disease. <i>Aging Cell</i> , 2020, 19, e13113.	3.0	58
2415	Melatonin affects the release of exosomes and tau-content in in vitro amyloid-beta toxicity model. <i>Journal of Clinical Neuroscience</i> , 2020, 73, 237-244.	0.8	18
2416	Beta amyloid aggregates induce sensitised TLR4 signalling causing long-term potentiation deficit and neuronal cell death. <i>Communications Biology</i> , 2020, 3, 79.	2.0	55
2417	Activated Bone Marrow-Derived Macrophages Eradicate Alzheimer's-Related A $\beta$ <sub>42</sub> Oligomers and Protect Synapses. <i>Frontiers in Immunology</i> , 2020, 11, 49.	2.2	32
2418	Oligomers Are Promising Targets for Drug Development in the Treatment of Proteinopathies. <i>Frontiers in Molecular Neuroscience</i> , 2019, 12, 319.	1.4	15
2419	Dissociation of somatostatin and parvalbumin interneurons circuit dysfunctions underlying hippocampal theta and gamma oscillations impaired by amyloid $\beta$ oligomers in vivo. <i>Brain Structure and Function</i> , 2020, 225, 935-954.	1.2	41
2420	Characterization and preclinical evaluation of the cGMP grade DNA based vaccine, AV-1959D to enter the first-in-human clinical trials. <i>Neurobiology of Disease</i> , 2020, 139, 104823.	2.1	20
2421	Inhibitory effects of curcumin on H <sub>2</sub> O <sub>2</sub> -induced cell damage and APP expression and processing in SH-SY5Y cells transfected with APP gene with Swedish mutation. <i>Molecular Biology Reports</i> , 2020, 47, 2047-2059.	1.0	9
2422	Single-nucleus RNA sequencing reveals transcriptional changes of hippocampal neurons in APP23 mouse model of Alzheimer's disease. <i>Bioscience, Biotechnology and Biochemistry</i> , 2020, 84, 919-926.	0.6	10
2423	$\beta$ -amyloid redirects norepinephrine signaling to activate the pathogenic GSK3 $\beta$ /tau cascade. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	86
2424	The Erythrocytic Hypothesis of Brain Energy Crisis in Sporadic Alzheimer Disease: Possible Consequences and Supporting Evidence. <i>Journal of Clinical Medicine</i> , 2020, 9, 206.	1.0	8
2425	New Insights Into the Pathogenesis of Alzheimer's Disease. <i>Frontiers in Neurology</i> , 2019, 10, 1312.	1.1	194
2426	Associative Interactions among Zinc, Apolipoprotein E, and Amyloid- $\beta$ in the Amyloid Pathology. <i>International Journal of Molecular Sciences</i> , 2020, 21, 802.	1.8	12



#	ARTICLE	IF	CITATIONS
2427	Organ-On-A-Chip in vitro Models of the Brain and the Blood-Brain Barrier and Their Value to Study the Microbiota-Gut-Brain Axis in Neurodegeneration. <i>Frontiers in Bioengineering and Biotechnology</i> , 2019, 7, 435.	2.0	73
2428	Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease by the Plasma and Serum Amyloid-beta 42 Assay through Highly Sensitive Peptoid Nanosheet Sensor. <i>ACS Applied Materials &amp; Interfaces</i> , 2020, 12, 9693-9700.	4.0	24
2429	Dendritic Spines in Alzheimer's Disease: How the Actin Cytoskeleton Contributes to Synaptic Failure. <i>International Journal of Molecular Sciences</i> , 2020, 21, 908.	1.8	65
2430	Passive immunotherapy for N-truncated tau ameliorates the cognitive deficits in two mouse Alzheimer's disease models. <i>Brain Communications</i> , 2020, 2, fcaa039.	1.5	29
2431	Amyloid $\beta$ -protein and beyond: the path forward in Alzheimer's disease. <i>Current Opinion in Neurobiology</i> , 2020, 61, 116-124.	2.0	87
2432	Chronic Presence of Oligomeric $A\beta$ Differentially Modulates Spine Parameters in the Hippocampus and Cortex of Mice With Low APP Transgene Expression. <i>Frontiers in Synaptic Neuroscience</i> , 2020, 12, 16.	1.3	7
2433	<i>N</i> -Amino peptide scanning reveals inhibitors of $A\beta_{42}$ aggregation. <i>RSC Advances</i> , 2020, 10, 14331-14336.	1.7	8
2434	Healthspan Maintenance and Prevention of Parkinson's-like Phenotypes with Hydroxytyrosol and Oleuropein Aglycone in <i>C. elegans</i> . <i>International Journal of Molecular Sciences</i> , 2020, 21, 2588.	1.8	110
2435	Assessing Reproducibility in Amyloid $\beta$ Research: Impact of $A\beta$ Sources on Experimental Outcomes. <i>ChemBioChem</i> , 2020, 21, 2425-2430.	1.3	8
2436	A facile biosensor for $A\beta_{40}$ based on fluorescence quenching of prussian blue nanoparticles. <i>Talanta</i> , 2020, 216, 120930.	2.9	29
2437	High-resolution probing of early events in amyloid- $\beta$ aggregation related to Alzheimer's disease. <i>Chemical Communications</i> , 2020, 56, 4627-4639.	2.2	71
2438	Complete aggregation pathway of amyloid $\beta$ (1-40) and (1-42) resolved on an atomically clean interface. <i>Science Advances</i> , 2020, 6, eaaz6014.	4.7	88
2439	Utility of spontaneous animal models of Alzheimer's disease in preclinical efficacy studies. <i>Cell and Tissue Research</i> , 2020, 380, 273-286.	1.5	10
2440	Discovery of Chemicals to Either Clear or Indicate Amyloid Aggregates by Targeting Memory-Impairing Anti-Parallel $A\beta$ Dimers. <i>Angewandte Chemie</i> , 2020, 132, 11588-11597.	1.6	3
2441	Introducing Virtual Oligomerization Inhibition to Identify Potent Inhibitors of $A\beta$ Oligomerization. <i>Journal of Chemical Theory and Computation</i> , 2020, 16, 3920-3935.	2.3	7
2442	Analysis of $\beta$ -synuclein species enriched from cerebral cortex of humans with sporadic dementia with Lewy bodies. <i>Brain Communications</i> , 2020, 2, fcaa010.	1.5	21
2443	A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease. <i>Frontiers in Immunology</i> , 2020, 11, 456.	2.2	201
2444	Acute Pannexin 1 Blockade Mitigates Early Synaptic Plasticity Defects in a Mouse Model of Alzheimer's Disease. <i>Frontiers in Cellular Neuroscience</i> , 2020, 14, 46.	1.8	19



#	ARTICLE	IF	CITATIONS
2445	Proteomic analysis involved with synaptic plasticity improvement by GABAA receptor blockade in hippocampus of a mouse model of Alzheimer's disease. <i>Neuroscience Research</i> , 2021, 165, 61-68.	1.0	7
2446	Crocinn attenuates the granular cells damages on the dentate gyrus and pyramidal neurons in the CA3 regions of the hippocampus and frontal cortex in the rat model of Alzheimer's disease. <i>Journal of Chemical Neuroanatomy</i> , 2021, 113, 101837.	1.0	16
2447	The $\beta$ -Secretase BACE1 in Alzheimer's Disease. <i>Biological Psychiatry</i> , 2021, 89, 745-756.	0.7	336
2448	Neurophysiological and molecular approaches to understanding the mechanisms of learning and memory. <i>Journal of the Royal Society of New Zealand</i> , 2021, 51, 4-23.	1.0	1
2449	Human EEG and the mechanisms of memory: investigating long-term potentiation (LTP) in sensory-evoked potentials. <i>Journal of the Royal Society of New Zealand</i> , 2021, 51, 24-40.	1.0	12
2450	Intranasal delivery of BDNF rescues memory deficits in AD11 mice and reduces brain microgliosis. <i>Ageing Clinical and Experimental Research</i> , 2021, 33, 1223-1238.	1.4	23
2451	Alzheimer's protection effect of A673T mutation may be driven by lower $A\beta$ oligomer binding affinity. <i>Journal of Neurochemistry</i> , 2021, 157, 1316-1330.	2.1	20
2452	TREM2 overexpression rescues cognitive deficits in APP/PS1 transgenic mice by reducing neuroinflammation via the JAK/STAT/SOCS signaling pathway. <i>Experimental Neurology</i> , 2021, 336, 113506.	2.0	39
2453	Sigma ligands as potent inhibitors of $A\beta$ and $A\beta$ Os in neurons and promising therapeutic agents of Alzheimer's disease. <i>Neuropharmacology</i> , 2021, 190, 108342.	2.0	8
2454	Functions of amyloid precursor protein in metabolic diseases. <i>Metabolism: Clinical and Experimental</i> , 2021, 115, 154454.	1.5	38
2455	Implications of Oligomeric Amyloid-Beta ( $\alpha A\beta_{42}$ ) Signaling through $\alpha 7\beta 2$ -Nicotinic Acetylcholine Receptors (nAChRs) on Basal Forebrain Cholinergic Neuronal Intrinsic Excitability and Cognitive Decline. <i>Journal of Neuroscience</i> , 2021, 41, 555-575.	1.7	26
2456	$\beta$ -amyloid: The known unknowns. <i>Ageing Research Reviews</i> , 2021, 65, 101212.	5.0	27
2457	TNF- $\alpha$ -mediated reduction in inhibitory neurotransmission precedes sporadic Alzheimer's disease pathology in young Trem2 rats. <i>Journal of Biological Chemistry</i> , 2021, 296, 100089.	1.6	23
2458	Hippocampal LAMP1 ameliorates chronic stress-mediated behavioral responses in a mouse model of unpredictable chronic mild stress. <i>Neuropharmacology</i> , 2021, 184, 108410.	2.0	4
2459	Emerging role of AMPA receptor subunit GluA1 in synaptic plasticity: Implications for Alzheimer's disease. <i>Cell Proliferation</i> , 2021, 54, e12959.	2.4	38
2460	Akt and calcium-permeable AMPA receptor are involved in the effect of pinoresinol on amyloid $\beta$ -induced synaptic plasticity and memory deficits. <i>Biochemical Pharmacology</i> , 2021, 184, 114366.	2.0	10
2461	Neuropathological and Biomarker Findings in Parkinson's Disease and Alzheimer's Disease: From Protein Aggregates to Synaptic Dysfunction. <i>Journal of Parkinson's Disease</i> , 2021, 11, 107-121.	1.5	28
2462	Suppression of the kinase for elongation factor 2 alleviates mGluR-LTD impairments in a mouse model of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2021, 98, 225-230.	1.5	13

#	ARTICLE	IF	CITATIONS
2463	The interaction of insoluble Amyloid $\beta$ with soluble Amyloid $\beta$ dimers decreases Amyloid $\beta$ plaque numbers. <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 603-610.	1.8	3
2464	Amyloid cross-seeding between A $\beta$ and hIAPP in relation to the pathogenesis of Alzheimer and type 2 diabetes. <i>Chinese Journal of Chemical Engineering</i> , 2021, 30, 225-235.	1.7	18
2465	Inhibition of Amyloid $\beta$ -Induced Lipid Membrane Permeation and Amyloid $\beta$ Aggregation by K162. <i>ACS Chemical Neuroscience</i> , 2021, 12, 531-541.	1.7	14
2466	Cognitive impairment in multiple sclerosis: lessons from cerebrospinal fluid biomarkers. <i>Neural Regeneration Research</i> , 2021, 16, 36.	1.6	23
2467	Soluble amyloid beta-containing aggregates are present throughout the brain at early stages of Alzheimer's disease. <i>Brain Communications</i> , 2021, 3, fcab147.	1.5	32
2468	The Pathogenesis Mechanism, Structure Properties, Potential Drugs and Therapeutic Nanoparticles against the Small Oligomers of Amyloid- $\beta$ . <i>Current Topics in Medicinal Chemistry</i> , 2021, 21, 151-167.	1.0	5
2469	Ultralow-power flexible transparent carbon nanotube synaptic transistors for emotional memory. <i>Nanoscale</i> , 2021, 13, 11360-11369.	2.8	22
2470	Origin, toxicity and characteristics of two amyloid oligomer polymorphs. <i>RSC Chemical Biology</i> , 2021, 2, 1631-1642.	2.0	5
2471	The p38MAPK-MK2 Signaling Axis as a Critical Link Between Inflammation and Synaptic Transmission. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 635636.	1.8	25
2472	<i>Celastrus paniculatus</i> . , 2021, , 425-435.		0
2473	Identification of biomarkers for diagnosing and monitoring therapy in the treatment of neurologic disorders. , 2021, , 291-310.		0
2474	The A $\beta$ (1-38) peptide is a negative regulator of the A $\beta$ (1-42) peptide implicated in Alzheimer disease progression. <i>Scientific Reports</i> , 2021, 11, 431.	1.6	32
2475	Leptin regulation of hippocampal synaptic function in health and disease. <i>Vitamins and Hormones</i> , 2021, 115, 105-127.	0.7	7
2476	Association of A $\beta$ deposition and regional synaptic density in early Alzheimer's disease: a PET imaging study with [11C]UCBJ. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 11.	3.0	53
2477	Molecular Simulations and Alzheimer's Disease. , 2021, , 54-70.		0
2479	Exploring the New Horizon of AdipoQ in Obesity-Related Alzheimer's Dementia. <i>Frontiers in Physiology</i> , 2020, 11, 567678.	1.3	12
2480	Dementia or no dementia in the elderly. Why?. , 2021, , 115-126.		0
2481	Alzheimer's Disease and Protein Kinases. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1275, 285-321.	0.8	19

#	ARTICLE	IF	CITATIONS
2482	Polyphenols attenuate mitochondrial dysfunction induced by amyloid peptides. , 2021, , 317-337.		0
2483	Infrared nanospectroscopy reveals the molecular interaction fingerprint of an aggregation inhibitor with single A $\beta$ 1-42 oligomers. Nature Communications, 2021, 12, 688.	5.8	52
2484	The role of astrocytes in prion-like mechanisms of neurodegeneration. Brain, 2022, 145, 17-26.	3.7	10
2485	Interaction of NF- $\kappa$ B and Wnt/ $\beta$ -catenin Signaling Pathways in Alzheimer's Disease and Potential Active Drug Treatments. Neurochemical Research, 2021, 46, 711-731.	1.6	16
2486	Accumulation of cellular prion protein within A $\beta$ 1-42 amyloid oligomer plaques in aged human brains. Brain Pathology, 2021, 31, e12941.	2.1	17
2487	Role of Retinal Amyloid- $\beta$ in Neurodegenerative Diseases: Overlapping Mechanisms and Emerging Clinical Applications. International Journal of Molecular Sciences, 2021, 22, 2360.	1.8	26
2488	A Mechanistic Model of NMDA and AMPA Receptor-Mediated Synaptic Transmission in Individual Hippocampal CA3-CA1 Synapses: A Computational Multiscale Approach. International Journal of Molecular Sciences, 2021, 22, 1536.	1.8	9
2489	Targeting Microglia-Synapse Interactions in Alzheimer's Disease. International Journal of Molecular Sciences, 2021, 22, 2342.	1.8	36
2490	A Scoping Review of Neuromodulation Techniques in Neurodegenerative Diseases: A Useful Tool for Clinical Practice?. Medicina (Lithuania), 2021, 57, 215.	0.8	12
2492	Insight into the role of phosphatidylserine in complement-mediated synapse loss in Alzheimer's disease. Faculty Reviews, 2021, 10, 19.	1.7	17
2493	Participaci3n de rafts en enfermedades neurol3gicas. Neurolog3a, 2021, , .	0.3	0
2494	Fluorine-19 Magnetic Resonance Imaging for Detection of Amyloid $\beta$ Oligomers Using a Keto Form of Curcumin Derivative in a Mouse Model of Alzheimer's Disease. Molecules, 2021, 26, 1362.	1.7	10
2495	Amyloid-Beta Mediates Homeostatic Synaptic Plasticity. Journal of Neuroscience, 2021, 41, 5157-5172.	1.7	26
2496	Early intervention attenuates synaptic plasticity impairment and neuroinflammation in 5xFAD mice. Journal of Psychiatric Research, 2021, 136, 204-216.	1.5	18
2497	Examining the effects of ovarian hormone loss and diet-induced obesity on Alzheimer's disease markers of amyloid- $\beta$ production and degradation. Journal of Neurophysiology, 2021, 125, 1068-1078.	0.9	3
2498	COVID-19 and Alzheimer's disease: how one crisis worsens the other. Translational Neurodegeneration, 2021, 10, 15.	3.6	74
2499	Ginkgolide B-induced AMPK pathway activation protects astrocytes by regulating endoplasmic reticulum stress, oxidative stress and energy metabolism induced by A $\beta$ 1-42. Molecular Medicine Reports, 2021, 23, .	1.1	12
2500	Sequence of proteome profiles in preclinical and symptomatic Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 946-958.	0.4	16

#	ARTICLE	IF	CITATIONS
2501	The Neuroprotective Beta Amyloid Hexapeptide Core Reverses Deficits in Synaptic Plasticity in the 5xFAD APP/PS1 Mouse Model. <i>Frontiers in Molecular Neuroscience</i> , 2021, 14, 576038.	1.4	6
2502	Insights into the Pathophysiology of Psychiatric Symptoms in Central Nervous System Disorders: Implications for Early and Differential Diagnosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4440.	1.8	17
2503	Amyloid-Mediated Mechanisms of Membrane Disruption. <i>Biophysica</i> , 2021, 1, 137-156.	0.6	14
2504	Regulation of hippocampal synaptic function by the metabolic hormone leptin: Implications for health and disease. <i>Progress in Lipid Research</i> , 2021, 82, 101098.	5.3	17
2505	Phase II (NAVIGATE-AD study) Results of LY3202626 Effects on Patients with Mild Alzheimer's Disease Dementia. <i>Journal of Alzheimer's Disease Reports</i> , 2021, 5, 321-336.	1.2	17
2506	Presenilin 1 mutation likely contributes to U1 small nuclear RNA dysregulation and Alzheimer's disease-like symptoms. <i>Neurobiology of Aging</i> , 2021, 100, 1-10.	1.5	9
2507	Microglia Phenotypes Converge in Aging and Neurodegenerative Disease. <i>Frontiers in Neurology</i> , 2021, 12, 660720.	1.1	26
2508	The application of multifunctional nanomaterials in Alzheimer's disease: A potential theranostics strategy. <i>Biomedicine and Pharmacotherapy</i> , 2021, 137, 111360.	2.5	15
2509	Different patterns of $\beta$ -amyloid deposition in patients with Alzheimer's disease according to the presence of mild parkinsonism. <i>Neurobiology of Aging</i> , 2021, 101, 199-206.	1.5	2
2510	Neuroprotective Effects of <i>Asparagus officinalis</i> Stem Extract in Transgenic Mice Overexpressing Amyloid Precursor Protein. <i>Journal of Immunology Research</i> , 2021, 2021, 1-10.	0.9	5
2511	Overexpression of protein kinase M $\bar{1}\eta$ in the hippocampal dentate gyrus rescues amyloid- $\beta$ -induced synaptic dysfunction within entorhinal-hippocampal circuit. <i>Neurobiology of Aging</i> , 2021, 101, 160-171.	1.5	6
2512	Multifunctional Gold Nanoparticle-Conjugated Cellulose Nanofibers Alleviate A $\beta$ <sup>242</sup> Fibrillation-Induced Toxicity via Regulation of Oxidative Stress and Ion Homeostasis. <i>Biomacromolecules</i> , 2021, 22, 2419-2435.	2.6	8
2513	Elevating the Levels of Calcium Ions Exacerbate Alzheimer's Disease via Inducing the Production and Aggregation of $\beta$ -Amyloid Protein and Phosphorylated Tau. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5900.	1.8	38
2514	RRY Inhibits Amyloid- $\beta$ 1-42 Peptide Aggregation and Neurotoxicity. <i>Journal of Alzheimer's Disease Reports</i> , 2021, 5, 479-495.	1.2	4
2515	VEGF counteracts amyloid- $\beta$ -induced synaptic dysfunction. <i>Cell Reports</i> , 2021, 35, 109121.	2.9	19
2516	The interplay between lipid and A $\beta$ <sup>2</sup> amyloid homeostasis in Alzheimer's Disease: risk factors and therapeutic opportunities. <i>Chemistry and Physics of Lipids</i> , 2021, 236, 105072.	1.5	16
2517	Transmission of cerebral amyloid pathology by peripheral administration of misfolded A $\beta$ <sup>2</sup> aggregates. <i>Molecular Psychiatry</i> , 2021, 26, 5690-5701.	4.1	18
2518	Cortical plasticity is correlated with cognitive improvement in Alzheimer's disease patients after rTMS treatment. <i>Brain Stimulation</i> , 2021, 14, 503-510.	0.7	62

#	ARTICLE	IF	CITATIONS
2519	Haploinsufficiency of microglial MyD88 ameliorates Alzheimer's pathology and vascular disorders in APP / PS1 transgenic mice. <i>Glia</i> , 2021, 69, 1987-2005.	2.5	6
2520	Alzheimer's Disease and microRNA-132: A Widespread Pathological Factor and Potential Therapeutic Target. <i>Frontiers in Neuroscience</i> , 2021, 15, 687973.	1.4	18
2521	A $\beta$ receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. <i>Nature Communications</i> , 2021, 12, 3451.	5.8	26
2522	An evaluation of the self-assembly enhancing properties of cell-derived hexameric amyloid- $\beta$ . <i>Scientific Reports</i> , 2021, 11, 11570.	1.6	9
2523	Early Effects of the Soluble Amyloid $\beta$ 25-35 Peptide in Rat Cortical Neurons: Modulation of Signal Transduction Mediated by Adenosine and Group I Metabotropic Glutamate Receptors. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6577.	1.8	9
2525	Amyloid- $\beta$ : a potential link between epilepsy and cognitive decline. <i>Nature Reviews Neurology</i> , 2021, 17, 469-485.	4.9	60
2526	Amyloid Prefibrillar Oligomers: The Surprising Commonalities in Their Structure and Activity. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6435.	1.8	15
2527	Reversible GABAergic dysfunction involved in hippocampal hyperactivity predicts early-stage Alzheimer disease in a mouse model. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 114.	3.0	23
2528	Illuminating Neural Circuits in Alzheimer's Disease. <i>Neuroscience Bulletin</i> , 2021, 37, 1203-1217.	1.5	16
2529	An Unbalanced Synaptic Transmission: Cause or Consequence of the Amyloid Oligomers Neurotoxicity?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5991.	1.8	28
2530	Synaptic Plasticity and Oscillations in Alzheimer's Disease: A Complex Picture of a Multifaceted Disease. <i>Frontiers in Molecular Neuroscience</i> , 2021, 14, 696476.	1.4	16
2531	Group 1 Metabotropic Glutamate Receptors in Neurological and Psychiatric Diseases: Mechanisms and Prospective. <i>Neuroscientist</i> , 2022, 28, 453-468.	2.6	19
2532	P38 $\beta$ -MAPK phosphorylates Snapin and reduces Snapin-mediated BACE1 transportation in APP transgenic mice. <i>FASEB Journal</i> , 2021, 35, e21691.	0.2	7
2533	Overexpression of LIMK1 in hippocampal excitatory neurons improves synaptic plasticity and social recognition memory in APP/PS1 mice. <i>Molecular Brain</i> , 2021, 14, 121.	1.3	7
2534	From reaction kinetics to dementia: A simple dimer model of Alzheimer's disease etiology. <i>PLoS Computational Biology</i> , 2021, 17, e1009114.	1.5	7
2535	Bolstered Neuronal Antioxidant Response May Confer Resistance to Development of Dementia in Individuals with Alzheimer's Neuropathology by Ameliorating Amyloid- $\beta$ -Induced Oxidative Stress. <i>Journal of Neuroscience</i> , 2021, 41, 6187-6189.	1.7	1
2537	A $\beta$ -1 $\pm$ and A $\beta$ -1 $\beta$ peptides impair LTP ex vivo within the low nanomolar range and impact neuronal activity in vivo. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 125.	3.0	7
2538	Sorting nexin-27 regulates AMPA receptor trafficking through the synaptic adhesion protein LRFN2. <i>ELife</i> , 2021, 10, .	2.8	12

#	ARTICLE	IF	CITATIONS
2539	Development of grape polyphenols as multi-targeting strategies for Alzheimer's disease. <i>Neurochemistry International</i> , 2021, 147, 105046.	1.9	16
2540	The effects of Cstb duplication on APP/amyloid- $\beta^2$ pathology and cathepsin B activity in a mouse model. <i>PLoS ONE</i> , 2021, 16, e0242236.	1.1	3
2541	Impairment of visual cortical plasticity by amyloid-beta species. <i>Neurobiology of Disease</i> , 2021, 154, 105344.	2.1	8
2542	Rationale and study design of a randomized, placebo-controlled, double-blind phase 2b trial to evaluate efficacy, safety, and tolerability of an oral glutaminy cyclase inhibitor varoglutamstat (PQ912) in study participants with MCI and mild AD. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 142.	3.0	14
2543	Mulberry fruit extract alleviates the intracellular amyloid- $\beta^2$ oligomer-induced cognitive disturbance and oxidative stress in Alzheimer's disease model mice. <i>Genes To Cells</i> , 2021, 26, 861-873.	0.5	7
2544	Impaired spike-gamma coupling of area CA3 fast-spiking interneurons as the earliest functional impairment in the AppNL-G-F mouse model of Alzheimer's disease. <i>Molecular Psychiatry</i> , 2021, 26, 5557-5567.	4.1	35
2545	Inhibitory synapse loss and accumulation of amyloid beta in inhibitory presynaptic terminals in Alzheimer's disease. <i>European Journal of Neurology</i> , 2022, 29, 1311-1323.	1.7	27
2546	Casein Kinase 2 dependent phosphorylation of eIF4B regulates BACE1 expression in Alzheimer's disease. <i>Cell Death and Disease</i> , 2021, 12, 769.	2.7	8
2547	A 3D flexible neural interface based on a microfluidic interconnection cable capable of chemical delivery. <i>Microsystems and Nanoengineering</i> , 2021, 7, 66.	3.4	15
2548	Noradrenaline in the aging brain: Promoting cognitive reserve or accelerating Alzheimer's disease?. <i>Seminars in Cell and Developmental Biology</i> , 2021, 116, 108-124.	2.3	32
2549	Long-term depression links amyloid- $\beta^2$ to the pathological hyperphosphorylation of tau. <i>Cell Reports</i> , 2021, 36, 109638.	2.9	16
2550	Molecular insight into the early stage of amyloid- $\beta^2$ (1-42) Homodimers aggregation influenced by histidine tautomerism. <i>International Journal of Biological Macromolecules</i> , 2021, 184, 887-897.	3.6	8
2551	Met35 Oxidation Hinders A $\beta$ <sup>25-35</sup> Peptide Aggregation within the Dimyristoylphosphatidylcholine Bilayer. <i>ACS Chemical Neuroscience</i> , 2021, 12, 3225-3236.	1.7	7
2552	Planar cell polarity signaling components are a direct target of $\beta^2$ -amyloid-associated degeneration of glutamatergic synapses. <i>Science Advances</i> , 2021, 7, .	4.7	14
2553	Green Tea Suppresses Amyloid $\beta^2$ Levels and Alleviates Cognitive Impairment by Inhibiting APP Cleavage and Preventing Neurotoxicity in 5XFAD Mice. <i>Molecular Nutrition and Food Research</i> , 2021, 65, e2100626.	1.5	11
2554	Targeted Lipidomics of Mitochondria in a Cellular Alzheimer's Disease Model. <i>Biomedicines</i> , 2021, 9, 1062.	1.4	9
2555	Identification of transmissible proteotoxic oligomer-like fibrils that expand conformational diversity of amyloid assemblies. <i>Communications Biology</i> , 2021, 4, 939.	2.0	15
2556	The Role of Perioperative Sleep Disturbance in Postoperative Neurocognitive Disorders. <i>Nature and Science of Sleep</i> , 2021, Volume 13, 1395-1410.	1.4	31



#	ARTICLE	IF	CITATIONS
2557	The Amyloid- $\beta$ Pathway in Alzheimer's Disease. <i>Molecular Psychiatry</i> , 2021, 26, 5481-5503.	4.1	478
2558	Amyloid- $\beta$ (1-42) peptide induces rapid NMDA receptor-dependent alterations at glutamatergic synapses in the entorhinal cortex. <i>Neurobiology of Aging</i> , 2021, 105, 296-309.	1.5	6
2559	Metallobiology and therapeutic chelation of biometals (copper, zinc and iron) in Alzheimer's disease: Limitations, and current and future perspectives. <i>Journal of Trace Elements in Medicine and Biology</i> , 2021, 67, 126779.	1.5	60
2560	Perinatal low-dose bisphenol AF exposure impairs synaptic plasticity and cognitive function of adult offspring in a sex-dependent manner. <i>Science of the Total Environment</i> , 2021, 788, 147918.	3.9	21
2561	Synthetic amyloid- $\beta$ oligomers drive early pathological progression of Alzheimer's disease in nonhuman primates. <i>IScience</i> , 2021, 24, 103207.	1.9	9
2562	Frustrated peptide chains at the fibril tip control the kinetics of growth of amyloid- $\beta$ fibrils. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	12
2563	Synaptic tau: A pathological or physiological phenomenon?. <i>Acta Neuropathologica Communications</i> , 2021, 9, 149.	2.4	30
2564	NMDAR-dependent somatic potentiation of synaptic inputs is correlated with $\beta$ amyloid-mediated neuronal hyperactivity. <i>Translational Neurodegeneration</i> , 2021, 10, 34.	3.6	8
2565	Dysregulated APP expression and $\beta$ -secretase processing of APP is involved in manganese-induced cognitive impairment. <i>Ecotoxicology and Environmental Safety</i> , 2021, 220, 112365.	2.9	12
2566	A familial Danish dementia rat shows impaired presynaptic and postsynaptic glutamatergic transmission. <i>Journal of Biological Chemistry</i> , 2021, 297, 101089.	1.6	9
2567	Novel multivalent design of a monoclonal antibody improves binding strength to soluble aggregates of amyloid beta. <i>Translational Neurodegeneration</i> , 2021, 10, 38.	3.6	17
2568	Research progress of multi-functional fluorescent probes for Alzheimer's disease monitoring. <i>Dyes and Pigments</i> , 2021, 193, 109466.	2.0	38
2569	Formaldehyde-Crosslinked Nontoxic $A\beta$ Monomers to Form Toxic $A\beta$ Dimers and Aggregates: Pathogenicity and Therapeutic Perspectives. <i>ChemMedChem</i> , 2021, 16, 3376-3390.	1.6	12
2570	Potentiation of amyloid beta phagocytosis and amelioration of synaptic dysfunction upon FAAH deletion in a mouse model of Alzheimer's disease. <i>Journal of Neuroinflammation</i> , 2021, 18, 223.	3.1	11
2572	Diagnostic contribution and therapeutic perspectives of transcranial magnetic stimulation in dementia. <i>Clinical Neurophysiology</i> , 2021, 132, 2568-2607.	0.7	85
2573	Roles of microglia in Alzheimer's disease and impact of new findings on microglial heterogeneity as a target for therapeutic intervention. <i>Biochemical Pharmacology</i> , 2021, 192, 114754.	2.0	24
2574	Spreading of Alzheimer tau seeds is enhanced by aging and template matching with limited impact of amyloid- $\beta$ . <i>Journal of Biological Chemistry</i> , 2021, 297, 101159.	1.6	10
2575	The role of microRNA-34 family in Alzheimer's disease: A potential molecular link between neurodegeneration and metabolic disorders. <i>Pharmacological Research</i> , 2021, 172, 105805.	3.1	23



#	ARTICLE	IF	CITATIONS
2576	Isoform-specific dysregulation of AMP-activated protein kinase signaling in a non-human primate model of Alzheimer's disease. <i>Neurobiology of Disease</i> , 2021, 158, 105463.	2.1	9
2577	The transmembrane amyloid precursor C99 protein exhibits non-specific interaction with tau. <i>Biochemical and Biophysical Research Communications</i> , 2021, 576, 48-52.	1.0	2
2578	Genetic deletion of $\alpha 7$ nicotinic acetylcholine receptors induces an age-dependent Alzheimer's disease-like pathology. <i>Progress in Neurobiology</i> , 2021, 206, 102154.	2.8	21
2579	Modulation of Neuroinflammation by Low-Dose Radiation Therapy in an Animal Model of Alzheimer's Disease. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 658-670.	0.4	17
2580	Emerging targets in drug discovery against neurodegenerative diseases: Control of synapsis dysfunction by the RhoA/ROCK pathway. <i>European Journal of Medicinal Chemistry</i> , 2021, 225, 113742.	2.6	13
2581	Differential effects of chronic immunosuppression on behavioral, epigenetic, and Alzheimer's disease-associated markers in 3xTg-AD mice. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 30.	3.0	7
2582	Spontaneous protein-protein crosslinking at glutamine and glutamic acid residues in long-lived proteins. <i>Biochemical Journal</i> , 2021, 478, 327-339.	1.7	5
2583	The GSK-3 $\beta$ -Catenin Signaling-Mediated Brain-Derived Neurotrophic Factor Pathway Is Involved in Aluminum-Induced Impairment of Hippocampal LTP In Vivo. <i>Biological Trace Element Research</i> , 2021, 199, 4635-4645.	1.9	8
2584	Cholesterol in Membranes Facilitates Aggregation of Amyloid $\beta$ Protein at Physiologically Relevant Concentrations. <i>ACS Chemical Neuroscience</i> , 2021, 12, 506-516.	1.7	32
2585	The Neuronal Actions of Leptin and the Implications for Treating Alzheimer's Disease. <i>Pharmaceuticals</i> , 2021, 14, 52.	1.7	18
2586	A conformation-specific antibody against oligomeric $\beta$ -amyloid restores neuronal integrity in a mouse model of Alzheimer's disease. <i>Journal of Biological Chemistry</i> , 2021, 296, 100241.	1.6	4
2587	A dopamine metabolite stabilizes neurotoxic amyloid- $\beta$ oligomers. <i>Communications Biology</i> , 2021, 4, 19.	2.0	25
2588	Hyperactivity Induced by Soluble Amyloid- $\beta$ Oligomers in the Early Stages of Alzheimer's Disease. <i>Frontiers in Molecular Neuroscience</i> , 2020, 13, 600084.	1.4	39
2589	Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification. <i>Alzheimer's and Dementia</i> , 2021, 17, 1365-1382.	0.4	43
2590	Prion Protein Misfolding at the Synapse. , 2011, , 289-312.		1
2591	Flow Cytometric Evaluation of Crude Synaptosome Preparation as a Way to Study Synaptic Alteration in Neurodegenerative Diseases. <i>NeuroMethods</i> , 2018, 141, 297-310.	0.2	5
2592	Connectivity Analysis of Hippocampus in Alzheimer's Brain Using Probabilistic Tractography. <i>Lecture Notes in Computer Science</i> , 2012, , 521-528.	1.0	2
2593	PET Tracers for Beta-Amyloid and Other Proteinopathies. , 2014, , 199-212.		2

#	ARTICLE	IF	CITATIONS
2594	Overview of Fibrillar and Oligomeric Assemblies of Amyloidogenic Proteins. , 2012, , 1-36.		3
2595	Role of Prion Protein Oligomers in the Pathogenesis of Transmissible Spongiform Encephalopathies. , 2012, , 319-335.		6
2596	The Role of A $\beta$ and Tau Oligomers in the Pathogenesis of Alzheimer's Disease. , 2012, , 135-188.		5
2597	Secondary Metabolites from Rosemary ( <i>Rosmarinus officinalis</i> L.): Structure, Biochemistry and Therapeutic Implications Against Neurodegenerative Diseases. , 2019, , 1-24.		8
2598	Contributions of Drug Transporters to Blood-Brain Barriers. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1141, 407-466.	0.8	10
2599	Neurobiological Mechanisms Involved in the Pathogenesis of Alzheimer's Disease. , 2019, , 235-269.		2
2600	The Role of Tau in the Post-synapse. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1184, 113-121.	0.8	5
2601	Neurodegenerative Diseases and Axonal Transport. , 2018, , 345-367.		1
2602	Trans-caryophyllene inhibits amyloid $\beta$ (A $\beta$ ) oligomer-induced neuroinflammation in BV-2 microglial cells. <i>International Immunopharmacology</i> , 2017, 51, 91-98.	1.7	46
2603	Single-subject gray matter networks predict future cortical atrophy in preclinical Alzheimer's disease. <i>Neurobiology of Aging</i> , 2020, 94, 71-80.	1.5	14
2604	Membrane affinity of individual toxic protein oligomers determined at the single-molecule level. <i>Physical Chemistry Chemical Physics</i> , 2020, 22, 14613-14620.	1.3	8
2605	Grey matter network trajectories across the Alzheimer's disease continuum and relation to cognition. <i>Brain Communications</i> , 2020, 2, fcaa177.	1.5	10
2606	Understanding and exploiting interactions between cellular proteostasis pathways and infectious prion proteins for therapeutic benefit. <i>Open Biology</i> , 2020, 10, 200282.	1.5	2
2614	Genetic reduction of eEF2 kinase alleviates pathophysiology in Alzheimer's disease model mice. <i>Journal of Clinical Investigation</i> , 2019, 129, 820-833.	3.9	67
2615	An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associated A $\beta$ oligomers. <i>Journal of Clinical Investigation</i> , 2012, 122, 1339-1353.	3.9	697
2616	Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. <i>Journal of Clinical Investigation</i> , 2012, 122, 1316-1338.	3.9	1,431
2617	Angiotensin-converting enzyme overexpression in myelomonocytes prevents Alzheimer's-like cognitive decline. <i>Journal of Clinical Investigation</i> , 2014, 124, 1000-1012.	3.9	82
2618	Fc $\gamma$ RIIb mediates amyloid- $\beta$ neurotoxicity and memory impairment in Alzheimer's disease. <i>Journal of Clinical Investigation</i> , 2013, 123, 2791-2802.	3.9	105

#	ARTICLE	IF	CITATIONS
2619	Blocking the apoE/A $\beta$ interaction ameliorates A $\beta$ -related pathology in APOE $\epsilon$ 2 and $\epsilon$ 4 targeted replacement Alzheimer model mice. <i>Acta Neuropathologica Communications</i> , 2014, 2, 75.	2.4	36
2620	Non-ionotropic signaling by the NMDA receptor: controversy and opportunity. <i>F1000Research</i> , 2016, 5, 1010.	0.8	23
2621	Misfolded Proteins in Neurodegenerative Dementias: Molecular Mechanisms. <i>Dementia and Neurocognitive Disorders</i> , 2012, 11, 38.	0.4	2
2623	Opposite Effects of Low and High Doses of A $\beta$ 242 on Electrical Network and Neuronal Excitability in the Rat Prefrontal Cortex. <i>PLoS ONE</i> , 2009, 4, e8366.	1.1	30
2624	A New Target for Amyloid Beta Toxicity Validated by Standard and High-Throughput Electrophysiology. <i>PLoS ONE</i> , 2010, 5, e8643.	1.1	50
2625	T Cells Specifically Targeted to Amyloid Plaques Enhance Plaque Clearance in a Mouse Model of Alzheimer's Disease. <i>PLoS ONE</i> , 2010, 5, e10830.	1.1	75
2626	A $\beta$ 240 Oligomers Identified as a Potential Biomarker for the Diagnosis of Alzheimer's Disease. <i>PLoS ONE</i> , 2010, 5, e15725.	1.1	96
2627	Non-Conjugated Small Molecule FRET for Differentiating Monomers from Higher Molecular Weight Amyloid Beta Species. <i>PLoS ONE</i> , 2011, 6, e19362.	1.1	41
2628	Amitriptyline-Mediated Cognitive Enhancement in Aged 3 $\times$ Tg Alzheimer's Disease Mice Is Associated with Neurogenesis and Neurotrophic Activity. <i>PLoS ONE</i> , 2011, 6, e21660.	1.1	82
2629	Activation of JNK Signaling Mediates Amyloid- $\beta$ -Dependent Cell Death. <i>PLoS ONE</i> , 2011, 6, e24361.	1.1	75
2630	Reversal of Fragile X Phenotypes by Manipulation of A $\beta$ 2PP/A $\beta$ 2 Levels in Fmr1KO Mice. <i>PLoS ONE</i> , 2011, 6, e26549.	1.1	103
2631	Natural Amyloid-Beta Oligomers Acutely Impair the Formation of a Contextual Fear Memory in Mice. <i>PLoS ONE</i> , 2012, 7, e29940.	1.1	29
2632	Excitability and Synaptic Alterations in the Cerebellum of APP/PS1 Mice. <i>PLoS ONE</i> , 2012, 7, e34726.	1.1	36
2633	Amyloid-Beta (A $\beta$ 2) D7H Mutation Increases Oligomeric A $\beta$ 242 and Alters Properties of A $\beta$ 2-Zinc/Copper Assemblies. <i>PLoS ONE</i> , 2012, 7, e35807.	1.1	94
2634	Transcriptional Alterations Related to Neuropathology and Clinical Manifestation of Alzheimer's Disease. <i>PLoS ONE</i> , 2012, 7, e48751.	1.1	39
2635	Cell Therapy: A Safe and Efficacious Therapeutic Treatment for Alzheimer's Disease in APP+PS1 Mice. <i>PLoS ONE</i> , 2012, 7, e49468.	1.1	13
2636	Ferulic Acid Is a Nutraceutical $\beta$ -Secretase Modulator That Improves Behavioral Impairment and Alzheimer-like Pathology in Transgenic Mice. <i>PLoS ONE</i> , 2013, 8, e55774.	1.1	155
2637	NMDA-Receptor Activation but Not Ion Flux Is Required for Amyloid-Beta Induced Synaptic Depression. <i>PLoS ONE</i> , 2013, 8, e65350.	1.1	56

#	ARTICLE	IF	CITATIONS
2638	Amyloid- $\beta$ Protofibrils: Size, Morphology and Synaptotoxicity of an Engineered Mimic. PLoS ONE, 2013, 8, e66101.	1.1	46
2639	Opposite Roles of NMDA Receptors in Relapsing and Primary Progressive Multiple Sclerosis. PLoS ONE, 2013, 8, e67357.	1.1	29
2640	Continuation of Exercise Is Necessary to Inhibit High Fat Diet-Induced $\beta$ -Amyloid Deposition and Memory Deficit in Amyloid Precursor Protein Transgenic Mice. PLoS ONE, 2013, 8, e72796.	1.1	34
2641	Investigating Interventions in Alzheimer's Disease with Computer Simulation Models. PLoS ONE, 2013, 8, e73631.	1.1	28
2642	FLZ Alleviates the Memory Deficits in Transgenic Mouse Model of Alzheimer's Disease via Decreasing Beta-Amyloid Production and Tau Hyperphosphorylation. PLoS ONE, 2013, 8, e78033.	1.1	29
2643	Amyloid- $\beta$ and Proinflammatory Cytokines Utilize a Prion Protein-Dependent Pathway to Activate NADPH Oxidase and Induce Cofilin-Actin Rods in Hippocampal Neurons. PLoS ONE, 2014, 9, e95995.	1.1	58
2644	Di-Tyrosine Cross-Link Decreases the Collisional Cross-Section of $A\beta$ Peptide Dimers and Trimers in the Gas Phase: An Ion Mobility Study. PLoS ONE, 2014, 9, e100200.	1.1	23
2645	Methyllycaconitine Alleviates Amyloid- $\beta$ Peptides-Induced Cytotoxicity in SH-SY5Y Cells. PLoS ONE, 2014, 9, e111536.	1.1	29
2646	Alzheimer's Therapeutics Targeting Amyloid Beta 1-42 Oligomers I: Abeta 42 Oligomer Binding to Specific Neuronal Receptors Is Displaced by Drug Candidates That Improve Cognitive Deficits. PLoS ONE, 2014, 9, e111898.	1.1	120
2647	Amyloid $\beta$ -Mediated $Zn^{2+}$ Influx into Dentate Granule Cells Transiently Induces a Short-Term Cognitive Deficit. PLoS ONE, 2014, 9, e115923.	1.1	33
2648	Characterization of a Novel Mouse Model of Alzheimer's Disease Amyloid Pathology and Unique $\beta$ -Amyloid Oligomer Profile. PLoS ONE, 2015, 10, e0126317.	1.1	23
2649	Neuronal Cx3cr1 Deficiency Protects against Amyloid $\beta$ -Induced Neurotoxicity. PLoS ONE, 2015, 10, e0127730.	1.1	26
2650	Drosophila Eye Model to Study Neuroprotective Role of CREB Binding Protein (CBP) in Alzheimer's Disease. PLoS ONE, 2015, 10, e0137691.	1.1	47
2651	Optimization of the All-D Peptide D3 for $A\beta$ Oligomer Elimination. PLoS ONE, 2016, 11, e0153035.	1.1	20
2652	A IS FOR AMYLOID. Journal of prevention of Alzheimer's disease, The, 2020, 7, 1-2.	1.5	9
2653	Synaptic plasticity in Alzheimer's disease and healthy aging. Reviews in the Neurosciences, 2020, 31, 245-268.	1.4	46
2654	Functional Amyloids and their Possible Influence on Alzheimer Disease. Discoveries, 2017, 5, e79.	1.5	9
2655	Inhibitory Parvalbumin Basket Cell Activity is Selectively Reduced during Hippocampal Sharp Wave Ripples in a Mouse Model of Familial Alzheimer's Disease. Journal of Neuroscience, 2020, 40, 5116-5136.	1.7	47

#	ARTICLE	IF	CITATIONS
2656	Large Soluble Oligomers of Amyloid $\beta$ -Protein from Alzheimer Brain Are Far Less Neuroactive Than the Smaller Oligomers to Which They Dissociate. <i>Journal of Neuroscience</i> , 2017, 37, 152-163.	1.7	19
2658	GSK3 $\beta$ , not GSK3 $\alpha$ , drives hippocampal NMDAR-dependent LTD via tau-mediated spine anchoring. <i>EMBO Journal</i> , 2021, 40, e105513.	3.5	75
2659	Brain Capillaries in Alzheimer's Disease. <i>Journal of Neurology &amp; Stroke</i> , 2015, 2, .	0.0	10
2660	Alzheimer's disease: amyloid-based pathogenesis and potential therapies. <i>Cell Stress</i> , 2018, 2, 150-161.	1.4	27
2661	Effect of Amyloid $\beta$ - Peptide on Passive Avoidance Learning in Rats: A Behavioral Study. <i>Avicenna Journal of Neuro Psycho Physiology</i> , 2014, 1, .	0.1	7
2662	Alzheimer Diseases. <i>Avicenna Journal of Neuro Psycho Physiology</i> , 2014, 1, .	0.1	3
2663	A $\beta$ Plaques. <i>Free Neuropathology</i> , 2020, 1, .	2.4	21
2664	Detection of mis-folded protein aggregates from a clinical perspective. <i>Journal of Clinical and Translational Research</i> , 2016, 2, .	0.3	2
2665	<i>Codonopsis pilosula</i> polysaccharide attenuates A $\beta$ toxicity and cognitive defects in APP/PS1 mice. <i>Aging</i> , 2020, 12, 13422-13436.	1.4	33
2666	ATP synthase and Alzheimer's disease: putting a spin on the mitochondrial hypothesis. <i>Aging</i> , 2020, 12, 16647-16662.	1.4	33
2667	VGF expression by T lymphocytes in patients with Alzheimer's disease. <i>Oncotarget</i> , 2015, 6, 14843-14851.	0.8	20
2668	Short Communication: Protective Effects of <i>Cyperus Rotundus</i> Extract on Amyloid $\beta$ -Peptide (1-40)-Induced Memory Impairment in Male Rats: A Behavioral Study. <i>Basic and Clinical Neuroscience</i> , 2017, 8, 249-254.	0.3	18
2669	The Effects of Soluble A $\beta$ Oligomers on Neurodegeneration in Alzheimer's Disease. <i>Current Pharmaceutical Design</i> , 2014, 20, 2506-2519.	0.9	30
2670	The Potential Effect of Fluorinated Compounds in the Treatment of Alzheimer's Disease. <i>Current Pharmaceutical Design</i> , 2015, 21, 5725-5735.	0.9	7
2671	Dual Functional Small Molecule Probes as Fluorophore and Ligand for Misfolding Proteins. <i>Current Organic Chemistry</i> , 2013, 17, 580-593.	0.9	25
2672	Preventing the Spread of Alzheimer's Disease Neuropathology: A Role for Calcilytics?. <i>Current Pharmaceutical Biotechnology</i> , 2015, 16, 696-706.	0.9	12
2673	Cofilin/Actin Rod Formation by Dysregulation of Cofilin-1 Activity as a Central Initial Step in Neurodegeneration. <i>Mini-Reviews in Medicinal Chemistry</i> , 2014, 14, 393-400.	1.1	26
2674	Prion-like Mechanisms in Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2014, 11, 755-764.	0.7	27

#	ARTICLE	IF	CITATIONS
2675	Pathogenesis of Abeta Oligomers in Synaptic Failure. <i>Current Alzheimer Research</i> , 2013, 10, 316-323.	0.7	77
2676	Therapeutic Strategies Targeting Amyloid- $\beta^2$ in Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2019, 16, 418-452.	0.7	88
2677	Biological Evaluation of 8-Hydroxyquinolines as Multi-Target Directed Ligands for Treating Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2019, 16, 801-814.	0.7	5
2678	Aggregation Prone Regions and Gatekeeping Residues in Protein Sequences. <i>Current Topics in Medicinal Chemistry</i> , 2013, 12, 2470-2478.	1.0	51
2679	Emerging Promise of Immunotherapy for Alzheimer's Disease: A New Hope for the Development of Alzheimer's Vaccine. <i>Current Topics in Medicinal Chemistry</i> , 2020, 20, 1214-1234.	1.0	22
2680	Combining in vitro and in silico Approaches to Find New Candidate Drugs Targeting the Pathological Proteins Related to the Alzheimer's Disease. <i>Current Neuropharmacology</i> , 2018, 16, 758-768.	1.4	12
2681	Anti-Amyloid Effects of Small Molecule A $\beta$ -Binding Agents in PS1/APP Mice. <i>Letters in Drug Design and Discovery</i> , 2009, 6, 437-444.	0.4	21
2682	Gonadotropin-Releasing Hormone Receptor System: Modulatory Role in Aging and Neurodegeneration. <i>CNS and Neurological Disorders - Drug Targets</i> , 2010, 9, 651-660.	0.8	57
2683	Insulin and the Future Treatment of Alzheimer's Disease. <i>CNS and Neurological Disorders - Drug Targets</i> , 2016, 15, 660-664.	0.8	5
2684	Methods for Studying and Structure-Function Relationships of Non-Fibrillar Protein Assemblies in Alzheimer's Disease and Related Disorders. , 2014, , 291-374.		1
2685	Mechanism-based treatments for Alzheimer's disease. <i>Dialogues in Clinical Neuroscience</i> , 2009, 11, 159-169.	1.8	18
2686	AMPA receptor trafficking and the mechanisms underlying synaptic plasticity and cognitive aging. <i>Dialogues in Clinical Neuroscience</i> , 2013, 15, 11-27.	1.8	180
2687	Role of Body-Fluid Biomarkers in Alzheimer's Disease Diagnosis. <i>Diagnostics</i> , 2020, 10, 326.	1.3	12
2688	A current view of Alzheimer's disease. <i>F1000 Biology Reports</i> , 2009, 1, 54.	4.0	10
2689	Promising Results from Alzheimer's Disease Passive Immunotherapy Support the Development of a Preventive Vaccine. <i>Research</i> , 2019, 2019, 5341375.	2.8	18
2690	Single-Atom Nanozymes Linked Immunosorbent Assay for Sensitive Detection of A $\beta$ 1-40: A Biomarker of Alzheimer's Disease. <i>Research</i> , 2020, 2020, 4724505.	2.8	52
2691	Pelargonidin exhibits restoring effects against amyloid $\beta^2$ -induced deficits in the hippocampus of male rats. <i>Medical Journal of the Islamic Republic of Iran</i> , 2019, 33, 135.	0.9	8
2692	The Effects of Probiotic <i>Lactobacillus</i> and <i>Bifidobacterium</i> Strains on Memory and Learning Behavior, Long-Term Potentiation (LTP), and Some Biochemical Parameters in $\beta^2$ -Amyloid-Induced Rat's Model of Alzheimer's Disease. <i>Preventive Nutrition and Food Science</i> , 2019, 24, 265-273.	0.7	46

#	ARTICLE	IF	CITATIONS
2693	NKX6.3 protects against gastric mucosal atrophy by downregulating $\beta$ -amyloid production. World Journal of Gastroenterology, 2019, 25, 330-345.	1.4	3
2694	Neural stem cell transplantation improves learning and memory by protecting cholinergic neurons and restoring synaptic impairment in an amyloid precursor protein/presenilin 1 transgenic mouse model of Alzheimer's disease. Molecular Medicine Reports, 2020, 21, 1172-1180.	1.1	16
2695	Challenges in understanding the structure/activity relationship of $A\beta$ oligomers. AIMS Biophysics, 2019, 6, 1-22.	0.3	3
2696	Novel strategies for Alzheimer's disease treatment: An overview of anti-amyloid beta monoclonal antibodies. Indian Journal of Pharmacology, 2016, 48, 629.	0.4	57
2697	Vincamine alleviates amyloid- $\beta$ 25-35 peptides-induced cytotoxicity in PC12 cells. Pharmacognosy Magazine, 2017, 13, 123.	0.3	13
2698	The complexities underlying age-related macular degeneration: could amyloid beta play an important role?. Neural Regeneration Research, 2017, 12, 538.	1.6	34
2699	Protective effects of Bushen Tiansui decoction on hippocampal synapses in a rat model of Alzheimer's disease. Neural Regeneration Research, 2017, 12, 1680.	1.6	20
2700	Cognitive deficits and Alzheimer-like neuropathological impairments during adolescence in a rat model of type 2 diabetes mellitus. Neural Regeneration Research, 2018, 13, 1995.	1.6	18
2701	Glutamate receptor delocalization in postsynaptic membrane and reduced hippocampal synaptic plasticity in the early stage of Alzheimer's disease. Neural Regeneration Research, 2019, 14, 1037.	1.6	17
2702	Exploring the efficacy of natural products in alleviating Alzheimer's disease. Neural Regeneration Research, 2019, 14, 1321.	1.6	66
2703	Knowledge domain and emerging trends in Alzheimer's disease: a scientometric review based on CiteSpace analysis. Neural Regeneration Research, 2019, 14, 1643.	1.6	102
2704	Effects of Cyperus rotundus extract on spatial memory impairment and neuronal differentiation in rat model of Alzheimer's disease. Advanced Biomedical Research, 2020, 9, 17.	0.2	8
2705	Low-Intensity Light Therapy (1068 nm) Protects CAD Neuroblastoma Cells from $\beta$ -Amyloid-Mediated Cell Death. Biology and Medicine (Aligarh), 2014, 01, .	0.3	3
2706	Recent Understanding of the Molecular Mechanisms of Alzheimer's Disease. Journal of Addiction Research & Therapy, 0, s5, .	0.2	4
2707	Amyloid Beta and the Brain: Where Are We Now?. Journal of Biomolecular Research & Therapeutics, 2016, 5, .	0.2	1
2708	Computational Analyses of Docosahexaenoic Acid (DHA, C22:6, n-3) with Alzheimer's Disease-Causing Amyloid Peptide $A\beta$ 1-42 Reassures Its Therapeutic Utility. Advances in Alzheimer's Disease, 2016, 05, 73-86.	0.3	2
2709	Selective manipulation of aging: a novel strategy for the treatment of neurodegenerative disorders. Swiss Medical Weekly, 2014, 144, w13917.	0.8	11
2710	Toxic oligomer species of amyloid- $\beta$ in Alzheimer's disease, a timing issue. Swiss Medical Weekly, 2014, 144, w14021.	0.8	27



#	ARTICLE	IF	CITATIONS
2711	The regulation of exosome function in the CNS: implications for neurodegeneration. <i>Swiss Medical Weekly</i> , 2015, 145, w14204.	0.8	36
2712	Gains and losses on the road to understanding Alzheimer's disease. <i>Swiss Medical Weekly</i> , 2015, 145, w14233.	0.8	6
2713	Mechanisms of protein homeostasis in health, aging and disease. <i>Swiss Medical Weekly</i> , 2016, 146, w14306.	0.8	26
2714	It All Starts at the Ends: Multifaceted Involvement of C- and N-Terminally Modified Cholinesterases in Alzheimer's Disease. <i>Rambam Maimonides Medical Journal</i> , 2010, 1, e0014.	0.4	9
2715	Cerebrospinal fluid and blood biomarkers in Alzheimer's disease. <i>World Journal of Psychiatry</i> , 2011, 1, 8.	1.3	34
2716	Pin1 Protects Against Alzheimer's Disease: One Goal, Multiple Mechanisms. , 0, , .		2
2717	A native interactor scaffolds and stabilizes toxic ATAXIN-1 oligomers in SCA1. <i>ELife</i> , 2015, 4, .	2.8	29
2718	Somatostatin binds to the human amyloid $\beta$ peptide and favors the formation of distinct oligomers. <i>ELife</i> , 2017, 6, .	2.8	37
2719	Reversal of ApoE4-induced recycling block as a novel prevention approach for Alzheimer's disease. <i>ELife</i> , 2018, 7, .	2.8	62
2720	A small molecule targeting protein translation does not rescue spatial learning and memory deficits in the hAPP-J20 mouse model of Alzheimer's disease. <i>PeerJ</i> , 2016, 4, e2565.	0.9	20
2722	Mechanism of Cellular Formation and In Vivo Seeding Effects of Hexameric $\beta$ -Amyloid Assemblies. <i>Molecular Neurobiology</i> , 2021, 58, 6647-6669.	1.9	8
2724	Past, present and future of therapeutic strategies against amyloid- $\beta$ peptides in Alzheimer's disease: a systematic review. <i>Ageing Research Reviews</i> , 2021, 72, 101496.	5.0	131
2725	Investigating Pathogenetic Mechanisms of Alzheimer's Disease by Systems Biology Approaches for Drug Discovery. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11280.	1.8	3
2726	Association Between Plasma Amyloid- $\beta$ and Neuropsychological Performance in Patients With Cognitive Decline. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 736937.	1.7	10
2727	Exosomes in Alzheimer's Disease: From Being Pathological Players to Potential Diagnostics and Therapeutics. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10794.	1.8	32
2728	Ferulic Acid in Animal Models of Alzheimer's Disease: A Systematic Review of Preclinical Studies. <i>Cells</i> , 2021, 10, 2653.	1.8	21
2729	Amyloid $\beta$ structural polymorphism, associated toxicity and therapeutic strategies. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 7185-7198.	2.4	7
2730	Mesenchymal Stem Cell-Derived Extracellular Vesicle-Based Therapy for Alzheimer's Disease: Progress and Opportunity. <i>Membranes</i> , 2021, 11, 796.	1.4	11

#	ARTICLE	IF	CITATIONS
2731	Activation of PLC $\beta$ 1 enhances endocannabinoid mobilization to restore hippocampal spike-timing-dependent potentiation and contextual fear memory impaired by Alzheimer's amyloidosis. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 165.	3.0	2
2732	Cofilin and Actin Dynamics: Multiple Modes of Regulation and Their Impacts in Neuronal Development and Degeneration. <i>Cells</i> , 2021, 10, 2726.	1.8	49
2733	$\beta$ -Amyloid disruption of LTP/LTD balance is mediated by AKAP150-anchored PKA and Calcineurin regulation of Ca <sup>2+</sup> -permeable AMPA receptors. <i>Cell Reports</i> , 2021, 37, 109786.	2.9	28
2734	Prion protein. <i>The AFCS-nature Molecule Pages</i> , 0, , .	0.2	3
2735	One-Compound-Multi-Targets at Amyloid $\beta$ Cascade Offered By Bis(7)-Cognitin, a Novel Anti-Alzheimer's Dimer. , 2010, , 165-183.		0
2736	Synapses and Alzheimer's Disease: Effect of Immunotherapy?. , 2011, , 269-287.		0
2737	Pathological Validation of Animal Models of Dementia. <i>Neuromethods</i> , 2011, , 99-141.	0.2	1
2739	Pathogenesis of Alzheimer's Disease with Special Reference to Amyloid $\beta$ Protein. <i>Nihon Ika Daigaku Igakkai Zasshi</i> , 2012, 8, 285-290.	0.0	0
2740	Chronic psychosocial stress exposes Alzheimer's disease phenotype in a novel at-risk model. <i>Frontiers in Bioscience - Elite</i> , 2012, E4, 214.	0.9	7
2741	The Amyloid $\beta$ -Protein and Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2012, , 1-85.	0.0	0
2742	The Current Status of Alzheimer's Disease Treatment. <i>Frontiers in Neuroscience</i> , 2012, , 117-161.	0.0	0
2743	Emerging Principles and Biomarkers in In Vitro Diagnostics for Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2012, , 87-102.	0.0	0
2744	Role of Cellular Prion Protein in the Amyloid- $\beta$ Oligomer Pathophysiology of Alzheimer's Disease. , 2013, , 35-48.		0
2745	Herpes Simplex Virus 1 (HSV-1)-Based Vectors. <i>Neuromethods</i> , 2014, , 51-93.	0.2	0
2746	Animal Models of Alzheimer's Disease. <i>Springer Protocols</i> , 2014, , 527-540.	0.1	0
2747	Long-Term Depression and Memory. , 2014, , 1-7.		0
2748	Mapping It out: A Novel Signaling Pathway Linking $\beta$ -PrP <sup>C</sup> -Fyn Complex to Cognitive Impairment in Alzheimer's Disease. <i>Advances in Alzheimer's Disease</i> , 2014, 03, 20-23.	0.3	0
2749	Neuroprotectants: Novel Approaches for Dementias. , 2014, , 1-5.		0

#	ARTICLE	IF	CITATIONS
2750	Potential Therapeutic Effects of Statins in Alzheimer's Disease. , 2014, , 2339-2354.		0
2751	Mitochondria and Alzheimer's Disease. Journal of Neurology & Stroke, 2014, 1, .	0.0	3
2752	Neuroprotectants: Novel Approaches for Dementias. , 2015, , 1073-1076.		0
2755	Periodontal Disease as a Possible Risk Factor for Alzheimer's Disease. , 2015, , 237-243.		0
2756	Protein Misfolding and Aggregation. Biological and Medical Physics Series, 2015, , 95-127.	0.3	0
2757	New Frontiers in Alzheimer's Disease Diagnosis. , 0, , .		0
2758	The Application of Biophysical Techniques to the Study of the Inhibition of Aggregation of A $\beta$ Using PINPs Liposomes. Springer Theses, 2016, , 121-137.	0.0	0
2759	Pathological Consequences of A $\beta$ From Extracellular to Intraneuronal. , 2016, , 69-113.		0
2760	Scanning Probe Microscopy Methods of Imaging Amyloid Peptides During the Aggregation Process. Springer Theses, 2016, , 87-106.	0.0	0
2771	A Novel Preclinical Rat Model of Alzheimer's Disease. Neuromethods, 2020, , 69-98.	0.2	0
2772	Mild Cognitive Impairment and Early Dementia. , 2020, , 215-236.		0
2775	GluA3-containing AMPA receptors: From physiology to synaptic dysfunction in brain disorders. Neurobiology of Disease, 2021, 161, 105539.	2.1	8
2780	Sleep-dependent cellular chemical changes in the aging brain. , 2020, , 71-80.		0
2782	Asymptomatic neurotoxicity of amyloid $\beta$ -peptides (A $\beta$ <sup>1-42</sup> and A $\beta$ <sup>25-35</sup> ) on mouse embryonic stem cell-derived neural cells. Bosnian Journal of Basic Medical Sciences, 2021, 21, 98-110.	0.6	3
2783	Characterization of Alzheimer's disease-like neuropathology in Duchenne's muscular dystrophy using the DBA/2J <i>mdx</i> mouse model. FEBS Open Bio, 2022, 12, 154-162.	1.0	11
2784	SPG302 Reverses Synaptic and Cognitive Deficits Without Altering Amyloid or Tau Pathology in a Transgenic Model of Alzheimer's Disease. Neurotherapeutics, 2021, 18, 2468-2483.	2.1	5
2787	Promising molecular targets for pharmacological therapy of neurodegenerative pathologies. Acta Naturae, 2020, 12, 60-80.	1.7	3
2793	Reelin-mediated Signaling during Normal and Pathological Forms of Aging. , 2010, 1, 12-29.		15

#	ARTICLE	IF	CITATIONS
2795	Current neuroimaging techniques in Alzheimer's disease and applications in animal models. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 2, 386-404.	1.0	20
2796	The protection of acetylcholinesterase inhibitor on $\text{A}\beta$ -induced the injury of neurite outgrowth via regulating axon guidance related genes expression in neuronal cells. <i>International Journal of Clinical and Experimental Pathology</i> , 2012, 5, 900-13.	0.5	6
2797	Advances in the development of vaccines for Alzheimer's disease. <i>Discovery Medicine</i> , 2013, 15, 319-26.	0.5	57
2798	Rapamycin, Autophagy, and Alzheimer's Disease. <i>Journal of Biochemical and Pharmacological Research</i> , 2013, 1, 84-90.	1.7	52
2799	An exploration of the potential mechanisms and translational potential of five medicinal plants for applications in Alzheimer's disease. <i>American Journal of Neurodegenerative Disease</i> , 2013, 2, 70-88.	0.1	7
2801	High-resolution optical tweezers for single-molecule manipulation. <i>Yale Journal of Biology and Medicine</i> , 2013, 86, 367-83.	0.2	30
2802	Construction of human Fab library and screening of a single-domain antibody of amyloid-beta 42 oligomers. <i>Neural Regeneration Research</i> , 2013, 8, 3107-15.	1.6	5
2803	Novel immunological approaches for the treatment of Alzheimer's disease. <i>Chinese Journal of Contemporary Neurology and Neurosurgery</i> , 2014, 14, 139-151.	0.0	0
2806	Amyloid-beta Alzheimer targets - protein processing, lipid rafts, and amyloid-beta pores. <i>Yale Journal of Biology and Medicine</i> , 2016, 89, 5-21.	0.2	71
2807	Alzheimer's Toxic Amyloid Beta Oligomers: Unwelcome Visitors to the Na/K ATPase alpha3 Docking Station. <i>Yale Journal of Biology and Medicine</i> , 2017, 90, 45-61.	0.2	23
2808	Detection of misfolded protein aggregates from a clinical perspective. <i>Journal of Clinical and Translational Research</i> , 2016, 2, 11-26.	0.3	3
2809	Specific knockdown of hippocampal astroglial EphB2 improves synaptic function via inhibition of D-serine secretion in APP/PS1 mice. <i>American Journal of Translational Research (discontinued)</i> , 2019, 11, 1073-1083.	0.0	2
2811	Therapeutic potential of against the $\text{A}\beta$ -induced oxidative stress and mitochondrial dysfunction in the rats. <i>American Journal of Neurodegenerative Disease</i> , 2021, 10, 13-27.	0.1	1
2812	Formaldehyde toxicity in age-related neurological dementia. <i>Ageing Research Reviews</i> , 2022, 73, 101512.	5.0	30
2813	An ultra-sensitive immunoassay detects and quantifies soluble $\text{A}\beta$ oligomers in human plasma. <i>Alzheimer's and Dementia</i> , 2022, 18, 1186-1202.	0.4	18
2814	Prions and Neurodegenerative Diseases: A Focus on Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2022, 85, 503-518.	1.2	17
2815	Advances in Proteasome Enhancement by Small Molecules. <i>Biomolecules</i> , 2021, 11, 1789.	1.8	13
2816	Significance of GABAA Receptor for Cognitive Function and Hippocampal Pathology. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12456.	1.8	23

#	ARTICLE	IF	CITATIONS
2817	Administration of anti-ERMAP antibody ameliorates Alzheimer's disease in mice. <i>Journal of Neuroinflammation</i> , 2021, 18, 268.	3.1	6
2818	Revisit the Cellular Transmission and Emerging Techniques in Understanding the Mechanisms of Proteinopathies. <i>Frontiers in Neuroscience</i> , 2021, 15, 781722.	1.4	1
2819	Positron Emission Tomography in Animal Models of Alzheimer's Disease Amyloidosis: Translational Implications. <i>Pharmaceuticals</i> , 2021, 14, 1179.	1.7	13
2820	Adiponectin Ameliorates Cognitive Behaviors and in vivo Synaptic Plasticity Impairments in 3xTg-AD Mice. <i>Journal of Alzheimer's Disease</i> , 2022, 85, 343-357.	1.2	7
2821	Precision Mapping of Amyloid- $\beta^2$ Binding Reveals Perisynaptic Localization and Spatially Restricted Plasticity Deficits. <i>ENeuro</i> , 2021, , ENEURO.0416-21.2021.	0.9	2
2822	Presenilin/ $\beta^3$ -Secretase Activity Is Located in Acidic Compartments of Live Neurons. <i>Journal of Neuroscience</i> , 2022, 42, 145-154.	1.7	19
2823	New Prospects for Stem Cell Therapy in Alzheimer's Disease. , 0, , .		0
2824	Inhibitor-Mediated Structural Transition in a Minimal Amyloid Model. <i>Angewandte Chemie - International Edition</i> , 2022, 61, e202113845.	7.2	7
2825	Magnetic Resonance Imaging in Animal Models of Alzheimer's Disease Amyloidosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12768.	1.8	18
2826	Proteotoxicity and Autophagy in Neurodegenerative and Cardiovascular Diseases. , 2022, , 219-237.		0
2827	Discovery of a novel pseudo $\beta^2$ -hairpin structure of N-truncated amyloid- $\beta^2$ for use as a vaccine against Alzheimer's disease. <i>Molecular Psychiatry</i> , 2021, , .	4.1	11
2828	Biological and methodological complexities of beta-amyloid peptide: Implications for Alzheimer's disease research. <i>Journal of Neurochemistry</i> , 2022, 160, 434-453.	2.1	12
2829	Localised streptozotocin-induced structural and cognitive changes in the hippocampal cornu ammonis 1 (CA-1) neurons and mitigating effects of <i>Zingiber officinale</i> . <i>Phytomedicine Plus</i> , 2021, 2, 100162.	0.9	2
2830	Inhibitor-Mediated Structural Transition in a Minimal Amyloid Model. <i>Angewandte Chemie</i> , 0, , .	1.6	0
2831	Analyzing Morphological Properties of Early-Stage Toxic Amyloid $\beta^2$ Oligomers by Atomic Force Microscopy. <i>Methods in Molecular Biology</i> , 2022, 2402, 227-241.	0.4	2
2832	Knowledge of Dementia Treatment : Prospects for Disease-modifying Therapy in Alzheimer's Disease. <i>Japanese Journal of Neurosurgery</i> , 2021, 30, 840-844.	0.0	0
2833	Downregulation of TREM2 expression exacerbates neuroinflammatory responses through TLR4-mediated MAPK signaling pathway in a transgenic mouse model of Alzheimer's disease. <i>Molecular Immunology</i> , 2022, 142, 22-36.	1.0	17
2834	Treadmill Exercise Prevents Decline in Spatial Learning and Memory in 3xTg-AD Mice through Enhancement of Structural Synaptic Plasticity of the Hippocampus and Prefrontal Cortex. <i>Cells</i> , 2022, 11, 244.	1.8	30

#	ARTICLE	IF	CITATIONS
2835	Protein degradation-associated mechanisms that are affected in Alzheimer's disease. <i>Molecular and Cellular Biochemistry</i> , 2022, 477, 915-925.	1.4	9
2836	Administration of mucuna beans ( <i>Mucuna pruriens</i> (L.) DC. var. <i>utilis</i> ) improves cognition and neuropathology of 3xTg-AD mice. <i>Scientific Reports</i> , 2022, 12, 996.	1.6	4
2837	Red-Beet Betalain Pigments Inhibit Amyloid- $\beta$ Aggregation and Toxicity in Amyloid- $\beta$ Expressing <i>Caenorhabditis elegans</i> . <i>Plant Foods for Human Nutrition</i> , 2022, 77, 90-97.	1.4	9
2838	Basic mechanisms of plasticity and learning. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2022, 184, 21-34.	1.0	9
2839	Trans $\beta$ -Viniferin Decreases Amyloid Deposits With Greater Efficiency Than Resveratrol in an Alzheimer's Mouse Model. <i>Frontiers in Neuroscience</i> , 2021, 15, 803927.	1.4	3
2840	Ursolic acid ameliorates amyloid $\beta$ -induced pathological symptoms in <i>Caenorhabditis elegans</i> by activating the proteasome. <i>NeuroToxicology</i> , 2022, 88, 231-240.	1.4	11
2841	Leptin participation in the processes of nervous impulse transmission and its influence on the formation of neuro-mental development of children. <i>Pacific Medical Journal</i> , 2022, , 21-25.	0.0	0
2842	Chemical Regulation of the Protein Quality Control E3 Ubiquitin Ligase C-terminal of Hsc70 Interacting Protein (CHIP). <i>ChemBioChem</i> , 2022, , .	1.3	1
2843	A calcium-sensitive antibody isolates soluble amyloid- $\beta$ aggregates and fibrils from Alzheimer's disease brain. <i>Brain</i> , 2022, , .	3.7	7
2844	A Disulfide-Stabilized $A\beta$ that Forms Dimers but Does Not Form Fibrils. <i>Biochemistry</i> , 2022, 61, 252-264.	1.2	4
2845	Recent Developments in Positron Emission Tomography Tracers for Proteinopathies Imaging in Dementia. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 751897.	1.7	12
2846	Mechanistic and therapeutic role of Drp1 in the pathogenesis of Alzheimer's disease. <i>European Journal of Neuroscience</i> , 2022, 56, 5516-5531.	1.2	13
2847	Disrupted neural correlates of anesthesia and sleep reveal early circuit dysfunctions in Alzheimer models. <i>Cell Reports</i> , 2022, 38, 110268.	2.9	13
2848	Amyloid- $\beta$ oligomers in the nucleus accumbens decrease motivation via insertion of calcium-permeable AMPA receptors. <i>Molecular Psychiatry</i> , 2022, 27, 2146-2157.	4.1	5
2849	Toward noninvasive brain stimulation 2.0 in Alzheimer's disease. <i>Ageing Research Reviews</i> , 2022, 75, 101555.	5.0	37
2850	Amyloid $\beta$ interaction with model cell membranes – What are the toxicity-defining properties of amyloid $\beta$ ?. <i>International Journal of Biological Macromolecules</i> , 2022, 200, 520-531.	3.6	19
2851	Targeting hippocampal amyloidogenesis with SV2A protein modulator levetiracetam. <i>Biochemical Pharmacology</i> , 2022, 197, 114927.	2.0	0
2852	The extraction, antioxidant and against $\beta$ -amyloid induced toxicity of polyphenols from <i>Alsephila spinulosa</i> leaves. <i>Arabian Journal of Chemistry</i> , 2022, 15, 103707.	2.3	7

#	ARTICLE	IF	CITATIONS
2853	Early aggregation mechanism of A $\beta$ 16~22 revealed by Markov state models. <i>International Journal of Biological Macromolecules</i> , 2022, 204, 606-616.	3.6	5
2854	Molecular insights into the primary nucleation of polymorphic amyloid $\beta$ 2 dimers in <sc>DOPC</sc> lipid bilayer membrane. <i>Protein Science</i> , 2022, 31, .	3.1	17
2855	Hydrogel-Coated Gate Field-Effect Transistor for Real-Time and Label-Free Monitoring of $\beta$ 2-Amyloid Aggregation and Its Inhibition. <i>Analytical Chemistry</i> , 2022, , .	3.2	2
2856	Proteasome activity modulates amyloid toxicity. <i>FEMS Yeast Research</i> , 2022, 22, .	1.1	1
2857	Mitochondrial and Golgi Apparatus™ Alterations in Alzheimer™s Disease: A Study of the Cerebellar Cortex Based on Silver Impregnation Technique and Electron Microscopy. , 2014, , 3-27.		1
2858	Molecular dynamics simulations of amyloid- $\beta$ 2 peptides in heterogeneous environments. <i>Biophysics and Physicobiology</i> , 2022, 19, n/a.	0.5	3
2859	All-Atom Molecular Dynamics Simulation Methods for the Aggregation of Protein and Peptides: Replica Exchange/Permutation and Nonequilibrium Simulations. <i>Methods in Molecular Biology</i> , 2022, 2340, 197-220.	0.4	5
2860	Amyloid- $\beta$ 242 stimulated hippocampal lactate release is coupled to glutamate uptake. <i>Scientific Reports</i> , 2022, 12, 2775.	1.6	4
2861	Bioavailability and Health Impact of Ingested Amyloid™like Protein Fibrils and their Link with Inflammatory Status: A Need for More Research?. <i>Molecular Nutrition and Food Research</i> , 2022, , 2101032.	1.5	2
2862	N-Acetyl-Cysteine: Modulating the Cysteine Redox Proteome in Neurodegenerative Diseases. <i>Antioxidants</i> , 2022, 11, 416.	2.2	10
2863	Optogenetics: implications for Alzheimer™s disease research and therapy. <i>Molecular Brain</i> , 2022, 15, 20.	1.3	14
2864	Amyloidosis in Alzheimer™s Disease: Pathogeny, Etiology, and Related Therapeutic Directions. <i>Molecules</i> , 2022, 27, 1210.	1.7	45
2865	Advances in stem cell therapy in Alzheimer™s disease: a comprehensive clinical trial review. <i>Stem Cell Investigation</i> , 2022, 9, 2-2.	1.3	8
2866	Structure Optimization of the Toxic Conformation Model of Amyloid $\beta$ 242 by Intramolecular Disulfide Bond Formation. <i>ChemBioChem</i> , 2022, 23, .	1.3	7
2867	Copper-mediated $\beta$ 2-amyloid toxicity and its chelation therapy in Alzheimer's disease. <i>Metallomics</i> , 2022, 14, .	1.0	17
2868	Memantine-Derived Schiff Bases as Transdermal Prodrug Candidates. <i>ACS Omega</i> , 2022, 7, 11678-11687.	1.6	2
2869	Amyloid- $\beta$ 242 oligomeric forms: AFM nanoscale structural characterization and impact on long-term memory of young and aged zebrafish. <i>Neuroscience</i> , 2022, , .	1.1	2
2871	Potential Mechanisms Underlying Resistance to Dementia in Non-Demented Individuals with Alzheimer™s Disease Neuropathology. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 51-81.	1.2	14



#	ARTICLE	IF	CITATIONS
2872	Structural Plasticity of the Hippocampus in Neurodegenerative Diseases. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3349.	1.8	34
2873	From synapses to circuits and back: Bridging levels of understanding in animal models of Alzheimer's disease. <i>European Journal of Neuroscience</i> , 2022, 56, 5564-5586.	1.2	2
2874	Microglial large extracellular vesicles propagate early synaptic dysfunction in Alzheimer's disease. <i>Brain</i> , 2022, 145, 2849-2868.	3.7	32
2875	Lesions without symptoms: understanding resilience to Alzheimer disease neuropathological changes. <i>Nature Reviews Neurology</i> , 2022, 18, 323-332.	4.9	29
2876	PCSK9 acts as a key regulator of A $\beta$ clearance across the blood-brain barrier. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 212.	2.4	16
2877	Mechanistic Insights into Selective Autophagy Subtypes in Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3609.	1.8	14
2878	Impairments of glutamatergic synaptic transmission in Alzheimer's disease. <i>Seminars in Cell and Developmental Biology</i> , 2023, 139, 24-34.	2.3	15
2879	A $\beta$ /tau oligomer interplay at human synapses supports shifting therapeutic targets for Alzheimer's disease. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 222.	2.4	14
2880	Eugenitol ameliorates memory impairments in 5XFAD mice by reducing A $\beta$ plaques and neuroinflammation. <i>Biomedicine and Pharmacotherapy</i> , 2022, 148, 112763.	2.5	4
2881	Altered pain sensitivity in 5 $\times$ familial Alzheimer disease mice is associated with dendritic spine loss in anterior cingulate cortex pyramidal neurons. <i>Pain</i> , 2022, 163, 2138-2153.	2.0	2
2882	The HSP40 chaperone Ydj1 drives amyloid beta 42 toxicity. <i>EMBO Molecular Medicine</i> , 2022, 14, e13952.	3.3	16
2883	Effects of involuntary treadmill running in combination with swimming on adult neurogenesis in an Alzheimer's mouse model. <i>Neurochemistry International</i> , 2022, 155, 105309.	1.9	4
2884	The Impact of Medium Chain and Polyunsaturated $\omega$ -3-Fatty Acids on Amyloid- $\beta$ Deposition, Oxidative Stress and Metabolic Dysfunction Associated with Alzheimer's Disease. <i>Antioxidants</i> , 2021, 10, 1991.	2.2	15
2885	MicroRNA-155-5p Targets SKP2, Activates IKK $\beta$ , Increases A $\beta$ Aggregation, and Aggravates a Mouse Alzheimer Disease Model. <i>Journal of Neuropathology and Experimental Neurology</i> , 2022, 81, 16-26.	0.9	6
2886	Long-term dynamics of aberrant neuronal activity in awake Alzheimer's disease transgenic mice. <i>Communications Biology</i> , 2021, 4, 1368.	2.0	14
2887	Evaluating effect of metallic ions on aggregation behavior of $\beta$ -amyloid peptides by atomic force microscope and surface-enhanced Raman Scattering. <i>BioMedical Engineering OnLine</i> , 2021, 20, 132.	1.3	6
2888	Lack of association between cortical amyloid deposition and glucose metabolism in early stage Alzheimer's disease patients. <i>Radiology and Oncology</i> , 2021, 56, 23-31.	0.6	0
2889	Modulating adult neurogenesis affects synaptic plasticity and cognitive functions in mouse models of Alzheimer's disease. <i>Stem Cell Reports</i> , 2021, 16, 3005-3019.	2.3	21

#	ARTICLE	IF	CITATIONS
2890	Astrocytic Cx36 motif chemokine ligand-1 mediates $\beta^2$ -amyloid-induced synaptotoxicity. <i>Journal of Neuroinflammation</i> , 2021, 18, 306.	3.1	16
2891	Friend or Foe? The Varied Faces of Homeostatic Synaptic Plasticity in Neurodegenerative Disease. <i>Frontiers in Cellular Neuroscience</i> , 2021, 15, 782768.	1.8	6
2892	Rational Design of a Cu Chelator That Mitigates Cu-Induced ROS Production by Amyloid Beta. <i>ChemBioChem</i> , 2022, 23, .	1.3	2
2893	Molecular Dynamics Simulation Studies on the Aggregation of Amyloid- $\beta^2$ Peptides and Their Disaggregation by Ultrasonic Wave and Infrared Laser Irradiation. <i>Molecules</i> , 2022, 27, 2483.	1.7	8
2894	Modulation of Amyloid $\beta^2$ -Induced Microglia Activation and Neuronal Cell Death by Curcumin and Analogues. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4381.	1.8	7
2895	Inhibition of Nogo-A rescues synaptic plasticity and associativity in APP/PS1 animal model of Alzheimer's disease. <i>Seminars in Cell and Developmental Biology</i> , 2023, 139, 111-120.	2.3	9
2896	The synapse as a treatment avenue for Alzheimer's Disease. <i>Molecular Psychiatry</i> , 2022, 27, 2940-2949.	4.1	48
2928	Involvement of cholesterol and $\beta^2$ -amyloid in the initiation and progression of Alzheimer's disease. , 2022, , 715-745.		0
2930	Autophagy Modulation in Aggresome Formation: Emerging Implications and Treatments of Alzheimer's Disease. <i>Biomedicines</i> , 2022, 10, 1027.	1.4	11
2931	Nicotinic Acetylcholine Receptors and Microglia as Therapeutic and Imaging Targets in Alzheimer's Disease. <i>Molecules</i> , 2022, 27, 2780.	1.7	10
2932	Bioactive human Alzheimer brain soluble $A\beta^2$ : pathophysiology and therapeutic opportunities. <i>Molecular Psychiatry</i> , 2022, 27, 3182-3191.	4.1	14
2933	Vagus Nerve Stimulation as a Potential Therapy in Early Alzheimer's Disease: A Review. <i>Frontiers in Human Neuroscience</i> , 2022, 16, 866434.	1.0	25
2934	Aluminium oxide nanoparticles compromise spatial memory performance and proBDNF-mediated neuronal function in the hippocampus of rats. <i>Particle and Fibre Toxicology</i> , 2022, 19, 34.	2.8	10
2935	Blocking Site-Specific Cleavage of Human Tau Delays Progression of Disease-Related Phenotypes in Genetically Matched Tau-Transgenic Mice Modeling Frontotemporal Dementia. <i>Journal of Neuroscience</i> , 2022, 42, 4737-4754.	1.7	5
2936	$A\beta^2$ -induced synaptic impairments require CaMKII activity that is stimulated by indirect signaling events. <i>IScience</i> , 2022, 25, 104368.	1.9	0
2937	Elevated spermidine serum levels in mild cognitive impairment, a potential biomarker of progression to Alzheimer dementia, a pilot study. <i>Journal of Clinical Neuroscience</i> , 2022, 100, 169-174.	0.8	5
2938	Comparative studies for amyloid beta degradation: $\beta$ -Nepriylisin vs insulysin, $\beta$ -monomeric vs aggregate, and whole $A\beta^{240}$ vs its peptide fragments. <i>Biochemistry and Biophysics Reports</i> , 2022, 30, 101268.	0.7	6
2939	Constructing conformational library for amyloid- $\beta^{242}$ dimers as the smallest toxic oligomers using two CHARMM force fields. <i>Journal of Molecular Graphics and Modelling</i> , 2022, 115, 108207.	1.3	5

#	ARTICLE	IF	CITATIONS
2940	Amyloid- $\beta^2$ Oligomers: Multiple Moving Targets. <i>Biophysica</i> , 2022, 2, 91-110.	0.6	17
2941	Regulation and function of eIF2B in neurological and metabolic disorders. <i>Bioscience Reports</i> , 2022, 42, .	1.1	9
2942	Traumatic axonal injury as a key driver of the relationship between traumatic brain injury, cognitive dysfunction, and dementia. , 2022, , 475-486.		0
2943	Conformational strains of pathogenic amyloid proteins in neurodegenerative diseases. <i>Nature Reviews Neuroscience</i> , 2022, 23, 523-534.	4.9	43
2944	Novel Stilbene-Nitroxyl Hybrid Compounds Display Discrete Modulation of Amyloid Beta Toxicity and Structure. <i>Frontiers in Chemistry</i> , 2022, 10, .	1.8	1
2945	PathogÃ©nie et physiopathologie de la maladie d'Alzheimer. , 2022, , 17-28.		0
2946	Amyloid Beta Peptide-Mediated Alterations in Mitochondrial Dynamics and its Implications for Alzheimer's Disease. <i>CNS and Neurological Disorders - Drug Targets</i> , 2023, 22, 1039-1056.	0.8	1
2947	Decreased Frontal Gamma Activity in Alzheimer Disease Patients. <i>Annals of Neurology</i> , 2022, 92, 464-475.	2.8	24
2948	p38 MAPK Is a Major Regulator of Amyloid Beta-Induced IL-6 Expression in Human Microglia. <i>Molecular Neurobiology</i> , 2022, 59, 5284-5298.	1.9	7
2952	Toxicity Mechanism of A $\beta^{242}$ Oligomer in the Binding between the GABA <sub>B</sub> R1a sushi1 Domain and Amyloid Precursor Protein 9mer: A Mechanism like Substitution Reaction. <i>ACS Chemical Neuroscience</i> , 2022, 13, 2048-2059.	1.7	1
2955	Possible Neuropathology of Sleep Disturbance Linking to Alzheimer's Disease: Astrocytic and Microglial Roles. <i>Frontiers in Cellular Neuroscience</i> , 0, 16, .	1.8	9
2956	Near-Infrared Fluorescent Probes as Imaging and Theranostic Modalities for Amyloid-Beta and Tau Aggregates in Alzheimer's Disease. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 8550-8595.	2.9	29
2957	Phenazopyridine promotes RPS23RG1/Rps23rg1 transcription and ameliorates Alzheimer-associated phenotypes in mice. <i>Neuropsychopharmacology</i> , 0, , .	2.8	0
2959	Joint Computational/Cell-Based Approach for Screening Inhibitors of Tau Oligomerization: A Proof-of-Concept Study. <i>Journal of Alzheimer's Disease</i> , 2022, 89, 107-119.	1.2	2
2960	Effect of Cholesterol on C99 Dimerization: Revealed by Molecular Dynamics Simulations. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	2
2961	Stigmasterol attenuates inflammatory response of microglia via NF- $\kappa$ B and NLRP3 signaling by AMPK activation. <i>Biomedicine and Pharmacotherapy</i> , 2022, 153, 113317.	2.5	29
2962	A $\beta^2$ oligomers from human brain impair mossy fiber LTP in CA3 of hippocampus, but activating cAMP-PKA and cGMP-PKG prevents this. <i>Neurobiology of Disease</i> , 2022, 172, 105816.	2.1	8
2963	Mathematical model of Alzheimer's disease with prion proteins interactions and treatment. <i>Applied Mathematics and Computation</i> , 2022, 433, 127377.	1.4	4

#	ARTICLE	IF	CITATIONS
2964	Inhibition of Rac1 in ventral hippocampal excitatory neurons improves social recognition memory and synaptic plasticity. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	3
2965	Beyond Amyloid Fibers: Accumulation, Biological Relevance, and Regulation of Higher-Order Prion Architectures. <i>Viruses</i> , 2022, 14, 1635.	1.5	4
2966	Synaptic Disruption by Soluble Oligomers in Patients with Alzheimerâ€™s and Parkinsonâ€™s Disease. <i>Biomedicines</i> , 2022, 10, 1743.	1.4	6
2968	Treatment of Alzheimer&rsquo;s disease by promoting the aggregation of small &beta;-amyloid peptides. <i>Scientia Sinica Vitae</i> , 2022, 52, 1184-1191.	0.1	2
2969	Binding Models of A $\beta$ 242 Peptide with Membranes Explored by Molecular Simulations. <i>Journal of Chemical Information and Modeling</i> , 2022, 62, 6482-6493.	2.5	6
2970	Extracellular vesicles and Alzheimerâ€™s disease in the novel era of Precision Medicine: implications for disease progression, diagnosis and treatment. <i>Experimental Neurology</i> , 2022, 358, 114183.	2.0	10
2971	Role of A $\beta$ 2 in Alzheimerâ€™s-related synaptic dysfunction. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	19
2972	A $\beta$ 242 oligomers trigger synaptic loss through CAMKK2-AMPK-dependent effectors coordinating mitochondrial fission and mitophagy. <i>Nature Communications</i> , 2022, 13, .	5.8	28
2973	Modeling the early stages of Alzheimerâ€™s disease by administering intracerebroventricular injections of human native A $\beta$ 2 oligomers to rats. <i>Acta Neuropathologica Communications</i> , 2022, 10, .	2.4	11
2974	Supramolecular organizing centers at the interface of inflammation and neurodegeneration. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
2975	Synthesis and Characterization of Propeller- and Parallel-Type Full-Length Amyloid $\beta$ 240 Trimer Models. <i>ACS Chemical Neuroscience</i> , 2022, 13, 2517-2528.	1.7	3
2976	News story miscasts Alzheimerâ€™s science. <i>Science</i> , 2022, 377, 934-935.	6.0	3
2977	Astrocyte energy and neurotransmitter metabolism in Alzheimerâ€™s disease: Integration of the glutamate/GABA-glutamine cycle. <i>Progress in Neurobiology</i> , 2022, 217, 102331.	2.8	69
2978	A systematic review on drugs for synaptic plasticity in the treatment of dementia. <i>Ageing Research Reviews</i> , 2022, 81, 101726.	5.0	6
2979	Signaling interactions among neurons impact cell fitness and death in Alzheimerâ€™s disease. <i>Neural Regeneration Research</i> , 2023, 18, 784.	1.6	4
2980	Locomotor Hyperactivity in the Early-Stage Alzheimerâ€™s Disease-like Pathology of APP/PS1 Mice: Associated with Impaired Polarization of Astrocyte Aquaporin 4. , 2022, 13, 1504.		8
2981	Recent advances in small molecular near-infrared fluorescence probes for a targeted diagnosis of the Alzheimer disease. <i>Analyst, The</i> , 2022, 147, 4701-4723.	1.7	26
2982	Based on molecular structures: Amyloid- $\beta$ 2 generation, clearance, toxicity and therapeutic strategies. <i>Frontiers in Molecular Neuroscience</i> , 0, 15, .	1.4	6

#	ARTICLE	IF	CITATIONS
2983	Circular RNAs in Alzheimer's Disease: A New Perspective of Diagnostic and Therapeutic Targets. <i>CNS and Neurological Disorders - Drug Targets</i> , 2023, 22, 1335-1354.	0.8	7
2984	TRPV1 Modulator Ameliorates Alzheimer-Like Amyloid- $\beta$ Neuropathology via Akt/Gsk3 $\beta$ -Mediated Nrf2 Activation in the Neuro-2a/APP Cell Model. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-15.	1.9	1
2985	Pin1 and Alzheimer's disease. <i>Translational Research</i> , 2023, 254, 24-33.	2.2	2
2986	Elevated ganglioside GM2 activator (GM2A) in human brain tissue reduces neurite integrity and spontaneous neuronal activity. <i>Molecular Neurodegeneration</i> , 2022, 17, .	4.4	5
2987	Optimization of the Linker Length in the Dimer Model of E22P-A $\beta$ 40 Tethered at Position 38. <i>ACS Chemical Neuroscience</i> , 2022, 13, 2913-2923.	1.7	4
2988	Concentration-Dependent Effects of Cholesterol on the Dimerization of Amyloid- $\beta$ Peptides in Lipid Bilayers. <i>ACS Chemical Neuroscience</i> , 2022, 13, 2709-2718.	1.7	2
2990	Novel Anti-Neuroinflammatory Properties of a Thiosemicarbazone-Pyridylhydrazone Copper(II) Complex. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10722.	1.8	5
2991	The Therapeutic Effects of Seven Lycophyte Compounds on Cell Models of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-15.	1.2	1
2992	Covalent fragment inhibits intramembrane proteolysis. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	0
2993	Assessing the mechanisms of brain plasticity by transcranial magnetic stimulation. <i>Neuropsychopharmacology</i> , 2023, 48, 191-208.	2.8	37
2994	ACU193, a Monoclonal Antibody that Selectively Binds Soluble A $\beta$ Oligomers: Development Rationale, Phase 1 Trial Design, and Clinical Development Plan. <i>Journal of Prevention of Alzheimer's Disease</i> , The, 0, , .	1.5	5
2995	Applications of Single-Molecule Vibrational Spectroscopic Techniques for the Structural Investigation of Amyloid Oligomers. <i>Molecules</i> , 2022, 27, 6448.	1.7	1
2996	Conformational Essentials Responsible for Neurotoxicity of A $\beta$ 42 Aggregates Revealed by Antibodies against Oligomeric A $\beta$ 42. <i>Molecules</i> , 2022, 27, 6751.	1.7	4
2997	Time-Resolved In Situ AFM Measurement of Growth Rates of A $\beta$ 40 Fibrils. <i>Methods in Molecular Biology</i> , 2023, , 63-77.	0.4	0
2998	Novel small molecular compound 2JY-OBZ4 alleviates AD pathology in cell models via regulating multiple targets. <i>Aging</i> , 2022, 14, 8077-8094.	1.4	1
3000	Internalized Amyloid- $\beta$ (1-42) Peptide Inhibits the Store-Operated Calcium Entry in HT-22 Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12678.	1.8	7
3002	Amyloid A $\beta$ 25-35 Aggregates Say $\text{e}^{-}\text{NO}^{\text{e}^{-}}$ to Long-Term Potentiation in the Hippocampus through Activation of Stress-Induced Phosphatase 1 and Mitochondrial Na $^{+}$ /Ca $^{2+}$ Exchanger. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11848.	1.8	2
3004	Identification of a Hydroxygallic Acid Derivative, Zingibroside R1 and a Sterol Lipid as Potential Active Ingredients of <i>Cuscuta chinensis</i> Extract That Has Neuroprotective and Antioxidant Effects in Aged <i>Caenorhabditis elegans</i> . <i>Nutrients</i> , 2022, 14, 4199.	1.7	4

#	ARTICLE	IF	CITATIONS
3005	The Hidden Role of Non-Canonical Amyloid $A\beta$ Isoforms in Alzheimer's Disease. <i>Cells</i> , 2022, 11, 3421.	1.8	3
3006	Preparation and Investigation of Crucial Oligomers in the Early Stages of $A\beta$ 40 and $A\beta$ 42 Aggregation. <i>Methods in Molecular Biology</i> , 2023, , 15-28.	0.4	0
3007	AmyP53, a Therapeutic Peptide Candidate for the Treatment of Alzheimer's and Parkinson's Disease: Safety, Stability, Pharmacokinetics Parameters and Nose-to Brain Delivery. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13383.	1.8	6
3008	TREM2 and Microglia Contribute to the Synaptic Plasticity: from Physiology to Pathology. <i>Molecular Neurobiology</i> , 2023, 60, 512-523.	1.9	8
3009	Suppression of amyloid- $A\beta$ fibril growth by drug-engineered polymorph transformation. <i>Journal of Biological Chemistry</i> , 2022, 298, 102662.	1.6	1
3010	Isoflurane impairs GluN2B-containing NMDA receptors trafficking and cognition via decreasing histone acetylation and EphB2 expression in aged hippocampal neurons. <i>Basic and Clinical Pharmacology and Toxicology</i> , 0, , .	1.2	0
3011	Current Conceptual View of Alzheimer's Disease. <i>Advances in Biological Psychiatry</i> , 2012, , 30-48.	0.2	5
3012	Linking the Amyloid, Tau, and Mitochondrial Hypotheses of Alzheimer's Disease and Identifying Promising Drug Targets. <i>Biomolecules</i> , 2022, 12, 1676.	1.8	24
3013	$A\beta$ and tau prions feature in the neuropathogenesis of Down syndrome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	10
3014	Late-long-term potentiation magnitude, but not $A\beta$ levels and amyloid pathology, is associated with behavioral performance in a rat knock-in model of Alzheimer disease. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	3
3015	Pathophysiological mechanism and natural preventive and therapeutic strategies of Alzheimer's disease. <i>Nutrition and Health</i> , 0, , 026010602211371.	0.6	1
3016	$A\beta$ and Tau Prions Causing Alzheimer's Disease. <i>Methods in Molecular Biology</i> , 2023, , 293-337.	0.4	6
3017	Alzheimer's Disease and Other Dementias. , 2023, , 1-20.		0
3018	The mevalonate suppressor $\beta$ -tocotrienol increases AMPA receptor-mediated neurotransmission. <i>Biochemical and Biophysical Research Communications</i> , 2022, , .	1.0	0
3019	Toward the Identification of Neurophysiological Biomarkers for Alzheimer's Disease in Down Syndrome: A Potential Role for Cross-Frequency Phase-Amplitude Coupling Analysis. , 2022, .		2
3020	Modulation of L-type calcium channels in Alzheimer's disease: A potential therapeutic target. <i>Computational and Structural Biotechnology Journal</i> , 2023, 21, 11-20.	1.9	4
3021	Non-competitive AMPA glutamate receptors antagonism by perampanel as a strategy to counteract hippocampal hyper-excitability and cognitive deficits in cerebral amyloidosis. <i>Neuropharmacology</i> , 2023, 225, 109373.	2.0	7
3022	Experimental evidence for temporal uncoupling of brain $A\beta$ deposition and neurodegenerative sequelae. <i>Nature Communications</i> , 2022, 13, .	5.8	6



#	ARTICLE	IF	CITATIONS
3023	Physiological Roles of $\beta^2$ -amyloid in Regulating Synaptic Function: Implications for AD Pathophysiology. <i>Neuroscience Bulletin</i> , 2023, 39, 1289-1308.	1.5	13
3024	Cannabinoid CB2 Receptors in Neurodegenerative Proteinopathies: New Insights and Therapeutic Potential. <i>Biomedicines</i> , 2022, 10, 3000.	1.4	2
3025	Development of Alkaline Phosphatase-Fused Mouse Prion Protein and Its Application in Toxic $A\beta^2$ Oligomer Detection. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14588.	1.8	1
3026	Synthetic, Cell-Derived, Brain-Derived, and Recombinant $\beta^2$ -Amyloid: Modelling Alzheimer's Disease for Research and Drug Development. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15036.	1.8	5
3027	Leptin-based hexamers facilitate memory and prevent amyloid-driven $\alpha$ -AMPA receptor internalisation and neuronal degeneration. <i>Journal of Neurochemistry</i> , 2023, 165, 809-826.	2.1	3
3028	Synaptic degeneration in Alzheimer disease. <i>Nature Reviews Neurology</i> , 2023, 19, 19-38.	4.9	84
3029	Simple, Reliable Protocol for High-Yield Solubilization of Seedless Amyloid- $\beta^2$ Monomer. <i>ACS Chemical Neuroscience</i> , 0, , .	1.7	0
3030	Inflammation context in Alzheimer's disease, a relationship intricate to define. <i>Biological Research</i> , 2022, 55, .	1.5	29
3032	The Impact of the Cellular Environment and Aging on Modeling Alzheimer's Disease in 3D Cell Culture Models. <i>Advanced Science</i> , 2023, 10, .	5.6	9
3033	Prion Protein Complex with mGluR5 Mediates Amyloid- $\beta^2$ Synaptic Loss in Alzheimer's Disease. , 2023, , 467-481.		0
3035	The interactions of amyloid $\beta^2$ aggregates with phospholipid membranes and the implications for neurodegeneration. <i>Biochemical Society Transactions</i> , 2023, 51, 147-159.	1.6	5
3036	$A\beta^{242}$ oligomer-specific antibody ALZ-201 reduces the neurotoxicity of Alzheimer's disease brain extracts. <i>Alzheimer's Research and Therapy</i> , 2022, 14, .	3.0	3
3037	Enhanced delivery of a low dose of aducanumab via FUS in 5 $\times$ FAD mice, an AD model. <i>Translational Neurodegeneration</i> , 2022, 11, .	3.6	11
3038	The Contribution of Transgenic Models to the Understanding of Alzheimer's Disease Progression and Therapeutic Development. , 2011, , 1-14.		0
3039	Animal Models of Amyloid/PS-1 Pathology. , 2011, , 15-38.		0
3040	Methods for the isolation and analysis of $A\beta^2$ from postmortem brain. <i>Frontiers in Neuroscience</i> , 0, 17, .	1.4	0
3041	A Function of Amyloid- $\beta^2$ in Mediating Activity-Dependent Axon/Synapse Competition May Unify Its Roles in Brain Physiology and Pathology. <i>Journal of Alzheimer's Disease</i> , 2023, , 1-29.	1.2	2
3045	Lysine Acetylation Changes the Mechanism of $A\beta^{25-35}$ Peptide Binding and Dimerization in the DMPC Bilayer. <i>ACS Chemical Neuroscience</i> , 2023, 14, 494-505.	1.7	0



#	ARTICLE	IF	CITATIONS
3046	SorCS1 inhibits amyloid- $\beta$ binding to neurexin and rescues amyloid- $\beta$ -induced synaptic pathology. <i>Life Science Alliance</i> , 2023, 6, e202201681.	1.3	5
3047	Peripheral administration of nanomicelle-encapsulated anti-A $\beta$ oligomer fragment antibody reduces various toxic A $\beta$ species in the brain. <i>Journal of Nanobiotechnology</i> , 2023, 21, .	4.2	4
3048	Deficiency of $\text{IKK}\beta$ in neurons ameliorates Alzheimer's disease pathology in APP transgenic mice. <i>FASEB Journal</i> , 2023, 37, .	0.2	0
3049	Detecting Early Cognitive Decline in Alzheimer's Disease with Brain Synaptic Structural and Functional Evaluation. <i>Biomedicines</i> , 2023, 11, 355.	1.4	5
3050	Etiology and Clinical Significance of Network Hyperexcitability in Alzheimer's Disease: Unanswered Questions and Next Steps. <i>Journal of Alzheimer's Disease</i> , 2023, 92, 13-27.	1.2	2
3051	Targeting galectin-3 to counteract spike-phase uncoupling of fast-spiking interneurons to gamma oscillations in Alzheimer's disease. <i>Translational Neurodegeneration</i> , 2023, 12, .	3.6	4
3052	Modelling the contributions to hyperexcitability in a mouse model of Alzheimer's disease. <i>Journal of Physiology</i> , 2023, 601, 3403-3437.	1.3	2
3053	Brain targeting based nanocarriers loaded with resveratrol in Alzheimer's disease: A review. <i>IET Nanobiotechnology</i> , 2023, 17, 154-170.	1.9	4
3055	Structural polymorphism and cytotoxicity of brain-derived $\beta$ -amyloid extracts. <i>Protein Science</i> , 2023, 32, .	3.1	4
3056	Role of microbial dysbiosis in the pathogenesis of Alzheimer's disease. <i>Neuropharmacology</i> , 2023, 229, 109478.	2.0	10
3057	Trpc6 knockout improves behavioral dysfunction and reduces A $\beta$ production by inhibiting CN-NFAT1 signaling in T2DM mice. <i>Experimental Neurology</i> , 2023, 363, 114350.	2.0	1
3058	Exploring the aggregation of amyloid- $\beta$ 42 through Monte Carlo simulations. <i>Biophysical Chemistry</i> , 2023, 297, 107011.	1.5	3
3059	Characterization of apathy-like behaviors in the 5xFAD mouse model of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2023, 126, 113-122.	1.5	4
3061	Phospholipase D1 Attenuation Therapeutics Promotes Resilience against Synaptotoxicity in 12-Month-Old 3xTg-AD Mouse Model of Progressive Neurodegeneration. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3372.	1.8	1
3062	Revisiting the intersection of microglial activation and neuroinflammation in Alzheimer's disease from the perspective of ferroptosis. <i>Chemico-Biological Interactions</i> , 2023, 375, 110387.	1.7	12
3063	Retinal pathological features and proteome signatures of Alzheimer's disease. <i>Acta Neuropathologica</i> , 2023, 145, 409-438.	3.9	20
3064	Oxidative Stress in Brain in Amnesic Mild Cognitive Impairment. <i>Antioxidants</i> , 2023, 12, 462.	2.2	4
3065	Tebuconazole mediates cognitive impairment via the microbe-gut-brain axis (MGBA) in mice. <i>Environment International</i> , 2023, 173, 107821.	4.8	5

#	ARTICLE	IF	CITATIONS
3066	Molecular dynamics simulations reveal the importance of amyloid-beta oligomer $\beta^2$ -sheet edge conformations in membrane permeabilization. <i>Journal of Biological Chemistry</i> , 2023, 299, 103034.	1.6	6
3067	Protein Interactome of Amyloid- $\beta^2$ as a Therapeutic Target. <i>Pharmaceuticals</i> , 2023, 16, 312.	1.7	4
3068	Impact of Nut Consumption on Cognition across the Lifespan. <i>Nutrients</i> , 2023, 15, 1000.	1.7	3
3069	The $\beta^2$ -adrenergic hypothesis of synaptic and microglial impairment in Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2023, 165, 289-302.	2.1	3
3070	Targeting BACE1-mediated production of amyloid beta improves hippocampal synaptic function in an experimental model of ischemic stroke. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 0, , 0271678X2311595.	2.4	1
3071	Soluble and insoluble protein aggregates, endoplasmic reticulum stress, and vascular dysfunction in Alzheimer's disease and cardiovascular diseases. <i>GeroScience</i> , 2023, 45, 1411-1438.	2.1	5
3072	Imaging Amyloid- $\beta^2$ Membrane Interactions: Ion-Channel Pores and Lipid-Bilayer Permeability in Alzheimer's Disease. <i>Angewandte Chemie</i> , 2023, 135, .	1.6	0
3073	Imaging Amyloid- $\beta^2$ Membrane Interactions: Ion-Channel Pores and Lipid-Bilayer Permeability in Alzheimer's Disease. <i>Angewandte Chemie - International Edition</i> , 2023, 62, .	7.2	9
3074	The Potential Roles of Exosomes Carrying APP and Tau Cleavage Products in Alzheimer's Disease. <i>Journal of Clinical Medicine</i> , 2023, 12, 1883.	1.0	3
3075	Cellular response to $\beta^2$ -amyloid neurotoxicity in Alzheimer's disease and implications in new therapeutics. <i>Animal Models and Experimental Medicine</i> , 2023, 6, 3-9.	1.3	6
3076	Sex differences in hippocampal $\beta^2$ -amyloid accumulation in the triple-transgenic mouse model of Alzheimer's disease and the potential role of local estrogens. <i>Frontiers in Neuroscience</i> , 0, 17, .	1.4	7
3077	The Physio-Pathological Role of Group I Metabotropic Glutamate Receptors Expressed by Microglia in Health and Disease with a Focus on Amyotrophic Lateral Sclerosis. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5240.	1.8	0
3078	Protein amyloid aggregate: Structure and function. <i>Aggregate</i> , 2023, 4, .	5.2	5
3079	Alleviating the unwanted effects of oxidative stress on $A\beta^2$ clearance: a review of related concepts and strategies for the development of computational modelling. <i>Translational Neurodegeneration</i> , 2023, 12, .	3.6	2
3080	Dityrosine cross-linking and its potential roles in Alzheimer's disease. <i>Frontiers in Neuroscience</i> , 0, 17, .	1.4	2
3081	Energy landscapes of $A\beta^2$ monomers are sculpted in accordance with Ostwald's rule of stages. <i>Science Advances</i> , 2023, 9, .	4.7	11
3082	Oligomeric $\beta^2$ -Amyloid Suppresses Hippocampal $\beta^3$ -Oscillations through Activation of the mTOR/S6K1 Pathway. , 2023, .		0
3083	Learnings about $A\beta^2$ from human brain recommend the use of a live-neuron bioassay for the discovery of next generation Alzheimer's disease immunotherapeutics. <i>Acta Neuropathologica Communications</i> , 2023, 11, .	2.4	2

#	ARTICLE	IF	CITATIONS
3084	Sigma-2 Receptorsâ€™ From Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative Diseases. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6251.	1.8	7
3085	Moving beyond amyloid and tau to capture the biological heterogeneity of Alzheimerâ€™s disease. <i>Trends in Neurosciences</i> , 2023, 46, 426-444.	4.2	11
3086	Investigation of Cyclo-Z Therapeutic Effect on Insulin Pathway in Alzheimer's Rat Model: Biochemical and Electrophysiological Parameters. <i>Molecular Neurobiology</i> , 2023, 60, 4030-4048.	1.9	1
3087	Geraniol improves passive avoidance memory and hippocampal synaptic plasticity deficits in a rat model of Alzheimer's disease. <i>European Journal of Pharmacology</i> , 2023, 951, 175714.	1.7	3
3088	Electrostatics-Induced Nucleated Conformational Transition of Protein Aggregation. <i>Physical Review Letters</i> , 2023, 130, .	2.9	6
3089	Artemisin and human endometrial-derived stem cells improve cognitive function and synaptic plasticity in a rat model of Alzheimer disease and diabetes. <i>Metabolic Brain Disease</i> , 2023, 38, 1925-1936.	1.4	2
3090	Advances in the Electrophysiological Recordings of Long-Term Potentiation. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7134.	1.8	3
3091	Recent Development in the Understanding of Molecular and Cellular Mechanisms Underlying the Etiopathogenesis of Alzheimerâ€™s Disease. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7258.	1.8	7
3092	Safety Analysis of Bapineuzumab in the Treatment of Mild to Moderate Alzheimerâ€™s Disease: A Systematic Review and Meta-Analysis. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2024, 27, 40-47.	0.6	1
3115	Amyloid Î²-based therapy for Alzheimerâ€™s disease: challenges, successes and future. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	49
3136	Anti-Amyloid Î² Aggregation Activity and Cell Viability Effect of Betacyanins from Red Pitahaya ( <i>Hylocereus polyrhizus</i> ) for Alzheimerâ€™s Disease. <i>Plant Foods for Human Nutrition</i> , 0, , .	1.4	0
3203	Amyloids as endogenous toxicants in neurodegenerative diseases. , 2024, , 1059-1081.		0
3213	Neurological Diseases. , 2023, , 295-314.		0
3217	Alzheimerâ€™s Disease and Other Dementias. , 2024, , 1027-1046.		0